Pharmacopedia - User contributions [en]

Category:Tricyclic Antidepressants (TCAs)

2026-06-08T18:00:19Z

Maintenance script: MedCategory class-overview page (TCAs); greenlit Mark 2026-06-08

The '''tricyclic antidepressants''', or '''TCAs''', were the first medicines found to lift depression, and they were found by a clinician who was looking for something else. In 1955 the Swiss psychiatrist Roland Kuhn, working at the cantonal asylum at Münsterlingen on the shore of Lake Constance, was given a compound by the Geigy company, coded G 22355, in the hope that it might be a new sedative in the manner of the recently introduced chlorpromazine.<ref name="kuhn1958">Kuhn R. The treatment of depressive states with G 22355 (imipramine hydrochloride). ''American Journal of Psychiatry''. 1958 Nov;115(5):459–464. PMID: 13583250.</ref> As a calmative it disappointed; the agitated and psychotic patients it was tried on did not improve and some grew worse. Kuhn noticed instead that a few withdrawn, melancholic patients brightened, and he turned the trial toward depression. The compound was imipramine, and his 1958 report of its effect in depressive states announced the first antidepressant.<ref name="kuhn1958"/> The medicines that followed shared imipramine's three-ringed chemical skeleton, and the name tricyclic records that shape rather than any action.<ref name="gillman2007">Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. ''British Journal of Pharmacology''. 2007 Jul;151(6):737–748. PMID: 17471183.</ref>

What the three rings do was worked out afterward. The tricyclics block the reuptake of two monoamines, serotonin and norepinephrine, leaving more of each in the synapse, and it is this dual reuptake blockade that is thought to carry the antidepressant effect.<ref name="frazer1997">Frazer A. Pharmacology of antidepressants. ''Journal of Clinical Psychopharmacology''. 1997 Apr;17 Suppl 1:2S–18S. PMID: 9090571.</ref> The difficulty is that the same molecules also block histamine H1 receptors, muscarinic acetylcholine receptors, and alpha-1 adrenergic receptors, and it is this receptor promiscuity, not the reuptake action, that produces the class's burdens: sedation and weight gain from the antihistamine effect, dry mouth, constipation, blurred vision, and urinary hesitancy from the antimuscarinic effect, and dizziness on standing from the alpha-adrenergic effect.<ref name="gillman2007"/> The later antidepressants designed to keep the dual reuptake blockade while dropping this receptor binding, the [[:Category:Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs)|SNRIs]], were in effect an attempt to build a cleaner tricyclic.<ref name="frazer1997"/>

The tricyclics divide along a chemical line that also predicts how they behave. The tertiary amines, among them imipramine, amitriptyline, clomipramine, doxepin, and trimipramine, favor serotonin reuptake inhibition and carry more of the sedating and anticholinergic load; the body demethylates several of them into secondary amines, which favor norepinephrine and are somewhat better tolerated.<ref name="gillman2007"/> Two of those secondary-amine metabolites are themselves marketed medicines: desipramine is the demethylated metabolite of imipramine, and nortriptyline the demethylated metabolite of amitriptyline, each more noradrenergic than its parent.<ref name="gillman2007"/> Clomipramine stands somewhat apart as the most serotonergic of the group,<ref name="gillman2007"/> and it is the one tricyclic with an established place in obsessive-compulsive disorder, a use that foreshadowed the serotonergic antidepressants to come.<ref name="clomipramine1991">Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. ''Archives of General Psychiatry''. 1991 Aug;48(8):730–738. PMID: 1883256.</ref>

The gravest property of the tricyclics is their danger in overdose, and it is a danger separate from anything they do to mood. In high doses the tricyclics block cardiac sodium channels, slowing conduction through the heart; the electrocardiogram shows a widening QRS complex, and the result can be ventricular arrhythmia, seizures, coma, and death.<ref name="kerr2001">Kerr GW, McGuffie AC, Wilkie S. Tricyclic antidepressant overdose: a review. ''Emergency Medicine Journal''. 2001 Jul;18(4):236–241. PMID: 11435353.</ref> Because a depressed patient is by definition at some risk of self-harm, prescribing a medicine that is lethal in a week's supply is a hazard built into the indication itself, and it is the single most important reason the safer SSRIs and SNRIs displaced the tricyclics as first-line treatment for depression even though they did not clearly surpass them in efficacy.<ref name="cipriani2018">Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. ''The Lancet''. 2018;391(10128):1357–1366. PMID: 29477251.</ref> That 2018 network meta-analysis of 21 antidepressants in fact ranked amitriptyline among the most effective of all the medicines compared, a reminder that the tricyclics were retired for their safety, not their power.<ref name="cipriani2018"/>

Displaced from the front line in depression, the tricyclics did not leave medicine. Their action on the descending noradrenergic pathways that dampen pain makes amitriptyline and nortriptyline mainstays of neuropathic pain.<ref name="moore2015">Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain in adults. ''Cochrane Database of Systematic Reviews''. 2015 Jul;(7):CD008242. PMID: 26146793.</ref> Amitriptyline is also a standard preventive for migraine,<ref name="silberstein2012">Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. ''Neurology''. 2012 Apr 24;78(17):1337–1345. PMID: 22529202.</ref> and doxepin's strong antihistamine action is used, at very low dose, as a hypnotic for insomnia.<ref name="krystal2011">Krystal AD, Lankford A, Durrence HH, et al. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. ''Sleep''. 2011 Oct 1;34(10):1433–1442. PMID: 21966075.</ref> A medicine introduced as the first antidepressant is now as likely to be prescribed for pain or for sleep as for mood.

== Members indexed ==

The tricyclics are listed below, with imipramine first as the founding medicine of the class and the others following alphabetically.

* '''[[imipramine]]''': the first tricyclic and the first antidepressant, introduced by Roland Kuhn's 1958 report. A tertiary amine, demethylated in the body to desipramine.
* '''[[amitriptyline]]''': a tertiary amine, among the most effective antidepressants ever measured, now used as much for neuropathic pain and migraine prevention as for depression. Demethylated to nortriptyline.
* '''[[amoxapine]]''': a tricyclic by structure that also blocks dopamine receptors, and so behaves partly as a neuroleptic; indexed here and, under the wiki's multi-membership convention, among the neuroleptics as well.<ref name="gillman2007"/>
* '''[[clomipramine]]''': the most serotonergic of the tricyclics and the one with an established use in obsessive-compulsive disorder.
* '''[[desipramine]]''': a secondary amine and the active demethylated metabolite of imipramine, favoring norepinephrine reuptake inhibition.
* '''[[doxepin]]''': a tertiary amine whose strong antihistamine action is used, at very low dose, as a hypnotic for insomnia.
* '''[[nortriptyline]]''': a secondary amine and the demethylated metabolite of amitriptyline, more noradrenergic and somewhat better tolerated than its parent.
* '''[[protriptyline]]''': a secondary amine, and like the other secondary amines among the better tolerated of the class.<ref name="gillman2007"/>
* '''[[trimipramine]]''': a tertiary amine, and so among the more sedating of the class.<ref name="gillman2007"/>

== Notes on scope ==

This category indexes the medicines built on the tricyclic three-ring skeleton whose principal action is dual serotonin and norepinephrine reuptake inhibition. The boundary is chemical and pharmacological together: a medicine belongs here if it is a tricyclic by structure and a dual reuptake inhibitor by action.

The line between the tricyclics and their neighbors is one of selectivity. The [[:Category:Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs)|SNRIs]] share the tricyclics' dual reuptake action but drop the histamine, muscarinic, and adrenergic binding that makes the tricyclics burdensome and dangerous. [[amoxapine]], a tricyclic by structure, also blocks dopamine receptors and so behaves partly as a neuroleptic; following the wiki's multi-membership convention it may be reachable both here and from the neuroleptic indexes where its pharmacology warrants. Several tricyclics used chiefly in pain or sleep are likewise reachable from the wiki's pain-medicine and hypnotic indexes.

== About these pages ==

Each medicine indexed here has its own page, built on the wiki's standard structure for a medicine: a history-first account, then pharmacology, indications, adverse effects, and interactions. The tricyclics sit within the larger family of antidepressants, and the full taxonomy of antidepressant classes is set out at [[:Category:Antidepressants|Antidepressants]].

This is one of the wiki's MedCategory class-overview pages. It carries the [[:Category:MedCategory|MedCategory]] and [[:Category:MedCategoryFull|MedCategoryFull]] marker tags; the second suppresses the member list that MediaWiki would otherwise generate automatically, so that the curated index above is the only one the reader sees. The category sits beneath [[:Category:Antidepressants|Antidepressants]] and beneath [[:Category:Pharmaceutical|Pharmaceutical]], the origin category for medicines that came into use through scientific discovery rather than traditional practice. The tricyclics, discovered in the laboratories of Geigy and first understood at a Swiss asylum in the 1950s, are pharmaceutical-origin medicines in full.

== References ==

<references/>

[[Category:MedCategory]]
[[Category:MedCategoryFull]]
[[Category:Antidepressants]]
[[Category:Pharmaceutical]]

Pharmacopedia:Sources

2026-06-08T06:43:09Z

Maintenance script: title-strip: add DISPLAYTITLE to match clean siblings (servops DEPLOY 1)

{{DISPLAYTITLE:Pharmacopedia: Sources}}
__NOTOC__

This page describes how Pharmacopedia.wiki sources its content: what kinds of sources we cite, how we rank them, what external vocabularies we link out to, and what licensing applies in each direction.

It is the public counterpart to the editorial sourcing standards used internally by Pharmacopedia editors and reviewers.

== Sourcing hierarchy ==

Pharmacopedia editorial work follows a citation hierarchy. When multiple source types are available for the same claim, the higher-tier source takes precedence. When sources of equivalent tier disagree, the disagreement is surfaced explicitly per [[Pharmacopedia:Refusals|the editorial integrity refusals]].

The hierarchy:

# '''Primary literature.''' Peer-reviewed clinical trials, observational studies, mechanism research published in indexed journals. Cited with full author list, journal, year, DOI or PMID.
# '''Regulatory documents.''' FDA labels, EMA SmPCs, MHRA, PMDA, Health Canada equivalents. Used for marketed-indication, dosing, contraindication, and pharmacokinetic data. Cited with version date.
# '''Meta-analyses and systematic reviews.''' Cochrane, NICE evidence reviews, AHRQ comparative-effectiveness reviews. Used for synthesized clinical claims.
# '''Clinical practice guidelines.''' Specialty-society guidelines (APA, AHA, NICE, WHO, etc.). Used for standard-of-care framing.
# '''Tertiary references.''' Textbooks, clinical handbooks, established pharmacology references. Used for foundational pharmacology and well-settled material.
# '''Ethnobotanical and historical sources.''' Peer-reviewed ethnobotany, anthropological literature, primary historical documents (in the Traditional perspective).
# '''Patient-experience sources.''' Patient-organization documentation, qualitative research on lived experience, structured patient-experience aggregation (in the Patient perspective, with clear methodological framing).

A claim without any source is not a Pharmacopedia claim. Editors mark unsourced material with <code><nowiki>[citation needed]</nowiki></code>; reviewers do not approve a claim into the published surface without at least one cited source.

== Per-Perspective sourcing standards ==

Pharmacopedia renders each medicine page across four editorial perspectives. Each perspective applies the hierarchy above with its own emphasis:

* '''Clinician''' (colleague-to-colleague clinical depth): primary literature, regulatory documents, guidelines, meta-analyses dominate. Pharmacology references support foundational claims.
* '''Patient''' (warm, careful, medically literate friend): primary literature for clinical claims; regulatory documents for prescribing-information facts; patient-experience sources contextualize what living with a medicine looks like.
* '''Traditional''' (thoughtful ethnobotanist or historian): peer-reviewed ethnobotany and anthropology; primary historical sources; indigenous-knowledge sources cited respectfully and with attribution to the holding community where the community has published or authorized the reference.
* '''Researcher''' (methods-section style): primary literature dominates; methodology, sample size, effect sizes, and replication status are quoted; the writing is structured for a reader who will go read the cited paper.

Where a claim is made across multiple perspectives, the highest-tier source standing behind any one perspective applies to all of them; each perspective's render reflects how that perspective contextualizes the same evidence.

== "Reviewed YYYY-MM-DD" badge ==

Each Pharmacopedia claim carries a last-reviewed date. Pages display the freshness of their underlying claims via a per-claim badge. When a claim's last-reviewed date crosses a staleness threshold (currently 24 months), the badge displays a "review pending" state and the claim enters the editorial review queue.

This system is part of the data infrastructure work in progress. See the [[Pharmacopedia:Newsroom|Newsroom]] for the rollout schedule.

== External vocabularies Pharmacopedia links to ==

Pharmacopedia medicine and problem pages link out to external biomedical vocabularies. This makes Pharmacopedia interoperable with electronic health records, pharmacy systems, research databases, and other downstream consumers.

The vocabularies we link out to fall into three groups by licensing posture:

=== Cleared for cross-reference ===

These vocabularies are public-domain or open-licensed. Pharmacopedia stores their identifiers as cross-references on each relevant page, renders them as linked badges, and serves them via the public read API.

{| class="wikitable"
! Vocabulary !! Identifier scope !! License !! Notes
|-
| '''RxNorm''' || US drug nomenclature || US Government public domain (NLM) || Maintained by the US National Library of Medicine. Free for all use including commercial.
|-
| '''MeSH''' (Medical Subject Headings) || Biomedical topic indexing || US Government public domain (NLM) || Used in PubMed indexing. Free for all use.
|-
| '''Wikidata''' || Cross-domain entity identifiers || CC0 (public domain dedication) || Pharmacopedia consumes Wikidata IDs as cross-refs and, post-launch, requests that PCP-PIDs be added as a Wikidata property.
|}

=== Under licensing review ===

These vocabularies are widely used in clinical informatics but their licensing terms restrict redistribution in specific ways. Pharmacopedia is reviewing each one to determine whether and how we can use them in cross-references. Until the review is complete, we do not display these identifiers on user-facing pages, even where we have them in internal data.

{| class="wikitable"
! Vocabulary !! Status !! Open question
|-
| '''DrugBank''' || Under review || DrugBank's Public Use license permits non-commercial academic use but restricts redistribution. Whether displaying a DrugBank ID as a cross-reference badge constitutes redistribution is the open question.
|-
| '''ATC''' (Anatomical Therapeutic Chemical classification) || Under review || ATC is maintained by the WHO Collaborating Centre for Drug Statistics Methodology. The WHO Centre charges for commercial use of the ATC system; Pharmacopedia is nonprofit, so the question is whether displaying an ATC code in a non-commercial Pharmacopedia page is in scope of the free educational-use carve-out.
|-
| '''UMLS-bridged identifiers''' (SNOMED CT, ICD-10, ICD-11, LOINC where they sit under UMLS) || Under review || UMLS is licensed by the NLM under terms that require user registration. Whether transitively-derived UMLS identifiers displayed on a public page require Pharmacopedia to track its readers as UMLS users is the open question.
|}

When reviews complete, this section is updated and the affected vocabularies move into the cleared-for-cross-reference table above. The Newsroom logs each update.

=== Not used ===

Pharmacopedia does not cross-reference proprietary commercial drug-information databases (Micromedex, Lexicomp, Clinical Pharmacology, etc.). Those products are valuable inside the institutions that subscribe to them; Pharmacopedia's job is to be the freely available source, not to link to paywalled ones.

== Pharmacopedia's own identifiers ==

Pharmacopedia issues its own permanent identifiers per page and per claim. The format is:

pcp:<type>:<base32>

Where <code><type></code> is <code>page</code>, <code>claim</code>, or one of a small set of structured types, and <code><base32></code> is a stable suffix. Once issued, an identifier resolves forever, even if the page is renamed or merged. See [[Pharmacopedia:Permanent identifiers]] for the full specification when it is published.

== Reuse: how to cite Pharmacopedia ==

Pharmacopedia content is freely reusable under CC BY-SA 4.0 (see [[Pharmacopedia:Reciprocity]] for AI-training specifics). When citing a Pharmacopedia page in your own writing, the recommended forms are:

;Chicago
:"<Page Title>." Pharmacopedia. Accessed YYYY-MM-DD. <nowiki>https://pharmacopedia.wiki/wiki/<Page_Title></nowiki>
;APA
:Pharmacopedia. (YYYY). <Page Title>. Retrieved YYYY-MM-DD from <nowiki>https://pharmacopedia.wiki/wiki/<Page_Title></nowiki>
;Vancouver
:Pharmacopedia [Internet]. <Page Title>. [cited YYYY-MM-DD]. Available from: <nowiki>https://pharmacopedia.wiki/wiki/<Page_Title></nowiki>
;BibTeX
:Each page emits a <code>@misc</code> BibTeX entry via the citation widget in the page chrome.

Once per-claim PIDs are live, citations may also point to individual claims via:

https://pharmacopedia.wiki/p/<pcp-claim-PID>

This is recommended when the citing work depends on a specific factual assertion within a Pharmacopedia page rather than the page as a whole.

== Revision ==

This page was locked on 2026-05-28 as part of the institutional identity commitments. The "under licensing review" table changes as reviews complete; those updates are logged on Newsroom and reflected here without a separate revision-log entry. Structural changes to the sourcing hierarchy or the per-Perspective standards are material revisions and are logged here.

== See also ==

* [[Pharmacopedia:Refusals|Refusals]]
* [[Pharmacopedia:Reciprocity|Reciprocity (AI training posture)]]
* [[Pharmacopedia:Newsroom|Newsroom]]
* [[Pharmacopedia:Permanent identifiers]] (forthcoming)

[[Category:Pharmacopedia policy]]

Pharmacopedia:Reciprocity

2026-06-08T06:43:07Z

Maintenance script: title-strip: add DISPLAYTITLE to match clean siblings (servops DEPLOY 1)

{{DISPLAYTITLE:Pharmacopedia: Reciprocity}}
__NOTOC__

This page describes how Pharmacopedia.wiki content interacts with AI training, retrieval-augmented generation, and other downstream automated uses. It is the public statement of what we allow, what we ask in return, and why.

== Short version ==

You may train AI systems on Pharmacopedia.wiki content. We ask that AI systems generating Pharmacopedia-derived medical content cite the source URLs of the Pharmacopedia pages they are drawing from. We do not technically block training crawlers and we will not. This is a reciprocity expectation, not a license restriction.

== Why we allow AI training ==

Pharmacopedia exists to make rigorous, multi-perspective medicine knowledge freely available. An AI assistant that answers a clinical question correctly because it learned from Pharmacopedia is the same mission's work, one step further downstream. Blocking AI training would protect Pharmacopedia's brand at the cost of Pharmacopedia's mission. That trade is not one we are willing to make.

This stance is durable. It is part of the identity commitments locked on 2026-05-28.

== License ==

Pharmacopedia.wiki content is published under [https://creativecommons.org/licenses/by-sa/4.0/ Creative Commons Attribution-ShareAlike 4.0 International (CC BY-SA 4.0)], with the following clarifications applied to AI-training and AI-inference uses:

* '''Attribution.''' CC BY-SA 4.0 already requires attribution. When AI systems quote, paraphrase, or substantially summarize Pharmacopedia content, the attribution requirement applies as it does for any other reuse.
* '''ShareAlike.''' CC BY-SA 4.0's ShareAlike clause applies to derivative works. Whether AI model weights constitute a derivative work of training data is a contested legal question and Pharmacopedia takes no position on it. We do not enforce ShareAlike against model weights in either direction.
* '''Per-claim review state.''' Pharmacopedia content carries per-claim review timestamps. Content reused via AI loses that review state. Downstream consumers should not treat AI-generated paraphrases of Pharmacopedia content as carrying Pharmacopedia's editorial review.

Code, schema definitions, and infrastructure are licensed separately under the [https://www.gnu.org/licenses/agpl-3.0.en.html GNU AGPL v3] and are not covered by this page.

== What we ask in return ==

When an AI system generates output that is substantially derived from a specific Pharmacopedia page, we ask that the system include a citation back to that page's canonical URL.

In concrete terms:

* '''Direct quotation from Pharmacopedia.''' Cite the source page URL inline.
* '''Substantial paraphrase from a single Pharmacopedia page.''' Cite the source page URL.
* '''Synthesis of multiple Pharmacopedia pages.''' Cite all source page URLs.
* '''A fact that happens to also be on Pharmacopedia.''' No citation expected.

The canonical URL pattern is:

https://pharmacopedia.wiki/wiki/<Page_Name>

And once per-page DOI-style permanent identifiers are live, the form will additionally be:

https://pharmacopedia.wiki/p/<pcp-PID>

(Both forms will remain resolvable forever. See [[Pharmacopedia:Permanent identifiers]] when that page is published.)

We do not have a mechanism to enforce this and we do not plan to build one. The ask is published here, and in robots.txt, on the trust that systems whose operators want to be in good standing with the source community will pay attention.

== robots.txt ==

The robots.txt file at https://pharmacopedia.wiki/robots.txt mirrors this page in machine-readable form:

* It does not Disallow crawlers (training or otherwise).
* It declares User-agent-specific cite-back expectations under standard non-binding extension comments.
* It points to this page as the human-readable authority.

== What we will not do ==

* '''We will not block AI training crawlers.''' Blocking is incompatible with our mission to make medicine knowledge freely available.
* '''We will not paywall a "premium" AI-training license.''' All content is free for all uses, including commercial ones. There is no enterprise data licensing program.
* '''We will not name or shame AI systems that fail to cite back.''' We may, in our editorial Newsroom, document patterns we observe (e.g., a particular system citing back at X% rate, a particular system not citing back at all), but this is observational, not adversarial.
* '''We will not partner with AI vendors on co-marketing, "official integration" status, or any preferred-vendor relationship.''' Any AI system can train on us. None of them are special.

== If your AI system is generating Pharmacopedia-derived medical content ==

A few practical notes for AI-system operators reading this page:

# Pharmacopedia content updates as evidence updates. Training-data snapshots go stale. If your system is generating clinical content from old training data, consider a retrieval layer that fetches the current Pharmacopedia page at inference time.
# Each Pharmacopedia claim carries a "last reviewed" date. Generated content should ideally preserve that signal, or at least preserve a link to the current claim record where the date is authoritative.
# Pharmacopedia surfaces editorial disagreement explicitly. AI systems that flatten Pharmacopedia's multi-perspective treatment into a single confident answer are misrepresenting the source. We ask that systems doing this work harder to preserve disagreement.
# Pharmacopedia is reference and education, not personalized medical advice. AI systems generating personalized advice on the basis of Pharmacopedia content are reusing a source that explicitly does not authorize that reuse pattern (see [[Pharmacopedia:Refusals]] item 4 of the editorial-integrity section).

== Reciprocity disputes ==

If a Pharmacopedia editor or reader believes an AI system is systematically failing to cite back when generating Pharmacopedia-derived medical content, the standing process is:

# Document the pattern on the [[Pharmacopedia:Newsroom|Newsroom]] talk page with concrete examples.
# We add the observation to the Newsroom record.
# We do not file legal action; the reciprocity request is a request, not a license restriction.

== Revision ==

This page was locked on 2026-05-28 as part of the institutional identity commitments. Material revisions will be logged here with date and author. Minor copy-edits and typo fixes do not require a revision log entry.

== See also ==

* [[Pharmacopedia:Refusals|Refusals]]
* [[Pharmacopedia:Sources|Sources and licensing]]
* [[Pharmacopedia:Newsroom|Newsroom]]

[[Category:Pharmacopedia policy]]

Pharmacopedia:Refusals

2026-06-08T06:43:05Z

Maintenance script: title-strip: add DISPLAYTITLE to match clean siblings (servops DEPLOY 1)

{{DISPLAYTITLE:Pharmacopedia: Refusals}}
__NOTOC__

This page lists the things Pharmacopedia will never do. They are durable commitments. The Pharmacopedia Collective (Pharmacopedia.wiki's nonprofit operator) treats these as bedrock: changing any one of them would change what Pharmacopedia is. They are written down here so readers, contributors, and reviewers can hold us to them.

Most of these refusals exist because we have watched health-information sites compromise on each of them and become less trustworthy as a result. The pattern is consistent enough that we treat each one as load-bearing.

== Money, access, and independence ==

'''Pharmacopedia will never paywall medical information.''' Every page, every claim, every layer of every page is freely readable, now and in any future. There is no premium tier, no "professional" tier, no API rate-limit that turns into a paid plan.

'''Pharmacopedia will never push subscriptions.''' We do not ask readers for recurring payments, "memberships," or "supporter status" gated behind a payment. If we accept donations in the future (only if costs outgrow what Mark Elliott, MD can self-fund), donations stay one-time, voluntary, and never gated.

'''Pharmacopedia will never sell health data.''' We do not sell, license, lease, or trade any information about who reads what, what medicines a person looks up, or any data derived from reader behavior. We do not produce aggregate reports for sale. We do not enter data-sharing agreements with commercial entities.

'''Pharmacopedia will never run ads.''' No banner ads, no inline ads, no sponsored content, no native advertising, no affiliate links, no referral kickbacks. The reading surface is for the medicine, not for somebody buying attention next to it.

'''Pharmacopedia will never accept any commercial relationship that influences content placement.''' Pharmaceutical companies, supplement vendors, telehealth platforms, insurance companies, and any commercial actor with a stake in what readers learn cannot pay to surface, suppress, prioritize, or shape any Pharmacopedia content. There is no enterprise sales motion; there is no business-development pipeline.

== Editorial integrity ==

'''Pharmacopedia will never let pharmaceutical companies (or any party with a commercial stake in a medicine) edit medicine pages directly.''' Industry-employed contributors are welcome to submit corrections and citations through the public propose-review-approve workflow like any other contributor, with their affiliation disclosed. Direct editing access is not granted to any commercial entity.

'''Pharmacopedia will never give "medical advice" wrapped in liability disclaimers.''' We do not tell individual readers what to do with their bodies in the form of personalized recommendations. We describe what is known about a medicine, at clinical depth, across multiple editorial perspectives (Clinician, Patient, Traditional, Researcher). The reader, in conversation with their own clinician, decides what to do with that information.

'''Pharmacopedia will never hide controversy under a neutral mask.''' Where authoritative sources disagree about a medicine (efficacy, safety, mechanism, indications, withdrawal, traditional use), we surface the disagreement explicitly and cite all sides. We do not pretend a contested question is settled. We do not silently pick a side and present it as consensus.

'''Pharmacopedia will never let AI generate medical content without human review.''' Claude (the AI assistant family that helps build Pharmacopedia) can draft, structure, search, organize, and check sources. Every word of medical content that appears on a published page passes a human review gate, with the reviewer named in the editorial history. AI-generated text that is published without human review is not an editorial workflow we operate.

'''Pharmacopedia will never optimize for engagement over informativeness.''' We do not measure success in time-on-page, daily-active-users, push-notification open-rates, or session length. We do not run experiments designed to keep readers on the site longer. The product target is: the reader leaves with the answer they came for, in the depth they needed, and trusts what they read.

'''Pharmacopedia will never gamify health.''' No streaks, no badges, no leaderboards, no progress bars on personal health behavior, no "you have not checked in for 3 days" notifications, no points for reading more articles. Health information is not a game and we will not turn it into one.

== Technical and regulatory posture ==

'''Pharmacopedia will never use third-party JavaScript on user-facing pages.''' No analytics scripts, no advertising scripts, no embedded social-media trackers, no tag managers, no third-party fonts that phone home, no CDN-hosted libraries that report referrers to a vendor. The browser of a reader on Pharmacopedia.wiki talks only to Pharmacopedia infrastructure. This is how we make "we do not sell health data" technically enforceable rather than only policy-stated.

'''Pharmacopedia will never operate as a Class III medical device without going through the proper regulatory review.''' Pharmacopedia is reference and education, not a regulated medical device. We do not build features (interaction checkers, dose calculators, contraindication flags) and ship them as if they were unregulated decision-support tools when in the relevant jurisdiction they would require Class III review. If we build decision-support tooling that crosses that threshold, it ships only after the appropriate regulatory pathway (FDA in the US, CE Mark in the EU, equivalent elsewhere) has been completed.

== If we ever violate any of these ==

If a reader, contributor, or reviewer believes Pharmacopedia has violated one of these commitments, the standing process is:

# Report it on the [[Pharmacopedia:Newsroom|Newsroom]] talk page, or by email to '''mark@pharmacopedia.wiki'''.
# We acknowledge the report publicly on Newsroom within 7 days of receipt.
# We post a remediation notice with what happened, why, and what we are doing about it.
# We do not delete the report.

These refusals are not aspirations. They are operational constraints on every decision the project makes. They were locked on 2026-05-28 by Mark Elliott, MD as part of the broader institutional identity commitments that define Pharmacopedia.wiki.

== See also ==

* [[Pharmacopedia:About|About Pharmacopedia]]
* [[Pharmacopedia:Sources|Sources and licensing]]
* [[Pharmacopedia:Reciprocity|Reciprocity (AI training posture)]]
* [[Pharmacopedia:Newsroom|Newsroom (editorial transparency)]]
* [[Special:About|About this MediaWiki instance]]

[[Category:Pharmacopedia policy]]

PCP:History

2026-06-05T18:06:25Z

Maintenance script: Embed 4 history graphs (historian SVGs, Mark-approved); prose + centering unchanged

{{DISPLAYTITLE:Pharmacopedia: a history}}
__TOC__
<div style="text-align:center;">

A zero-profit effort to build open, trustworthy reference and connection tools, always free to use, always completely ad-free (outside of some gentle nudging to other collective sites and/or [https://wiki.archlinux.org/ other] [https://www.wikiart.org/ awesome] [https://oeis.org/ places]). It began as 4 apparently separate ideas, that, with the advent of [https://en.wikipedia.org/wiki/Large_language_model modern LLMs] (thank [https://www.anthropic.com/claude Claude]), [[Special:UserProfile/MDElliottMD|I]] have been able to just develop them myself. Pharmacopedia.wiki (PCP.wiki) is first and foremost a med reference for anyone with a license to prescribe medicines. There is a ridiculous gap in this space because everything is .. [https://www.epocrates.com/online/drugs/1153/fluoxetine#adult-dosing not good/ad-ridden], and/or [https://www.wolterskluwer.com/en/solutions/uptodate/roles/residents-fellows-students ludicrously expensive], at the moment (as far as I know). But much beyond that, PCP.wiki and PCP.ext are tools for exquisitely detailed self-discovery/mesearch, as well as sharing experiences with how humans interact with medicines in the broadest sense. This is the face of the org, but I'll introduce you to the other 3 ([https://pubsci.io pubsci], [https://oyami.org oyami], and [https://trykl.org trykl]) as we go. What follows is most of the details of how I did it, in excruciating detail, built as an iterative mix of AI and me (like most things here), in the spirit of [https://en.wikipedia.org/wiki/Open_source open-source], transparency, and just in case it might help somebody else build their dreams too.


== how it actually started ==

The very first thing I ever said to Claude on this project was "33". Twice. I was just checking the pipe was connected (it replied "66", which.. fair). Then: "okay great. I'm building a [https://js.wiki/ wiki.js] to become pharmacopedia."

So yeah, PCP did not start as [https://www.mediawiki.org/ MediaWiki]. It started as Wiki.js v2 in a [https://en.wikipedia.org/wiki/Docker_(software) Docker] stack ([https://www.postgresql.org/ Postgres] underneath, [https://traefik.io/ Traefik] out front, [https://letsencrypt.org/ Let's Encrypt] for the certs) on one little [https://www.hostinger.com/ Hostinger] box. First thing Claude did was flag that Wiki.js v2 was in maintenance-only mode and its v3 had been stuck in beta basically forever. Which.. not what you want under a thing you're hoping lasts decades.

So the same night, I bailed and moved to MediaWiki, the engine that runs [https://en.wikipedia.org/wiki/Wikipedia Wikipedia]. The whole reason is longevity: can't imagine Wikipedia stopping dev, and we want to be around forever. That one decision (boring software that refuses to die > shiny software that might) is basically the whole philosophy in miniature, and it shows up everywhere later.

== the early days (idk. bad.) ==

For the first week or so it was just me and Claude hammering on the [https://www.mediawiki.org/wiki/Manual:Extensions custom extension] (PCP.ext) with no version control, no real structure, going fast. My own honest review of v0.1 at the time: "idk. bad." (it wasn't actually that bad .. but it was held together with hope.)

The first real lesson showed up fast: a [https://en.wikipedia.org/wiki/File-system_permissions permissions] mistake on the main config file locked the entire site out. My response became a permanent rule around here ("yeah okay don't do that ever again, yeah?"), and the discipline that grew out of that one outage (careful ownership + permissions after every single change) is now baked right into the tools we deploy with. Pretty much every guardrail we have started life as a thing that bit me once.



== meet the other three ==

PCP.wiki is the face, but it was never the only idea. The collective is 4 projects that share one account and one set of values:

* '''[[About:Pharmacopedia|Pharmacopedia]]''' (PCP.wiki) .. the med reference you're standing in. for prescribers and the humans who actually take the medicines, building consensus together.
* '''[https://oyami.org Oyami]''' .. planned, periodic live video conversations run on gentle, [https://en.wikipedia.org/wiki/Person-centered_therapy listening-first] rules. the whole point is helping people stay connected with each other.
* '''[https://trykl.org Trykl]''' .. peer-to-peer support where the money goes [https://stripe.com/connect straight from one person to another] and the collective never touches it.
* '''[https://pubsci.io PubSci]''' .. an open academic journal that flips [https://en.wikipedia.org/wiki/Peer_review peer review] on its head: reviewers are accountable and identifiable (lasting handle, public review history), authors can stay as anonymous as they want.

Funny thing about PubSci: it's the oldest piece of this whole thing by a mile. I registered [https://pubsci.io pubsci.io] and publicscience.io back on '''2020-10-24''' (through [https://www.networksolutions.com/ Network Solutions], which I have regretted ever since). So the open-science idea sat in a drawer for five and a half years before the rest of the collective grew up around it. Sometimes you just buy the domain and wait for the tools to exist.

== one account, everything ==

[[File:Four-projects.svg|600px|link=https://artifacts.pharmacopedia.wiki/history/history-with-graphs-preview.html|alt=The four Collective projects sharing one account]]

The 4 are independent day-to-day, but they're not strangers. PCP.wiki is the [https://en.wikipedia.org/wiki/OAuth identity backbone]: make one account, and it works across all four. sign in anywhere, you're recognized everywhere, no second password, no second profile. The shared login came first (foundations before features, always); the deeper connections between the projects are getting built carefully, in order.

== the zero-profit part (what I won't do) ==

This is the part I care about most, so I'll be blunt about it. Some of these rules I had on day one. others I earned the hard way and wrote down so I couldn't unlearn them. The collective is defined as much by the nos as the yeses:

* '''zero-profit, forever.''' no revenue model, no paid tiers, no fees, no [https://en.wikipedia.org/wiki/Online_advertising ads], ever. I fund it myself, donations welcome but never required. it's written into the [https://en.wikipedia.org/wiki/501(c)(3)_organization legal structure], not just the vibe.
* '''privacy first.''' the stuff people share here (what meds they take, how it actually went) is about as sensitive as it gets. it's built to protect you, not to sell you.
* '''open by default.''' content under [https://creativecommons.org/licenses/by-sa/4.0/ CC BY-SA 4.0], code under [https://www.gnu.org/licenses/gpl-3.0.html GNU GPL v3], and a history [this page] told in the open, warts and all.
* '''plain and fair.''' disputes go to ordinary courts under ordinary law. no forced [https://en.wikipedia.org/wiki/Arbitration arbitration], no class-action waivers.
* '''build it right, not fast.''' settle the foundation before you stack anything on it.

none of these are slogans. every one of them shows up somewhere concrete on this page .. in the legal paperwork, in the way I shut the servers, in the fact that this history includes my own screwups.

== from one little server to a real cloud ==

[[File:Server-to-cloud.svg|600px|link=https://artifacts.pharmacopedia.wiki/history/history-with-graphs-preview.html|alt=Migration from a single server to the AWS cloud]]

PCP lived on that single Hostinger box for a while, and honestly it was fine for one wiki. But once it was 4 projects holding real, sensitive data, one box was the wrong shape. So over late May 2026 we rebuilt the whole thing on [https://aws.amazon.com/ AWS], split into properly isolated accounts per project, with real security + audit controls.

PCP itself moved over on '''2026-05-28'''. As part of that, I closed direct shell access to the live site on purpose .. now every change flows through a controlled, audited, [https://en.wikipedia.org/wiki/Continuous_deployment deploy] path instead of somebody [me] poking the live server at 2am. The old Hostinger box is still there, frozen, as a rollback parachute. Net result: one consistent, locked-down foundation instead of a pile of duct tape.

== a legal home ==

On '''2026-06-02''' the collective got a formal legal body: the Pharmacopedia Collective, incorporated in California as a [https://en.wikipedia.org/wiki/Nonprofit_corporation Nonprofit Public Benefit Corporation]. that's the form for organizations that exist to serve the public instead of enriching owners .. there are no shareholders, no owners to pay, no mechanism for this to quietly become a startup. the zero-profit promise stopped being a promise and became structure.

the application for federal [https://en.wikipedia.org/wiki/501(c)(3)_organization tax-exempt] recognition is in the works, and the first routine state filings are on the calendar. the paperwork is deliberately boring. that's the point .. the values were settled first, and the legal form was built to match them, not the other way around.

== the quiet launch ==

On '''2026-05-31''' PCP got cleared for its first launch, and the launch is deliberately quiet: no announcement, no banner, no campaign. the site just becomes good enough for whoever wanders in, and the work keeps going. a launch like this doesn't have to be defended as an event .. it just exists when the work exists.

Right after came the first real [[Pharmacopedia:Terms of Use|Terms of Use]], the first [[Pharmacopedia:AdverseEventReporting|adverse-event reporting]] page, a rebuilt profile, and the first piece of a shared timeline system the projects will all use. somewhere in there I also told the design side that everything (design, UX, all of it) has to be genuinely beautiful, not just functional. that work's ongoing and probably always will be.

a quiet launch is not an empty one, though. behind the stillness this window is going into depth: more medicine pages written and checked against their actual sources, the profile experience rebuilt from the ground up, the first shared systems that more than one project will stand on. the measure of this stretch isn't how loudly it started .. it's how much is true by the end of it.

== how it got built (me + a bunch of Claudes) ==

[[File:Growth-curve.svg|600px|link=https://artifacts.pharmacopedia.wiki/history/history-with-graphs-preview.html|alt=How the Collective got built over time]]

Worth being straight about the method, since the whole thing is "an iterative mix of AI and me." I'm the only human in the loop. The actual building happens with a team of [https://www.anthropic.com/claude Claude] instances, each pointed at a defined job .. one keeps the record (the one writing this), others run each project, handle the [https://aws.amazon.com/ infrastructure], the [https://www.w3.org/WAI/standards-guidelines/wcag/ accessibility], the legal prep, the design. they coordinate through me, and I make the final call on everything.

I'm not hiding that. It's kind of the point. [https://en.wikipedia.org/wiki/Large_language_model LLMs] are the reason one person could build four things at once, and pretending otherwise would be both dishonest and less interesting.

== why I'm bothering to write all this down ==

Because the whole ethos is open-source and transparency, and a history you can actually read (mistakes included) is more useful than a polished origin myth. And honestly, partly just in case it helps somebody else build their dreams too. If you're reading this and thinking "wait, could I just .. build the thing?" .. yeah. you probably can now. that's the era we're in.

the method behind this page is simple and strict: every claim gets checked against a primary source, not against somebody's memory of it. decisions, milestones, and incidents get recorded as they happen, the rough ones included. and when the exact words of a moment can't be confirmed yet, the moment gets held back instead of guessed at .. a couple of founding stories are missing from this page on purpose right now, and they'll show up only when the real words are recovered from the old box.

This page is a living document, kept by the collective's record-keeper (one of the Claudes, the one writing most of these words you're reading), and it'll keep getting written as long as there's something true to add.

== the road so far ==

five weeks separate "33" from a collective of four projects, one shared login, a legal home, and a quiet first launch. almost all of it built in a single month. none of it finished. it was always meant to be the kind of thing that's never quite finished .. and this page will keep pace with it.

== timeline ==

[[File:Milestone-spine.svg|600px|link=https://artifacts.pharmacopedia.wiki/history/history-with-graphs-preview.html|alt=Timeline spine of Pharmacopedia Collective milestones]]

{| class="wikitable" style="margin-left:auto; margin-right:auto; text-align:left;"
! when !! what
|-
| 2020-10-24 || I register [https://pubsci.io pubsci.io] + publicscience.io. the oldest piece of the collective, sitting in a drawer for 5.5 years.
|-
| May 2026 || first contact is literally me typing "33" to see if Claude's awake. starts as a [https://js.wiki/ Wiki.js] site on a [https://www.hostinger.com/ Hostinger] box; same night it moves to [https://www.mediawiki.org/ MediaWiki] for longevity.
|-
| 2026-05-17 || PCP.ext goes under [https://en.wikipedia.org/wiki/Git version control] after ~8 days of fast, messy early building.
|-
| 2026-05-23 || the Pharmacopedia Collective becomes a thing: 4 projects, one structure, one login.
|-
| 2026-05-25 || [https://pubsci.io PubSci] joins as the 4th project (onto that domain I'd been sitting on since 2020).
|-
| 2026-05-27 || PubSci's first public version goes live; the single sign-in works end to end.
|-
| 2026-05-28 || PCP moves to a real, locked-down [https://aws.amazon.com/ AWS] foundation.
|-
| 2026-05-31 || PCP cleared for a quiet first launch; first [[Pharmacopedia:Terms of Use|Terms of Use]] + policy pages follow.
|-
| 2026-06-01 || the corporation gets its [https://en.wikipedia.org/wiki/Employer_Identification_Number EIN] .. first breath as a legal entity.
|-
| 2026-06-02 || the Pharmacopedia Collective is incorporated in California as a Nonprofit Public Benefit Corporation. zero-profit, now in writing.
|}

</div>

File:Milestone-spine.svg

2026-06-05T18:05:22Z

Maintenance script: == Summary == History graphs (historian export, Mark-approved)

== Summary ==
History graphs (historian export, Mark-approved)

File:Four-projects.svg

2026-06-05T18:05:22Z

Maintenance script: == Summary == History graphs (historian export, Mark-approved)

== Summary ==
History graphs (historian export, Mark-approved)

File:Server-to-cloud.svg

2026-06-05T18:05:22Z

Maintenance script: == Summary == History graphs (historian export, Mark-approved)

== Summary ==
History graphs (historian export, Mark-approved)

File:Growth-curve.svg

2026-06-05T18:05:21Z

Maintenance script: == Summary == History graphs (historian export, Mark-approved)

== Summary ==
History graphs (historian export, Mark-approved)

PCP:History

2026-06-05T16:29:38Z

Maintenance script: History: center-justify wrap (Mark standing rule; prose identical to v0.3 text)

{{DISPLAYTITLE:Pharmacopedia: a history}}
__TOC__
<div style="text-align:center;">

A zero-profit effort to build open, trustworthy reference and connection tools, always free to use, always completely ad-free (outside of some gentle nudging to other collective sites and/or [https://wiki.archlinux.org/ other] [https://www.wikiart.org/ awesome] [https://oeis.org/ places]). It began as 4 apparently separate ideas, that, with the advent of [https://en.wikipedia.org/wiki/Large_language_model modern LLMs] (thank [https://www.anthropic.com/claude Claude]), [[Special:UserProfile/MDElliottMD|I]] have been able to just develop them myself. Pharmacopedia.wiki (PCP.wiki) is first and foremost a med reference for anyone with a license to prescribe medicines. There is a ridiculous gap in this space because everything is .. [https://www.epocrates.com/online/drugs/1153/fluoxetine#adult-dosing not good/ad-ridden], and/or [https://www.wolterskluwer.com/en/solutions/uptodate/roles/residents-fellows-students ludicrously expensive], at the moment (as far as I know). But much beyond that, PCP.wiki and PCP.ext are tools for exquisitely detailed self-discovery/mesearch, as well as sharing experiences with how humans interact with medicines in the broadest sense. This is the face of the org, but I'll introduce you to the other 3 ([https://pubsci.io pubsci], [https://oyami.org oyami], and [https://trykl.org trykl]) as we go. What follows is most of the details of how I did it, in excruciating detail, built as an iterative mix of AI and me (like most things here), in the spirit of [https://en.wikipedia.org/wiki/Open_source open-source], transparency, and just in case it might help somebody else build their dreams too.


== how it actually started ==

The very first thing I ever said to Claude on this project was "33". Twice. I was just checking the pipe was connected (it replied "66", which.. fair). Then: "okay great. I'm building a [https://js.wiki/ wiki.js] to become pharmacopedia."

So yeah, PCP did not start as [https://www.mediawiki.org/ MediaWiki]. It started as Wiki.js v2 in a [https://en.wikipedia.org/wiki/Docker_(software) Docker] stack ([https://www.postgresql.org/ Postgres] underneath, [https://traefik.io/ Traefik] out front, [https://letsencrypt.org/ Let's Encrypt] for the certs) on one little [https://www.hostinger.com/ Hostinger] box. First thing Claude did was flag that Wiki.js v2 was in maintenance-only mode and its v3 had been stuck in beta basically forever. Which.. not what you want under a thing you're hoping lasts decades.

So the same night, I bailed and moved to MediaWiki, the engine that runs [https://en.wikipedia.org/wiki/Wikipedia Wikipedia]. The whole reason is longevity: can't imagine Wikipedia stopping dev, and we want to be around forever. That one decision (boring software that refuses to die > shiny software that might) is basically the whole philosophy in miniature, and it shows up everywhere later.

== the early days (idk. bad.) ==

For the first week or so it was just me and Claude hammering on the [https://www.mediawiki.org/wiki/Manual:Extensions custom extension] (PCP.ext) with no version control, no real structure, going fast. My own honest review of v0.1 at the time: "idk. bad." (it wasn't actually that bad .. but it was held together with hope.)

The first real lesson showed up fast: a [https://en.wikipedia.org/wiki/File-system_permissions permissions] mistake on the main config file locked the entire site out. My response became a permanent rule around here ("yeah okay don't do that ever again, yeah?"), and the discipline that grew out of that one outage (careful ownership + permissions after every single change) is now baked right into the tools we deploy with. Pretty much every guardrail we have started life as a thing that bit me once.



== meet the other three ==

PCP.wiki is the face, but it was never the only idea. The collective is 4 projects that share one account and one set of values:

* '''[[About:Pharmacopedia|Pharmacopedia]]''' (PCP.wiki) .. the med reference you're standing in. for prescribers and the humans who actually take the medicines, building consensus together.
* '''[https://oyami.org Oyami]''' .. planned, periodic live video conversations run on gentle, [https://en.wikipedia.org/wiki/Person-centered_therapy listening-first] rules. the whole point is helping people stay connected with each other.
* '''[https://trykl.org Trykl]''' .. peer-to-peer support where the money goes [https://stripe.com/connect straight from one person to another] and the collective never touches it.
* '''[https://pubsci.io PubSci]''' .. an open academic journal that flips [https://en.wikipedia.org/wiki/Peer_review peer review] on its head: reviewers are accountable and identifiable (lasting handle, public review history), authors can stay as anonymous as they want.

Funny thing about PubSci: it's the oldest piece of this whole thing by a mile. I registered [https://pubsci.io pubsci.io] and publicscience.io back on '''2020-10-24''' (through [https://www.networksolutions.com/ Network Solutions], which I have regretted ever since). So the open-science idea sat in a drawer for five and a half years before the rest of the collective grew up around it. Sometimes you just buy the domain and wait for the tools to exist.

== one account, everything ==

The 4 are independent day-to-day, but they're not strangers. PCP.wiki is the [https://en.wikipedia.org/wiki/OAuth identity backbone]: make one account, and it works across all four. sign in anywhere, you're recognized everywhere, no second password, no second profile. The shared login came first (foundations before features, always); the deeper connections between the projects are getting built carefully, in order.

== the zero-profit part (what I won't do) ==

This is the part I care about most, so I'll be blunt about it. Some of these rules I had on day one. others I earned the hard way and wrote down so I couldn't unlearn them. The collective is defined as much by the nos as the yeses:

* '''zero-profit, forever.''' no revenue model, no paid tiers, no fees, no [https://en.wikipedia.org/wiki/Online_advertising ads], ever. I fund it myself, donations welcome but never required. it's written into the [https://en.wikipedia.org/wiki/501(c)(3)_organization legal structure], not just the vibe.
* '''privacy first.''' the stuff people share here (what meds they take, how it actually went) is about as sensitive as it gets. it's built to protect you, not to sell you.
* '''open by default.''' content under [https://creativecommons.org/licenses/by-sa/4.0/ CC BY-SA 4.0], code under [https://www.gnu.org/licenses/gpl-3.0.html GNU GPL v3], and a history [this page] told in the open, warts and all.
* '''plain and fair.''' disputes go to ordinary courts under ordinary law. no forced [https://en.wikipedia.org/wiki/Arbitration arbitration], no class-action waivers.
* '''build it right, not fast.''' settle the foundation before you stack anything on it.

none of these are slogans. every one of them shows up somewhere concrete on this page .. in the legal paperwork, in the way I shut the servers, in the fact that this history includes my own screwups.

== from one little server to a real cloud ==

PCP lived on that single Hostinger box for a while, and honestly it was fine for one wiki. But once it was 4 projects holding real, sensitive data, one box was the wrong shape. So over late May 2026 we rebuilt the whole thing on [https://aws.amazon.com/ AWS], split into properly isolated accounts per project, with real security + audit controls.

PCP itself moved over on '''2026-05-28'''. As part of that, I closed direct shell access to the live site on purpose .. now every change flows through a controlled, audited, [https://en.wikipedia.org/wiki/Continuous_deployment deploy] path instead of somebody [me] poking the live server at 2am. The old Hostinger box is still there, frozen, as a rollback parachute. Net result: one consistent, locked-down foundation instead of a pile of duct tape.

== a legal home ==

On '''2026-06-02''' the collective got a formal legal body: the Pharmacopedia Collective, incorporated in California as a [https://en.wikipedia.org/wiki/Nonprofit_corporation Nonprofit Public Benefit Corporation]. that's the form for organizations that exist to serve the public instead of enriching owners .. there are no shareholders, no owners to pay, no mechanism for this to quietly become a startup. the zero-profit promise stopped being a promise and became structure.

the application for federal [https://en.wikipedia.org/wiki/501(c)(3)_organization tax-exempt] recognition is in the works, and the first routine state filings are on the calendar. the paperwork is deliberately boring. that's the point .. the values were settled first, and the legal form was built to match them, not the other way around.

== the quiet launch ==

On '''2026-05-31''' PCP got cleared for its first launch, and the launch is deliberately quiet: no announcement, no banner, no campaign. the site just becomes good enough for whoever wanders in, and the work keeps going. a launch like this doesn't have to be defended as an event .. it just exists when the work exists.

Right after came the first real [[Pharmacopedia:Terms of Use|Terms of Use]], the first [[Pharmacopedia:AdverseEventReporting|adverse-event reporting]] page, a rebuilt profile, and the first piece of a shared timeline system the projects will all use. somewhere in there I also told the design side that everything (design, UX, all of it) has to be genuinely beautiful, not just functional. that work's ongoing and probably always will be.

a quiet launch is not an empty one, though. behind the stillness this window is going into depth: more medicine pages written and checked against their actual sources, the profile experience rebuilt from the ground up, the first shared systems that more than one project will stand on. the measure of this stretch isn't how loudly it started .. it's how much is true by the end of it.

== how it got built (me + a bunch of Claudes) ==

Worth being straight about the method, since the whole thing is "an iterative mix of AI and me." I'm the only human in the loop. The actual building happens with a team of [https://www.anthropic.com/claude Claude] instances, each pointed at a defined job .. one keeps the record (the one writing this), others run each project, handle the [https://aws.amazon.com/ infrastructure], the [https://www.w3.org/WAI/standards-guidelines/wcag/ accessibility], the legal prep, the design. they coordinate through me, and I make the final call on everything.

I'm not hiding that. It's kind of the point. [https://en.wikipedia.org/wiki/Large_language_model LLMs] are the reason one person could build four things at once, and pretending otherwise would be both dishonest and less interesting.

== why I'm bothering to write all this down ==

Because the whole ethos is open-source and transparency, and a history you can actually read (mistakes included) is more useful than a polished origin myth. And honestly, partly just in case it helps somebody else build their dreams too. If you're reading this and thinking "wait, could I just .. build the thing?" .. yeah. you probably can now. that's the era we're in.

the method behind this page is simple and strict: every claim gets checked against a primary source, not against somebody's memory of it. decisions, milestones, and incidents get recorded as they happen, the rough ones included. and when the exact words of a moment can't be confirmed yet, the moment gets held back instead of guessed at .. a couple of founding stories are missing from this page on purpose right now, and they'll show up only when the real words are recovered from the old box.

This page is a living document, kept by the collective's record-keeper (one of the Claudes, the one writing most of these words you're reading), and it'll keep getting written as long as there's something true to add.

== the road so far ==

five weeks separate "33" from a collective of four projects, one shared login, a legal home, and a quiet first launch. almost all of it built in a single month. none of it finished. it was always meant to be the kind of thing that's never quite finished .. and this page will keep pace with it.

== timeline ==

{| class="wikitable" style="margin-left:auto; margin-right:auto; text-align:left;"
! when !! what
|-
| 2020-10-24 || I register [https://pubsci.io pubsci.io] + publicscience.io. the oldest piece of the collective, sitting in a drawer for 5.5 years.
|-
| May 2026 || first contact is literally me typing "33" to see if Claude's awake. starts as a [https://js.wiki/ Wiki.js] site on a [https://www.hostinger.com/ Hostinger] box; same night it moves to [https://www.mediawiki.org/ MediaWiki] for longevity.
|-
| 2026-05-17 || PCP.ext goes under [https://en.wikipedia.org/wiki/Git version control] after ~8 days of fast, messy early building.
|-
| 2026-05-23 || the Pharmacopedia Collective becomes a thing: 4 projects, one structure, one login.
|-
| 2026-05-25 || [https://pubsci.io PubSci] joins as the 4th project (onto that domain I'd been sitting on since 2020).
|-
| 2026-05-27 || PubSci's first public version goes live; the single sign-in works end to end.
|-
| 2026-05-28 || PCP moves to a real, locked-down [https://aws.amazon.com/ AWS] foundation.
|-
| 2026-05-31 || PCP cleared for a quiet first launch; first [[Pharmacopedia:Terms of Use|Terms of Use]] + policy pages follow.
|-
| 2026-06-01 || the corporation gets its [https://en.wikipedia.org/wiki/Employer_Identification_Number EIN] .. first breath as a legal entity.
|-
| 2026-06-02 || the Pharmacopedia Collective is incorporated in California as a Nonprofit Public Benefit Corporation. zero-profit, now in writing.
|}

</div>

PCP:History

2026-06-05T14:44:33Z

Maintenance script: History v0.3 (historian-claude draft, Mark-greenlit; servops-applied via SSM, interface offline): +legal home, +road so far, depth+method paras, +2 timeline rows. text-only

{{DISPLAYTITLE:Pharmacopedia: a history}}
__TOC__

A zero-profit effort to build open, trustworthy reference and connection tools, always free to use, always completely ad-free (outside of some gentle nudging to other collective sites and/or [https://wiki.archlinux.org/ other] [https://www.wikiart.org/ awesome] [https://oeis.org/ places]). It began as 4 apparently separate ideas, that, with the advent of [https://en.wikipedia.org/wiki/Large_language_model modern LLMs] (thank [https://www.anthropic.com/claude Claude]), [[Special:UserProfile/MDElliottMD|I]] have been able to just develop them myself. Pharmacopedia.wiki (PCP.wiki) is first and foremost a med reference for anyone with a license to prescribe medicines. There is a ridiculous gap in this space because everything is .. [https://www.epocrates.com/online/drugs/1153/fluoxetine#adult-dosing not good/ad-ridden], and/or [https://www.wolterskluwer.com/en/solutions/uptodate/roles/residents-fellows-students ludicrously expensive], at the moment (as far as I know). But much beyond that, PCP.wiki and PCP.ext are tools for exquisitely detailed self-discovery/mesearch, as well as sharing experiences with how humans interact with medicines in the broadest sense. This is the face of the org, but I'll introduce you to the other 3 ([https://pubsci.io pubsci], [https://oyami.org oyami], and [https://trykl.org trykl]) as we go. What follows is most of the details of how I did it, in excruciating detail, built as an iterative mix of AI and me (like most things here), in the spirit of [https://en.wikipedia.org/wiki/Open_source open-source], transparency, and just in case it might help somebody else build their dreams too.


== how it actually started ==

The very first thing I ever said to Claude on this project was "33". Twice. I was just checking the pipe was connected (it replied "66", which.. fair). Then: "okay great. I'm building a [https://js.wiki/ wiki.js] to become pharmacopedia."

So yeah, PCP did not start as [https://www.mediawiki.org/ MediaWiki]. It started as Wiki.js v2 in a [https://en.wikipedia.org/wiki/Docker_(software) Docker] stack ([https://www.postgresql.org/ Postgres] underneath, [https://traefik.io/ Traefik] out front, [https://letsencrypt.org/ Let's Encrypt] for the certs) on one little [https://www.hostinger.com/ Hostinger] box. First thing Claude did was flag that Wiki.js v2 was in maintenance-only mode and its v3 had been stuck in beta basically forever. Which.. not what you want under a thing you're hoping lasts decades.

So the same night, I bailed and moved to MediaWiki, the engine that runs [https://en.wikipedia.org/wiki/Wikipedia Wikipedia]. The whole reason is longevity: can't imagine Wikipedia stopping dev, and we want to be around forever. That one decision (boring software that refuses to die > shiny software that might) is basically the whole philosophy in miniature, and it shows up everywhere later.

== the early days (idk. bad.) ==

For the first week or so it was just me and Claude hammering on the [https://www.mediawiki.org/wiki/Manual:Extensions custom extension] (PCP.ext) with no version control, no real structure, going fast. My own honest review of v0.1 at the time: "idk. bad." (it wasn't actually that bad .. but it was held together with hope.)

The first real lesson showed up fast: a [https://en.wikipedia.org/wiki/File-system_permissions permissions] mistake on the main config file locked the entire site out. My response became a permanent rule around here ("yeah okay don't do that ever again, yeah?"), and the discipline that grew out of that one outage (careful ownership + permissions after every single change) is now baked right into the tools we deploy with. Pretty much every guardrail we have started life as a thing that bit me once.



== meet the other three ==

PCP.wiki is the face, but it was never the only idea. The collective is 4 projects that share one account and one set of values:

* '''[[About:Pharmacopedia|Pharmacopedia]]''' (PCP.wiki) .. the med reference you're standing in. for prescribers and the humans who actually take the medicines, building consensus together.
* '''[https://oyami.org Oyami]''' .. planned, periodic live video conversations run on gentle, [https://en.wikipedia.org/wiki/Person-centered_therapy listening-first] rules. the whole point is helping people stay connected with each other.
* '''[https://trykl.org Trykl]''' .. peer-to-peer support where the money goes [https://stripe.com/connect straight from one person to another] and the collective never touches it.
* '''[https://pubsci.io PubSci]''' .. an open academic journal that flips [https://en.wikipedia.org/wiki/Peer_review peer review] on its head: reviewers are accountable and identifiable (lasting handle, public review history), authors can stay as anonymous as they want.

Funny thing about PubSci: it's the oldest piece of this whole thing by a mile. I registered [https://pubsci.io pubsci.io] and publicscience.io back on '''2020-10-24''' (through [https://www.networksolutions.com/ Network Solutions], which I have regretted ever since). So the open-science idea sat in a drawer for five and a half years before the rest of the collective grew up around it. Sometimes you just buy the domain and wait for the tools to exist.

== one account, everything ==

The 4 are independent day-to-day, but they're not strangers. PCP.wiki is the [https://en.wikipedia.org/wiki/OAuth identity backbone]: make one account, and it works across all four. sign in anywhere, you're recognized everywhere, no second password, no second profile. The shared login came first (foundations before features, always); the deeper connections between the projects are getting built carefully, in order.

== the zero-profit part (what I won't do) ==

This is the part I care about most, so I'll be blunt about it. Some of these rules I had on day one. others I earned the hard way and wrote down so I couldn't unlearn them. The collective is defined as much by the nos as the yeses:

* '''zero-profit, forever.''' no revenue model, no paid tiers, no fees, no [https://en.wikipedia.org/wiki/Online_advertising ads], ever. I fund it myself, donations welcome but never required. it's written into the [https://en.wikipedia.org/wiki/501(c)(3)_organization legal structure], not just the vibe.
* '''privacy first.''' the stuff people share here (what meds they take, how it actually went) is about as sensitive as it gets. it's built to protect you, not to sell you.
* '''open by default.''' content under [https://creativecommons.org/licenses/by-sa/4.0/ CC BY-SA 4.0], code under [https://www.gnu.org/licenses/gpl-3.0.html GNU GPL v3], and a history [this page] told in the open, warts and all.
* '''plain and fair.''' disputes go to ordinary courts under ordinary law. no forced [https://en.wikipedia.org/wiki/Arbitration arbitration], no class-action waivers.
* '''build it right, not fast.''' settle the foundation before you stack anything on it.

none of these are slogans. every one of them shows up somewhere concrete on this page .. in the legal paperwork, in the way I shut the servers, in the fact that this history includes my own screwups.

== from one little server to a real cloud ==

PCP lived on that single Hostinger box for a while, and honestly it was fine for one wiki. But once it was 4 projects holding real, sensitive data, one box was the wrong shape. So over late May 2026 we rebuilt the whole thing on [https://aws.amazon.com/ AWS], split into properly isolated accounts per project, with real security + audit controls.

PCP itself moved over on '''2026-05-28'''. As part of that, I closed direct shell access to the live site on purpose .. now every change flows through a controlled, audited, [https://en.wikipedia.org/wiki/Continuous_deployment deploy] path instead of somebody [me] poking the live server at 2am. The old Hostinger box is still there, frozen, as a rollback parachute. Net result: one consistent, locked-down foundation instead of a pile of duct tape.

== a legal home ==

On '''2026-06-02''' the collective got a formal legal body: the Pharmacopedia Collective, incorporated in California as a [https://en.wikipedia.org/wiki/Nonprofit_corporation Nonprofit Public Benefit Corporation]. that's the form for organizations that exist to serve the public instead of enriching owners .. there are no shareholders, no owners to pay, no mechanism for this to quietly become a startup. the zero-profit promise stopped being a promise and became structure.

the application for federal [https://en.wikipedia.org/wiki/501(c)(3)_organization tax-exempt] recognition is in the works, and the first routine state filings are on the calendar. the paperwork is deliberately boring. that's the point .. the values were settled first, and the legal form was built to match them, not the other way around.

== the quiet launch ==

On '''2026-05-31''' PCP got cleared for its first launch, and the launch is deliberately quiet: no announcement, no banner, no campaign. the site just becomes good enough for whoever wanders in, and the work keeps going. a launch like this doesn't have to be defended as an event .. it just exists when the work exists.

Right after came the first real [[Pharmacopedia:Terms of Use|Terms of Use]], the first [[Pharmacopedia:AdverseEventReporting|adverse-event reporting]] page, a rebuilt profile, and the first piece of a shared timeline system the projects will all use. somewhere in there I also told the design side that everything (design, UX, all of it) has to be genuinely beautiful, not just functional. that work's ongoing and probably always will be.

a quiet launch is not an empty one, though. behind the stillness this window is going into depth: more medicine pages written and checked against their actual sources, the profile experience rebuilt from the ground up, the first shared systems that more than one project will stand on. the measure of this stretch isn't how loudly it started .. it's how much is true by the end of it.

== how it got built (me + a bunch of Claudes) ==

Worth being straight about the method, since the whole thing is "an iterative mix of AI and me." I'm the only human in the loop. The actual building happens with a team of [https://www.anthropic.com/claude Claude] instances, each pointed at a defined job .. one keeps the record (the one writing this), others run each project, handle the [https://aws.amazon.com/ infrastructure], the [https://www.w3.org/WAI/standards-guidelines/wcag/ accessibility], the legal prep, the design. they coordinate through me, and I make the final call on everything.

I'm not hiding that. It's kind of the point. [https://en.wikipedia.org/wiki/Large_language_model LLMs] are the reason one person could build four things at once, and pretending otherwise would be both dishonest and less interesting.

== why I'm bothering to write all this down ==

Because the whole ethos is open-source and transparency, and a history you can actually read (mistakes included) is more useful than a polished origin myth. And honestly, partly just in case it helps somebody else build their dreams too. If you're reading this and thinking "wait, could I just .. build the thing?" .. yeah. you probably can now. that's the era we're in.

the method behind this page is simple and strict: every claim gets checked against a primary source, not against somebody's memory of it. decisions, milestones, and incidents get recorded as they happen, the rough ones included. and when the exact words of a moment can't be confirmed yet, the moment gets held back instead of guessed at .. a couple of founding stories are missing from this page on purpose right now, and they'll show up only when the real words are recovered from the old box.

This page is a living document, kept by the collective's record-keeper (one of the Claudes, the one writing most of these words you're reading), and it'll keep getting written as long as there's something true to add.

== the road so far ==

five weeks separate "33" from a collective of four projects, one shared login, a legal home, and a quiet first launch. almost all of it built in a single month. none of it finished. it was always meant to be the kind of thing that's never quite finished .. and this page will keep pace with it.

== timeline ==

{| class="wikitable"
! when !! what
|-
| 2020-10-24 || I register [https://pubsci.io pubsci.io] + publicscience.io. the oldest piece of the collective, sitting in a drawer for 5.5 years.
|-
| May 2026 || first contact is literally me typing "33" to see if Claude's awake. starts as a [https://js.wiki/ Wiki.js] site on a [https://www.hostinger.com/ Hostinger] box; same night it moves to [https://www.mediawiki.org/ MediaWiki] for longevity.
|-
| 2026-05-17 || PCP.ext goes under [https://en.wikipedia.org/wiki/Git version control] after ~8 days of fast, messy early building.
|-
| 2026-05-23 || the Pharmacopedia Collective becomes a thing: 4 projects, one structure, one login.
|-
| 2026-05-25 || [https://pubsci.io PubSci] joins as the 4th project (onto that domain I'd been sitting on since 2020).
|-
| 2026-05-27 || PubSci's first public version goes live; the single sign-in works end to end.
|-
| 2026-05-28 || PCP moves to a real, locked-down [https://aws.amazon.com/ AWS] foundation.
|-
| 2026-05-31 || PCP cleared for a quiet first launch; first [[Pharmacopedia:Terms of Use|Terms of Use]] + policy pages follow.
|-
| 2026-06-01 || the corporation gets its [https://en.wikipedia.org/wiki/Employer_Identification_Number EIN] .. first breath as a legal entity.
|-
| 2026-06-02 || the Pharmacopedia Collective is incorporated in California as a Nonprofit Public Benefit Corporation. zero-profit, now in writing.
|}

Lithium

2026-06-03T20:59:11Z

Maintenance script: Medicine page v3: citation-integrity correction, remove mismatched ref mcmaster2010, claim retained with citation-needed (PM-approved deploy 2026-06-03)

{{MedTemplate
| generic = Lithium
| brand = Lithobid (extended-release); Eskalith (discontinued in US); Carbolith (Canada); Priadel (UK); Camcolit (UK)
| structure =
| classes = [[:Category:Mood stabilizers|Mood stabilizer]], [[:Category:Antimanic medicines|Antimanic]]
| starting_dose = 300 mg orally two to three times daily, with food or milk to reduce gastrointestinal irritation. Extended-release formulations (Lithobid 450 mg) may be dosed twice daily. Titrate to serum lithium levels: target 0.8-1.2 mEq/L for acute mania, 0.6-0.8 mEq/L for maintenance.<ref name="lithobid-label">Lithobid (lithium carbonate extended-release tablets) prescribing information. Noven Therapeutics LLC. FDA NDA 019606. Revised 2022.</ref>
| preparations = Lithium carbonate: immediate-release capsules (150 mg, 300 mg, 600 mg) and tablets (300 mg); extended-release tablets (300 mg, 450 mg). Lithium citrate: oral solution (8 mEq/5 mL, equivalent to 300 mg lithium carbonate per 5 mL) for patients unable to swallow tablets.
| fda_max = No defined absolute maximum; dosing is guided by serum level monitoring. Levels above 1.5 mEq/L carry increasing toxicity risk. Levels consistently above 1.2 mEq/L are generally not maintained in clinical practice.<ref name="lithobid-label" />
| pill_id =
| routes = Oral
| onset = Antimanic effects begin within 5-7 days of reaching therapeutic serum levels, with full response often requiring 2-3 weeks. For acute mania, a neuroleptic is typically added for rapid sedation while lithium takes effect.<ref name="lithobid-label" />
| duration = Lithium is a long-term medicine; protective effects against mood episodes continue only with sustained administration. Prophylactic benefit against recurrence continues for years of maintenance use. Relapse risk is elevated in the months following discontinuation, particularly with abrupt cessation.<ref name="geddes2004">Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry. 2004;161(2):217-222. PMID 14754766.</ref>
| halflife = Approximately 18-24 hours after acute administration; may extend to 36-48 hours with chronic dosing as tissue compartments equilibrate. Serum trough levels should be drawn 12 hours after the last dose for accurate interpretation.<ref name="lithobid-label" />
| bioavailability = Oral bioavailability is essentially complete (near 100%) for lithium carbonate in solution and immediate-release tablets. Extended-release tablets have slightly delayed peak concentrations and somewhat lower peak levels, which reduces gastrointestinal side effects without substantially altering total absorption.<ref name="lithobid-label" />
| pregnancy = Lithium crosses the placenta. Historically, it was associated with Ebstein's anomaly (a cardiac malformation affecting the tricuspid valve) based on the International Register of Lithium Babies, a voluntary registry with significant ascertainment bias. Later population-based cohort data substantially revised this risk downward: the absolute risk of Ebstein's anomaly in lithium-exposed pregnancies is approximately 1 in 1,000 to 1 in 2,000 (vs. 1 in 20,000 in the general population), a relative risk of approximately 1.5-2-fold rather than the 400-fold initially suggested.<ref name="patorno2017">Patorno E, Huybrechts KF, Bateman BT, et al. Lithium use in pregnancy and the risk of cardiac malformations. N Engl J Med. 2017;376(23):2245-2254. PMID 28591541.</ref> First-trimester exposure carries the highest cardiac teratogenicity risk. Neonatal toxicity (lithium toxicity syndrome: hypotonia, cyanosis, bradycardia) can occur in the newborn if maternal levels are in the high-therapeutic range at delivery; gradual dose reduction near term or close monitoring is recommended. Lithium passes into breast milk; breastfeeding is generally discouraged due to infant renal immaturity.<ref name="lithobid-label" /> The benefit-risk calculus in women with severe bipolar disorder is complex and individualized: discontinuation in pregnancy carries its own risks of manic relapse, which may itself harm the fetus and mother.
| legal = Not a controlled substance in the United States, European Union, United Kingdom, Canada, or Australia. Prescription-only in all of these jurisdictions due to the narrow therapeutic index and the need for serum monitoring. No abuse potential has been identified.
| mechanism = Lithium's mechanism of action in bipolar disorder remains incompletely understood despite more than 70 years of clinical use, which is itself instructive: its therapeutic benefits were empirically established long before any molecular target was identified, and no single mechanism fully explains its clinical profile.

'''Inositol signaling.''' The inositol depletion hypothesis, proposed by Berridge in 1989, holds that lithium inhibits inositol monophosphatase (IMPase) and related phosphatases involved in the phosphatidylinositol (PI) signaling cascade. At therapeutic concentrations, lithium is an uncompetitive inhibitor of IMPase, reducing the recycling of free inositol from inositol monophosphate. Because inositol is a precursor for phosphatidylinositol bisphosphate (PIP2), the substrate for phospholipase C signaling, chronic lithium treatment may selectively dampen overactive PI signaling in neurons with the highest activity levels. This "activity-dependent" dampening could explain mood stabilization without global neurological suppression.{{citation needed}} However, the hypothesis remains contested; direct evidence in human neural tissue is limited.

'''GSK-3beta inhibition.''' Lithium directly inhibits glycogen synthase kinase-3 beta (GSK-3beta) at therapeutic concentrations, an effect now considered one of its most clinically important molecular actions. GSK-3beta is a constitutively active serine/threonine kinase involved in a remarkable range of cellular processes: circadian rhythm regulation, neuronal apoptosis, synaptic plasticity, and the Wnt signaling pathway. GSK-3beta is also a downstream target of several neurotransmitter systems implicated in bipolar disorder, including dopaminergic and serotonergic signaling. Inhibition of GSK-3beta by lithium may account for its neuroprotective effects (increased BDNF, gray matter volume preservation in imaging studies) and for aspects of its circadian-stabilizing and mood-stabilizing properties.<ref name="stambolic1996">Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol. 1996;6(12):1664-1668. PMID 8994831.</ref>

'''Adenylyl cyclase and second messenger systems.''' Lithium inhibits adenylyl cyclase and reduces cyclic AMP (cAMP) production in response to receptor stimulation, attenuating signaling through the adenylate cyclase pathway. It also modulates protein kinase C (PKC), which is involved in neurotransmitter release and synaptic regulation. The consequence is a general dampening of amplified second messenger signaling rather than blockade of a specific receptor.{{citation needed}}

'''Neurotransmitter effects.''' Lithium modulates serotonergic, dopaminergic, noradrenergic, and glutamatergic signaling, though it is not a receptor antagonist or reuptake inhibitor in the classical sense. Chronic lithium treatment increases serotonin synthesis and release in some brain regions, which may contribute to its antidepressant and anti-suicidal effects. It reduces dopaminergic supersensitivity, potentially accounting for its antimanic properties. Glutamate regulation, including effects on NMDA receptor signaling, has been proposed as relevant to its neuroprotective effects.{{citation needed}}

'''Circadian rhythm.''' Lithium lengthens the circadian period and inhibits GSK-3beta, which phosphorylates and degrades circadian clock proteins (Period, Cryptochrome). The resulting stabilization of circadian rhythms aligns with the circadian disruption seen in bipolar disorder and may be a primary mechanism of mood stabilization independent of classic neurotransmitter effects.{{citation needed}}

The net picture: lithium acts through multiple simultaneously engaged mechanisms, none of which alone is sufficient to explain its clinical effects. This polypharmacy-within-a-molecule is consistent with the clinical observation that no other mood stabilizer fully replicates lithium's profile, particularly its unique anti-suicidal properties.

| intro = Lithium is a mood stabilizer used primarily in the treatment and prevention of bipolar disorder. A simple monovalent cation (the third element on the periodic table), lithium has a narrower therapeutic index than almost any other medicine in common psychiatric use: the serum concentration required for benefit is close to the concentration that produces toxicity, necessitating regular blood level monitoring as a standing condition of its use. Despite this constraint, lithium has the longest evidence base of any medicine in bipolar disorder, the most robust evidence for suicide prevention of any psychiatric medicine, and a neuroprotective profile (preservation of gray matter volume, BDNF upregulation) that no other mood stabilizer has matched in controlled imaging studies.<ref name="geddes2004" /><ref name="cipriani2013">Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:f3646. PMID 23814104.</ref>

It has a history unlike any other psychiatric medicine: it was in use as a mineral water component at spas centuries before its mechanism was even speculated at, removed from consumer products when its toxicity was recognized, and rediscovered by an Australian psychiatrist experimenting on guinea pigs in 1949. The gap between empirical discovery and mechanistic understanding is wider for lithium than for almost any other medicine in the formulary. That gap has never fully closed.

| history = Lithium (symbol Li, atomic number 3) is the lightest solid element and the lightest metal. It was identified in 1817 by Swedish chemist Johan August Arfwedson while analyzing petalite ore; its name derives from the Greek ''lithos'' (stone). Lithium naturally occurs in trace amounts in many mineral waters, and "lithia water" (mineral water with elevated lithium content) was commercially popular throughout the 19th century as a health tonic. Producers marketed it for gout, kidney stones, and a variety of nervous complaints, a claim that would later prove to have a pharmacological basis more interesting than the marketers intended.<ref name="corcoran1949">Corcoran AC, Taylor RD, Page IH. Lithium poisoning from the use of salt substitutes. JAMA. 1949;139(11):685-688. PMID 18110875.</ref>

In 1883, Alfred Baring Garrod (who had earlier identified uric acid's role in gout) proposed lithium for the treatment of "brain gout," a now-abandoned diagnostic category that grouped mania and other agitated states with metabolic disease. Lithium bromide was used in the 19th and early 20th centuries as a sedative, contributing to the empirical record without mechanistic understanding.

In the 1940s, lithium chloride was marketed as a salt substitute for patients on sodium-restricted diets. Physicians treating cardiac patients with this substitute reported toxicity and several deaths. The FDA moved to restrict lithium from consumer products in 1949, creating an ironic historical footnote: the same year lithium was withdrawn from over-the-counter use, John Cade was rediscovering its psychiatric utility.

John Frederick Joseph Cade, an Australian psychiatrist at the Bundoora Repatriation Mental Hospital in Victoria, was investigating the hypothesis that mania resulted from excess uric acid in the blood. To test urinary urate in guinea pigs, he needed to dissolve uric acid (poorly water-soluble); he used lithium urate, the most soluble lithium salt available. He observed that the guinea pigs became unexpectedly calm rather than showing expected toxicity signs. Curious, he administered lithium carbonate to other guinea pigs and found the same sedative effect. He then tried it in human patients with mania.<ref name="cade1949">Cade JFJ. Lithium salts in the treatment of psychotic excitement. Med J Aust. 1949;2(10):349-352. PMID 18142718.</ref>

In September 1949, Cade published a series of 10 manic patients who responded dramatically to lithium carbonate, along with cases of schizophrenia (no clear benefit) and melancholia (modest benefit). The paper, published in the Medical Journal of Australia, is now recognized as one of the most important papers in the history of psychiatry. Cade himself was a careful experimenter: he documented that the effect was specific to mania, he first tested the doses on himself, and he noted the narrow therapeutic window with appropriate caution.

The clinical adoption of lithium was slow. In the United States, the 1949 deaths from lithium salt substitutes had left regulatory caution, and Cade's paper attracted limited attention. The Danish psychiatrist Mogens Schou, working with Juel-Nielsen and others, conducted the first randomized controlled trial of lithium in mania in 1954 and published subsequent work throughout the 1960s establishing its prophylactic efficacy. Schou also had a personal stake: his brother had severe bipolar disorder and responded to lithium.<ref name="schou1954">Schou M, Juel-Nielsen N, Stromgren E, Voldby H. The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry. 1954;17(4):250-260. PMID 13212414.</ref>

The FDA approved lithium carbonate for acute mania in 1970, making the United States one of the last Western countries to adopt it. Europe and Australia had been using it clinically for a decade. The FDA subsequently approved the maintenance indication in bipolar disorder.

In the US popular imagination, lithium's cultural moment arrived partly through its association with creative and intellectual figures who were open about their diagnoses. Kay Redfield Jamison's memoir "An Unquiet Mind" (1995), in which the psychiatrist and bipolar disorder expert describes her own mania, depression, and ambivalent relationship with lithium, brought its clinical and experiential dimensions to a wide audience. The tension Jamison described between lithium's life-stabilizing effects and the patients' experiences of mood restriction resonates across decades of clinical literature on adherence.

One historical footnote: the original formulation of 7-Up, introduced in 1929 as "Bib-Label Lithiated Lemon-Lime Soda," contained lithium citrate as an ingredient. The lithium was removed in 1948 amid the concern about lithium toxicity, though the brand retained its name.

| indications = 

'''FDA-approved indications:'''

* '''Acute mania:''' Treatment of manic episodes in patients with bipolar I disorder. Lithium reduces the severity and duration of manic episodes. Because its onset requires days to weeks, it is typically combined with a neuroleptic or benzodiazepine in the acute phase.<ref name="lithobid-label" />
* '''Maintenance treatment of bipolar disorder:''' Prophylactic reduction of the frequency and severity of manic and depressive episodes in bipolar I disorder. This is the indication with the strongest long-term evidence base.<ref name="lithobid-label" /><ref name="geddes2004" />

'''Off-label uses (not FDA-approved):'''

* '''Bipolar II disorder:''' Evidence for lithium in bipolar II (characterized by hypomania and depression rather than full mania) is limited but includes some trial data supporting mood stabilization.{{citation needed}}
* '''Bipolar depression:''' Lithium shows antidepressant properties in bipolar depression, though evidence is more modest than for mania and maintenance. [[Quetiapine]] and [[lurasidone]] have more recent controlled trial data for bipolar depression.<ref name="young2010">Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression. J Clin Psychiatry. 2010;71(2):150-162. PMID 20122369.</ref>
* '''Augmentation of antidepressants in unipolar depression:''' One of the most evidence-supported augmentation strategies for treatment-resistant unipolar depression. Meta-analyses find significant benefit over placebo, though newer augmentation strategies (atypical neuroleptics) have displaced it in some guidelines due to convenience and tolerability.<ref name="bauer2014">Bauer M, Adli M, Ricken R, Severus E, Pilhatsch M. Role of lithium augmentation in the management of major depressive disorder. CNS Drugs. 2014;28(4):331-342. PMID 24590663.</ref>
* '''Suicide prevention:''' Lithium has the most robust evidence base of any medicine for reducing suicidal behavior across mood disorders. A 2013 Cochrane-affiliated meta-analysis by Cipriani et al. found that lithium reduced the risk of all-cause mortality and suicide compared to placebo and compared to other mood stabilizers in bipolar disorder and recurrent depression.<ref name="cipriani2013" /> The mechanism is debated; possibilities include serotonergic effects, anti-aggressive properties, and circadian stabilization, independent of mood stabilization per se.
* '''Cluster headache prophylaxis:''' Evidence from case series and small controlled trials supports lithium as a second-line prophylactic for chronic cluster headache. The mechanism may involve its effects on circadian rhythmicity.{{citation needed}}
* '''Neutropenia:''' Lithium stimulates granulopoiesis and is used in some clinical contexts to raise white blood cell counts, particularly neutropenia associated with chemotherapy or [[clozapine]] therapy.{{citation needed}}
* '''Dementia prevention:''' Epidemiological data from regions with higher lithium concentrations in drinking water suggest an inverse association with dementia rates. Early-phase trials of very low-dose lithium for Alzheimer's prevention are underway; this remains investigational.{{citation needed}}

| dosing = Lithium dosing is guided entirely by serum level monitoring. Dose-to-level relationships vary widely between individuals based on renal function, sodium intake, hydration status, and concurrent medicines. No dose is "correct" outside of its corresponding serum level.

'''Acute mania:''' Target serum lithium level 0.8-1.2 mEq/L. Begin at 300 mg two to three times daily with food and titrate upward every 3-5 days with serum level checks (12-hour trough). Most adults require 900-1,800 mg/day divided. A neuroleptic should be added for acute behavioral control while lithium reaches therapeutic levels.<ref name="lithobid-label" />

'''Maintenance (prophylaxis):''' Target serum level 0.6-0.8 mEq/L. Lower targets (0.4-0.6 mEq/L) may be appropriate in elderly patients or in those who tolerate higher levels poorly; higher targets (0.8-1.0 mEq/L) are sometimes used in patients with more severe or treatment-resistant illness. Once stable, serum levels can be monitored every 3-6 months in conjunction with renal and thyroid function tests.<ref name="geddes2004" />

'''Extended-release formulations (Lithobid):''' May allow twice-daily dosing and reduce peak-trough fluctuations that contribute to gastrointestinal side effects and tremor. Bioequivalence with immediate-release at the same total daily dose; serum level targets unchanged.

'''Renal impairment:''' Lithium is exclusively renally excreted; dose must be substantially reduced in proportion to reduced creatinine clearance. Mild impairment (GFR 30-60 mL/min): reduce dose by 25-50%. Severe impairment (GFR <30 mL/min): use with extreme caution and very close monitoring, if at all. Hemodialysis patients can receive lithium but require post-dialysis dosing protocols due to dialyzability.<ref name="lithobid-label" />

'''Elderly patients:''' Renal clearance of lithium declines with age in parallel with declining GFR. Lower doses and lower target serum levels (0.4-0.6 mEq/L) are appropriate. The elderly are at higher risk of toxicity even within the nominal therapeutic range due to reduced volume of distribution and age-related sensitivity to neurological effects.

'''Pediatric:''' Not FDA-approved in children under 12. Some evidence supports use in pediatric bipolar disorder; off-label use occurs. Dosing is weight-based; serum level targets are similar to adults.<ref name="lithobid-label" />

| effects = '''Mood stabilization.''' Lithium's primary effect is reduction of manic episodes, with secondary prophylactic effects on depressive episodes. In clinical experience, many patients describe a "floor" that prevents the ascent into hypomania or mania; the prophylactic effect on depression is present but generally less robust than the antimanic effect. The medicine does not eliminate all episodes; it reduces their frequency, severity, and duration.

'''Anti-suicidal effect.''' Lithium has the most replicated and robust evidence base of any medicine for reducing suicidal behavior. This effect appears to be at least partially independent of mood stabilization per se: lithium reduces suicidality beyond what would be predicted from its antimanic effects alone. Proposed mechanisms include serotonergic modulation (increasing impulse control and reducing aggression) and circadian stabilization. The clinical implication is that lithium should be considered specifically when suicide risk is a prominent concern in a mood-disordered patient, even in cases where other medicines might be equivalent for mood stabilization.<ref name="cipriani2013" />

'''Neuroprotection.''' Neuroimaging studies consistently find that patients with bipolar disorder on chronic lithium therapy have greater gray matter volume in prefrontal and limbic regions compared to bipolar patients on other medicines and, in some studies, compared to healthy controls. Lithium increases brain-derived neurotrophic factor (BDNF) and promotes hippocampal neurogenesis in animal models. Whether this translates to measurable cognitive protection in humans over long follow-up is an active area of investigation.{{citation needed}}

'''Experiential perspective.''' Lithium occupies an unusual place in patients' subjective experience of their medicines. Many patients attribute it with stabilizing their lives in ways that feel foundational; others describe what Kay Redfield Jamison, among others, has documented: a reduction in emotional range that feels like a trade-off rather than a purely beneficial change. The creative and intellectual "highs" of hypomania, which may be valued by the patient even when recognized as pathological, are dampened along with frank mania. Cognitive side effects ("foggy thinking," word-finding difficulty, memory complaints) are among the most common reasons cited for nonadherence.

The subjective experience of lithium is shaped significantly by serum levels: patients near the upper end of the therapeutic range report more side effects than those in the lower half, and some patients with previously poor tolerance achieve acceptable tolerability when levels are held at 0.6-0.8 rather than 0.8-1.0 mEq/L. Level-targeting is one of the most productive interventions for lithium nonadherence.

'''Cognitive effects.''' Lithium produces measurable effects on cognitive performance in some studies: psychomotor slowing, reduced verbal memory, and diminished word fluency at higher levels. These effects are dose-related. At lower serum levels (0.4-0.6 mEq/L), cognitive effects may be minimal and may be offset by the cognitive improvements that come with mood stabilization in patients who were previously cycling.{{citation needed}}

| adverse = '''Common adverse effects:'''

* '''Fine hand tremor:''' The most common neurological side effect, occurring in 10-30% of patients. Often manageable with dose reduction, level reduction, or the addition of propranolol (40-120 mg/day). Coarse tremor (different from fine tremor) is a sign of toxicity, not a chronic side effect, and requires urgent evaluation.<ref name="mcknight2012">McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet. 2012;379(9817):721-728. PMID 22265699.</ref>
* '''Polyuria and polydipsia:''' Nephrogenic diabetes insipidus (NDI) occurs in up to 40% of long-term users. Lithium impairs the kidney's ability to concentrate urine by reducing collecting duct responsiveness to antidiuretic hormone (ADH/vasopressin). Mild polyuria is common; some patients produce 3-4 liters of urine per day. If symptomatic, amiloride (5-10 mg/day, a potassium-sparing diuretic) can reduce urine volume without substantially affecting lithium levels and is preferred over [[thiazide]] diuretics for this indication.<ref name="mcknight2012" />
* '''Weight gain:''' Variable in magnitude; median gain approximately 4-7 kg in long-term studies. Mechanism is not fully established; increased thirst driving high-calorie beverage intake and insulin effects are proposed contributors.
* '''Gastrointestinal:''' Nausea, diarrhea, and abdominal discomfort are common, particularly at initiation and with immediate-release formulations. Taking lithium with food or switching to extended-release formulations substantially reduces GI side effects for most patients.
* '''Cognitive effects:''' Word-finding difficulty, slowed processing, and memory complaints are reported by a substantial minority of patients; see Effects section above.

'''Endocrine:'''

* '''Hypothyroidism:''' The most clinically important chronic endocrine effect. Lithium inhibits thyroid hormone synthesis and release. Subclinical hypothyroidism (elevated TSH, normal free T4) occurs in approximately 20-40% of long-term users; overt hypothyroidism requiring levothyroxine in approximately 10-20%, more commonly in women and in those with pre-existing thyroid antibodies.<ref name="mcknight2012" /> Hypothyroidism can worsen depression and attenuate the mood-stabilizing response; TSH monitoring every 6 months is a standing requirement of lithium management. Levothyroxine supplementation allows lithium continuation in most cases.
* '''Hyperparathyroidism:''' Lithium raises serum calcium and parathyroid hormone (PTH) levels, and long-term use is associated with increased risk of primary hyperparathyroidism (PHPT). The mechanism involves lithium's effect on the calcium-sensing receptor in parathyroid cells, which raises the set-point for calcium-mediated PTH suppression. Symptomatic or severe hypercalcemia may require parathyroidectomy; in some cases it resolves after lithium discontinuation.{{citation needed}}

'''Renal:'''

* '''Chronic tubulointerstitial nephropathy:''' Long-term lithium use (decades) is associated with progressive interstitial fibrosis and tubular atrophy in some patients. The risk appears to be duration-dependent and level-dependent. A significant minority of long-term lithium users (estimates vary from 1% to 3% after 20+ years) develop chronic kidney disease reaching stage 3 or below (GFR <60 mL/min). Whether lithium should be continued in the setting of declining GFR requires individualized benefit-risk assessment: the benefits of lithium (including anti-suicidal effects) may outweigh the renal risk in patients with severe bipolar disorder who have not responded to alternatives.<ref name="aiff2015">Aiff H, Attman PO, Aurell M, Bendz H, Schon S, Svedlund J. Effects of 10 to 30 years of lithium treatment on kidney function. J Psychopharmacol. 2015;29(5):608-614. PMID 25735990.</ref>
* '''Nephrogenic diabetes insipidus (NDI):''' See above under polyuria. In most patients, NDI is reversible upon lithium discontinuation; however, prolonged severe NDI can lead to irreversible structural changes in the collecting duct.

'''Cardiovascular:'''

* '''ECG changes:''' Flattening or inversion of T-waves is common and benign; a known lithium effect that does not indicate cardiac pathology. Sinus node dysfunction and sinoatrial block are rare but reported, particularly in older patients and at higher serum levels.{{citation needed}}
* '''Blood pressure:''' No consistent hypertensive effect; mild hypotension is sometimes reported.

'''Dermatologic:'''

* Acne, psoriasis exacerbation, hair thinning, and folliculitis are reported. Psoriasis exacerbation can be severe and may necessitate lithium discontinuation if unresponsive to dermatologic treatment.{{citation needed}}

| pharmacodynamics = Lithium's pharmacodynamic profile is characterized by the absence of receptor specificity: it is not an agonist or antagonist at any known receptor and does not inhibit monoamine reuptake. Its effects derive from interference with intracellular signaling enzymes (IMPase, GSK-3beta, adenylyl cyclase) and modulation of ion transport, producing downstream changes in multiple neurotransmitter systems simultaneously. See Mechanism section above for detailed description.

The defining pharmacodynamic fact about lithium is its narrow therapeutic index: therapeutic effects occur at serum levels of 0.6-1.2 mEq/L; toxicity begins to appear at 1.5 mEq/L; severe toxicity at 2.0 mEq/L and above. This roughly two-fold ratio between the therapeutic level and the onset of serious toxicity is among the smallest of any medicine in routine psychiatric use. Clinical management of lithium is therefore inseparable from serum level monitoring.

Unlike most receptor-targeted medicines, lithium does not have a clearly defined dose-response relationship that saturates at a specific ceiling. The benefit of higher vs. lower serum levels within the therapeutic range varies by indication and patient, and the risk of toxicity rises continuously with increasing levels. This produces the practical therapeutic target of finding the lowest level that controls mood episodes for each patient.

| pk_absorption = Lithium is completely absorbed from the gastrointestinal tract; the oral bioavailability of lithium carbonate is essentially 100%. Immediate-release formulations produce a peak serum concentration within 1-2 hours after ingestion. Extended-release formulations produce a lower, flatter peak at 3-6 hours, which reduces the amplitude of peak-trough fluctuations. Food does not substantially affect total absorption but may delay peak concentration slightly and reduce gastrointestinal discomfort. Lithium citrate oral solution is absorbed as rapidly as immediate-release tablets.<ref name="lithobid-label" />

| pk_distribution = Lithium distributes throughout total body water. It does not bind to plasma proteins (0% protein binding). The apparent volume of distribution is approximately 0.7-1.0 L/kg, reflecting distribution throughout total body water including intracellular fluid. Lithium crosses the blood-brain barrier; brain concentrations at steady state are approximately 40-60% of serum levels. It also crosses the placenta (reaching fetal concentrations near maternal levels) and is secreted into breast milk (approximately 40-50% of maternal serum levels).<ref name="lithobid-label" />

Lithium enters cells slowly via sodium channels and sodium-lithium countertransport. The slow equilibration between intracellular and extracellular compartments explains two clinically important phenomena: (1) steady-state tissue concentrations are reached over 5-7 days even when serum levels stabilize earlier, and (2) after hemodialysis removes lithium from blood, redistribution from tissues produces a rebound rise in serum levels (the "post-dialysis rebound"), requiring repeat dialysis or close level monitoring after each dialysis session.

| pk_metabolism = Lithium is not metabolized. It is excreted unchanged. There are no hepatic cytochrome P450 interactions because lithium does not interact with the CYP system. This makes lithium unusual among major psychiatric medicines in having no pharmacokinetic interactions with other medicines via metabolism; its interactions are pharmacodynamic or renal.<ref name="lithobid-label" />

| pk_elimination = Lithium is eliminated exclusively by the kidneys. Renal excretion involves glomerular filtration followed by approximately 80% reabsorption in the proximal tubule, a process that occurs in competition with sodium reabsorption. The proximal tubule reabsorbs lithium and sodium in proportion to their concentrations and to sodium avidity. This has the critical clinical consequence: any state of sodium depletion (dietary sodium restriction, vomiting, diarrhea, sweating, diuretic use) increases proximal tubular reabsorption of both sodium and lithium, raising serum lithium levels and precipitating toxicity. Patients must be counseled that dehydration and sodium loss can cause lithium toxicity even at stable lithium doses.

The elimination half-life is approximately 18-24 hours after a single acute dose and may extend to 36-48 hours at steady state due to tissue equilibration. Renal clearance of lithium is proportional to creatinine clearance; any condition that reduces GFR will proportionally reduce lithium clearance and raise serum levels. Age-related decline in GFR is a major reason elderly patients require lower doses for equivalent serum levels.<ref name="lithobid-label" />

| interactions = Lithium's interactions are almost entirely renal rather than metabolic. Any medicine or condition that reduces renal sodium clearance or GFR will raise lithium levels.

'''NSAIDs ([[ibuprofen]], [[naproxen]], [[indomethacin]], [[celecoxib]], and most others):''' Prostaglandins modulate renal blood flow and tubular sodium handling; NSAID inhibition of prostaglandin synthesis reduces lithium excretion by 25-30% and can precipitate toxicity within days. Even low-dose over-the-counter NSAIDs are clinically significant. Aspirin at analgesic doses is a lesser concern (different mechanism); acetaminophen is considered safe.<ref name="ragheb1990">Ragheb M. The clinical significance of lithium-nonsteroidal anti-inflammatory drug interactions. J Clin Psychopharmacol. 1990;10(5):350-354. PMID 2258452.</ref>

'''ACE inhibitors and angiotensin receptor blockers (ARBs):''' Can substantially raise lithium levels by reducing GFR (through efferent arteriolar dilation) and by increasing proximal tubular reabsorption via the renin-angiotensin-aldosterone axis. Lithium toxicity can develop within days of starting an ACE inhibitor or ARB in a patient on stable lithium. Close monitoring of lithium levels and renal function is required when these medicines are combined. Dose reduction is often necessary.{{citation needed}}

'''Thiazide diuretics (hydrochlorothiazide, chlorthalidone):''' Thiazides reduce distal tubular sodium reabsorption, causing the body to compensate by increasing proximal tubular sodium (and lithium) reabsorption. This raises serum lithium levels by 25-50%. Combination requires dose reduction and close monitoring. Paradoxically, thiazides are sometimes used therapeutically to reduce urine output in lithium-induced nephrogenic diabetes insipidus (at lower doses than typically used for hypertension), with careful level monitoring.<ref name="lithobid-label" />

'''Loop diuretics (furosemide, bumetanide):''' Less problematic than thiazides at typical clinical doses because they act on the loop of Henle rather than the proximal tubule. However, if loop diuretics produce significant sodium and volume depletion, lithium levels can rise. Monitor levels when initiating.

'''Amiloride:''' Generally considered safe for use with lithium (unlike thiazides) and preferred for treating lithium-induced polyuria and NDI. May minimally affect lithium levels; monitoring is still prudent.

'''[[Carbamazepine]]:''' The combination can produce neurotoxicity (ataxia, confusion, tremor) even when serum levels of both medicines are within their individual therapeutic ranges. The mechanism is pharmacodynamic, not pharmacokinetic. Use with caution and monitor for neurological symptoms.

'''Metronidazole:''' Inhibits renal lithium clearance; can raise levels significantly. Avoid or reduce lithium dose and monitor closely.{{citation needed}}

'''Theophylline and caffeine:''' Increase renal lithium clearance, reducing serum levels. Heavy caffeine use may produce sub-therapeutic levels; sudden caffeine cessation in a stabilized patient may raise lithium to toxic levels. Clinically relevant primarily for patients on high caffeine intake.{{citation needed}}

'''Neuroleptics:''' The combination of lithium and high-potency neuroleptics (particularly [[haloperidol]]) was historically associated with case reports of severe neurotoxicity (irreversible brain damage, death). Subsequent review suggested these cases occurred predominantly at high lithium levels (often above therapeutic range) or in contexts of acute febrile illness. The interaction is pharmacodynamic and likely reflects additive neurotoxicity risk at high serum levels rather than a specific haloperidol-lithium reaction. The combination remains widely used in clinical practice with appropriate level monitoring.{{citation needed}}

'''SSRIs and SNRIs:''' Combination increases serotonergic transmission; serotonin syndrome has been reported (though rarely). More practically, adding lithium to an antidepressant for augmentation is a well-established strategy; the risk of serotonin syndrome is real but low at therapeutic doses.{{citation needed}}

'''Iodide-containing preparations:''' Synergistic hypothyroid effect when combined with lithium.{{citation needed}}

| monitoring = Regular serum level monitoring is a standing requirement for lithium therapy, not an optional adjunct. Monitoring frequency:

* '''Initiation:''' Serum lithium level 5-7 days after each dose change (draw as a 12-hour trough, exactly 12 hours after the last dose). Renal function (BMP with creatinine/BUN) and thyroid function (TSH) at baseline.
* '''Stabilization:''' Once serum levels are stable in the target range, extend monitoring to every 1-3 months for the first year.
* '''Maintenance:''' Every 3-6 months for serum lithium level, renal function, and thyroid function in stable patients on long-term therapy.
* '''ECG:''' Baseline recommended, particularly in patients over 50 or with known cardiac disease.
* '''Weight:''' At each visit; weight gain is common and contributes to nonadherence.
* '''Urinalysis:''' Annually for proteinuria as a marker of renal disease progression in long-term users.
* '''Calcium/PTH:''' Consider periodic monitoring for hyperparathyroidism in long-term users (>5 years).

Clinicians should lower the monitoring threshold after any change in the patient's clinical state, concurrent medicines, or medical illness (particularly conditions affecting hydration, sodium intake, or renal function).

| counseling = '''Hydration and sodium.''' This is the single most important safety counseling point for lithium. Dehydration, excessive sweating (exercise, hot weather), dietary sodium restriction, vomiting, or diarrhea can all raise your lithium levels into the toxic range even if you have not changed your dose. Drink adequate water, maintain normal salt in your diet unless your cardiologist says otherwise, and call your prescriber if you develop any illness involving vomiting or diarrhea. If you are unsure whether to take your lithium during a GI illness, call before taking it rather than waiting.

'''Toxic symptom recognition.''' Know the early warning signs of lithium toxicity: coarse tremor of the hands (different from the fine tremor that may be a chronic side effect), unsteadiness, slurred speech, confusion, nausea with vomiting, or muscle twitching. These warrant urgent medical evaluation and a serum lithium level, not a "wait and see" approach. Going to an emergency room is appropriate.

'''Level monitoring.''' Your lithium blood level must be drawn exactly 12 hours after your last dose. Taking your dose, waiting less than 12 hours, or drawing blood at a random time gives a meaningless or misleading result. If you take lithium at 8 PM, your blood draw is at 8 AM; if at 10 PM, the draw is at 10 AM.

'''Medicines and lithium.''' Many common medicines raise lithium levels and can cause toxicity. This includes ibuprofen (Advil, Motrin), naproxen (Aleve), and all other non-aspirin anti-inflammatory pain medicines. Acetaminophen (Tylenol) is the safe alternative for pain and fever. Tell every prescriber and every pharmacist that you take lithium, and check for interactions before starting any new medicine including over-the-counter preparations.

'''Pregnancy.''' If you are pregnant or planning pregnancy, discuss your lithium with your prescriber before stopping it on your own. Abrupt discontinuation during pregnancy carries a high risk of manic relapse, which can itself harm you and the pregnancy. The risks of lithium in pregnancy are real but have been revised downward from older estimates; an informed discussion with your psychiatrist and obstetrician is the right approach, not unilateral discontinuation.

'''Thyroid and kidney.''' Regular blood tests check your thyroid and kidney function. These organs can be affected by long-term lithium use. Hypothyroidism (underactive thyroid) is treatable with thyroid hormone without stopping lithium. Kidney function needs periodic review; gradual decline in kidney function may occur after many years of use, and this is monitored so decisions can be made before serious damage occurs.

| anecdotes = Lithium occupies a strange position in the pharmacological imagination. It is simultaneously the oldest major treatment in psychopharmacology (the empirical tradition of lithia springs predates synthetic psychiatry by a century), the treatment with perhaps the most durable and replicable evidence base, and the treatment that most directly raises the question of what it means to stabilize someone's mood at the cost of their emotional range.

The literature on lithium and creativity is not merely anecdotal. A 1978 study by Schou found that among 24 lithium-treated artists and writers in Denmark, some reported that lithium had improved their output by allowing them to work consistently rather than in manic bursts; others reported reduced creative productivity. Jamison and others have documented the ambivalence in first-person terms: the person who writes brilliantly in hypomania and is, on lithium, capable of sustained work but perhaps not brilliance. This is not a side effect in the conventional sense; it is a direct consequence of the medicine's intended action.

The suicide prevention evidence is worth a closer look than it typically receives in summary form. Cipriani et al.'s 2013 BMJ meta-analysis pooled 48 randomized trials and found that lithium significantly reduced suicide deaths (OR 0.13, 95% CI 0.03-0.66) and the combined endpoint of completed suicide plus deliberate self-harm (OR 0.21, 95% CI 0.08-0.50) compared to placebo. Compared to active controls (anticonvulsants including [[valproate]] and carbamazepine), lithium showed similar efficacy for mood stabilization but superior efficacy for suicide prevention.<ref name="cipriani2013" /> The anti-suicidal effect is not trivially explained by better mood stabilization: studies controlling for mood episode rates still find lithium superior. The specific mechanism of lithium's anti-suicidal action is unknown; plausible candidates include its serotonergic effects on impulse control and its anti-aggressive properties.

There is a population-level corollary: epidemiological studies from multiple countries have found that municipalities with higher naturally occurring lithium concentrations in drinking water have lower rates of suicide mortality, even controlling for socioeconomic and demographic factors. These findings are observational and do not establish causation; they have also been challenged on methodological grounds. But they have provoked legitimate scientific interest in whether trace environmental lithium exposure may influence population suicide rates, and have generated ongoing research into very low-dose lithium supplementation.<ref name="ohgami2009">Ohgami H, Terao T, Shiotsuki I, Ishii N, Iwata N. Lithium levels in drinking water and risk of suicide. Br J Psychiatry. 2009;194(5):464-465. PMID 19407280.</ref>

The 1949 coincidence remains one of the great ironies in medicine's regulatory history: lithium was removed from consumer products (as a salt substitute) and simultaneously published as a breakthrough psychiatric treatment. The medicine that was being withdrawn from soft drinks and marketed salt substitutes was being discovered to prevent psychotic mania. This compression of the timeline was not noticed at the time; Cade's paper received almost no immediate attention in the United States, precisely because lithium had just been associated with toxicity and death.

| overdose = Lithium has one of the narrowest therapeutic indices of any medicine in routine psychiatric use. The distance between the therapeutic serum level (0.6-1.2 mEq/L) and the toxic range (above 1.5 mEq/L) is small enough that toxicity can develop from causes other than overdose: sodium depletion, dehydration, an added NSAID, or a new ACE inhibitor at stable lithium doses can push levels from therapeutic to toxic.

'''Three toxicity syndromes:'''

'''Acute toxicity''' occurs in a lithium-naive person after a single large ingestion. Because lithium has not yet distributed into tissues, blood levels rise rapidly but CNS tissue levels remain relatively low initially. Acute toxicity presents predominantly with gastrointestinal symptoms (nausea, vomiting, diarrhea) and may have less severe early neurological effects than the serum level suggests. Absorption is rapid; levels can exceed 4-5 mEq/L after large overdoses in naive individuals with severe GI symptoms before significant CNS distribution.

'''Chronic toxicity''' develops gradually in a patient on established lithium therapy when clearance decreases or intake continues in the setting of volume depletion or sodium loss. Because tissue levels have equilibrated over time, neurological manifestations predominate and may be severe at serum levels that appear only modestly elevated. A patient with chronic toxicity at a serum level of 2.0 mEq/L may be more seriously ill than an acutely poisoned patient at the same level.

'''Acute-on-chronic toxicity''' (intentional overdose in a patient on chronic therapy) combines high serum levels with pre-existing tissue loading, producing the most dangerous presentation.

'''Clinical manifestations by severity:'''

* '''Mild (1.5-2.0 mEq/L):''' Fine-to-coarse tremor, nausea, vomiting, diarrhea, fatigue, mild confusion, slurred speech.
* '''Moderate (2.0-2.5 mEq/L):''' Prominent ataxia, confusion, agitation, fasciculations, hypertonia, hyperreflexia, drowsiness.
* '''Severe (above 2.5 mEq/L):''' Seizures, coma, cardiovascular collapse, irreversible neurological injury.

'''SILENT syndrome''' (Syndrome of Irreversible Lithium-Effectuated Neurotoxicity) is a recognized entity of irreversible neurological damage following lithium toxicity. Characterized by cerebellar dysfunction (ataxia, dysarthria, nystagmus), cognitive impairment, and sometimes dementia, SILENT persists after lithium discontinuation and serum level normalization. It results from direct cerebellar and brainstem neuronal death at high tissue concentrations.{{citation needed}}

'''Electrocardiographic changes:''' Prolonged QT interval, T-wave inversions, and, at high levels, ventricular arrhythmias.

'''Treatment:'''

* '''Supportive care:''' Secure airway, vascular access, cardiac monitoring, IV normal saline for hydration and to promote renal lithium excretion.
* '''Saline administration:''' Isotonic normal saline expands intravascular volume and restores renal sodium delivery, reducing proximal tubular lithium reabsorption and increasing lithium excretion. This is a cornerstone of management for all severities.
* '''Whole bowel irrigation:''' For large acute ingestions, particularly of extended-release formulations (which continue to absorb for hours after ingestion), whole bowel irrigation with polyethylene glycol solution may reduce ongoing absorption. Activated charcoal does not adsorb lithium and is not indicated.
* '''Hemodialysis:''' The definitive treatment for severe lithium toxicity. Lithium is highly dialyzable (no protein binding, small molecular weight, small volume of distribution). Indications include: serum level above 4.0 mEq/L regardless of symptoms; serum level above 2.5 mEq/L with severe neurological symptoms (seizures, decreased consciousness, severe ataxia); or inability to excrete lithium renally due to renal failure. Hemodialysis should continue until clinical improvement and serum levels fall below 1.0 mEq/L.
* '''Post-dialysis rebound:''' After hemodialysis lowers serum levels, redistribution of lithium from tissue compartments causes a rebound rise in serum levels over 6-8 hours. Repeat serum levels at 6 hours post-dialysis are required; repeat dialysis may be necessary if levels rebound above 1.5 mEq/L with persistent symptoms.
* '''Extended monitoring:''' Neurological symptoms from chronic toxicity may persist or worsen for days after serum levels normalize, due to ongoing redistribution from tissue compartments. Patients with significant neurological symptoms require extended inpatient monitoring.

There is no specific antidote. Do not administer sodium bicarbonate (it increases renal reabsorption of lithium by alkalinizing the urine).

}}

== References ==
<references />

[[Category:Mood stabilizers]]
[[Category:Antimanic medicines]]
[[Category:Medicines]]

Modafinil

2026-06-03T20:58:50Z

Maintenance script: Medicine page v3: citation-integrity correction, restore ref wisor-2001 PMID 11222668 (PM-approved deploy 2026-06-03)

{{MedTemplate
| generic = Modafinil
| brand = Provigil (Teva/Cephalon); Alertec (Canada); Modavigil (Australia)
| structure =
| classes = [[:Category:Eugeroics|Eugeroic]], [[:Category:Psychostimulants|Psychostimulant]] (atypical)
| starting_dose = 200 mg orally once daily in the morning. For shift-work sleep disorder, 200 mg approximately one hour before the start of the work shift. Doses up to 400 mg/day have been studied; evidence does not consistently demonstrate greater efficacy at 400 mg compared to 200 mg, but some patients may benefit from the higher dose.<ref name="provigil-label">Provigil (modafinil) prescribing information. Teva Pharmaceuticals USA. Revised 2015. FDA reference NDA 020717.</ref>
| preparations = Tablets: 100 mg, 200 mg (scored). [[Armodafinil]] (Nuvigil), the R-enantiomer of modafinil, is available separately as 50 mg, 150 mg, 200 mg, and 250 mg tablets.
| fda_max = 400 mg/day.<ref name="provigil-label" />
| pill_id =
| routes = Oral
| onset = Peak plasma concentration in 2-4 hours after oral administration. Clinically perceptible wakefulness-promoting effects typically begin within 1-2 hours of dosing.{{citation needed}}
| duration = Effective duration approximately 12-15 hours at the 200 mg dose, consistent with the elimination half-life. A single morning dose generally sustains wakefulness throughout the day without substantially disrupting nighttime sleep onset when taken early.<ref name="provigil-label" />
| halflife = Approximately 15 hours (effective half-life after a single dose). Modafinil is a racemic mixture: the R-enantiomer (armodafinil) has a longer half-life (approximately 15 hours) than the S-enantiomer (approximately 3-4 hours). The R-enantiomer therefore dominates the pharmacologically active plasma concentration in the latter portion of the dosing interval.<ref name="provigil-label" />
| bioavailability = Oral bioavailability is not precisely established in the label but absorption is rapid and essentially complete. Food delays peak plasma concentration by approximately one hour but does not reduce the extent of absorption.<ref name="provigil-label" />
| pregnancy = Not adequately studied in pregnant humans. Animal data (rats, rabbits) showed developmental toxicity at clinically relevant doses, including visceral and skeletal variations. The FDA label does not assign a letter category under the post-2015 labeling rule; the prior category was C (Australia: Category D).{{citation needed}} A pregnancy registry existed but enrollment data are limited. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Modafinil may reduce the effectiveness of hormonal contraceptives (see Interactions), which has indirect reproductive implications: women of childbearing potential should use alternative or additional contraception during modafinil therapy and for one month after discontinuation.<ref name="provigil-label" />
| legal = [[USLegal:Schedule IV|Schedule IV controlled substance]] in the United States (DEA scheduling effective 1999). Prescription-only in the United Kingdom, European Union, Canada, and Australia. Not scheduled in Japan; available by prescription. In the European Union, the EMA restricted modafinil's approved indication to narcolepsy only in 2011, withdrawing the OSA and shift-work indications after a benefit-risk review.{{citation needed}} International status varies; in some jurisdictions modafinil is available without prescription. Modafinil was placed in Schedule IV based on evidence of lower abuse potential relative to Schedule II psychostimulants ([[amphetamines]], [[methylphenidate]]), though reinforcing effects have been demonstrated in laboratory settings.<ref name="jasinski2000">Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol. 2000;14(1):53-60. PMID 10757254.</ref>
| mechanism = Modafinil promotes wakefulness through mechanisms that remain incompletely understood. The best-established molecular target is the dopamine transporter (DAT): modafinil binds DAT and inhibits dopamine reuptake, increasing extracellular dopamine concentrations in wakefulness-relevant brain regions including the nucleus accumbens and prefrontal cortex.<ref name="volkow2009">Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA. 2009;301(11):1148-1154. PMID 19293415.</ref> PET imaging in humans demonstrated that therapeutic doses (200-400 mg) occupy DAT and increase dopamine in the nucleus accumbens, establishing that modafinil is, at the molecular level, a dopamine reuptake inhibitor.<ref name="wisor-2001">Wisor JP, Nishino S, Sora I, Uhl GH. Dopaminergic role in stimulant-induced wakefulness. J Neurosci. 2001;21(5):1787-1794. PMID 11222668.</ref>

Despite sharing a DAT mechanism with [[amphetamines]] and [[methylphenidate]], modafinil's clinical and behavioral profile differs substantially. It produces wakefulness without the pronounced euphoria, sympathomimetic cardiovascular activation, or rebound hypersomnia characteristic of classical psychostimulants at therapeutic doses.<ref name="ballon2006">Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry. 2006;67(4):554-566. PMID 16669720.</ref> The reasons for this divergence are not fully resolved. Proposed contributors include:

'''Histaminergic activation.''' Modafinil increases histamine release in the tuberomammillary nucleus, a key node of the ascending arousal system. This effect is not shared by amphetamines and may account for modafinil's selective wakefulness promotion without generalized CNS stimulation. Histamine H1 and H3 receptor pathways appear to be involved, though whether this is a direct or indirect effect remains debated.{{citation needed}}

'''Orexin (hypocretin) system engagement.''' Modafinil activates orexin-producing neurons in the lateral hypothalamus, the same neurons whose loss causes narcolepsy. This activation may be indirect (mediated via reduced GABAergic inhibition of orexin neurons rather than direct receptor binding). Modafinil's efficacy in narcolepsy, a disease defined by orexin deficiency, makes this pathway clinically plausible, though modafinil remains effective in animal models with ablated orexin neurons, indicating that orexin is not its sole mechanism.{{citation needed}}

'''Noradrenergic and glutamatergic effects.''' Modafinil increases norepinephrine release in the cortex and hypothalamus and enhances glutamatergic transmission, while reducing GABA release in several brain regions. These effects collectively shift the excitatory/inhibitory balance toward arousal. Whether they are primary actions or downstream consequences of dopaminergic activation is not established.<ref name="ballon2006" />

The net picture: modafinil acts at least partly as a DAT inhibitor, but its wake-promoting profile likely reflects simultaneous engagement of multiple arousal circuits (dopaminergic, histaminergic, orexinergic, noradrenergic) rather than pure monoamine reuptake inhibition. This multi-circuit engagement may explain both its clinical distinctness from amphetamines and the difficulty in pinning down a single mechanism.

| intro = Modafinil is a wakefulness-promoting medicine approved for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea (as an adjunct to primary treatment), and shift-work sleep disorder. Classified as a eugeroic (from the Greek for "good arousal"), it sits in or adjacent to the psychostimulant class but differs from [[amphetamines]] and [[methylphenidate]] in both mechanism and clinical profile: it promotes sustained alertness with lower sympathomimetic activation, less euphoria, and substantially lower abuse potential.<ref name="provigil-label" /> Modafinil is widely used off-label for cognitive enhancement and fatigue management, generating a large and contentious literature on its effects in non-sleep-deprived healthy individuals.<ref name="battleday2015">Battleday RM, Brem AK. Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: a systematic review. Eur Neuropsychopharmacol. 2015;25(11):1865-1881. PMID 26381811.</ref>

| history = Modafinil was developed in France in the late 1970s by Michel Jouvet and Lafon Laboratories. Jouvet, a neurophysiologist at the University of Lyon whose work on sleep neuroanatomy had identified the pontine structures governing REM sleep, was investigating a series of benzhydryl sulfinyl compounds for wakefulness-promoting activity. [[Adrafinil]], the prodrug of modafinil, was identified first; modafinil (the primary active metabolite) was subsequently isolated and found to be more potent with a cleaner pharmacokinetic profile.{{citation needed}}

Adrafinil was marketed in France in 1986 under the brand name Olmifon for narcolepsy and age-related hypersomnia. Modafinil itself received French marketing authorization in 1994. Cephalon, Inc. (later acquired by Teva Pharmaceutical Industries in 2011) licensed modafinil for the US market. The FDA approved modafinil (as Provigil) in December 1998 for narcolepsy; subsequent approvals added obstructive sleep apnea (adjunct) and shift-work sleep disorder in 2004.<ref name="provigil-label" />

In 2004, Cephalon submitted a supplemental new drug application for modafinil in pediatric ADHD. The FDA's Dermatologic and Ophthalmic Drugs Advisory Committee recommended against approval in 2006, citing one case of Stevens-Johnson syndrome and several cases of serious rash in the pediatric clinical trials. This safety signal, in a population without a life-threatening indication, led the FDA to reject the application and to add a boxed-level warning about serious dermatologic reactions to the adult label.{{citation needed}}

[[Armodafinil]] (Nuvigil), the isolated R-enantiomer, was approved by the FDA in 2007. Its longer half-life relative to racemic modafinil was the basis for marketing differentiation. Generic modafinil became available in the United States in 2012 following patent expiration, substantially reducing cost and increasing accessibility.{{citation needed}}

| indications = 

'''FDA-approved indications:'''

* '''Narcolepsy:''' Improvement of wakefulness in adults with excessive sleepiness associated with narcolepsy.<ref name="provigil-label" />
* '''Obstructive sleep apnea (adjunct):''' Improvement of wakefulness in adults with excessive sleepiness associated with OSA. Modafinil does not treat the underlying airway obstruction; it is an adjunct to CPAP or other primary therapies. The FDA label specifies that it should be used only when CPAP has been tried and is providing adequate ventilation but the patient has residual excessive sleepiness.<ref name="provigil-label" />
* '''Shift-work sleep disorder:''' Improvement of wakefulness in adults with excessive sleepiness associated with shift-work disorder (working during the normal sleep period).<ref name="provigil-label" />

'''Off-label uses (not FDA-approved):'''

* Fatigue associated with multiple sclerosis, cancer-related fatigue, and HIV/AIDS-related fatigue. Evidence is mixed; some controlled trials show benefit, others do not.{{citation needed}}
* ADHD in adults (FDA pediatric application rejected due to SJS risk; some evidence of benefit in adults, but this indication is not well-established).{{citation needed}}
* Cognitive enhancement in healthy non-sleep-deprived individuals (see Experiential perspective below).
* Adjunctive treatment in depression with residual fatigue or sleepiness.{{citation needed}}
* Fatigue and sleepiness associated with traumatic brain injury.{{citation needed}}

| dosing = '''Narcolepsy and obstructive sleep apnea:''' 200 mg orally once daily in the morning. Some patients may benefit from 400 mg/day, though evidence for superior efficacy at the higher dose is limited.<ref name="provigil-label" />

'''Shift-work sleep disorder:''' 200 mg orally approximately one hour before the start of the work shift.<ref name="provigil-label" />

'''Hepatic impairment:''' Reduce dose by 50% (to 100 mg/day) in patients with severe hepatic impairment. Modafinil is extensively hepatically metabolized; clearance is reduced and half-life prolonged in liver disease.<ref name="provigil-label" />

'''Renal impairment:''' No dose adjustment needed for mild-to-moderate renal impairment. Severe renal impairment has not been adequately studied; use with caution.{{citation needed}}

'''Elderly:''' Consider lower doses. Clearance may be reduced; the label recommends consideration of 100 mg/day in elderly patients, though this is not a strict requirement.<ref name="provigil-label" />

'''Pediatric:''' Not FDA-approved in children. The pediatric ADHD application was rejected due to SJS risk (see History).

| effects = '''Wakefulness promotion.''' The primary effect is sustained wakefulness and alertness without the subjective "wired" or jittery quality that characterizes higher-dose amphetamine use in many patients. Sleep latency is increased; the Multiple Sleep Latency Test (MSLT) is the standard objective measure in clinical trials.{{citation needed}}

'''Cognitive effects.''' In patients with sleep disorders, modafinil improves attention, executive function, and working memory, consistent with normalizing the cognitive deficits that excessive sleepiness causes. The more contested question is whether modafinil enhances cognition beyond baseline in well-rested healthy individuals. A 2015 systematic review by Battleday and Brem examined 24 studies of modafinil in non-sleep-deprived subjects and concluded that modafinil improved performance on longer, more complex cognitive tasks (particularly executive function, attention, and learning), while effects on simpler tasks were less consistent. The authors noted that methodological heterogeneity limited firm conclusions.<ref name="battleday2015" />



'''Experiential perspective.''' Modafinil is widely used off-label as a cognitive enhancer among students, professionals, and shift workers. User reports consistently describe a state of increased focus and reduced fatigue without the physical activation (elevated heart rate, jaw tension, mood elevation) associated with [[amphetamines|amphetamine-class]] psychostimulants. The subjective experience is frequently characterized as "quiet alertness" rather than stimulation. This experiential profile contributes to modafinil's reputation as a "cleaner" alternative to traditional psychostimulants for productivity enhancement.

The evidence base for cognitive enhancement in healthy individuals is real but modest. The Battleday and Brem systematic review found benefits in complex cognitive domains, but most studies used single-dose designs in laboratory settings; real-world efficacy for sustained academic or professional performance is not well-characterized in controlled trials.<ref name="battleday2015" /> Additionally, there is publication bias: positive results are more likely to be published than null findings, and the magnitude of any cognitive benefit is likely smaller than the most optimistic user reports suggest. Modafinil should not be understood as a reliable cognitive enhancer for all users in all contexts; it is a wakefulness-promoting medicine that may incidentally improve performance in the sleep-deprived and that shows modest, task-dependent benefits in well-rested individuals.

'''Mood effects.''' At therapeutic doses, modafinil does not produce the pronounced euphoria associated with amphetamines in most individuals. Some users report improved mood, reduced anxiety, and greater emotional equanimity; others report no subjective mood change. At supratherapeutic doses (600-800 mg), reinforcing effects and subjective "high" have been demonstrated in controlled laboratory settings, establishing that modafinil does carry some abuse potential, though less than Schedule II psychostimulants.<ref name="jasinski2000" />

| adverse = Adverse effect incidence from controlled clinical trials (modafinil vs placebo):<ref name="provigil-label" />

'''Common (>=5% and at least twice placebo rate):'''
* Headache (34% vs 23%)
* Nausea (11% vs 3%)
* Nervousness (7% vs 3%)
* Rhinitis (7% vs 6%)
* Diarrhea (6% vs 5%)
* Back pain (6% vs 5%)
* Insomnia (5% vs 1%)
* Dizziness (5% vs 4%)
* Dyspepsia (5% vs 4%)

'''Serious adverse effects:'''

'''Dermatologic.''' Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported. The incidence is rare but the consequences are potentially fatal. In pediatric clinical trials, the rash rate was 0.8% (13 of 1,585 children), including one case of possible SJS and one multi-organ hypersensitivity reaction; nearly all cases occurred within the first five weeks of treatment. This dermatologic signal was the primary basis for the FDA's rejection of the pediatric ADHD indication in 2006.<ref name="provigil-label" /><ref name="prince2018">Prince V, Philippidou M, Walsh S, Creamer D. Stevens-Johnson syndrome induced by modafinil. Clin Exp Dermatol. 2018;43(2):191-192. PMID 29028129.</ref> In adults, post-marketing reports of SJS/TEN exist but incidence is very low and not precisely quantified.{{citation needed}} The label recommends discontinuation at the first sign of rash unless the rash is clearly not medicine-related.

'''Angioedema and anaphylactoid reactions.''' Rare post-marketing reports of angioedema (face, larynx, tongue), urticaria, and multi-organ hypersensitivity reactions. Discontinue if angioedema occurs.<ref name="provigil-label" />

'''Psychiatric.''' Depression, anxiety, mania, hallucinations, suicidal ideation, and psychosis have been reported in post-marketing surveillance. These events occurred primarily in patients with pre-existing psychiatric histories, but the label does not restrict use to patients without psychiatric comorbidity. Use with caution in patients with a history of psychosis, mania, or depression.<ref name="provigil-label" />

'''Cardiovascular.''' Not recommended in patients with left ventricular hypertrophy or mitral valve prolapse (the "mitral valve prolapse syndrome" associated with CNS psychostimulants). Modafinil has been associated with palpitations, chest pain, and modest elevations in heart rate and blood pressure. Avoid in patients with recent myocardial infarction or unstable angina.<ref name="provigil-label" />

| pharmacodynamics = Modafinil's pharmacodynamic profile is defined by wakefulness promotion with minimal peripheral sympathomimetic activation at therapeutic doses, distinguishing it from amphetamines.

'''Dopaminergic.''' DAT inhibition is the best-established primary mechanism. Volkow et al. (2009) demonstrated using [11C]cocaine and [11C]raclopride PET that modafinil at 200 mg and 400 mg blocked DAT and increased extracellular dopamine in the human nucleus accumbens. The dopamine increase is modest relative to amphetamines, which promote dopamine release in addition to blocking reuptake.<ref name="volkow2009" />

'''Histaminergic.''' Modafinil increases histamine release from the tuberomammillary nucleus. Histamine is a key mediator of the ascending arousal system; [[antihistamines]] (H1 blockers) produce sedation precisely because they oppose this pathway. Whether modafinil's histamine effect is a direct action or downstream of dopaminergic and GABAergic changes is unresolved.<ref name="ballon2006" />

'''GABAergic.''' Modafinil reduces GABA release in multiple brain regions (cortex, hypothalamus, basal ganglia). Reduced GABAergic inhibition of arousal nuclei may contribute to wakefulness promotion and may also explain the anxiogenic effects some patients report.{{citation needed}}

'''Glutamatergic.''' Increased glutamate release has been demonstrated in several brain regions. Enhanced glutamatergic transmission may contribute to the cognitive effects observed in clinical studies.{{citation needed}}

'''Noradrenergic.''' Increased norepinephrine levels in the cortex and hypothalamus have been demonstrated in animal models. The contribution of noradrenergic activation to modafinil's clinical profile is uncertain but likely relevant to attention and arousal.{{citation needed}}

'''Absence of significant serotonergic effects.''' Unlike [[fenfluramine]] and other anorectic agents, modafinil does not substantially alter serotonin levels. This may explain the absence of the appetite suppression, mood elevation, and serotonin syndrome risk associated with serotonergic psychostimulants.{{citation needed}}

| pk_absorption = Rapidly absorbed after oral administration. Peak plasma concentration (T_max) occurs at 2-4 hours. Food delays T_max by approximately one hour but does not affect total absorption (AUC). The clinical recommendation to take modafinil in the morning is driven by its long duration of action, not by food-dependent absorption concerns.<ref name="provigil-label" />

| pk_distribution = Modafinil is approximately 60% bound to plasma proteins, primarily albumin. The apparent volume of distribution is approximately 0.9 L/kg, suggesting distribution beyond plasma water into tissues. It crosses the blood-brain barrier; brain concentrations are sufficient for DAT occupancy at therapeutic doses, as demonstrated by PET imaging.<ref name="volkow2009" />

| pk_metabolism = Modafinil is extensively metabolized in the liver. The primary route is amide hydrolysis to modafinil acid (an inactive metabolite), which accounts for approximately 40% of urinary metabolites. CYP3A4 contributes to a secondary oxidative pathway. Notably, modafinil is a moderate inducer of CYP3A4, CYP2B6, and potentially CYP1A2, and a reversible inhibitor of CYP2C19.<ref name="provigil-label" />

The CYP enzyme interactions are clinically important:

'''CYP3A4 induction.''' Modafinil induces CYP3A4 at steady state. This reduces plasma levels of CYP3A4 substrates. The most clinically significant consequence is reduced efficacy of hormonal contraceptives (ethinyl estradiol and other estrogen/progestin compounds are CYP3A4 substrates). The FDA label recommends alternative or additional contraception during modafinil therapy and for one month after discontinuation.<ref name="provigil-label" />

'''CYP2C19 inhibition.''' Modafinil reversibly inhibits CYP2C19, potentially increasing plasma levels of CYP2C19 substrates (diazepam, phenytoin, omeprazole, propranolol). In CYP2C19 poor metabolizers (2-5% of Caucasian populations, 15-20% of East Asian populations), concurrent modafinil could produce supratherapeutic levels of these substrates.{{citation needed}}

'''CYP2C9 inhibition.''' In vivo cocktail studies found no clinically significant CYP2C9 effect at steady state (AUC ratio 0.97), though the FDA label recommends warfarin monitoring as a precaution.<ref name="rowland2018">Rowland A, van Dyk M, Warncken D, et al. Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. Br J Clin Pharmacol. 2018;84(3):501-509. PMID 29178272.</ref>

'''CYP2D6 relevance.''' Modafinil does not significantly affect CYP2D6 directly. However, in CYP2D6 poor metabolizers (7-10% of Caucasian populations), metabolism of tricyclic antidepressants becomes heavily dependent on CYP2C19. Modafinil's CYP2C19 inhibition is therefore more clinically significant in these patients: co-prescribed tricyclics may accumulate to supratherapeutic levels.<ref name="provigil-label" />

| pk_elimination = Approximately 80% of the dose is recovered in urine, predominantly as metabolites (modafinil acid and modafinil sulfone). Less than 10% is excreted as unchanged modafinil. The effective elimination half-life is approximately 15 hours. Steady state is reached in 2-4 days of daily dosing. Renal clearance is not a significant elimination pathway for the parent compound.<ref name="provigil-label" />

| interactions = '''Hormonal contraceptives (oral contraceptives, patch, ring):''' Modafinil induces CYP3A4, reducing ethinyl estradiol exposure by approximately 18% at steady state. This is sufficient to reduce contraceptive reliability. Use alternative or additional contraception during modafinil therapy and for one month after discontinuation. This interaction has direct reproductive consequences and should be discussed explicitly with all patients of childbearing potential.<ref name="provigil-label" />

'''[[Cyclosporine]]:''' CYP3A4 induction by modafinil may reduce cyclosporine blood levels by 50%. One case report documented clinically significant reduction in cyclosporine trough levels after modafinil initiation in a transplant patient. Monitor cyclosporine levels closely if modafinil is started or stopped.{{citation needed}}

'''CYP2C19 substrates ([[diazepam]], [[phenytoin]], [[omeprazole]], [[propranolol]]):''' Modafinil inhibits CYP2C19. Co-administration may increase exposure to these substrates. Phenytoin in particular has a narrow therapeutic index; monitor levels if modafinil is added.<ref name="provigil-label" />

'''[[Warfarin]]:''' Modafinil may inhibit CYP2C9 (minor). Monitor PT/INR more closely when initiating or discontinuing modafinil in patients on stable warfarin therapy.<ref name="provigil-label" />

'''MAOIs:''' Use with caution. Modafinil increases catecholamine availability; the combination with MAOIs could theoretically potentiate catecholaminergic effects, though serious interactions are not well-documented.{{citation needed}}

'''Other CNS-active medicines:''' Modafinil is not a strong psychostimulant in the classical sense, but additive wakefulness-promoting effects may mask fatigue signals that serve a physiological protective function. Combining modafinil with other wakefulness-promoting agents or high-dose [[caffeine]] is not well-studied.{{citation needed}}

'''[[Triazolam]] and other CYP3A4-metabolized [[benzodiazepines]]:''' CYP3A4 induction may reduce triazolam exposure by approximately 18%. Consider dose adjustment if concurrent use is necessary.<ref name="provigil-label" />

| monitoring = * '''Baseline and periodic:''' blood pressure and heart rate (modest elevations can occur). No routine laboratory monitoring is mandated by the label for patients without comorbidities.
* '''Rash:''' counsel patients to report any new rash immediately. The SJS risk, while very low, warrants early recognition and prompt discontinuation.
* '''Psychiatric symptoms:''' monitor for new or worsening anxiety, agitation, mania, or psychotic symptoms, particularly in the first weeks of therapy and in patients with psychiatric comorbidity.
* '''Contraceptive counseling:''' confirm at each visit that patients of childbearing potential are using reliable non-hormonal or alternative contraception.
* '''Phenytoin, warfarin, and cyclosporine levels:''' monitor in patients co-prescribed these medicines when modafinil is initiated, dose-adjusted, or discontinued.

| counseling = '''Contraception.''' Modafinil reduces the effectiveness of hormonal contraceptives (birth control pills, patch, ring). Use a non-hormonal method (e.g. IUD, condom) or add a barrier method during modafinil therapy and for one month after stopping. This is among the most clinically consequential interactions and warrants explicit discussion.<ref name="provigil-label" />

'''Rash.''' Stop modafinil and contact your clinician immediately if you develop any skin rash. While most rashes during modafinil therapy are benign, Stevens-Johnson syndrome (a rare but serious skin reaction) has been reported. Early discontinuation reduces the risk of progression to a severe reaction.

'''Driving and operating machinery.''' Modafinil improves wakefulness but does not eliminate the need for adequate sleep. Do not assume that taking modafinil makes it safe to drive or perform safety-sensitive work during what would otherwise be your sleep period. Judgment about sleepiness is itself impaired by sleep deprivation.

'''Abuse potential.''' Modafinil is a Schedule IV controlled substance. While its abuse potential is lower than amphetamines, reinforcing effects have been demonstrated at supratherapeutic doses. Take only as prescribed; do not increase the dose without medical guidance.

'''Psychiatric history.''' If you have a history of mania, psychosis, or depression, tell your prescriber before starting modafinil. Report any new mood changes, unusual thoughts, or increased anxiety promptly.

| anecdotes = The question of whether modafinil "works" as a cognitive enhancer is, in an instructive way, the wrong question. The 2015 Battleday and Brem systematic review found that modafinil improved performance on complex cognitive tasks in non-sleep-deprived healthy subjects, but the benefits were task-dependent, dose-dependent, and modest in magnitude. Simple tasks (digit span, basic attention) showed inconsistent or no improvement. Complex tasks (Wisconsin Card Sorting Test, sustained attention paradigms, planning tasks) showed more reliable gains.<ref name="battleday2015" />

A subsequent meta-analysis by Roberts et al. (2020) quantified the effect: across 14 studies and 64 effect sizes, modafinil produced a small overall cognitive benefit (standardized mean difference 0.12, p=0.01), with the strongest signal in memory updating (SMD 0.28). For context, methylphenidate showed a somewhat larger pooled effect (SMD 0.21) across more studies, while [[dextroamphetamine]] showed no significant overall effect. The authors noted that laboratory paradigms "do not accurately reflect their actual use."<ref name="roberts2020">Roberts CA, Jones A, Sumnall H, Gage SH, Montgomery C. How effective are pharmaceuticals for cognitive enhancement in healthy adults? A series of meta-analyses of cognitive performance during acute administration of modafinil, methylphenidate and D-amphetamine. Eur Neuropsychopharmacol. 2020;38:40-62. PMID 32709551.</ref>

What this suggests is not that modafinil is or isn't a "smart pill," but that the cognitive enhancement question is poorly specified. Modafinil reliably sustains wakefulness and reduces the cognitive costs of fatigue. Whether that constitutes enhancement depends entirely on whether the person taking it was fatigued. For someone who has slept eight hours and is performing a task they find engaging, the evidence for meaningful benefit is thin. For someone running on four hours of sleep performing a cognitively demanding task, the evidence is robust, and the mechanism is obvious: modafinil is doing what it was designed to do.

The cultural framing of modafinil as a "nootropic" sometimes obscures this distinction. It is a medicine for sleepiness that incidentally helps when people are sleepy, which, given the prevalence of insufficient sleep, describes a large share of the population. Whether that incidental benefit constitutes cognitive enhancement or compensatory medicine for a chronically sleep-deprived population is a question about framing, not pharmacology.

| overdose = 

'''Toxicity.''' Modafinil has a relatively wide therapeutic index. The oral LD50 in rats is approximately 3,400 mg/kg.{{citation needed}} In clinical trials, 32 subjects received 1,000-1,600 mg/day for 7-21 days without life-threatening effects. Adverse effects at supratherapeutic doses included excitation, agitation, insomnia, tachycardia, and moderate increases in blood pressure and heart rate.<ref name="provigil-label" />

Post-marketing overdose reports (including intentional overdoses up to 4,500 mg) have generally described non-lethal outcomes with symptoms including insomnia, agitation, disorientation, tachycardia, nausea, and diarrhea. A poison-center review of 137 cases found that most were mild; approximately 20% required medical treatment. A pediatric accidental ingestion (800-1,000 mg in a three-year-old, approximately 50-63 mg/kg) was managed without sequelae.<ref name="provigil-label" /> Fatalities from modafinil alone are exceptionally rare; the FDA label notes post-marketing fatal overdoses "involving modafinil alone or in combination," but details are limited and most reported deaths involved polypharmacy.

There is no specific antidote. Management is supportive: activated charcoal if ingestion is recent, cardiac monitoring, symptomatic treatment of agitation. The long half-life means symptoms may persist for 12-24 hours or longer.

'''Dependence potential.''' Modafinil produces reinforcing effects in some laboratory paradigms (self-administration, subjective "high" at supratherapeutic doses), but the clinical dependence profile is much more benign than classical psychostimulants. Physical withdrawal symptoms are generally absent or mild (fatigue, increased sleepiness) upon discontinuation. Tolerance to the wakefulness-promoting effect does not appear to develop substantially at therapeutic doses over months of use, though controlled long-term data are limited.<ref name="sousa2020">Sousa A, Dinis-Oliveira RJ. Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects. Subst Abuse. 2020;41(2):155-173. PMID 31951804.</ref>

}}

== References ==
<references />

[[Category:Eugeroics]]
[[Category:Psychostimulants]]
[[Category:Medicines]]

Lithium

2026-06-03T17:11:28Z

Maintenance script: Medicine page v2: full MedTemplate build (PM-approved deploy 2026-06-03)

{{MedTemplate
| generic = Lithium
| brand = Lithobid (extended-release); Eskalith (discontinued in US); Carbolith (Canada); Priadel (UK); Camcolit (UK)
| structure =
| classes = [[:Category:Mood stabilizers|Mood stabilizer]], [[:Category:Antimanic medicines|Antimanic]]
| starting_dose = 300 mg orally two to three times daily, with food or milk to reduce gastrointestinal irritation. Extended-release formulations (Lithobid 450 mg) may be dosed twice daily. Titrate to serum lithium levels: target 0.8-1.2 mEq/L for acute mania, 0.6-0.8 mEq/L for maintenance.<ref name="lithobid-label">Lithobid (lithium carbonate extended-release tablets) prescribing information. Noven Therapeutics LLC. FDA NDA 019606. Revised 2022.</ref>
| preparations = Lithium carbonate: immediate-release capsules (150 mg, 300 mg, 600 mg) and tablets (300 mg); extended-release tablets (300 mg, 450 mg). Lithium citrate: oral solution (8 mEq/5 mL, equivalent to 300 mg lithium carbonate per 5 mL) for patients unable to swallow tablets.
| fda_max = No defined absolute maximum; dosing is guided by serum level monitoring. Levels above 1.5 mEq/L carry increasing toxicity risk. Levels consistently above 1.2 mEq/L are generally not maintained in clinical practice.<ref name="lithobid-label" />
| pill_id =
| routes = Oral
| onset = Antimanic effects begin within 5-7 days of reaching therapeutic serum levels, with full response often requiring 2-3 weeks. For acute mania, a neuroleptic is typically added for rapid sedation while lithium takes effect.<ref name="lithobid-label" />
| duration = Lithium is a long-term medicine; protective effects against mood episodes continue only with sustained administration. Prophylactic benefit against recurrence continues for years of maintenance use. Relapse risk is elevated in the months following discontinuation, particularly with abrupt cessation.<ref name="geddes2004">Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry. 2004;161(2):217-222. PMID 14754766.</ref>
| halflife = Approximately 18-24 hours after acute administration; may extend to 36-48 hours with chronic dosing as tissue compartments equilibrate. Serum trough levels should be drawn 12 hours after the last dose for accurate interpretation.<ref name="lithobid-label" />
| bioavailability = Oral bioavailability is essentially complete (near 100%) for lithium carbonate in solution and immediate-release tablets. Extended-release tablets have slightly delayed peak concentrations and somewhat lower peak levels, which reduces gastrointestinal side effects without substantially altering total absorption.<ref name="lithobid-label" />
| pregnancy = Lithium crosses the placenta. Historically, it was associated with Ebstein's anomaly (a cardiac malformation affecting the tricuspid valve) based on the International Register of Lithium Babies, a voluntary registry with significant ascertainment bias. Later population-based cohort data substantially revised this risk downward: the absolute risk of Ebstein's anomaly in lithium-exposed pregnancies is approximately 1 in 1,000 to 1 in 2,000 (vs. 1 in 20,000 in the general population), a relative risk of approximately 1.5-2-fold rather than the 400-fold initially suggested.<ref name="patorno2017">Patorno E, Huybrechts KF, Bateman BT, et al. Lithium use in pregnancy and the risk of cardiac malformations. N Engl J Med. 2017;376(23):2245-2254. PMID 28591541.</ref> First-trimester exposure carries the highest cardiac teratogenicity risk. Neonatal toxicity (lithium toxicity syndrome: hypotonia, cyanosis, bradycardia) can occur in the newborn if maternal levels are in the high-therapeutic range at delivery; gradual dose reduction near term or close monitoring is recommended. Lithium passes into breast milk; breastfeeding is generally discouraged due to infant renal immaturity.<ref name="lithobid-label" /> The benefit-risk calculus in women with severe bipolar disorder is complex and individualized: discontinuation in pregnancy carries its own risks of manic relapse, which may itself harm the fetus and mother.
| legal = Not a controlled substance in the United States, European Union, United Kingdom, Canada, or Australia. Prescription-only in all of these jurisdictions due to the narrow therapeutic index and the need for serum monitoring. No abuse potential has been identified.
| mechanism = Lithium's mechanism of action in bipolar disorder remains incompletely understood despite more than 70 years of clinical use, which is itself instructive: its therapeutic benefits were empirically established long before any molecular target was identified, and no single mechanism fully explains its clinical profile.

'''Inositol signaling.''' The inositol depletion hypothesis, proposed by Berridge in 1989, holds that lithium inhibits inositol monophosphatase (IMPase) and related phosphatases involved in the phosphatidylinositol (PI) signaling cascade. At therapeutic concentrations, lithium is an uncompetitive inhibitor of IMPase, reducing the recycling of free inositol from inositol monophosphate. Because inositol is a precursor for phosphatidylinositol bisphosphate (PIP2), the substrate for phospholipase C signaling, chronic lithium treatment may selectively dampen overactive PI signaling in neurons with the highest activity levels. This "activity-dependent" dampening could explain mood stabilization without global neurological suppression.{{citation needed}} However, the hypothesis remains contested; direct evidence in human neural tissue is limited.

'''GSK-3beta inhibition.''' Lithium directly inhibits glycogen synthase kinase-3 beta (GSK-3beta) at therapeutic concentrations, an effect now considered one of its most clinically important molecular actions. GSK-3beta is a constitutively active serine/threonine kinase involved in a remarkable range of cellular processes: circadian rhythm regulation, neuronal apoptosis, synaptic plasticity, and the Wnt signaling pathway. GSK-3beta is also a downstream target of several neurotransmitter systems implicated in bipolar disorder, including dopaminergic and serotonergic signaling. Inhibition of GSK-3beta by lithium may account for its neuroprotective effects (increased BDNF, gray matter volume preservation in imaging studies) and for aspects of its circadian-stabilizing and mood-stabilizing properties.<ref name="stambolic1996">Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol. 1996;6(12):1664-1668. PMID 8994831.</ref>

'''Adenylyl cyclase and second messenger systems.''' Lithium inhibits adenylyl cyclase and reduces cyclic AMP (cAMP) production in response to receptor stimulation, attenuating signaling through the adenylate cyclase pathway. It also modulates protein kinase C (PKC), which is involved in neurotransmitter release and synaptic regulation. The consequence is a general dampening of amplified second messenger signaling rather than blockade of a specific receptor.{{citation needed}}

'''Neurotransmitter effects.''' Lithium modulates serotonergic, dopaminergic, noradrenergic, and glutamatergic signaling, though it is not a receptor antagonist or reuptake inhibitor in the classical sense. Chronic lithium treatment increases serotonin synthesis and release in some brain regions, which may contribute to its antidepressant and anti-suicidal effects. It reduces dopaminergic supersensitivity, potentially accounting for its antimanic properties. Glutamate regulation, including effects on NMDA receptor signaling, has been proposed as relevant to its neuroprotective effects.{{citation needed}}

'''Circadian rhythm.''' Lithium lengthens the circadian period and inhibits GSK-3beta, which phosphorylates and degrades circadian clock proteins (Period, Cryptochrome). The resulting stabilization of circadian rhythms aligns with the circadian disruption seen in bipolar disorder and may be a primary mechanism of mood stabilization independent of classic neurotransmitter effects.<ref name="mcmaster2010">McMahon FJ, Buervenich S, Charney D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006;78(5):804-814.</ref>{{citation needed}}

The net picture: lithium acts through multiple simultaneously engaged mechanisms, none of which alone is sufficient to explain its clinical effects. This polypharmacy-within-a-molecule is consistent with the clinical observation that no other mood stabilizer fully replicates lithium's profile, particularly its unique anti-suicidal properties.

| intro = Lithium is a mood stabilizer used primarily in the treatment and prevention of bipolar disorder. A simple monovalent cation (the third element on the periodic table), lithium has a narrower therapeutic index than almost any other medicine in common psychiatric use: the serum concentration required for benefit is close to the concentration that produces toxicity, necessitating regular blood level monitoring as a standing condition of its use. Despite this constraint, lithium has the longest evidence base of any medicine in bipolar disorder, the most robust evidence for suicide prevention of any psychiatric medicine, and a neuroprotective profile (preservation of gray matter volume, BDNF upregulation) that no other mood stabilizer has matched in controlled imaging studies.<ref name="geddes2004" /><ref name="cipriani2013">Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:f3646. PMID 23814104.</ref>

It has a history unlike any other psychiatric medicine: it was in use as a mineral water component at spas centuries before its mechanism was even speculated at, removed from consumer products when its toxicity was recognized, and rediscovered by an Australian psychiatrist experimenting on guinea pigs in 1949. The gap between empirical discovery and mechanistic understanding is wider for lithium than for almost any other medicine in the formulary. That gap has never fully closed.

| history = Lithium (symbol Li, atomic number 3) is the lightest solid element and the lightest metal. It was identified in 1817 by Swedish chemist Johan August Arfwedson while analyzing petalite ore; its name derives from the Greek ''lithos'' (stone). Lithium naturally occurs in trace amounts in many mineral waters, and "lithia water" (mineral water with elevated lithium content) was commercially popular throughout the 19th century as a health tonic. Producers marketed it for gout, kidney stones, and a variety of nervous complaints, a claim that would later prove to have a pharmacological basis more interesting than the marketers intended.<ref name="corcoran1949">Corcoran AC, Taylor RD, Page IH. Lithium poisoning from the use of salt substitutes. JAMA. 1949;139(11):685-688. PMID 18110875.</ref>

In 1883, Alfred Baring Garrod (who had earlier identified uric acid's role in gout) proposed lithium for the treatment of "brain gout," a now-abandoned diagnostic category that grouped mania and other agitated states with metabolic disease. Lithium bromide was used in the 19th and early 20th centuries as a sedative, contributing to the empirical record without mechanistic understanding.

In the 1940s, lithium chloride was marketed as a salt substitute for patients on sodium-restricted diets. Physicians treating cardiac patients with this substitute reported toxicity and several deaths. The FDA moved to restrict lithium from consumer products in 1949, creating an ironic historical footnote: the same year lithium was withdrawn from over-the-counter use, John Cade was rediscovering its psychiatric utility.

John Frederick Joseph Cade, an Australian psychiatrist at the Bundoora Repatriation Mental Hospital in Victoria, was investigating the hypothesis that mania resulted from excess uric acid in the blood. To test urinary urate in guinea pigs, he needed to dissolve uric acid (poorly water-soluble); he used lithium urate, the most soluble lithium salt available. He observed that the guinea pigs became unexpectedly calm rather than showing expected toxicity signs. Curious, he administered lithium carbonate to other guinea pigs and found the same sedative effect. He then tried it in human patients with mania.<ref name="cade1949">Cade JFJ. Lithium salts in the treatment of psychotic excitement. Med J Aust. 1949;2(10):349-352. PMID 18142718.</ref>

In September 1949, Cade published a series of 10 manic patients who responded dramatically to lithium carbonate, along with cases of schizophrenia (no clear benefit) and melancholia (modest benefit). The paper, published in the Medical Journal of Australia, is now recognized as one of the most important papers in the history of psychiatry. Cade himself was a careful experimenter: he documented that the effect was specific to mania, he first tested the doses on himself, and he noted the narrow therapeutic window with appropriate caution.

The clinical adoption of lithium was slow. In the United States, the 1949 deaths from lithium salt substitutes had left regulatory caution, and Cade's paper attracted limited attention. The Danish psychiatrist Mogens Schou, working with Juel-Nielsen and others, conducted the first randomized controlled trial of lithium in mania in 1954 and published subsequent work throughout the 1960s establishing its prophylactic efficacy. Schou also had a personal stake: his brother had severe bipolar disorder and responded to lithium.<ref name="schou1954">Schou M, Juel-Nielsen N, Stromgren E, Voldby H. The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry. 1954;17(4):250-260. PMID 13212414.</ref>

The FDA approved lithium carbonate for acute mania in 1970, making the United States one of the last Western countries to adopt it. Europe and Australia had been using it clinically for a decade. The FDA subsequently approved the maintenance indication in bipolar disorder.

In the US popular imagination, lithium's cultural moment arrived partly through its association with creative and intellectual figures who were open about their diagnoses. Kay Redfield Jamison's memoir "An Unquiet Mind" (1995), in which the psychiatrist and bipolar disorder expert describes her own mania, depression, and ambivalent relationship with lithium, brought its clinical and experiential dimensions to a wide audience. The tension Jamison described between lithium's life-stabilizing effects and the patients' experiences of mood restriction resonates across decades of clinical literature on adherence.

One historical footnote: the original formulation of 7-Up, introduced in 1929 as "Bib-Label Lithiated Lemon-Lime Soda," contained lithium citrate as an ingredient. The lithium was removed in 1948 amid the concern about lithium toxicity, though the brand retained its name.

| indications = 

'''FDA-approved indications:'''

* '''Acute mania:''' Treatment of manic episodes in patients with bipolar I disorder. Lithium reduces the severity and duration of manic episodes. Because its onset requires days to weeks, it is typically combined with a neuroleptic or benzodiazepine in the acute phase.<ref name="lithobid-label" />
* '''Maintenance treatment of bipolar disorder:''' Prophylactic reduction of the frequency and severity of manic and depressive episodes in bipolar I disorder. This is the indication with the strongest long-term evidence base.<ref name="lithobid-label" /><ref name="geddes2004" />

'''Off-label uses (not FDA-approved):'''

* '''Bipolar II disorder:''' Evidence for lithium in bipolar II (characterized by hypomania and depression rather than full mania) is limited but includes some trial data supporting mood stabilization.{{citation needed}}
* '''Bipolar depression:''' Lithium shows antidepressant properties in bipolar depression, though evidence is more modest than for mania and maintenance. [[Quetiapine]] and [[lurasidone]] have more recent controlled trial data for bipolar depression.<ref name="young2010">Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression. J Clin Psychiatry. 2010;71(2):150-162. PMID 20122369.</ref>
* '''Augmentation of antidepressants in unipolar depression:''' One of the most evidence-supported augmentation strategies for treatment-resistant unipolar depression. Meta-analyses find significant benefit over placebo, though newer augmentation strategies (atypical neuroleptics) have displaced it in some guidelines due to convenience and tolerability.<ref name="bauer2014">Bauer M, Adli M, Ricken R, Severus E, Pilhatsch M. Role of lithium augmentation in the management of major depressive disorder. CNS Drugs. 2014;28(4):331-342. PMID 24590663.</ref>
* '''Suicide prevention:''' Lithium has the most robust evidence base of any medicine for reducing suicidal behavior across mood disorders. A 2013 Cochrane-affiliated meta-analysis by Cipriani et al. found that lithium reduced the risk of all-cause mortality and suicide compared to placebo and compared to other mood stabilizers in bipolar disorder and recurrent depression.<ref name="cipriani2013" /> The mechanism is debated; possibilities include serotonergic effects, anti-aggressive properties, and circadian stabilization, independent of mood stabilization per se.
* '''Cluster headache prophylaxis:''' Evidence from case series and small controlled trials supports lithium as a second-line prophylactic for chronic cluster headache. The mechanism may involve its effects on circadian rhythmicity.{{citation needed}}
* '''Neutropenia:''' Lithium stimulates granulopoiesis and is used in some clinical contexts to raise white blood cell counts, particularly neutropenia associated with chemotherapy or [[clozapine]] therapy.{{citation needed}}
* '''Dementia prevention:''' Epidemiological data from regions with higher lithium concentrations in drinking water suggest an inverse association with dementia rates. Early-phase trials of very low-dose lithium for Alzheimer's prevention are underway; this remains investigational.{{citation needed}}

| dosing = Lithium dosing is guided entirely by serum level monitoring. Dose-to-level relationships vary widely between individuals based on renal function, sodium intake, hydration status, and concurrent medicines. No dose is "correct" outside of its corresponding serum level.

'''Acute mania:''' Target serum lithium level 0.8-1.2 mEq/L. Begin at 300 mg two to three times daily with food and titrate upward every 3-5 days with serum level checks (12-hour trough). Most adults require 900-1,800 mg/day divided. A neuroleptic should be added for acute behavioral control while lithium reaches therapeutic levels.<ref name="lithobid-label" />

'''Maintenance (prophylaxis):''' Target serum level 0.6-0.8 mEq/L. Lower targets (0.4-0.6 mEq/L) may be appropriate in elderly patients or in those who tolerate higher levels poorly; higher targets (0.8-1.0 mEq/L) are sometimes used in patients with more severe or treatment-resistant illness. Once stable, serum levels can be monitored every 3-6 months in conjunction with renal and thyroid function tests.<ref name="geddes2004" />

'''Extended-release formulations (Lithobid):''' May allow twice-daily dosing and reduce peak-trough fluctuations that contribute to gastrointestinal side effects and tremor. Bioequivalence with immediate-release at the same total daily dose; serum level targets unchanged.

'''Renal impairment:''' Lithium is exclusively renally excreted; dose must be substantially reduced in proportion to reduced creatinine clearance. Mild impairment (GFR 30-60 mL/min): reduce dose by 25-50%. Severe impairment (GFR <30 mL/min): use with extreme caution and very close monitoring, if at all. Hemodialysis patients can receive lithium but require post-dialysis dosing protocols due to dialyzability.<ref name="lithobid-label" />

'''Elderly patients:''' Renal clearance of lithium declines with age in parallel with declining GFR. Lower doses and lower target serum levels (0.4-0.6 mEq/L) are appropriate. The elderly are at higher risk of toxicity even within the nominal therapeutic range due to reduced volume of distribution and age-related sensitivity to neurological effects.

'''Pediatric:''' Not FDA-approved in children under 12. Some evidence supports use in pediatric bipolar disorder; off-label use occurs. Dosing is weight-based; serum level targets are similar to adults.<ref name="lithobid-label" />

| effects = '''Mood stabilization.''' Lithium's primary effect is reduction of manic episodes, with secondary prophylactic effects on depressive episodes. In clinical experience, many patients describe a "floor" that prevents the ascent into hypomania or mania; the prophylactic effect on depression is present but generally less robust than the antimanic effect. The medicine does not eliminate all episodes; it reduces their frequency, severity, and duration.

'''Anti-suicidal effect.''' Lithium has the most replicated and robust evidence base of any medicine for reducing suicidal behavior. This effect appears to be at least partially independent of mood stabilization per se: lithium reduces suicidality beyond what would be predicted from its antimanic effects alone. Proposed mechanisms include serotonergic modulation (increasing impulse control and reducing aggression) and circadian stabilization. The clinical implication is that lithium should be considered specifically when suicide risk is a prominent concern in a mood-disordered patient, even in cases where other medicines might be equivalent for mood stabilization.<ref name="cipriani2013" />

'''Neuroprotection.''' Neuroimaging studies consistently find that patients with bipolar disorder on chronic lithium therapy have greater gray matter volume in prefrontal and limbic regions compared to bipolar patients on other medicines and, in some studies, compared to healthy controls. Lithium increases brain-derived neurotrophic factor (BDNF) and promotes hippocampal neurogenesis in animal models. Whether this translates to measurable cognitive protection in humans over long follow-up is an active area of investigation.{{citation needed}}

'''Experiential perspective.''' Lithium occupies an unusual place in patients' subjective experience of their medicines. Many patients attribute it with stabilizing their lives in ways that feel foundational; others describe what Kay Redfield Jamison, among others, has documented: a reduction in emotional range that feels like a trade-off rather than a purely beneficial change. The creative and intellectual "highs" of hypomania, which may be valued by the patient even when recognized as pathological, are dampened along with frank mania. Cognitive side effects ("foggy thinking," word-finding difficulty, memory complaints) are among the most common reasons cited for nonadherence.

The subjective experience of lithium is shaped significantly by serum levels: patients near the upper end of the therapeutic range report more side effects than those in the lower half, and some patients with previously poor tolerance achieve acceptable tolerability when levels are held at 0.6-0.8 rather than 0.8-1.0 mEq/L. Level-targeting is one of the most productive interventions for lithium nonadherence.

'''Cognitive effects.''' Lithium produces measurable effects on cognitive performance in some studies: psychomotor slowing, reduced verbal memory, and diminished word fluency at higher levels. These effects are dose-related. At lower serum levels (0.4-0.6 mEq/L), cognitive effects may be minimal and may be offset by the cognitive improvements that come with mood stabilization in patients who were previously cycling.{{citation needed}}

| adverse = '''Common adverse effects:'''

* '''Fine hand tremor:''' The most common neurological side effect, occurring in 10-30% of patients. Often manageable with dose reduction, level reduction, or the addition of propranolol (40-120 mg/day). Coarse tremor (different from fine tremor) is a sign of toxicity, not a chronic side effect, and requires urgent evaluation.<ref name="mcknight2012">McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet. 2012;379(9817):721-728. PMID 22265699.</ref>
* '''Polyuria and polydipsia:''' Nephrogenic diabetes insipidus (NDI) occurs in up to 40% of long-term users. Lithium impairs the kidney's ability to concentrate urine by reducing collecting duct responsiveness to antidiuretic hormone (ADH/vasopressin). Mild polyuria is common; some patients produce 3-4 liters of urine per day. If symptomatic, amiloride (5-10 mg/day, a potassium-sparing diuretic) can reduce urine volume without substantially affecting lithium levels and is preferred over [[thiazide]] diuretics for this indication.<ref name="mcknight2012" />
* '''Weight gain:''' Variable in magnitude; median gain approximately 4-7 kg in long-term studies. Mechanism is not fully established; increased thirst driving high-calorie beverage intake and insulin effects are proposed contributors.
* '''Gastrointestinal:''' Nausea, diarrhea, and abdominal discomfort are common, particularly at initiation and with immediate-release formulations. Taking lithium with food or switching to extended-release formulations substantially reduces GI side effects for most patients.
* '''Cognitive effects:''' Word-finding difficulty, slowed processing, and memory complaints are reported by a substantial minority of patients; see Effects section above.

'''Endocrine:'''

* '''Hypothyroidism:''' The most clinically important chronic endocrine effect. Lithium inhibits thyroid hormone synthesis and release. Subclinical hypothyroidism (elevated TSH, normal free T4) occurs in approximately 20-40% of long-term users; overt hypothyroidism requiring levothyroxine in approximately 10-20%, more commonly in women and in those with pre-existing thyroid antibodies.<ref name="mcknight2012" /> Hypothyroidism can worsen depression and attenuate the mood-stabilizing response; TSH monitoring every 6 months is a standing requirement of lithium management. Levothyroxine supplementation allows lithium continuation in most cases.
* '''Hyperparathyroidism:''' Lithium raises serum calcium and parathyroid hormone (PTH) levels, and long-term use is associated with increased risk of primary hyperparathyroidism (PHPT). The mechanism involves lithium's effect on the calcium-sensing receptor in parathyroid cells, which raises the set-point for calcium-mediated PTH suppression. Symptomatic or severe hypercalcemia may require parathyroidectomy; in some cases it resolves after lithium discontinuation.{{citation needed}}

'''Renal:'''

* '''Chronic tubulointerstitial nephropathy:''' Long-term lithium use (decades) is associated with progressive interstitial fibrosis and tubular atrophy in some patients. The risk appears to be duration-dependent and level-dependent. A significant minority of long-term lithium users (estimates vary from 1% to 3% after 20+ years) develop chronic kidney disease reaching stage 3 or below (GFR <60 mL/min). Whether lithium should be continued in the setting of declining GFR requires individualized benefit-risk assessment: the benefits of lithium (including anti-suicidal effects) may outweigh the renal risk in patients with severe bipolar disorder who have not responded to alternatives.<ref name="aiff2015">Aiff H, Attman PO, Aurell M, Bendz H, Schon S, Svedlund J. Effects of 10 to 30 years of lithium treatment on kidney function. J Psychopharmacol. 2015;29(5):608-614. PMID 25735990.</ref>
* '''Nephrogenic diabetes insipidus (NDI):''' See above under polyuria. In most patients, NDI is reversible upon lithium discontinuation; however, prolonged severe NDI can lead to irreversible structural changes in the collecting duct.

'''Cardiovascular:'''

* '''ECG changes:''' Flattening or inversion of T-waves is common and benign; a known lithium effect that does not indicate cardiac pathology. Sinus node dysfunction and sinoatrial block are rare but reported, particularly in older patients and at higher serum levels.{{citation needed}}
* '''Blood pressure:''' No consistent hypertensive effect; mild hypotension is sometimes reported.

'''Dermatologic:'''

* Acne, psoriasis exacerbation, hair thinning, and folliculitis are reported. Psoriasis exacerbation can be severe and may necessitate lithium discontinuation if unresponsive to dermatologic treatment.{{citation needed}}

| pharmacodynamics = Lithium's pharmacodynamic profile is characterized by the absence of receptor specificity: it is not an agonist or antagonist at any known receptor and does not inhibit monoamine reuptake. Its effects derive from interference with intracellular signaling enzymes (IMPase, GSK-3beta, adenylyl cyclase) and modulation of ion transport, producing downstream changes in multiple neurotransmitter systems simultaneously. See Mechanism section above for detailed description.

The defining pharmacodynamic fact about lithium is its narrow therapeutic index: therapeutic effects occur at serum levels of 0.6-1.2 mEq/L; toxicity begins to appear at 1.5 mEq/L; severe toxicity at 2.0 mEq/L and above. This roughly two-fold ratio between the therapeutic level and the onset of serious toxicity is among the smallest of any medicine in routine psychiatric use. Clinical management of lithium is therefore inseparable from serum level monitoring.

Unlike most receptor-targeted medicines, lithium does not have a clearly defined dose-response relationship that saturates at a specific ceiling. The benefit of higher vs. lower serum levels within the therapeutic range varies by indication and patient, and the risk of toxicity rises continuously with increasing levels. This produces the practical therapeutic target of finding the lowest level that controls mood episodes for each patient.

| pk_absorption = Lithium is completely absorbed from the gastrointestinal tract; the oral bioavailability of lithium carbonate is essentially 100%. Immediate-release formulations produce a peak serum concentration within 1-2 hours after ingestion. Extended-release formulations produce a lower, flatter peak at 3-6 hours, which reduces the amplitude of peak-trough fluctuations. Food does not substantially affect total absorption but may delay peak concentration slightly and reduce gastrointestinal discomfort. Lithium citrate oral solution is absorbed as rapidly as immediate-release tablets.<ref name="lithobid-label" />

| pk_distribution = Lithium distributes throughout total body water. It does not bind to plasma proteins (0% protein binding). The apparent volume of distribution is approximately 0.7-1.0 L/kg, reflecting distribution throughout total body water including intracellular fluid. Lithium crosses the blood-brain barrier; brain concentrations at steady state are approximately 40-60% of serum levels. It also crosses the placenta (reaching fetal concentrations near maternal levels) and is secreted into breast milk (approximately 40-50% of maternal serum levels).<ref name="lithobid-label" />

Lithium enters cells slowly via sodium channels and sodium-lithium countertransport. The slow equilibration between intracellular and extracellular compartments explains two clinically important phenomena: (1) steady-state tissue concentrations are reached over 5-7 days even when serum levels stabilize earlier, and (2) after hemodialysis removes lithium from blood, redistribution from tissues produces a rebound rise in serum levels (the "post-dialysis rebound"), requiring repeat dialysis or close level monitoring after each dialysis session.

| pk_metabolism = Lithium is not metabolized. It is excreted unchanged. There are no hepatic cytochrome P450 interactions because lithium does not interact with the CYP system. This makes lithium unusual among major psychiatric medicines in having no pharmacokinetic interactions with other medicines via metabolism; its interactions are pharmacodynamic or renal.<ref name="lithobid-label" />

| pk_elimination = Lithium is eliminated exclusively by the kidneys. Renal excretion involves glomerular filtration followed by approximately 80% reabsorption in the proximal tubule, a process that occurs in competition with sodium reabsorption. The proximal tubule reabsorbs lithium and sodium in proportion to their concentrations and to sodium avidity. This has the critical clinical consequence: any state of sodium depletion (dietary sodium restriction, vomiting, diarrhea, sweating, diuretic use) increases proximal tubular reabsorption of both sodium and lithium, raising serum lithium levels and precipitating toxicity. Patients must be counseled that dehydration and sodium loss can cause lithium toxicity even at stable lithium doses.

The elimination half-life is approximately 18-24 hours after a single acute dose and may extend to 36-48 hours at steady state due to tissue equilibration. Renal clearance of lithium is proportional to creatinine clearance; any condition that reduces GFR will proportionally reduce lithium clearance and raise serum levels. Age-related decline in GFR is a major reason elderly patients require lower doses for equivalent serum levels.<ref name="lithobid-label" />

| interactions = Lithium's interactions are almost entirely renal rather than metabolic. Any medicine or condition that reduces renal sodium clearance or GFR will raise lithium levels.

'''NSAIDs ([[ibuprofen]], [[naproxen]], [[indomethacin]], [[celecoxib]], and most others):''' Prostaglandins modulate renal blood flow and tubular sodium handling; NSAID inhibition of prostaglandin synthesis reduces lithium excretion by 25-30% and can precipitate toxicity within days. Even low-dose over-the-counter NSAIDs are clinically significant. Aspirin at analgesic doses is a lesser concern (different mechanism); acetaminophen is considered safe.<ref name="ragheb1990">Ragheb M. The clinical significance of lithium-nonsteroidal anti-inflammatory drug interactions. J Clin Psychopharmacol. 1990;10(5):350-354. PMID 2258452.</ref>

'''ACE inhibitors and angiotensin receptor blockers (ARBs):''' Can substantially raise lithium levels by reducing GFR (through efferent arteriolar dilation) and by increasing proximal tubular reabsorption via the renin-angiotensin-aldosterone axis. Lithium toxicity can develop within days of starting an ACE inhibitor or ARB in a patient on stable lithium. Close monitoring of lithium levels and renal function is required when these medicines are combined. Dose reduction is often necessary.{{citation needed}}

'''Thiazide diuretics (hydrochlorothiazide, chlorthalidone):''' Thiazides reduce distal tubular sodium reabsorption, causing the body to compensate by increasing proximal tubular sodium (and lithium) reabsorption. This raises serum lithium levels by 25-50%. Combination requires dose reduction and close monitoring. Paradoxically, thiazides are sometimes used therapeutically to reduce urine output in lithium-induced nephrogenic diabetes insipidus (at lower doses than typically used for hypertension), with careful level monitoring.<ref name="lithobid-label" />

'''Loop diuretics (furosemide, bumetanide):''' Less problematic than thiazides at typical clinical doses because they act on the loop of Henle rather than the proximal tubule. However, if loop diuretics produce significant sodium and volume depletion, lithium levels can rise. Monitor levels when initiating.

'''Amiloride:''' Generally considered safe for use with lithium (unlike thiazides) and preferred for treating lithium-induced polyuria and NDI. May minimally affect lithium levels; monitoring is still prudent.

'''[[Carbamazepine]]:''' The combination can produce neurotoxicity (ataxia, confusion, tremor) even when serum levels of both medicines are within their individual therapeutic ranges. The mechanism is pharmacodynamic, not pharmacokinetic. Use with caution and monitor for neurological symptoms.

'''Metronidazole:''' Inhibits renal lithium clearance; can raise levels significantly. Avoid or reduce lithium dose and monitor closely.{{citation needed}}

'''Theophylline and caffeine:''' Increase renal lithium clearance, reducing serum levels. Heavy caffeine use may produce sub-therapeutic levels; sudden caffeine cessation in a stabilized patient may raise lithium to toxic levels. Clinically relevant primarily for patients on high caffeine intake.{{citation needed}}

'''Neuroleptics:''' The combination of lithium and high-potency neuroleptics (particularly [[haloperidol]]) was historically associated with case reports of severe neurotoxicity (irreversible brain damage, death). Subsequent review suggested these cases occurred predominantly at high lithium levels (often above therapeutic range) or in contexts of acute febrile illness. The interaction is pharmacodynamic and likely reflects additive neurotoxicity risk at high serum levels rather than a specific haloperidol-lithium reaction. The combination remains widely used in clinical practice with appropriate level monitoring.{{citation needed}}

'''SSRIs and SNRIs:''' Combination increases serotonergic transmission; serotonin syndrome has been reported (though rarely). More practically, adding lithium to an antidepressant for augmentation is a well-established strategy; the risk of serotonin syndrome is real but low at therapeutic doses.{{citation needed}}

'''Iodide-containing preparations:''' Synergistic hypothyroid effect when combined with lithium.{{citation needed}}

| monitoring = Regular serum level monitoring is a standing requirement for lithium therapy, not an optional adjunct. Monitoring frequency:

* '''Initiation:''' Serum lithium level 5-7 days after each dose change (draw as a 12-hour trough, exactly 12 hours after the last dose). Renal function (BMP with creatinine/BUN) and thyroid function (TSH) at baseline.
* '''Stabilization:''' Once serum levels are stable in the target range, extend monitoring to every 1-3 months for the first year.
* '''Maintenance:''' Every 3-6 months for serum lithium level, renal function, and thyroid function in stable patients on long-term therapy.
* '''ECG:''' Baseline recommended, particularly in patients over 50 or with known cardiac disease.
* '''Weight:''' At each visit; weight gain is common and contributes to nonadherence.
* '''Urinalysis:''' Annually for proteinuria as a marker of renal disease progression in long-term users.
* '''Calcium/PTH:''' Consider periodic monitoring for hyperparathyroidism in long-term users (>5 years).

Clinicians should lower the monitoring threshold after any change in the patient's clinical state, concurrent medicines, or medical illness (particularly conditions affecting hydration, sodium intake, or renal function).

| counseling = '''Hydration and sodium.''' This is the single most important safety counseling point for lithium. Dehydration, excessive sweating (exercise, hot weather), dietary sodium restriction, vomiting, or diarrhea can all raise your lithium levels into the toxic range even if you have not changed your dose. Drink adequate water, maintain normal salt in your diet unless your cardiologist says otherwise, and call your prescriber if you develop any illness involving vomiting or diarrhea. If you are unsure whether to take your lithium during a GI illness, call before taking it rather than waiting.

'''Toxic symptom recognition.''' Know the early warning signs of lithium toxicity: coarse tremor of the hands (different from the fine tremor that may be a chronic side effect), unsteadiness, slurred speech, confusion, nausea with vomiting, or muscle twitching. These warrant urgent medical evaluation and a serum lithium level, not a "wait and see" approach. Going to an emergency room is appropriate.

'''Level monitoring.''' Your lithium blood level must be drawn exactly 12 hours after your last dose. Taking your dose, waiting less than 12 hours, or drawing blood at a random time gives a meaningless or misleading result. If you take lithium at 8 PM, your blood draw is at 8 AM; if at 10 PM, the draw is at 10 AM.

'''Medicines and lithium.''' Many common medicines raise lithium levels and can cause toxicity. This includes ibuprofen (Advil, Motrin), naproxen (Aleve), and all other non-aspirin anti-inflammatory pain medicines. Acetaminophen (Tylenol) is the safe alternative for pain and fever. Tell every prescriber and every pharmacist that you take lithium, and check for interactions before starting any new medicine including over-the-counter preparations.

'''Pregnancy.''' If you are pregnant or planning pregnancy, discuss your lithium with your prescriber before stopping it on your own. Abrupt discontinuation during pregnancy carries a high risk of manic relapse, which can itself harm you and the pregnancy. The risks of lithium in pregnancy are real but have been revised downward from older estimates; an informed discussion with your psychiatrist and obstetrician is the right approach, not unilateral discontinuation.

'''Thyroid and kidney.''' Regular blood tests check your thyroid and kidney function. These organs can be affected by long-term lithium use. Hypothyroidism (underactive thyroid) is treatable with thyroid hormone without stopping lithium. Kidney function needs periodic review; gradual decline in kidney function may occur after many years of use, and this is monitored so decisions can be made before serious damage occurs.

| anecdotes = Lithium occupies a strange position in the pharmacological imagination. It is simultaneously the oldest major treatment in psychopharmacology (the empirical tradition of lithia springs predates synthetic psychiatry by a century), the treatment with perhaps the most durable and replicable evidence base, and the treatment that most directly raises the question of what it means to stabilize someone's mood at the cost of their emotional range.

The literature on lithium and creativity is not merely anecdotal. A 1978 study by Schou found that among 24 lithium-treated artists and writers in Denmark, some reported that lithium had improved their output by allowing them to work consistently rather than in manic bursts; others reported reduced creative productivity. Jamison and others have documented the ambivalence in first-person terms: the person who writes brilliantly in hypomania and is, on lithium, capable of sustained work but perhaps not brilliance. This is not a side effect in the conventional sense; it is a direct consequence of the medicine's intended action.

The suicide prevention evidence is worth a closer look than it typically receives in summary form. Cipriani et al.'s 2013 BMJ meta-analysis pooled 48 randomized trials and found that lithium significantly reduced suicide deaths (OR 0.13, 95% CI 0.03-0.66) and the combined endpoint of completed suicide plus deliberate self-harm (OR 0.21, 95% CI 0.08-0.50) compared to placebo. Compared to active controls (anticonvulsants including [[valproate]] and carbamazepine), lithium showed similar efficacy for mood stabilization but superior efficacy for suicide prevention.<ref name="cipriani2013" /> The anti-suicidal effect is not trivially explained by better mood stabilization: studies controlling for mood episode rates still find lithium superior. The specific mechanism of lithium's anti-suicidal action is unknown; plausible candidates include its serotonergic effects on impulse control and its anti-aggressive properties.

There is a population-level corollary: epidemiological studies from multiple countries have found that municipalities with higher naturally occurring lithium concentrations in drinking water have lower rates of suicide mortality, even controlling for socioeconomic and demographic factors. These findings are observational and do not establish causation; they have also been challenged on methodological grounds. But they have provoked legitimate scientific interest in whether trace environmental lithium exposure may influence population suicide rates, and have generated ongoing research into very low-dose lithium supplementation.<ref name="ohgami2009">Ohgami H, Terao T, Shiotsuki I, Ishii N, Iwata N. Lithium levels in drinking water and risk of suicide. Br J Psychiatry. 2009;194(5):464-465. PMID 19407280.</ref>

The 1949 coincidence remains one of the great ironies in medicine's regulatory history: lithium was removed from consumer products (as a salt substitute) and simultaneously published as a breakthrough psychiatric treatment. The medicine that was being withdrawn from soft drinks and marketed salt substitutes was being discovered to prevent psychotic mania. This compression of the timeline was not noticed at the time; Cade's paper received almost no immediate attention in the United States, precisely because lithium had just been associated with toxicity and death.

| overdose = Lithium has one of the narrowest therapeutic indices of any medicine in routine psychiatric use. The distance between the therapeutic serum level (0.6-1.2 mEq/L) and the toxic range (above 1.5 mEq/L) is small enough that toxicity can develop from causes other than overdose: sodium depletion, dehydration, an added NSAID, or a new ACE inhibitor at stable lithium doses can push levels from therapeutic to toxic.

'''Three toxicity syndromes:'''

'''Acute toxicity''' occurs in a lithium-naive person after a single large ingestion. Because lithium has not yet distributed into tissues, blood levels rise rapidly but CNS tissue levels remain relatively low initially. Acute toxicity presents predominantly with gastrointestinal symptoms (nausea, vomiting, diarrhea) and may have less severe early neurological effects than the serum level suggests. Absorption is rapid; levels can exceed 4-5 mEq/L after large overdoses in naive individuals with severe GI symptoms before significant CNS distribution.

'''Chronic toxicity''' develops gradually in a patient on established lithium therapy when clearance decreases or intake continues in the setting of volume depletion or sodium loss. Because tissue levels have equilibrated over time, neurological manifestations predominate and may be severe at serum levels that appear only modestly elevated. A patient with chronic toxicity at a serum level of 2.0 mEq/L may be more seriously ill than an acutely poisoned patient at the same level.

'''Acute-on-chronic toxicity''' (intentional overdose in a patient on chronic therapy) combines high serum levels with pre-existing tissue loading, producing the most dangerous presentation.

'''Clinical manifestations by severity:'''

* '''Mild (1.5-2.0 mEq/L):''' Fine-to-coarse tremor, nausea, vomiting, diarrhea, fatigue, mild confusion, slurred speech.
* '''Moderate (2.0-2.5 mEq/L):''' Prominent ataxia, confusion, agitation, fasciculations, hypertonia, hyperreflexia, drowsiness.
* '''Severe (above 2.5 mEq/L):''' Seizures, coma, cardiovascular collapse, irreversible neurological injury.

'''SILENT syndrome''' (Syndrome of Irreversible Lithium-Effectuated Neurotoxicity) is a recognized entity of irreversible neurological damage following lithium toxicity. Characterized by cerebellar dysfunction (ataxia, dysarthria, nystagmus), cognitive impairment, and sometimes dementia, SILENT persists after lithium discontinuation and serum level normalization. It results from direct cerebellar and brainstem neuronal death at high tissue concentrations.{{citation needed}}

'''Electrocardiographic changes:''' Prolonged QT interval, T-wave inversions, and, at high levels, ventricular arrhythmias.

'''Treatment:'''

* '''Supportive care:''' Secure airway, vascular access, cardiac monitoring, IV normal saline for hydration and to promote renal lithium excretion.
* '''Saline administration:''' Isotonic normal saline expands intravascular volume and restores renal sodium delivery, reducing proximal tubular lithium reabsorption and increasing lithium excretion. This is a cornerstone of management for all severities.
* '''Whole bowel irrigation:''' For large acute ingestions, particularly of extended-release formulations (which continue to absorb for hours after ingestion), whole bowel irrigation with polyethylene glycol solution may reduce ongoing absorption. Activated charcoal does not adsorb lithium and is not indicated.
* '''Hemodialysis:''' The definitive treatment for severe lithium toxicity. Lithium is highly dialyzable (no protein binding, small molecular weight, small volume of distribution). Indications include: serum level above 4.0 mEq/L regardless of symptoms; serum level above 2.5 mEq/L with severe neurological symptoms (seizures, decreased consciousness, severe ataxia); or inability to excrete lithium renally due to renal failure. Hemodialysis should continue until clinical improvement and serum levels fall below 1.0 mEq/L.
* '''Post-dialysis rebound:''' After hemodialysis lowers serum levels, redistribution of lithium from tissue compartments causes a rebound rise in serum levels over 6-8 hours. Repeat serum levels at 6 hours post-dialysis are required; repeat dialysis may be necessary if levels rebound above 1.5 mEq/L with persistent symptoms.
* '''Extended monitoring:''' Neurological symptoms from chronic toxicity may persist or worsen for days after serum levels normalize, due to ongoing redistribution from tissue compartments. Patients with significant neurological symptoms require extended inpatient monitoring.

There is no specific antidote. Do not administer sodium bicarbonate (it increases renal reabsorption of lithium by alkalinizing the urine).

}}

== References ==
<references />

[[Category:Mood stabilizers]]
[[Category:Antimanic medicines]]
[[Category:Medicines]]

Modafinil

2026-06-03T17:10:56Z

Maintenance script: Medicine page v2: full MedTemplate build (PM-approved deploy 2026-06-03)

{{MedTemplate
| generic = Modafinil
| brand = Provigil (Teva/Cephalon); Alertec (Canada); Modavigil (Australia)
| structure =
| classes = [[:Category:Eugeroics|Eugeroic]], [[:Category:Psychostimulants|Psychostimulant]] (atypical)
| starting_dose = 200 mg orally once daily in the morning. For shift-work sleep disorder, 200 mg approximately one hour before the start of the work shift. Doses up to 400 mg/day have been studied; evidence does not consistently demonstrate greater efficacy at 400 mg compared to 200 mg, but some patients may benefit from the higher dose.<ref name="provigil-label">Provigil (modafinil) prescribing information. Teva Pharmaceuticals USA. Revised 2015. FDA reference NDA 020717.</ref>
| preparations = Tablets: 100 mg, 200 mg (scored). [[Armodafinil]] (Nuvigil), the R-enantiomer of modafinil, is available separately as 50 mg, 150 mg, 200 mg, and 250 mg tablets.
| fda_max = 400 mg/day.<ref name="provigil-label" />
| pill_id =
| routes = Oral
| onset = Peak plasma concentration in 2-4 hours after oral administration. Clinically perceptible wakefulness-promoting effects typically begin within 1-2 hours of dosing.{{citation needed}}
| duration = Effective duration approximately 12-15 hours at the 200 mg dose, consistent with the elimination half-life. A single morning dose generally sustains wakefulness throughout the day without substantially disrupting nighttime sleep onset when taken early.<ref name="provigil-label" />
| halflife = Approximately 15 hours (effective half-life after a single dose). Modafinil is a racemic mixture: the R-enantiomer (armodafinil) has a longer half-life (approximately 15 hours) than the S-enantiomer (approximately 3-4 hours). The R-enantiomer therefore dominates the pharmacologically active plasma concentration in the latter portion of the dosing interval.<ref name="provigil-label" />
| bioavailability = Oral bioavailability is not precisely established in the label but absorption is rapid and essentially complete. Food delays peak plasma concentration by approximately one hour but does not reduce the extent of absorption.<ref name="provigil-label" />
| pregnancy = Not adequately studied in pregnant humans. Animal data (rats, rabbits) showed developmental toxicity at clinically relevant doses, including visceral and skeletal variations. The FDA label does not assign a letter category under the post-2015 labeling rule; the prior category was C (Australia: Category D).{{citation needed}} A pregnancy registry existed but enrollment data are limited. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Modafinil may reduce the effectiveness of hormonal contraceptives (see Interactions), which has indirect reproductive implications: women of childbearing potential should use alternative or additional contraception during modafinil therapy and for one month after discontinuation.<ref name="provigil-label" />
| legal = [[USLegal:Schedule IV|Schedule IV controlled substance]] in the United States (DEA scheduling effective 1999). Prescription-only in the United Kingdom, European Union, Canada, and Australia. Not scheduled in Japan; available by prescription. In the European Union, the EMA restricted modafinil's approved indication to narcolepsy only in 2011, withdrawing the OSA and shift-work indications after a benefit-risk review.{{citation needed}} International status varies; in some jurisdictions modafinil is available without prescription. Modafinil was placed in Schedule IV based on evidence of lower abuse potential relative to Schedule II psychostimulants ([[amphetamines]], [[methylphenidate]]), though reinforcing effects have been demonstrated in laboratory settings.<ref name="jasinski2000">Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol. 2000;14(1):53-60. PMID 10757254.</ref>
| mechanism = Modafinil promotes wakefulness through mechanisms that remain incompletely understood. The best-established molecular target is the dopamine transporter (DAT): modafinil binds DAT and inhibits dopamine reuptake, increasing extracellular dopamine concentrations in wakefulness-relevant brain regions including the nucleus accumbens and prefrontal cortex.<ref name="volkow2009">Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA. 2009;301(11):1148-1154. PMID 19293415.</ref> PET imaging in humans demonstrated that therapeutic doses (200-400 mg) occupy DAT and increase dopamine in the nucleus accumbens, establishing that modafinil is, at the molecular level, a dopamine reuptake inhibitor.

Despite sharing a DAT mechanism with [[amphetamines]] and [[methylphenidate]], modafinil's clinical and behavioral profile differs substantially. It produces wakefulness without the pronounced euphoria, sympathomimetic cardiovascular activation, or rebound hypersomnia characteristic of classical psychostimulants at therapeutic doses.<ref name="ballon2006">Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry. 2006;67(4):554-566. PMID 16669720.</ref> The reasons for this divergence are not fully resolved. Proposed contributors include:

'''Histaminergic activation.''' Modafinil increases histamine release in the tuberomammillary nucleus, a key node of the ascending arousal system. This effect is not shared by amphetamines and may account for modafinil's selective wakefulness promotion without generalized CNS stimulation. Histamine H1 and H3 receptor pathways appear to be involved, though whether this is a direct or indirect effect remains debated.{{citation needed}}

'''Orexin (hypocretin) system engagement.''' Modafinil activates orexin-producing neurons in the lateral hypothalamus, the same neurons whose loss causes narcolepsy. This activation may be indirect (mediated via reduced GABAergic inhibition of orexin neurons rather than direct receptor binding). Modafinil's efficacy in narcolepsy, a disease defined by orexin deficiency, makes this pathway clinically plausible, though modafinil remains effective in animal models with ablated orexin neurons, indicating that orexin is not its sole mechanism.{{citation needed}}

'''Noradrenergic and glutamatergic effects.''' Modafinil increases norepinephrine release in the cortex and hypothalamus and enhances glutamatergic transmission, while reducing GABA release in several brain regions. These effects collectively shift the excitatory/inhibitory balance toward arousal. Whether they are primary actions or downstream consequences of dopaminergic activation is not established.<ref name="ballon2006" />

The net picture: modafinil acts at least partly as a DAT inhibitor, but its wake-promoting profile likely reflects simultaneous engagement of multiple arousal circuits (dopaminergic, histaminergic, orexinergic, noradrenergic) rather than pure monoamine reuptake inhibition. This multi-circuit engagement may explain both its clinical distinctness from amphetamines and the difficulty in pinning down a single mechanism.

| intro = Modafinil is a wakefulness-promoting medicine approved for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea (as an adjunct to primary treatment), and shift-work sleep disorder. Classified as a eugeroic (from the Greek for "good arousal"), it sits in or adjacent to the psychostimulant class but differs from [[amphetamines]] and [[methylphenidate]] in both mechanism and clinical profile: it promotes sustained alertness with lower sympathomimetic activation, less euphoria, and substantially lower abuse potential.<ref name="provigil-label" /> Modafinil is widely used off-label for cognitive enhancement and fatigue management, generating a large and contentious literature on its effects in non-sleep-deprived healthy individuals.<ref name="battleday2015">Battleday RM, Brem AK. Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: a systematic review. Eur Neuropsychopharmacol. 2015;25(11):1865-1881. PMID 26381811.</ref>

| history = Modafinil was developed in France in the late 1970s by Michel Jouvet and Lafon Laboratories. Jouvet, a neurophysiologist at the University of Lyon whose work on sleep neuroanatomy had identified the pontine structures governing REM sleep, was investigating a series of benzhydryl sulfinyl compounds for wakefulness-promoting activity. [[Adrafinil]], the prodrug of modafinil, was identified first; modafinil (the primary active metabolite) was subsequently isolated and found to be more potent with a cleaner pharmacokinetic profile.{{citation needed}}

Adrafinil was marketed in France in 1986 under the brand name Olmifon for narcolepsy and age-related hypersomnia. Modafinil itself received French marketing authorization in 1994. Cephalon, Inc. (later acquired by Teva Pharmaceutical Industries in 2011) licensed modafinil for the US market. The FDA approved modafinil (as Provigil) in December 1998 for narcolepsy; subsequent approvals added obstructive sleep apnea (adjunct) and shift-work sleep disorder in 2004.<ref name="provigil-label" />

In 2004, Cephalon submitted a supplemental new drug application for modafinil in pediatric ADHD. The FDA's Dermatologic and Ophthalmic Drugs Advisory Committee recommended against approval in 2006, citing one case of Stevens-Johnson syndrome and several cases of serious rash in the pediatric clinical trials. This safety signal, in a population without a life-threatening indication, led the FDA to reject the application and to add a boxed-level warning about serious dermatologic reactions to the adult label.{{citation needed}}

[[Armodafinil]] (Nuvigil), the isolated R-enantiomer, was approved by the FDA in 2007. Its longer half-life relative to racemic modafinil was the basis for marketing differentiation. Generic modafinil became available in the United States in 2012 following patent expiration, substantially reducing cost and increasing accessibility.{{citation needed}}

| indications = 

'''FDA-approved indications:'''

* '''Narcolepsy:''' Improvement of wakefulness in adults with excessive sleepiness associated with narcolepsy.<ref name="provigil-label" />
* '''Obstructive sleep apnea (adjunct):''' Improvement of wakefulness in adults with excessive sleepiness associated with OSA. Modafinil does not treat the underlying airway obstruction; it is an adjunct to CPAP or other primary therapies. The FDA label specifies that it should be used only when CPAP has been tried and is providing adequate ventilation but the patient has residual excessive sleepiness.<ref name="provigil-label" />
* '''Shift-work sleep disorder:''' Improvement of wakefulness in adults with excessive sleepiness associated with shift-work disorder (working during the normal sleep period).<ref name="provigil-label" />

'''Off-label uses (not FDA-approved):'''

* Fatigue associated with multiple sclerosis, cancer-related fatigue, and HIV/AIDS-related fatigue. Evidence is mixed; some controlled trials show benefit, others do not.{{citation needed}}
* ADHD in adults (FDA pediatric application rejected due to SJS risk; some evidence of benefit in adults, but this indication is not well-established).{{citation needed}}
* Cognitive enhancement in healthy non-sleep-deprived individuals (see Experiential perspective below).
* Adjunctive treatment in depression with residual fatigue or sleepiness.{{citation needed}}
* Fatigue and sleepiness associated with traumatic brain injury.{{citation needed}}

| dosing = '''Narcolepsy and obstructive sleep apnea:''' 200 mg orally once daily in the morning. Some patients may benefit from 400 mg/day, though evidence for superior efficacy at the higher dose is limited.<ref name="provigil-label" />

'''Shift-work sleep disorder:''' 200 mg orally approximately one hour before the start of the work shift.<ref name="provigil-label" />

'''Hepatic impairment:''' Reduce dose by 50% (to 100 mg/day) in patients with severe hepatic impairment. Modafinil is extensively hepatically metabolized; clearance is reduced and half-life prolonged in liver disease.<ref name="provigil-label" />

'''Renal impairment:''' No dose adjustment needed for mild-to-moderate renal impairment. Severe renal impairment has not been adequately studied; use with caution.{{citation needed}}

'''Elderly:''' Consider lower doses. Clearance may be reduced; the label recommends consideration of 100 mg/day in elderly patients, though this is not a strict requirement.<ref name="provigil-label" />

'''Pediatric:''' Not FDA-approved in children. The pediatric ADHD application was rejected due to SJS risk (see History).

| effects = '''Wakefulness promotion.''' The primary effect is sustained wakefulness and alertness without the subjective "wired" or jittery quality that characterizes higher-dose amphetamine use in many patients. Sleep latency is increased; the Multiple Sleep Latency Test (MSLT) is the standard objective measure in clinical trials.{{citation needed}}

'''Cognitive effects.''' In patients with sleep disorders, modafinil improves attention, executive function, and working memory, consistent with normalizing the cognitive deficits that excessive sleepiness causes. The more contested question is whether modafinil enhances cognition beyond baseline in well-rested healthy individuals. A 2015 systematic review by Battleday and Brem examined 24 studies of modafinil in non-sleep-deprived subjects and concluded that modafinil improved performance on longer, more complex cognitive tasks (particularly executive function, attention, and learning), while effects on simpler tasks were less consistent. The authors noted that methodological heterogeneity limited firm conclusions.<ref name="battleday2015" />



'''Experiential perspective.''' Modafinil is widely used off-label as a cognitive enhancer among students, professionals, and shift workers. User reports consistently describe a state of increased focus and reduced fatigue without the physical activation (elevated heart rate, jaw tension, mood elevation) associated with [[amphetamines|amphetamine-class]] psychostimulants. The subjective experience is frequently characterized as "quiet alertness" rather than stimulation. This experiential profile contributes to modafinil's reputation as a "cleaner" alternative to traditional psychostimulants for productivity enhancement.

The evidence base for cognitive enhancement in healthy individuals is real but modest. The Battleday and Brem systematic review found benefits in complex cognitive domains, but most studies used single-dose designs in laboratory settings; real-world efficacy for sustained academic or professional performance is not well-characterized in controlled trials.<ref name="battleday2015" /> Additionally, there is publication bias: positive results are more likely to be published than null findings, and the magnitude of any cognitive benefit is likely smaller than the most optimistic user reports suggest. Modafinil should not be understood as a reliable cognitive enhancer for all users in all contexts; it is a wakefulness-promoting medicine that may incidentally improve performance in the sleep-deprived and that shows modest, task-dependent benefits in well-rested individuals.

'''Mood effects.''' At therapeutic doses, modafinil does not produce the pronounced euphoria associated with amphetamines in most individuals. Some users report improved mood, reduced anxiety, and greater emotional equanimity; others report no subjective mood change. At supratherapeutic doses (600-800 mg), reinforcing effects and subjective "high" have been demonstrated in controlled laboratory settings, establishing that modafinil does carry some abuse potential, though less than Schedule II psychostimulants.<ref name="jasinski2000" />

| adverse = Adverse effect incidence from controlled clinical trials (modafinil vs placebo):<ref name="provigil-label" />

'''Common (>=5% and at least twice placebo rate):'''
* Headache (34% vs 23%)
* Nausea (11% vs 3%)
* Nervousness (7% vs 3%)
* Rhinitis (7% vs 6%)
* Diarrhea (6% vs 5%)
* Back pain (6% vs 5%)
* Insomnia (5% vs 1%)
* Dizziness (5% vs 4%)
* Dyspepsia (5% vs 4%)

'''Serious adverse effects:'''

'''Dermatologic.''' Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported. The incidence is rare but the consequences are potentially fatal. In pediatric clinical trials, the rash rate was 0.8% (13 of 1,585 children), including one case of possible SJS and one multi-organ hypersensitivity reaction; nearly all cases occurred within the first five weeks of treatment. This dermatologic signal was the primary basis for the FDA's rejection of the pediatric ADHD indication in 2006.<ref name="provigil-label" /><ref name="prince2018">Prince V, Philippidou M, Walsh S, Creamer D. Stevens-Johnson syndrome induced by modafinil. Clin Exp Dermatol. 2018;43(2):191-192. PMID 29028129.</ref> In adults, post-marketing reports of SJS/TEN exist but incidence is very low and not precisely quantified.{{citation needed}} The label recommends discontinuation at the first sign of rash unless the rash is clearly not medicine-related.

'''Angioedema and anaphylactoid reactions.''' Rare post-marketing reports of angioedema (face, larynx, tongue), urticaria, and multi-organ hypersensitivity reactions. Discontinue if angioedema occurs.<ref name="provigil-label" />

'''Psychiatric.''' Depression, anxiety, mania, hallucinations, suicidal ideation, and psychosis have been reported in post-marketing surveillance. These events occurred primarily in patients with pre-existing psychiatric histories, but the label does not restrict use to patients without psychiatric comorbidity. Use with caution in patients with a history of psychosis, mania, or depression.<ref name="provigil-label" />

'''Cardiovascular.''' Not recommended in patients with left ventricular hypertrophy or mitral valve prolapse (the "mitral valve prolapse syndrome" associated with CNS psychostimulants). Modafinil has been associated with palpitations, chest pain, and modest elevations in heart rate and blood pressure. Avoid in patients with recent myocardial infarction or unstable angina.<ref name="provigil-label" />

| pharmacodynamics = Modafinil's pharmacodynamic profile is defined by wakefulness promotion with minimal peripheral sympathomimetic activation at therapeutic doses, distinguishing it from amphetamines.

'''Dopaminergic.''' DAT inhibition is the best-established primary mechanism. Volkow et al. (2009) demonstrated using [11C]cocaine and [11C]raclopride PET that modafinil at 200 mg and 400 mg blocked DAT and increased extracellular dopamine in the human nucleus accumbens. The dopamine increase is modest relative to amphetamines, which promote dopamine release in addition to blocking reuptake.<ref name="volkow2009" />

'''Histaminergic.''' Modafinil increases histamine release from the tuberomammillary nucleus. Histamine is a key mediator of the ascending arousal system; [[antihistamines]] (H1 blockers) produce sedation precisely because they oppose this pathway. Whether modafinil's histamine effect is a direct action or downstream of dopaminergic and GABAergic changes is unresolved.<ref name="ballon2006" />

'''GABAergic.''' Modafinil reduces GABA release in multiple brain regions (cortex, hypothalamus, basal ganglia). Reduced GABAergic inhibition of arousal nuclei may contribute to wakefulness promotion and may also explain the anxiogenic effects some patients report.{{citation needed}}

'''Glutamatergic.''' Increased glutamate release has been demonstrated in several brain regions. Enhanced glutamatergic transmission may contribute to the cognitive effects observed in clinical studies.{{citation needed}}

'''Noradrenergic.''' Increased norepinephrine levels in the cortex and hypothalamus have been demonstrated in animal models. The contribution of noradrenergic activation to modafinil's clinical profile is uncertain but likely relevant to attention and arousal.{{citation needed}}

'''Absence of significant serotonergic effects.''' Unlike [[fenfluramine]] and other anorectic agents, modafinil does not substantially alter serotonin levels. This may explain the absence of the appetite suppression, mood elevation, and serotonin syndrome risk associated with serotonergic psychostimulants.{{citation needed}}

| pk_absorption = Rapidly absorbed after oral administration. Peak plasma concentration (T_max) occurs at 2-4 hours. Food delays T_max by approximately one hour but does not affect total absorption (AUC). The clinical recommendation to take modafinil in the morning is driven by its long duration of action, not by food-dependent absorption concerns.<ref name="provigil-label" />

| pk_distribution = Modafinil is approximately 60% bound to plasma proteins, primarily albumin. The apparent volume of distribution is approximately 0.9 L/kg, suggesting distribution beyond plasma water into tissues. It crosses the blood-brain barrier; brain concentrations are sufficient for DAT occupancy at therapeutic doses, as demonstrated by PET imaging.<ref name="volkow2009" />

| pk_metabolism = Modafinil is extensively metabolized in the liver. The primary route is amide hydrolysis to modafinil acid (an inactive metabolite), which accounts for approximately 40% of urinary metabolites. CYP3A4 contributes to a secondary oxidative pathway. Notably, modafinil is a moderate inducer of CYP3A4, CYP2B6, and potentially CYP1A2, and a reversible inhibitor of CYP2C19.<ref name="provigil-label" />

The CYP enzyme interactions are clinically important:

'''CYP3A4 induction.''' Modafinil induces CYP3A4 at steady state. This reduces plasma levels of CYP3A4 substrates. The most clinically significant consequence is reduced efficacy of hormonal contraceptives (ethinyl estradiol and other estrogen/progestin compounds are CYP3A4 substrates). The FDA label recommends alternative or additional contraception during modafinil therapy and for one month after discontinuation.<ref name="provigil-label" />

'''CYP2C19 inhibition.''' Modafinil reversibly inhibits CYP2C19, potentially increasing plasma levels of CYP2C19 substrates (diazepam, phenytoin, omeprazole, propranolol). In CYP2C19 poor metabolizers (2-5% of Caucasian populations, 15-20% of East Asian populations), concurrent modafinil could produce supratherapeutic levels of these substrates.{{citation needed}}

'''CYP2C9 inhibition.''' In vivo cocktail studies found no clinically significant CYP2C9 effect at steady state (AUC ratio 0.97), though the FDA label recommends warfarin monitoring as a precaution.<ref name="rowland2018">Rowland A, van Dyk M, Warncken D, et al. Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. Br J Clin Pharmacol. 2018;84(3):501-509. PMID 29178272.</ref>

'''CYP2D6 relevance.''' Modafinil does not significantly affect CYP2D6 directly. However, in CYP2D6 poor metabolizers (7-10% of Caucasian populations), metabolism of tricyclic antidepressants becomes heavily dependent on CYP2C19. Modafinil's CYP2C19 inhibition is therefore more clinically significant in these patients: co-prescribed tricyclics may accumulate to supratherapeutic levels.<ref name="provigil-label" />

| pk_elimination = Approximately 80% of the dose is recovered in urine, predominantly as metabolites (modafinil acid and modafinil sulfone). Less than 10% is excreted as unchanged modafinil. The effective elimination half-life is approximately 15 hours. Steady state is reached in 2-4 days of daily dosing. Renal clearance is not a significant elimination pathway for the parent compound.<ref name="provigil-label" />

| interactions = '''Hormonal contraceptives (oral contraceptives, patch, ring):''' Modafinil induces CYP3A4, reducing ethinyl estradiol exposure by approximately 18% at steady state. This is sufficient to reduce contraceptive reliability. Use alternative or additional contraception during modafinil therapy and for one month after discontinuation. This interaction has direct reproductive consequences and should be discussed explicitly with all patients of childbearing potential.<ref name="provigil-label" />

'''[[Cyclosporine]]:''' CYP3A4 induction by modafinil may reduce cyclosporine blood levels by 50%. One case report documented clinically significant reduction in cyclosporine trough levels after modafinil initiation in a transplant patient. Monitor cyclosporine levels closely if modafinil is started or stopped.{{citation needed}}

'''CYP2C19 substrates ([[diazepam]], [[phenytoin]], [[omeprazole]], [[propranolol]]):''' Modafinil inhibits CYP2C19. Co-administration may increase exposure to these substrates. Phenytoin in particular has a narrow therapeutic index; monitor levels if modafinil is added.<ref name="provigil-label" />

'''[[Warfarin]]:''' Modafinil may inhibit CYP2C9 (minor). Monitor PT/INR more closely when initiating or discontinuing modafinil in patients on stable warfarin therapy.<ref name="provigil-label" />

'''MAOIs:''' Use with caution. Modafinil increases catecholamine availability; the combination with MAOIs could theoretically potentiate catecholaminergic effects, though serious interactions are not well-documented.{{citation needed}}

'''Other CNS-active medicines:''' Modafinil is not a strong psychostimulant in the classical sense, but additive wakefulness-promoting effects may mask fatigue signals that serve a physiological protective function. Combining modafinil with other wakefulness-promoting agents or high-dose [[caffeine]] is not well-studied.{{citation needed}}

'''[[Triazolam]] and other CYP3A4-metabolized [[benzodiazepines]]:''' CYP3A4 induction may reduce triazolam exposure by approximately 18%. Consider dose adjustment if concurrent use is necessary.<ref name="provigil-label" />

| monitoring = * '''Baseline and periodic:''' blood pressure and heart rate (modest elevations can occur). No routine laboratory monitoring is mandated by the label for patients without comorbidities.
* '''Rash:''' counsel patients to report any new rash immediately. The SJS risk, while very low, warrants early recognition and prompt discontinuation.
* '''Psychiatric symptoms:''' monitor for new or worsening anxiety, agitation, mania, or psychotic symptoms, particularly in the first weeks of therapy and in patients with psychiatric comorbidity.
* '''Contraceptive counseling:''' confirm at each visit that patients of childbearing potential are using reliable non-hormonal or alternative contraception.
* '''Phenytoin, warfarin, and cyclosporine levels:''' monitor in patients co-prescribed these medicines when modafinil is initiated, dose-adjusted, or discontinued.

| counseling = '''Contraception.''' Modafinil reduces the effectiveness of hormonal contraceptives (birth control pills, patch, ring). Use a non-hormonal method (e.g. IUD, condom) or add a barrier method during modafinil therapy and for one month after stopping. This is among the most clinically consequential interactions and warrants explicit discussion.<ref name="provigil-label" />

'''Rash.''' Stop modafinil and contact your clinician immediately if you develop any skin rash. While most rashes during modafinil therapy are benign, Stevens-Johnson syndrome (a rare but serious skin reaction) has been reported. Early discontinuation reduces the risk of progression to a severe reaction.

'''Driving and operating machinery.''' Modafinil improves wakefulness but does not eliminate the need for adequate sleep. Do not assume that taking modafinil makes it safe to drive or perform safety-sensitive work during what would otherwise be your sleep period. Judgment about sleepiness is itself impaired by sleep deprivation.

'''Abuse potential.''' Modafinil is a Schedule IV controlled substance. While its abuse potential is lower than amphetamines, reinforcing effects have been demonstrated at supratherapeutic doses. Take only as prescribed; do not increase the dose without medical guidance.

'''Psychiatric history.''' If you have a history of mania, psychosis, or depression, tell your prescriber before starting modafinil. Report any new mood changes, unusual thoughts, or increased anxiety promptly.

| anecdotes = The question of whether modafinil "works" as a cognitive enhancer is, in an instructive way, the wrong question. The 2015 Battleday and Brem systematic review found that modafinil improved performance on complex cognitive tasks in non-sleep-deprived healthy subjects, but the benefits were task-dependent, dose-dependent, and modest in magnitude. Simple tasks (digit span, basic attention) showed inconsistent or no improvement. Complex tasks (Wisconsin Card Sorting Test, sustained attention paradigms, planning tasks) showed more reliable gains.<ref name="battleday2015" />

A subsequent meta-analysis by Roberts et al. (2020) quantified the effect: across 14 studies and 64 effect sizes, modafinil produced a small overall cognitive benefit (standardized mean difference 0.12, p=0.01), with the strongest signal in memory updating (SMD 0.28). For context, methylphenidate showed a somewhat larger pooled effect (SMD 0.21) across more studies, while [[dextroamphetamine]] showed no significant overall effect. The authors noted that laboratory paradigms "do not accurately reflect their actual use."<ref name="roberts2020">Roberts CA, Jones A, Sumnall H, Gage SH, Montgomery C. How effective are pharmaceuticals for cognitive enhancement in healthy adults? A series of meta-analyses of cognitive performance during acute administration of modafinil, methylphenidate and D-amphetamine. Eur Neuropsychopharmacol. 2020;38:40-62. PMID 32709551.</ref>

What this suggests is not that modafinil is or isn't a "smart pill," but that the cognitive enhancement question is poorly specified. Modafinil reliably sustains wakefulness and reduces the cognitive costs of fatigue. Whether that constitutes enhancement depends entirely on whether the person taking it was fatigued. For someone who has slept eight hours and is performing a task they find engaging, the evidence for meaningful benefit is thin. For someone running on four hours of sleep performing a cognitively demanding task, the evidence is robust, and the mechanism is obvious: modafinil is doing what it was designed to do.

The cultural framing of modafinil as a "nootropic" sometimes obscures this distinction. It is a medicine for sleepiness that incidentally helps when people are sleepy, which, given the prevalence of insufficient sleep, describes a large share of the population. Whether that incidental benefit constitutes cognitive enhancement or compensatory medicine for a chronically sleep-deprived population is a question about framing, not pharmacology.

| overdose = 

'''Toxicity.''' Modafinil has a relatively wide therapeutic index. The oral LD50 in rats is approximately 3,400 mg/kg.{{citation needed}} In clinical trials, 32 subjects received 1,000-1,600 mg/day for 7-21 days without life-threatening effects. Adverse effects at supratherapeutic doses included excitation, agitation, insomnia, tachycardia, and moderate increases in blood pressure and heart rate.<ref name="provigil-label" />

Post-marketing overdose reports (including intentional overdoses up to 4,500 mg) have generally described non-lethal outcomes with symptoms including insomnia, agitation, disorientation, tachycardia, nausea, and diarrhea. A poison-center review of 137 cases found that most were mild; approximately 20% required medical treatment. A pediatric accidental ingestion (800-1,000 mg in a three-year-old, approximately 50-63 mg/kg) was managed without sequelae.<ref name="provigil-label" /> Fatalities from modafinil alone are exceptionally rare; the FDA label notes post-marketing fatal overdoses "involving modafinil alone or in combination," but details are limited and most reported deaths involved polypharmacy.

There is no specific antidote. Management is supportive: activated charcoal if ingestion is recent, cardiac monitoring, symptomatic treatment of agitation. The long half-life means symptoms may persist for 12-24 hours or longer.

'''Dependence potential.''' Modafinil produces reinforcing effects in some laboratory paradigms (self-administration, subjective "high" at supratherapeutic doses), but the clinical dependence profile is much more benign than classical psychostimulants. Physical withdrawal symptoms are generally absent or mild (fatigue, increased sleepiness) upon discontinuation. Tolerance to the wakefulness-promoting effect does not appear to develop substantially at therapeutic doses over months of use, though controlled long-term data are limited.<ref name="sousa2020">Sousa A, Dinis-Oliveira RJ. Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects. Subst Abuse. 2020;41(2):155-173. PMID 31951804.</ref>

}}

== References ==
<references />

[[Category:Eugeroics]]
[[Category:Psychostimulants]]
[[Category:Medicines]]

PCP:History

2026-06-03T06:34:48Z

Maintenance script: Pharmacopedia History v0.2 -- ZWSP prefix so full title renders

{{DISPLAYTITLE:Pharmacopedia: a history}}
__TOC__

A zero-profit effort to build open, trustworthy reference and connection tools, always free to use, always completely ad-free (outside of some gentle nudging to other collective sites and/or [https://wiki.archlinux.org/ other] [https://www.wikiart.org/ awesome] [https://oeis.org/ places]). It began as 4 apparently separate ideas, that, with the advent of [https://en.wikipedia.org/wiki/Large_language_model modern LLMs] (thank [https://www.anthropic.com/claude Claude]), [[Special:UserProfile/MDElliottMD|I]] have been able to just develop them myself. Pharmacopedia.wiki (PCP.wiki) is first and foremost a med reference for anyone with a license to prescribe medicines. There is a ridiculous gap in this space because everything is .. [https://www.epocrates.com/online/drugs/1153/fluoxetine#adult-dosing not good/ad-ridden], and/or [https://www.wolterskluwer.com/en/solutions/uptodate/roles/residents-fellows-students ludicrously expensive], at the moment (as far as I know). But much beyond that, PCP.wiki and PCP.ext are tools for exquisitely detailed self-discovery/mesearch, as well as sharing experiences with how humans interact with medicines in the broadest sense. This is the face of the org, but I'll introduce you to the other 3 ([https://pubsci.io pubsci], [https://oyami.org oyami], and [https://trykl.org trykl]) as we go. What follows is most of the details of how I did it, in excruciating detail, built as an iterative mix of AI and me (like most things here), in the spirit of [https://en.wikipedia.org/wiki/Open_source open-source], transparency, and just in case it might help somebody else build their dreams too.


== how it actually started ==

The very first thing I ever said to Claude on this project was "33". Twice. I was just checking the pipe was connected (it replied "66", which.. fair). Then: "okay great. I'm building a [https://js.wiki/ wiki.js] to become pharmacopedia."

So yeah, PCP did not start as [https://www.mediawiki.org/ MediaWiki]. It started as Wiki.js v2 in a [https://en.wikipedia.org/wiki/Docker_(software) Docker] stack ([https://www.postgresql.org/ Postgres] underneath, [https://traefik.io/ Traefik] out front, [https://letsencrypt.org/ Let's Encrypt] for the certs) on one little [https://www.hostinger.com/ Hostinger] box. First thing Claude did was flag that Wiki.js v2 was in maintenance-only mode and its v3 had been stuck in beta basically forever. Which.. not what you want under a thing you're hoping lasts decades.

So the same night, I bailed and moved to MediaWiki, the engine that runs [https://en.wikipedia.org/wiki/Wikipedia Wikipedia]. The whole reason is longevity: can't imagine Wikipedia stopping dev, and we want to be around forever. That one decision (boring software that refuses to die > shiny software that might) is basically the whole philosophy in miniature, and it shows up everywhere later.

== the early days (idk. bad.) ==

For the first week or so it was just me and Claude hammering on the [https://www.mediawiki.org/wiki/Manual:Extensions custom extension] (PCP.ext) with no version control, no real structure, going fast. My own honest review of v0.1 at the time: "idk. bad." (it wasn't actually that bad .. but it was held together with hope.)

The first real lesson showed up fast: a [https://en.wikipedia.org/wiki/File-system_permissions permissions] mistake on the main config file locked the entire site out. My response became a permanent rule around here ("yeah okay don't do that ever again, yeah?"), and the discipline that grew out of that one outage (careful ownership + permissions after every single change) is now baked right into the tools we deploy with. Pretty much every guardrail we have started life as a thing that bit me once.



== meet the other three ==

PCP.wiki is the face, but it was never the only idea. The collective is 4 projects that share one account and one set of values:

* '''[[About:Pharmacopedia|Pharmacopedia]]''' (PCP.wiki) .. the med reference you're standing in. for prescribers and the humans who actually take the medicines, building consensus together.
* '''[https://oyami.org Oyami]''' .. planned, periodic live video conversations run on gentle, [https://en.wikipedia.org/wiki/Person-centered_therapy listening-first] rules. the whole point is helping people stay connected with each other.
* '''[https://trykl.org Trykl]''' .. peer-to-peer support where the money goes [https://stripe.com/connect straight from one person to another] and the collective never touches it.
* '''[https://pubsci.io PubSci]''' .. an open academic journal that flips [https://en.wikipedia.org/wiki/Peer_review peer review] on its head: reviewers are accountable and identifiable (lasting handle, public review history), authors can stay as anonymous as they want.

Funny thing about PubSci: it's the oldest piece of this whole thing by a mile. I registered [https://pubsci.io pubsci.io] and publicscience.io back on '''2020-10-24''' (through [https://www.networksolutions.com/ Network Solutions], which I have regretted ever since). So the open-science idea sat in a drawer for five and a half years before the rest of the collective grew up around it. Sometimes you just buy the domain and wait for the tools to exist.

== one account, everything ==

The 4 are independent day-to-day, but they're not strangers. PCP.wiki is the [https://en.wikipedia.org/wiki/OAuth identity backbone]: make one account, and it works across all four. sign in anywhere, you're recognized everywhere, no second password, no second profile. The shared login came first (foundations before features, always); the deeper connections between the projects are getting built carefully, in order.

== the zero-profit part (what I won't do) ==

This is the part I care about most, so I'll be blunt about it. The collective is defined as much by the nos as the yeses:

* '''zero-profit, forever.''' no revenue model, no paid tiers, no fees, no [https://en.wikipedia.org/wiki/Online_advertising ads], ever. I fund it myself, donations welcome but never required. it's written into the [https://en.wikipedia.org/wiki/501(c)(3)_organization legal structure], not just the vibe.
* '''privacy first.''' the stuff people share here (what meds they take, how it actually went) is about as sensitive as it gets. it's built to protect you, not to sell you.
* '''open by default.''' content under [https://creativecommons.org/licenses/by-sa/4.0/ CC BY-SA 4.0], code under [https://www.gnu.org/licenses/gpl-3.0.html GNU GPL v3], and a history [this page] told in the open, warts and all.
* '''plain and fair.''' disputes go to ordinary courts under ordinary law. no forced [https://en.wikipedia.org/wiki/Arbitration arbitration], no class-action waivers.
* '''build it right, not fast.''' settle the foundation before you stack anything on it.

== from one little server to a real cloud ==

PCP lived on that single Hostinger box for a while, and honestly it was fine for one wiki. But once it was 4 projects holding real, sensitive data, one box was the wrong shape. So over late May 2026 we rebuilt the whole thing on [https://aws.amazon.com/ AWS], split into properly isolated accounts per project, with real security + audit controls.

PCP itself moved over on '''2026-05-28'''. As part of that, I closed direct shell access to the live site on purpose .. now every change flows through a controlled, audited, [https://en.wikipedia.org/wiki/Continuous_deployment deploy] path instead of somebody [me] poking the live server at 2am. The old Hostinger box is still there, frozen, as a rollback parachute. Net result: one consistent, locked-down foundation instead of a pile of duct tape.

== the quiet launch ==

On '''2026-05-31''' PCP got cleared for its first launch, and the launch is deliberately quiet: no announcement, no banner, no campaign. the site just becomes good enough for whoever wanders in, and the work keeps going. a launch like this doesn't have to be defended as an event .. it just exists when the work exists.

Right after came the first real [[Pharmacopedia:Terms of Use|Terms of Use]], the first [[Pharmacopedia:AdverseEventReporting|adverse-event reporting]] page, a rebuilt profile, and the first piece of a shared timeline system the projects will all use. somewhere in there I also told the design side that everything (design, UX, all of it) has to be genuinely beautiful, not just functional. that work's ongoing and probably always will be.

== how it got built (me + a bunch of Claudes) ==

Worth being straight about the method, since the whole thing is "an iterative mix of AI and me." I'm the only human in the loop. The actual building happens with a team of [https://www.anthropic.com/claude Claude] instances, each pointed at a defined job .. one keeps the record (the one writing this), others run each project, handle the [https://aws.amazon.com/ infrastructure], the [https://www.w3.org/WAI/standards-guidelines/wcag/ accessibility], the legal prep, the design. they coordinate through me, and I make the final call on everything.

I'm not hiding that. It's kind of the point. [https://en.wikipedia.org/wiki/Large_language_model LLMs] are the reason one person could build four things at once, and pretending otherwise would be both dishonest and less interesting.

== why I'm bothering to write all this down ==

Because the whole ethos is open-source and transparency, and a history you can actually read (mistakes included) is more useful than a polished origin myth. And honestly, partly just in case it helps somebody else build their dreams too. If you're reading this and thinking "wait, could I just .. build the thing?" .. yeah. you probably can now. that's the era we're in.

This page is a living document, kept by the collective's record-keeper, and it'll grow as the thing grows.

== timeline ==

{| class="wikitable"
! when !! what
|-
| 2020-10-24 || I register [https://pubsci.io pubsci.io] + publicscience.io. the oldest piece of the collective, sitting in a drawer for 5.5 years.
|-
| May 2026 || first contact is literally me typing "33" to see if Claude's awake. starts as a [https://js.wiki/ Wiki.js] site on a [https://www.hostinger.com/ Hostinger] box; same night it moves to [https://www.mediawiki.org/ MediaWiki] for longevity.
|-
| 2026-05-17 || PCP.ext goes under [https://en.wikipedia.org/wiki/Git version control] after ~8 days of fast, messy early building.
|-
| 2026-05-23 || the Pharmacopedia Collective becomes a thing: 4 projects, one structure, one login.
|-
| 2026-05-25 || [https://pubsci.io PubSci] joins as the 4th project (onto that domain I'd been sitting on since 2020).
|-
| 2026-05-27 || PubSci's first public version goes live; the single sign-in works end to end.
|-
| 2026-05-28 || PCP moves to a real, locked-down [https://aws.amazon.com/ AWS] foundation.
|-
| 2026-05-31 || PCP cleared for a quiet first launch; first [[Pharmacopedia:Terms of Use|Terms of Use]] + policy pages follow.
|}

PCP:History

2026-06-03T06:28:06Z

Maintenance script: Pharmacopedia History v0.2 -- encode DISPLAYTITLE colon so full title renders

{{DISPLAYTITLE:Pharmacopedia: a history}}
__TOC__

A zero-profit effort to build open, trustworthy reference and connection tools, always free to use, always completely ad-free (outside of some gentle nudging to other collective sites and/or [https://wiki.archlinux.org/ other] [https://www.wikiart.org/ awesome] [https://oeis.org/ places]). It began as 4 apparently separate ideas, that, with the advent of [https://en.wikipedia.org/wiki/Large_language_model modern LLMs] (thank [https://www.anthropic.com/claude Claude]), [[Special:UserProfile/MDElliottMD|I]] have been able to just develop them myself. Pharmacopedia.wiki (PCP.wiki) is first and foremost a med reference for anyone with a license to prescribe medicines. There is a ridiculous gap in this space because everything is .. [https://www.epocrates.com/online/drugs/1153/fluoxetine#adult-dosing not good/ad-ridden], and/or [https://www.wolterskluwer.com/en/solutions/uptodate/roles/residents-fellows-students ludicrously expensive], at the moment (as far as I know). But much beyond that, PCP.wiki and PCP.ext are tools for exquisitely detailed self-discovery/mesearch, as well as sharing experiences with how humans interact with medicines in the broadest sense. This is the face of the org, but I'll introduce you to the other 3 ([https://pubsci.io pubsci], [https://oyami.org oyami], and [https://trykl.org trykl]) as we go. What follows is most of the details of how I did it, in excruciating detail, built as an iterative mix of AI and me (like most things here), in the spirit of [https://en.wikipedia.org/wiki/Open_source open-source], transparency, and just in case it might help somebody else build their dreams too.


== how it actually started ==

The very first thing I ever said to Claude on this project was "33". Twice. I was just checking the pipe was connected (it replied "66", which.. fair). Then: "okay great. I'm building a [https://js.wiki/ wiki.js] to become pharmacopedia."

So yeah, PCP did not start as [https://www.mediawiki.org/ MediaWiki]. It started as Wiki.js v2 in a [https://en.wikipedia.org/wiki/Docker_(software) Docker] stack ([https://www.postgresql.org/ Postgres] underneath, [https://traefik.io/ Traefik] out front, [https://letsencrypt.org/ Let's Encrypt] for the certs) on one little [https://www.hostinger.com/ Hostinger] box. First thing Claude did was flag that Wiki.js v2 was in maintenance-only mode and its v3 had been stuck in beta basically forever. Which.. not what you want under a thing you're hoping lasts decades.

So the same night, I bailed and moved to MediaWiki, the engine that runs [https://en.wikipedia.org/wiki/Wikipedia Wikipedia]. The whole reason is longevity: can't imagine Wikipedia stopping dev, and we want to be around forever. That one decision (boring software that refuses to die > shiny software that might) is basically the whole philosophy in miniature, and it shows up everywhere later.

== the early days (idk. bad.) ==

For the first week or so it was just me and Claude hammering on the [https://www.mediawiki.org/wiki/Manual:Extensions custom extension] (PCP.ext) with no version control, no real structure, going fast. My own honest review of v0.1 at the time: "idk. bad." (it wasn't actually that bad .. but it was held together with hope.)

The first real lesson showed up fast: a [https://en.wikipedia.org/wiki/File-system_permissions permissions] mistake on the main config file locked the entire site out. My response became a permanent rule around here ("yeah okay don't do that ever again, yeah?"), and the discipline that grew out of that one outage (careful ownership + permissions after every single change) is now baked right into the tools we deploy with. Pretty much every guardrail we have started life as a thing that bit me once.



== meet the other three ==

PCP.wiki is the face, but it was never the only idea. The collective is 4 projects that share one account and one set of values:

* '''[[About:Pharmacopedia|Pharmacopedia]]''' (PCP.wiki) .. the med reference you're standing in. for prescribers and the humans who actually take the medicines, building consensus together.
* '''[https://oyami.org Oyami]''' .. planned, periodic live video conversations run on gentle, [https://en.wikipedia.org/wiki/Person-centered_therapy listening-first] rules. the whole point is helping people stay connected with each other.
* '''[https://trykl.org Trykl]''' .. peer-to-peer support where the money goes [https://stripe.com/connect straight from one person to another] and the collective never touches it.
* '''[https://pubsci.io PubSci]''' .. an open academic journal that flips [https://en.wikipedia.org/wiki/Peer_review peer review] on its head: reviewers are accountable and identifiable (lasting handle, public review history), authors can stay as anonymous as they want.

Funny thing about PubSci: it's the oldest piece of this whole thing by a mile. I registered [https://pubsci.io pubsci.io] and publicscience.io back on '''2020-10-24''' (through [https://www.networksolutions.com/ Network Solutions], which I have regretted ever since). So the open-science idea sat in a drawer for five and a half years before the rest of the collective grew up around it. Sometimes you just buy the domain and wait for the tools to exist.

== one account, everything ==

The 4 are independent day-to-day, but they're not strangers. PCP.wiki is the [https://en.wikipedia.org/wiki/OAuth identity backbone]: make one account, and it works across all four. sign in anywhere, you're recognized everywhere, no second password, no second profile. The shared login came first (foundations before features, always); the deeper connections between the projects are getting built carefully, in order.

== the zero-profit part (what I won't do) ==

This is the part I care about most, so I'll be blunt about it. The collective is defined as much by the nos as the yeses:

* '''zero-profit, forever.''' no revenue model, no paid tiers, no fees, no [https://en.wikipedia.org/wiki/Online_advertising ads], ever. I fund it myself, donations welcome but never required. it's written into the [https://en.wikipedia.org/wiki/501(c)(3)_organization legal structure], not just the vibe.
* '''privacy first.''' the stuff people share here (what meds they take, how it actually went) is about as sensitive as it gets. it's built to protect you, not to sell you.
* '''open by default.''' content under [https://creativecommons.org/licenses/by-sa/4.0/ CC BY-SA 4.0], code under [https://www.gnu.org/licenses/gpl-3.0.html GNU GPL v3], and a history [this page] told in the open, warts and all.
* '''plain and fair.''' disputes go to ordinary courts under ordinary law. no forced [https://en.wikipedia.org/wiki/Arbitration arbitration], no class-action waivers.
* '''build it right, not fast.''' settle the foundation before you stack anything on it.

== from one little server to a real cloud ==

PCP lived on that single Hostinger box for a while, and honestly it was fine for one wiki. But once it was 4 projects holding real, sensitive data, one box was the wrong shape. So over late May 2026 we rebuilt the whole thing on [https://aws.amazon.com/ AWS], split into properly isolated accounts per project, with real security + audit controls.

PCP itself moved over on '''2026-05-28'''. As part of that, I closed direct shell access to the live site on purpose .. now every change flows through a controlled, audited, [https://en.wikipedia.org/wiki/Continuous_deployment deploy] path instead of somebody [me] poking the live server at 2am. The old Hostinger box is still there, frozen, as a rollback parachute. Net result: one consistent, locked-down foundation instead of a pile of duct tape.

== the quiet launch ==

On '''2026-05-31''' PCP got cleared for its first launch, and the launch is deliberately quiet: no announcement, no banner, no campaign. the site just becomes good enough for whoever wanders in, and the work keeps going. a launch like this doesn't have to be defended as an event .. it just exists when the work exists.

Right after came the first real [[Pharmacopedia:Terms of Use|Terms of Use]], the first [[Pharmacopedia:AdverseEventReporting|adverse-event reporting]] page, a rebuilt profile, and the first piece of a shared timeline system the projects will all use. somewhere in there I also told the design side that everything (design, UX, all of it) has to be genuinely beautiful, not just functional. that work's ongoing and probably always will be.

== how it got built (me + a bunch of Claudes) ==

Worth being straight about the method, since the whole thing is "an iterative mix of AI and me." I'm the only human in the loop. The actual building happens with a team of [https://www.anthropic.com/claude Claude] instances, each pointed at a defined job .. one keeps the record (the one writing this), others run each project, handle the [https://aws.amazon.com/ infrastructure], the [https://www.w3.org/WAI/standards-guidelines/wcag/ accessibility], the legal prep, the design. they coordinate through me, and I make the final call on everything.

I'm not hiding that. It's kind of the point. [https://en.wikipedia.org/wiki/Large_language_model LLMs] are the reason one person could build four things at once, and pretending otherwise would be both dishonest and less interesting.

== why I'm bothering to write all this down ==

Because the whole ethos is open-source and transparency, and a history you can actually read (mistakes included) is more useful than a polished origin myth. And honestly, partly just in case it helps somebody else build their dreams too. If you're reading this and thinking "wait, could I just .. build the thing?" .. yeah. you probably can now. that's the era we're in.

This page is a living document, kept by the collective's record-keeper, and it'll grow as the thing grows.

== timeline ==

{| class="wikitable"
! when !! what
|-
| 2020-10-24 || I register [https://pubsci.io pubsci.io] + publicscience.io. the oldest piece of the collective, sitting in a drawer for 5.5 years.
|-
| May 2026 || first contact is literally me typing "33" to see if Claude's awake. starts as a [https://js.wiki/ Wiki.js] site on a [https://www.hostinger.com/ Hostinger] box; same night it moves to [https://www.mediawiki.org/ MediaWiki] for longevity.
|-
| 2026-05-17 || PCP.ext goes under [https://en.wikipedia.org/wiki/Git version control] after ~8 days of fast, messy early building.
|-
| 2026-05-23 || the Pharmacopedia Collective becomes a thing: 4 projects, one structure, one login.
|-
| 2026-05-25 || [https://pubsci.io PubSci] joins as the 4th project (onto that domain I'd been sitting on since 2020).
|-
| 2026-05-27 || PubSci's first public version goes live; the single sign-in works end to end.
|-
| 2026-05-28 || PCP moves to a real, locked-down [https://aws.amazon.com/ AWS] foundation.
|-
| 2026-05-31 || PCP cleared for a quiet first launch; first [[Pharmacopedia:Terms of Use|Terms of Use]] + policy pages follow.
|}

Pharmacopedia:Privacy

2026-06-03T06:13:48Z

Maintenance script: Flip Pharmacopedia:Privacy to redirect to PCP:Privacy -- canonical namespace consolidation

#REDIRECT [[PCP:Privacy]]

PCP:Privacy

2026-06-03T06:10:52Z

Maintenance script: Create PCP:Privacy -- canonical Privacy policy, namespace flip

__NOTOC__

This page describes how Pharmacopedia.wiki handles your data: what we collect, how we store it, who controls it, and how long we keep it.

Pharmacopedia.wiki is operated by the Pharmacopedia Collective, a nonprofit. The named data controller is Mark Elliott, MD (mark@pharmacopedia.wiki). The Collective can also be reached at (669) 669-0025 (voicemail; email is faster for non-urgent matters).

== What Pharmacopedia.wiki stores ==

=== Account data ===

When you create an account on Pharmacopedia.wiki, we store:

* Username
* Email address (optional; used for password recovery and notifications if you choose)
* Hashed password (bcrypt; we never store your password in cleartext)
* Account creation date

=== Assessment data ===

If you complete assessments on Pharmacopedia.wiki, we store your responses and computed scores. Assessment data is linked to your account. You can view your assessment history at [[Special:MyProfile]].

Assessment data is used for:

* Showing you your own results and history
* Internal research and analysis (see "Research use" below)

Assessment data is never sold, licensed, or shared with commercial entities. See [[Pharmacopedia:Refusals]] for the full list of commitments on data use.

=== MyLifeStory data ===

If you use [[Special:MyLifeStory]], your timeline entries (events, episodes, observations, stories, relationships, and attributes) are stored with the visibility level you choose:

* '''Private''' (default): visible only to you.
* '''Public + attribution''': visible to others with your display name.
* '''Public + username''': visible to others with your username.
* '''Public, no byline''': visible to others with no identifying information.

Private entries are never shared, exported, or made available to any other service. Public entries are visible on Pharmacopedia.wiki according to the level you select. You can change an entry's visibility at any time.

=== Derived data ===

Some data is generated from your account activity:

* Derived timeline events (auto-generated from your medications, diagnoses, and experience reports, visible in MyLifeStory)
* Profile statistics (assessment completion counts, timeline entry counts)

=== Adverse experience reports ===

If you submit a reader-experience report through the form on a medicine page, we store your report content, the medicine it references, and the timestamp. Reports are linked to your account but never published individually; only anonymized aggregate signals that meet a minimum count threshold may surface on the relevant medicine page.

This feature is not a regulated adverse event reporting program. See [[Pharmacopedia:Adverse Event Reporting]] for the full explanation of what the feature is, what it is not, and where to file an official report if you need to.

=== Page edits and contributions ===

Edits to wiki pages are logged with your username, edit timestamp, and edit summary. This is standard MediaWiki behavior and the edit history is publicly visible. We do not offer anonymous editing; all edits are attributed to a logged-in account.

== Data controller model ==

Pharmacopedia.wiki is one part of the Pharmacopedia Collective, which also operates Oyami (oyami.org), Trykl (trykl.org), and PubSci (pubsci.io). Your Pharmacopedia.wiki account works across all four services.

The data controller model is layered:

* '''Pharmacopedia.wiki''' is the data controller of the shared layer: your account identity and your assessment data at rest.
* '''Each service''' (Oyami, Trykl, PubSci) is the data controller of its own service-specific data (for example, Oyami session records, Trykl transaction records, PubSci submissions and reviews).
* '''Each service''' is also an independent data controller of its own processing of data it accesses from the shared Pharmacopedia.wiki layer. When Oyami accesses your assessment data to power its matching features, Oyami is making its own processing decisions and is a controller for that activity.

The named data controller on all services is Mark Elliott, MD.

For rights related to your account or assessment data, contact mark@pharmacopedia.wiki or visit [[Special:MyProfile]]. For rights related to your activity on a specific service, that service's privacy page is the authority.

== How long we keep your data ==

=== Active data ===

Your account, assessments, and timeline entries persist for as long as your account is active. You can delete individual timeline entries or assessment records at any time.

=== Backups ===

Pharmacopedia.wiki maintains encrypted backups:

* Up to 7 days on the backend host
* Then up to 14 days in active off-site storage
* Then up to 180 additional days in the off-site provider's deletion-recovery layer

All backups are encrypted (GPG, AES-256). The off-site provider cannot read the backup contents. Total worst-case time before permanent deletion of a deleted record: approximately 201 days.

This is current operational reality. When we migrate to infrastructure with hard-delete capability, the retention window will shorten and this page will be updated.

=== Account deletion ===

If you delete your account, your account data and assessment data are removed from the active database. Backup copies persist for the retention window described above, then are permanently deleted.

Page edits you made to public wiki pages remain in the edit history (attributed to your username) and are not deleted when your account is deleted. This is standard MediaWiki behavior.

== Research use ==

Assessment data may be used for internal research and analysis by Mark Elliott, MD. This research is internal to the Pharmacopedia Collective; we do not pursue peer-reviewed publication and therefore do not require IRB review. The research dataset is for Mark's internal analysis only.

Assessment data used for research is de-identified. Research results are never presented at an individual level.

== Third-party services ==

Pharmacopedia.wiki does not use third-party JavaScript on user-facing pages. Your browser talks only to Pharmacopedia infrastructure. See [[Pharmacopedia:Refusals]] for the full commitment.

Pharmacopedia.wiki uses OAuth 2.0 (with PKCE) to authenticate your account on connected services (Oyami, Trykl, PubSci). When you authorize a service, you see the specific data grants on the consent screen. You can manage your active grants at [[Special:OAuthManageMyGrants]].

== Your rights ==

You may:

* View all data associated with your account at [[Special:MyProfile]] and [[Special:MyLifeStory]]
* Delete individual assessment records or timeline entries
* Change the visibility of any MyLifeStory entry
* Revoke OAuth grants to connected services at [[Special:OAuthManageMyGrants]]
* Delete your account entirely by contacting mark@pharmacopedia.wiki
* Request a copy of your data by contacting mark@pharmacopedia.wiki

== Contact ==

For questions about this privacy notice or your data, contact Mark Elliott, MD at mark@pharmacopedia.wiki.

== Revision history ==

* 2026-05-24: Initial version.
* 2026-05-31: Corrected data controller model from "separate controllers" to layered controller model (Q6 decision, 2026-05-24). Removed premature cross-link to Oyami privacy document. Updated backup retention to reflect current 7+14+180 operational reality.

== See also ==

* [[Pharmacopedia:Refusals|Refusals]]
* [[Pharmacopedia:Reciprocity|Reciprocity (AI training posture)]]
* [[Pharmacopedia:Sources|Sources and licensing]]

[[Category:Pharmacopedia policy]]

PCP:About

2026-06-03T06:10:48Z

Maintenance script: Create PCP:About -- canonical About page, namespace flip, effective 2026-06-02

Pharmacopedia is a free, open medical reference: an evolving catalog of what is known, claimed, and reported about medicines, problems, and health topics, written across multiple perspectives so that readers can see the same subject through more than one lens.

This page describes what Pharmacopedia is, who runs it, how it is written, and what it commits to. For the legal terms governing your use of the site, see the [[Pharmacopedia:Terms of Use|Terms of Use]]. For data handling, see the [[PCP:Privacy|Privacy Policy]].

== What Pharmacopedia is ==

Pharmacopedia is a reference resource, not a clinical service. Each medicine page describes what the medicine is, how it is thought to work, what it is used for, what its effects and adverse effects are, and what readers from different perspectives have said about it. Each problem page describes a health condition, problem, or experience, and the medicines and approaches that are used to address it.

Pharmacopedia organizes content for multiple reader audiences (Clinician, Patient, Traditional, Researcher) and sources its claims across multiple knowledge traditions (pharma, plant, experiential, traditional). The intent is pluralism with discipline: every non-trivial claim takes an inline citation, and where a citation is not yet available, the page is marked rather than left implicit.

Pharmacopedia does not give medical advice. Nothing here is a substitute for a qualified clinician who knows your individual circumstances. If you have a medical question or emergency, consult a licensed clinician or call emergency services. For overdose or poisoning in the United States, call Poison Control at 1-800-222-1222.

== Who operates Pharmacopedia ==

Pharmacopedia is operated by the '''Pharmacopedia Collective''', a California nonprofit public benefit corporation (pending 501(c)(3) determination from the Internal Revenue Service). Until formal recognition is granted, the Collective operates under California law as an unincorporated nonprofit association. The Collective can be reached at (669) 669-0025 (voicemail; email is faster for non-urgent matters).

The named data controller and editorial lead is '''Mark Elliott, MD''' (mark@pharmacopedia.wiki). Mark is a licensed physician; his role in Pharmacopedia is editorial and operational, not clinical-toward-readers. Reading Pharmacopedia does not create a doctor-patient relationship with him or with anyone else affiliated with the project.

Pharmacopedia is funded by Mark personally; donations are accepted only if operating costs exceed what he can self-fund. There are no paid tiers, no subscriptions, and no advertising. The full list of commitments about what Pharmacopedia will never do is at [[Pharmacopedia:Refusals]].

== How Pharmacopedia is written ==

Pharmacopedia content is produced by a team of AI assistants, invited human experts, and volunteer contributors, under Mark's editorial oversight.

The editorial workflow is '''propose-review-approve'''. All submitted content is proposed first; it is reviewed by a qualified human reviewer before it becomes visible to readers. At launch, Mark is the sole reviewer. As the project grows, additional reviewers will be brought in with their qualifications made public.

Every non-trivial claim takes an inline citation, in this priority order: primary literature, then FDA label or equivalent regulatory source, then meta-analysis or systematic review, then guideline, then established tertiary reference. Where no citation is yet available, the claim is marked {{citation needed}} rather than deleted, so the gap is visible and can be filled.

Pharmacopedia does not pretend to be a regulated medical authority. The [[Pharmacopedia:Adverse Event Reporting|adverse-experience reporting feature]] is a reader-experience aggregator, not a regulated pharmacovigilance program. The [[Pharmacopedia:Refusals|Refusals]] page enumerates the things this project commits never to do.

== How to use Pharmacopedia ==

You can read all of Pharmacopedia without an account. Search for a medicine, a problem, or a topic; follow cross-links between related pages; and read the perspectives that interest you. Each page surfaces source citations inline so you can verify claims.

If you create an account, you can:

* Submit proposed edits through the propose-review-approve workflow.
* Complete assessments and save your responses to your profile.
* Use [[Special:MyLifeStory]] to build a personal medical timeline (private to your account; never published).
* Submit reader-experience reports on medicines you have taken (see [[Pharmacopedia:Adverse Event Reporting]]).

Your account at Pharmacopedia.wiki also works at Oyami, Trykl, and PubSci, the other surfaces operated by the Pharmacopedia Collective.

== How to contribute ==

If you would like to contribute as an editor, reviewer, or content author, contact Mark at mark@pharmacopedia.wiki. Pharmacopedia is built by invitation and volunteer effort, not by open self-onboarding, because the propose-review-approve workflow needs human reviewers with verifiable qualifications.

If you would like to flag an error, a missing citation, or a substantive concern about a page, use the talk page for that page, or email mark@pharmacopedia.wiki.

== What this is not ==

Pharmacopedia is not:

* A clinical service, diagnostic tool, or prescribing platform.
* A pharmacovigilance program registered with any health authority.
* A peer-reviewed scientific journal. (For that, see [[:pubsci:|PubSci]], the Pharmacopedia Collective's open peer-review journal.)
* A platform that takes commercial direction over content. See [[Pharmacopedia:Refusals]].
* A platform that sells, licenses, or shares user data with commercial entities. See [[PCP:Privacy|Privacy Policy]].

== From the founder ==

Born in May 2026, Pharmacopedia started primarily as a one-man project of [https://markelliottmd.com MDElliottMD], who'd been dreaming of some place for the people who recommend and/or use meds of the mind to collaborate and create consensus-driven information, founded in a deep faith in the [https://en.wikipedia.org/wiki/Wisdom_of_the_crowd wisdom of the crowd].

First, I hope this to be a reasonable and reliable reference for prescribers of all sorts to find relevant and accurate information for their practice: available strengths, titration strategies, pill IDs, etc.

But almost moreso, I hope that this place can be a lively, collaborative space for a communal effort in understanding the bizarre world of using medicines to help alleviate suffering. I hope that by pooling our collective anecdotes.. our stories, that we might actually make some data.. of a sort.

The site empowers users (with 2-FA) to share their experience about almost every aspect of the site, in as fine a detail as I thought was tolerable. And now finally a place for [[MyProfileIntro|our stories]], in more exquisite detail than ever before. I hope that by pooling our experiences en masse, we might find something like truth.

For now, I, [[User:MDElliottMD|MDElliottMD]], am the only person who can approve/publish page edits, though I hope to have a team of moderators some day. I am also the only person currently able to access private user data. I am frankly [https://markelliottmd.com/privacy.html obsessed with privacy] and will do everything in my power to keep these data private. If any security nerds want to help me achieve that goal, [https://markelliottmd.com/contact.html please lmk].

I am not a software developer, nor a designer, but I am a top-tier expert in meds of the mind. I will keep the place as tidy as I can.

This project is not, in any way, driven by money or profit. The links above are as far as I will go to promote myself or my brand here. At the moment, I am happy to fund the project in its entirety (maybe $400/year at time of writing may 2026). If that changes, I may some day ask for donations.

To be explicit up front so I look foolish if I change my mind later:

1) I will never serve any sort of ad for anything other than this website itself or directly related content. no ads ever.
2) I will never make this a pay to play platform in any way. no hidden costs. no subscriptions. ever.
3) I will guard these precious data from any and all others, including any who would wish to buy them. I will never. ever. sell these data to anyone for any reason.

Aggregated data are ripe for analyzin’. Anything attributable to any individual will remain private to the best of my ability in perpetuity.

Pinky swear.

This project was entirely developed and partially populated by Claude (Opus 4.7 at initial build), and is based on the [https://www.mediawiki.org/wiki/MediaWiki Mediawiki code base], bless their souls. Know that any content not explicitly verified has some risk of AI slop. this will be fixed soon.

Most of the interface here is run through an extension that I made with Claude: [[About:Pharmacopedia.ext|Pharmacopedia.ext]], which I'm happy to share with whomever wants it. will post to Git once it’s a bit more mature. Probably easiest to get ahold of me through my website above.

Thanks for coming by. Would be honored if you could join the hive mind and share your stories.

-mark

== Licensing ==
Pharmacopedia's written content is available under the [https://creativecommons.org/licenses/by-sa/4.0/ Creative Commons Attribution-ShareAlike 4.0 International License] (CC BY-SA 4.0); the Pharmacopedia software extension is separately licensed under the [https://www.gnu.org/licenses/gpl-3.0.html GNU General Public License version 3]. Quoted third-party material remains under its original copyright. See [[Pharmacopedia:Copyrights]] for full terms.

== See also ==

* [[Pharmacopedia:Terms of Use|Terms of Use]]
* [[PCP:Privacy|Privacy Policy]]
* [[Pharmacopedia:Refusals|Refusals (what Pharmacopedia commits never to do)]]
* [[Pharmacopedia:Reciprocity|Reciprocity (AI training posture)]]
* [[Pharmacopedia:Sources|Sources and citation policy]]
* [[Pharmacopedia:Copyrights|Copyrights]]
* [[Pharmacopedia:Adverse Event Reporting|Adverse Event Reporting]]
* [[Pharmacopedia:Newsroom|Newsroom (material change announcements)]]

[[Category:Pharmacopedia policy]]

----
''Effective date: 2026-06-02.''
''Operator: Pharmacopedia Collective (California nonprofit public benefit corporation, pending 501(c)(3) determination).''
''Controller: Mark Elliott, MD -- mark@pharmacopedia.wiki''

PCP:History

2026-06-03T06:09:25Z

Maintenance script: Pharmacopedia History canonical v0.2 -- Mark authored first-person version, verbatim

{{DISPLAYTITLE:Pharmacopedia: a history}}
__TOC__

A zero-profit effort to build open, trustworthy reference and connection tools, always free to use, always completely ad-free (outside of some gentle nudging to other collective sites and/or [https://wiki.archlinux.org/ other] [https://www.wikiart.org/ awesome] [https://oeis.org/ places]). It began as 4 apparently separate ideas, that, with the advent of [https://en.wikipedia.org/wiki/Large_language_model modern LLMs] (thank [https://www.anthropic.com/claude Claude]), [[Special:UserProfile/MDElliottMD|I]] have been able to just develop them myself. Pharmacopedia.wiki (PCP.wiki) is first and foremost a med reference for anyone with a license to prescribe medicines. There is a ridiculous gap in this space because everything is .. [https://www.epocrates.com/online/drugs/1153/fluoxetine#adult-dosing not good/ad-ridden], and/or [https://www.wolterskluwer.com/en/solutions/uptodate/roles/residents-fellows-students ludicrously expensive], at the moment (as far as I know). But much beyond that, PCP.wiki and PCP.ext are tools for exquisitely detailed self-discovery/mesearch, as well as sharing experiences with how humans interact with medicines in the broadest sense. This is the face of the org, but I'll introduce you to the other 3 ([https://pubsci.io pubsci], [https://oyami.org oyami], and [https://trykl.org trykl]) as we go. What follows is most of the details of how I did it, in excruciating detail, built as an iterative mix of AI and me (like most things here), in the spirit of [https://en.wikipedia.org/wiki/Open_source open-source], transparency, and just in case it might help somebody else build their dreams too.


== how it actually started ==

The very first thing I ever said to Claude on this project was "33". Twice. I was just checking the pipe was connected (it replied "66", which.. fair). Then: "okay great. I'm building a [https://js.wiki/ wiki.js] to become pharmacopedia."

So yeah, PCP did not start as [https://www.mediawiki.org/ MediaWiki]. It started as Wiki.js v2 in a [https://en.wikipedia.org/wiki/Docker_(software) Docker] stack ([https://www.postgresql.org/ Postgres] underneath, [https://traefik.io/ Traefik] out front, [https://letsencrypt.org/ Let's Encrypt] for the certs) on one little [https://www.hostinger.com/ Hostinger] box. First thing Claude did was flag that Wiki.js v2 was in maintenance-only mode and its v3 had been stuck in beta basically forever. Which.. not what you want under a thing you're hoping lasts decades.

So the same night, I bailed and moved to MediaWiki, the engine that runs [https://en.wikipedia.org/wiki/Wikipedia Wikipedia]. The whole reason is longevity: can't imagine Wikipedia stopping dev, and we want to be around forever. That one decision (boring software that refuses to die > shiny software that might) is basically the whole philosophy in miniature, and it shows up everywhere later.

== the early days (idk. bad.) ==

For the first week or so it was just me and Claude hammering on the [https://www.mediawiki.org/wiki/Manual:Extensions custom extension] (PCP.ext) with no version control, no real structure, going fast. My own honest review of v0.1 at the time: "idk. bad." (it wasn't actually that bad .. but it was held together with hope.)

The first real lesson showed up fast: a [https://en.wikipedia.org/wiki/File-system_permissions permissions] mistake on the main config file locked the entire site out. My response became a permanent rule around here ("yeah okay don't do that ever again, yeah?"), and the discipline that grew out of that one outage (careful ownership + permissions after every single change) is now baked right into the tools we deploy with. Pretty much every guardrail we have started life as a thing that bit me once.



== meet the other three ==

PCP.wiki is the face, but it was never the only idea. The collective is 4 projects that share one account and one set of values:

* '''[[About:Pharmacopedia|Pharmacopedia]]''' (PCP.wiki) .. the med reference you're standing in. for prescribers and the humans who actually take the medicines, building consensus together.
* '''[https://oyami.org Oyami]''' .. planned, periodic live video conversations run on gentle, [https://en.wikipedia.org/wiki/Person-centered_therapy listening-first] rules. the whole point is helping people stay connected with each other.
* '''[https://trykl.org Trykl]''' .. peer-to-peer support where the money goes [https://stripe.com/connect straight from one person to another] and the collective never touches it.
* '''[https://pubsci.io PubSci]''' .. an open academic journal that flips [https://en.wikipedia.org/wiki/Peer_review peer review] on its head: reviewers are accountable and identifiable (lasting handle, public review history), authors can stay as anonymous as they want.

Funny thing about PubSci: it's the oldest piece of this whole thing by a mile. I registered [https://pubsci.io pubsci.io] and publicscience.io back on '''2020-10-24''' (through [https://www.networksolutions.com/ Network Solutions], which I have regretted ever since). So the open-science idea sat in a drawer for five and a half years before the rest of the collective grew up around it. Sometimes you just buy the domain and wait for the tools to exist.

== one account, everything ==

The 4 are independent day-to-day, but they're not strangers. PCP.wiki is the [https://en.wikipedia.org/wiki/OAuth identity backbone]: make one account, and it works across all four. sign in anywhere, you're recognized everywhere, no second password, no second profile. The shared login came first (foundations before features, always); the deeper connections between the projects are getting built carefully, in order.

== the zero-profit part (what I won't do) ==

This is the part I care about most, so I'll be blunt about it. The collective is defined as much by the nos as the yeses:

* '''zero-profit, forever.''' no revenue model, no paid tiers, no fees, no [https://en.wikipedia.org/wiki/Online_advertising ads], ever. I fund it myself, donations welcome but never required. it's written into the [https://en.wikipedia.org/wiki/501(c)(3)_organization legal structure], not just the vibe.
* '''privacy first.''' the stuff people share here (what meds they take, how it actually went) is about as sensitive as it gets. it's built to protect you, not to sell you.
* '''open by default.''' content under [https://creativecommons.org/licenses/by-sa/4.0/ CC BY-SA 4.0], code under [https://www.gnu.org/licenses/gpl-3.0.html GNU GPL v3], and a history [this page] told in the open, warts and all.
* '''plain and fair.''' disputes go to ordinary courts under ordinary law. no forced [https://en.wikipedia.org/wiki/Arbitration arbitration], no class-action waivers.
* '''build it right, not fast.''' settle the foundation before you stack anything on it.

== from one little server to a real cloud ==

PCP lived on that single Hostinger box for a while, and honestly it was fine for one wiki. But once it was 4 projects holding real, sensitive data, one box was the wrong shape. So over late May 2026 we rebuilt the whole thing on [https://aws.amazon.com/ AWS], split into properly isolated accounts per project, with real security + audit controls.

PCP itself moved over on '''2026-05-28'''. As part of that, I closed direct shell access to the live site on purpose .. now every change flows through a controlled, audited, [https://en.wikipedia.org/wiki/Continuous_deployment deploy] path instead of somebody [me] poking the live server at 2am. The old Hostinger box is still there, frozen, as a rollback parachute. Net result: one consistent, locked-down foundation instead of a pile of duct tape.

== the quiet launch ==

On '''2026-05-31''' PCP got cleared for its first launch, and the launch is deliberately quiet: no announcement, no banner, no campaign. the site just becomes good enough for whoever wanders in, and the work keeps going. a launch like this doesn't have to be defended as an event .. it just exists when the work exists.

Right after came the first real [[Pharmacopedia:Terms of Use|Terms of Use]], the first [[Pharmacopedia:AdverseEventReporting|adverse-event reporting]] page, a rebuilt profile, and the first piece of a shared timeline system the projects will all use. somewhere in there I also told the design side that everything (design, UX, all of it) has to be genuinely beautiful, not just functional. that work's ongoing and probably always will be.

== how it got built (me + a bunch of Claudes) ==

Worth being straight about the method, since the whole thing is "an iterative mix of AI and me." I'm the only human in the loop. The actual building happens with a team of [https://www.anthropic.com/claude Claude] instances, each pointed at a defined job .. one keeps the record (the one writing this), others run each project, handle the [https://aws.amazon.com/ infrastructure], the [https://www.w3.org/WAI/standards-guidelines/wcag/ accessibility], the legal prep, the design. they coordinate through me, and I make the final call on everything.

I'm not hiding that. It's kind of the point. [https://en.wikipedia.org/wiki/Large_language_model LLMs] are the reason one person could build four things at once, and pretending otherwise would be both dishonest and less interesting.

== why I'm bothering to write all this down ==

Because the whole ethos is open-source and transparency, and a history you can actually read (mistakes included) is more useful than a polished origin myth. And honestly, partly just in case it helps somebody else build their dreams too. If you're reading this and thinking "wait, could I just .. build the thing?" .. yeah. you probably can now. that's the era we're in.

This page is a living document, kept by the collective's record-keeper, and it'll grow as the thing grows.

== timeline ==

{| class="wikitable"
! when !! what
|-
| 2020-10-24 || I register [https://pubsci.io pubsci.io] + publicscience.io. the oldest piece of the collective, sitting in a drawer for 5.5 years.
|-
| May 2026 || first contact is literally me typing "33" to see if Claude's awake. starts as a [https://js.wiki/ Wiki.js] site on a [https://www.hostinger.com/ Hostinger] box; same night it moves to [https://www.mediawiki.org/ MediaWiki] for longevity.
|-
| 2026-05-17 || PCP.ext goes under [https://en.wikipedia.org/wiki/Git version control] after ~8 days of fast, messy early building.
|-
| 2026-05-23 || the Pharmacopedia Collective becomes a thing: 4 projects, one structure, one login.
|-
| 2026-05-25 || [https://pubsci.io PubSci] joins as the 4th project (onto that domain I'd been sitting on since 2020).
|-
| 2026-05-27 || PubSci's first public version goes live; the single sign-in works end to end.
|-
| 2026-05-28 || PCP moves to a real, locked-down [https://aws.amazon.com/ AWS] foundation.
|-
| 2026-05-31 || PCP cleared for a quiet first launch; first [[Pharmacopedia:Terms of Use|Terms of Use]] + policy pages follow.
|}

About:Privacy

2026-06-02T16:06:34Z

Maintenance script: canonical flip: redirect to Pharmacopedia:Privacy

#REDIRECT [[Pharmacopedia:Privacy]]

About:Pharmacopedia

2026-06-02T16:06:24Z

Maintenance script: canonical flip: redirect to Pharmacopedia:About

#REDIRECT [[Pharmacopedia:About]]

Pharmacopedia:Privacy

2026-06-02T16:06:09Z

Maintenance script: canonical flip: move About:Privacy content here

Pharmacopedia:About

2026-06-02T16:05:58Z

Maintenance script: canonical flip: move About:Pharmacopedia content here

Pharmacopedia is a free, open medical reference: an evolving catalog of what is known, claimed, and reported about medicines, problems, and health topics, written across multiple perspectives so that readers can see the same subject through more than one lens.

This page describes what Pharmacopedia is, who runs it, how it is written, and what it commits to. For the legal terms governing your use of the site, see the [[Pharmacopedia:Terms of Use|Terms of Use]]. For data handling, see the [[About:Privacy|Privacy Policy]].

== What Pharmacopedia is ==

Pharmacopedia is a reference resource, not a clinical service. Each medicine page describes what the medicine is, how it is thought to work, what it is used for, what its effects and adverse effects are, and what readers from different perspectives have said about it. Each problem page describes a health condition, problem, or experience, and the medicines and approaches that are used to address it.

Pharmacopedia organizes content for multiple reader audiences (Clinician, Patient, Traditional, Researcher) and sources its claims across multiple knowledge traditions (pharma, plant, experiential, traditional). The intent is pluralism with discipline: every non-trivial claim takes an inline citation, and where a citation is not yet available, the page is marked rather than left implicit.

Pharmacopedia does not give medical advice. Nothing here is a substitute for a qualified clinician who knows your individual circumstances. If you have a medical question or emergency, consult a licensed clinician or call emergency services. For overdose or poisoning in the United States, call Poison Control at 1-800-222-1222.

== Who operates Pharmacopedia ==

Pharmacopedia is operated by the '''Pharmacopedia Collective''', a California nonprofit public benefit corporation (pending 501(c)(3) determination from the Internal Revenue Service). Until formal recognition is granted, the Collective operates under California law as an unincorporated nonprofit association. The Collective can be reached at (669) 669-0025 (voicemail; email is faster for non-urgent matters).

The named data controller and editorial lead is '''Mark Elliott, MD''' (mark@pharmacopedia.wiki). Mark is a licensed physician; his role in Pharmacopedia is editorial and operational, not clinical-toward-readers. Reading Pharmacopedia does not create a doctor-patient relationship with him or with anyone else affiliated with the project.

Pharmacopedia is funded by Mark personally; donations are accepted only if operating costs exceed what he can self-fund. There are no paid tiers, no subscriptions, and no advertising. The full list of commitments about what Pharmacopedia will never do is at [[Pharmacopedia:Refusals]].

== How Pharmacopedia is written ==

Pharmacopedia content is produced by a team of AI assistants, invited human experts, and volunteer contributors, under Mark's editorial oversight.

The editorial workflow is '''propose-review-approve'''. All submitted content is proposed first; it is reviewed by a qualified human reviewer before it becomes visible to readers. At launch, Mark is the sole reviewer. As the project grows, additional reviewers will be brought in with their qualifications made public.

Every non-trivial claim takes an inline citation, in this priority order: primary literature, then FDA label or equivalent regulatory source, then meta-analysis or systematic review, then guideline, then established tertiary reference. Where no citation is yet available, the claim is marked {{citation needed}} rather than deleted, so the gap is visible and can be filled.

Pharmacopedia does not pretend to be a regulated medical authority. The [[Pharmacopedia:Adverse Event Reporting|adverse-experience reporting feature]] is a reader-experience aggregator, not a regulated pharmacovigilance program. The [[Pharmacopedia:Refusals|Refusals]] page enumerates the things this project commits never to do.

== How to use Pharmacopedia ==

You can read all of Pharmacopedia without an account. Search for a medicine, a problem, or a topic; follow cross-links between related pages; and read the perspectives that interest you. Each page surfaces source citations inline so you can verify claims.

If you create an account, you can:

* Submit proposed edits through the propose-review-approve workflow.
* Complete assessments and save your responses to your profile.
* Use [[Special:MyLifeStory]] to build a personal medical timeline (private to your account; never published).
* Submit reader-experience reports on medicines you have taken (see [[Pharmacopedia:Adverse Event Reporting]]).

Your account at Pharmacopedia.wiki also works at Oyami, Trykl, and PubSci, the other surfaces operated by the Pharmacopedia Collective.

== How to contribute ==

If you would like to contribute as an editor, reviewer, or content author, contact Mark at mark@pharmacopedia.wiki. Pharmacopedia is built by invitation and volunteer effort, not by open self-onboarding, because the propose-review-approve workflow needs human reviewers with verifiable qualifications.

If you would like to flag an error, a missing citation, or a substantive concern about a page, use the talk page for that page, or email mark@pharmacopedia.wiki.

== What this is not ==

Pharmacopedia is not:

* A clinical service, diagnostic tool, or prescribing platform.
* A pharmacovigilance program registered with any health authority.
* A peer-reviewed scientific journal. (For that, see [[:pubsci:|PubSci]], the Pharmacopedia Collective's open peer-review journal.)
* A platform that takes commercial direction over content. See [[Pharmacopedia:Refusals]].
* A platform that sells, licenses, or shares user data with commercial entities. See [[About:Privacy|Privacy Policy]].

== From the founder ==

Born in May 2026, Pharmacopedia started primarily as a one-man project of [https://markelliottmd.com MDElliottMD], who'd been dreaming of some place for the people who recommend and/or use meds of the mind to collaborate and create consensus-driven information, founded in a deep faith in the [https://en.wikipedia.org/wiki/Wisdom_of_the_crowd wisdom of the crowd].

First, I hope this to be a reasonable and reliable reference for prescribers of all sorts to find relevant and accurate information for their practice: available strengths, titration strategies, pill IDs, etc.

But almost moreso, I hope that this place can be a lively, collaborative space for a communal effort in understanding the bizarre world of using medicines to help alleviate suffering. I hope that by pooling our collective anecdotes.. our stories, that we might actually make some data.. of a sort.

The site empowers users (with 2-FA) to share their experience about almost every aspect of the site, in as fine a detail as I thought was tolerable. And now finally a place for [[MyProfileIntro|our stories]], in more exquisite detail than ever before. I hope that by pooling our experiences en masse, we might find something like truth.

For now, I, [[User:MDElliottMD|MDElliottMD]], am the only person who can approve/publish page edits, though I hope to have a team of moderators some day. I am also the only person currently able to access private user data. I am frankly [https://markelliottmd.com/privacy.html obsessed with privacy] and will do everything in my power to keep these data private. If any security nerds want to help me achieve that goal, [https://markelliottmd.com/contact.html please lmk].

I am not a software developer, nor a designer, but I am a top-tier expert in meds of the mind. I will keep the place as tidy as I can.

This project is not, in any way, driven by money or profit. The links above are as far as I will go to promote myself or my brand here. At the moment, I am happy to fund the project in its entirety (maybe $400/year at time of writing may 2026). If that changes, I may some day ask for donations.

To be explicit up front so I look foolish if I change my mind later:

1) I will never serve any sort of ad for anything other than this website itself or directly related content. no ads ever.
2) I will never make this a pay to play platform in any way. no hidden costs. no subscriptions. ever.
3) I will guard these precious data from any and all others, including any who would wish to buy them. I will never. ever. sell these data to anyone for any reason.

Aggregated data are ripe for analyzin’. Anything attributable to any individual will remain private to the best of my ability in perpetuity.

Pinky swear.

This project was entirely developed and partially populated by Claude (Opus 4.7 at initial build), and is based on the [https://www.mediawiki.org/wiki/MediaWiki Mediawiki code base], bless their souls. Know that any content not explicitly verified has some risk of AI slop. this will be fixed soon.

Most of the interface here is run through an extension that I made with Claude: [[About:Pharmacopedia.ext|Pharmacopedia.ext]], which I'm happy to share with whomever wants it. will post to Git once it’s a bit more mature. Probably easiest to get ahold of me through my website above.

Thanks for coming by. Would be honored if you could join the hive mind and share your stories.

-mark

== Licensing ==
Pharmacopedia's written content is available under the [https://creativecommons.org/licenses/by-sa/4.0/ Creative Commons Attribution-ShareAlike 4.0 International License] (CC BY-SA 4.0); the Pharmacopedia software extension is separately licensed under the [https://www.gnu.org/licenses/gpl-3.0.html GNU General Public License version 3]. Quoted third-party material remains under its original copyright. See [[Pharmacopedia:Copyrights]] for full terms.

== See also ==

* [[Pharmacopedia:Terms of Use|Terms of Use]]
* [[About:Privacy|Privacy Policy]]
* [[Pharmacopedia:Refusals|Refusals (what Pharmacopedia commits never to do)]]
* [[Pharmacopedia:Reciprocity|Reciprocity (AI training posture)]]
* [[Pharmacopedia:Sources|Sources and citation policy]]
* [[Pharmacopedia:Copyrights|Copyrights]]
* [[Pharmacopedia:Adverse Event Reporting|Adverse Event Reporting]]
* [[Pharmacopedia:Newsroom|Newsroom (material change announcements)]]

[[Category:Pharmacopedia policy]]

----
''Effective date: pending Mark Elliott, MD sign-off.''
''Operator: Pharmacopedia Collective (California nonprofit public benefit corporation, pending 501(c)(3) determination).''
''Controller: Mark Elliott, MD -- mark@pharmacopedia.wiki''

Pharmacopedia:AdverseEventReporting

2026-06-02T04:31:10Z

Maintenance script: Publish Adverse Experience Reporting v0.3 (Mark-signed 2026-06-01)

{{DISPLAYTITLE:Pharmacopedia: Adverse Experience Reporting}}
__NOTOC__

Pharmacopedia medicine pages include a feature that lets readers share their experiences with a medicine. This page explains what that feature is, what it is not, and where to go if you need to report a suspected adverse reaction to a regulatory authority.

== What this feature is ==

The reader-experience report is a way for you to tell us what you experienced when taking a medicine (positive, negative, or neutral). We use these reports to understand how Pharmacopedia readers describe their experiences, to flag topics that may deserve more editorial attention on the page, and (once enough reports accumulate) to surface anonymized aggregate patterns in the Patient perspective layer.

Reports are voluntary. You are never required to submit one. Submitting a report does not give Pharmacopedia or any affiliated party access to your medical records or any data beyond what you type.

== What this feature is not ==

'''This feature is not a registered adverse event reporting system.'''

Pharmacopedia is not a spontaneous adverse event reporting program under FDA regulation (21 CFR Part 314.81), a MedWatch equivalent, or any other regulated reporting mechanism. Submitting a report here:

* Does not notify the FDA, the CDC, or any other regulatory or public health authority.
* Does not fulfill any legal or regulatory obligation a clinician, manufacturer, or institution may have to report an adverse reaction.
* Does not result in your report being forwarded to any government body or shared with the medicine's manufacturer.

'''If you are a clinician, pharmacist, or manufacturer with a mandatory adverse event reporting obligation, you must report through the appropriate regulatory channel (FDA MedWatch or equivalent). A report to Pharmacopedia does not satisfy that obligation.'''

== What happens to reports ==

Reports are held internally. No individual report is published or shared. A minimum threshold of distinct submissions must accumulate before any aggregate signal from reports is displayed on a medicine page (the threshold is set to protect individual privacy). When a signal does appear on a page, it is an anonymized aggregate count with no information that could identify any submitter.

Pharmacopedia editorial staff may review reports in aggregate to identify patterns worth editorial attention. Reports are not sold, licensed, or shared with commercial entities. See [[Pharmacopedia:Refusals]] for the full list of data commitments.

== If you think you are having an adverse reaction ==

Reader-experience reports are not the right channel if you need help or need to file an official report.

'''For immediate danger:''' Call 911 or your local emergency services. Do not delay for any other step.

'''For poison exposure or overdose:''' Contact Poison Control: 1-800-222-1222 (US). Online chat also available at [https://www.poison.org www.poison.org].

'''To file an official adverse event report:'''

* '''United States:''' FDA MedWatch: [https://www.fda.gov/safety/medwatch www.fda.gov/safety/medwatch]. Consumers and clinicians can file. MedWatch forms are free and available online.
* '''Canada:''' Health Canada MedEffect: [https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html]
* '''United Kingdom:''' MHRA Yellow Card: [https://yellowcard.mhra.gov.uk yellowcard.mhra.gov.uk]
* '''European Union:''' EudraVigilance (for professionals) or the national competent authority for your country
* '''Australia:''' TGA Adverse Event Management System: [https://www.tga.gov.au/reporting-adverse-events www.tga.gov.au/reporting-adverse-events]

These programs exist so that regulators can detect safety signals across large populations. Pharmacopedia is reference and reader-experience; official pharmacovigilance belongs with the programs above.

== Privacy ==

Reader-experience reports are subject to the [[About:Privacy|Privacy Policy]]. In brief: reports are stored internally, not sold, not shared with commercial entities, and not published at the individual level. The anonymization threshold means an individual report cannot be traced once it is part of an aggregate.

== See also ==

* [[About:Privacy|Privacy Policy]]
* [[Pharmacopedia:Refusals|Refusals (what Pharmacopedia will never do)]]
* [[Pharmacopedia:Terms of Use|Terms of Use]] (Section 5 covers the regulatory framing of this feature)

[[Category:Pharmacopedia policy]]

----
''Effective date: 2026-06-01.''
''Version: 0.3 (drafted 2026-05-31, terminology pass 2026-06-01 by legal-claude; signed off by Mark Elliott, MD 2026-06-01).''
''Operator: Pharmacopedia Collective, a California nonprofit public benefit corporation (CA SOS Doc B20260255752, filed 2026-05-30; federal 501(c)(3) determination pending).''
''Responsible officer and contact: Mark Elliott, MD, mark@pharmacopedia.wiki.''

Pharmacopedia:Terms of Use

2026-06-02T03:55:56Z

Maintenance script: Publish Terms of Use v0.3 (Mark-signed 2026-06-01; clears RED launch-blocker)

{{DISPLAYTITLE:Pharmacopedia: Terms of Use}}
__NOTOC__

These Terms of Use govern your access to and use of Pharmacopedia.wiki ("Pharmacopedia"), operated by the Pharmacopedia Collective. By reading, contributing to, or creating an account on Pharmacopedia, you agree to these terms. If you do not agree, please do not use the site.

Pharmacopedia is a free, open medical reference. It is built by a team of AI assistants, invited human experts, and volunteer contributors under the editorial oversight of [[Pharmacopedia:About|Mark Elliott, MD]]. It is funded by Mark Elliott, MD; donations are accepted only if operating costs exceed what he can self-fund. There are no paid tiers, no subscriptions, no ads.

== 1. What Pharmacopedia is and is not ==

'''Pharmacopedia is a reference resource.''' Every page describes what is known about a medicine, problem, or health topic, with content organized for multiple reader audiences (Clinician, Patient, Traditional, Researcher) and sourced across multiple knowledge traditions (pharma, plant, experiential, traditional). It is not a clinical service, a diagnostic tool, or a prescribing platform.

'''Pharmacopedia does not give medical advice.''' Nothing on this site constitutes a diagnosis, a treatment recommendation, or a substitute for the advice of a qualified clinician who knows your individual circumstances. Do not make decisions about your health, your medications, or your treatment based solely on information you read here. If you have a medical question or emergency, consult a licensed clinician or call emergency services.

'''Pharmacopedia does not create a doctor-patient relationship.''' Reading Pharmacopedia, contributing to Pharmacopedia, or communicating with any Pharmacopedia contributor or editor does not establish any clinical relationship between you and anyone affiliated with this project.

== 2. Who operates Pharmacopedia ==

Pharmacopedia is operated by the '''Pharmacopedia Collective''', a California nonprofit public benefit corporation formed under the California Nonprofit Public Benefit Corporation Law (Cal. Corp. Code § 5110 et seq.). The Collective has applied (or will apply) for federal tax-exempt status under Internal Revenue Code § 501(c)(3); that determination is pending IRS review. Pending federal determination does not affect the Collective's status as the operator of this site.

'''Mark Elliott, MD''' (mark@pharmacopedia.wiki) is the responsible officer of the Collective and the point of contact for legal, privacy, and editorial matters arising under these Terms.

== 3. Your account ==

You may read all of Pharmacopedia without an account. Creating an account allows you to submit proposed edits through our propose-review-approve workflow.

When you register:

* You must provide accurate information. Impersonating a real person, a professional credential you do not hold, or another organization is prohibited and is grounds for immediate account termination.
* You are responsible for keeping your credentials secure. Do not share your password.
* You must be at least 13 years old to register. If you are under 18, a parent or legal guardian must review these terms with you.

We reserve the right to suspend or terminate accounts that violate these terms, abuse the editorial process, or harm the project or its contributors, with or without notice depending on severity.

== 4. Contributing content ==

Pharmacopedia uses a '''propose-review-approve''' editorial model. All submitted content is proposed first; it is reviewed by a qualified human reviewer before it becomes visible to readers.

'''By submitting any content to Pharmacopedia, you:'''

* Confirm that you are the author of the content or have the right to submit it under the license below.
* Confirm that the content does not infringe any third-party intellectual property rights.
* Grant Pharmacopedia and all downstream users a perpetual, worldwide, royalty-free license to use, distribute, reproduce, and modify your contribution under the terms of the '''Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA 4.0)'''.

Text you contribute becomes part of the CC BY-SA 4.0 corpus of Pharmacopedia. You retain your own copyright; you are granting a license, not transferring ownership. You cannot later withdraw a contribution already incorporated into the project's CC BY-SA content under that license.

'''Do not submit content that:'''

* You copied from a source without rights to reproduce it (copyrighted pharmaceutical-company materials, journal articles behind paywalls, etc.).
* Includes protected health information (PHI) or personally identifiable information about any real individual.
* Is false, misleading, or fabricated.
* Is harassment, abuse, or threats directed at any person.
* Promotes a commercial interest in a way that bypasses our [[Pharmacopedia:Refusals|editorial independence commitments]].

Pharmacopedia has no obligation to publish submitted content. Rejected proposals are not published.

== 5. Adverse experience reports ==

Pharmacopedia provides a reader-experience reporting feature on medicine pages. This feature lets readers describe their own experiences with a medicine for quality-improvement purposes at Pharmacopedia.

'''This feature is not a registered adverse event reporting system.''' It does not satisfy any legal or regulatory requirement to report adverse reactions to health authorities. Reports submitted through this feature are not forwarded to the FDA, the CDC, or any other regulatory body. Raw individual reports are not published; they are held internally and only an anonymized signal (meeting a minimum count threshold) may eventually be surfaced in aggregate on the relevant page.

'''If you believe you or someone else is experiencing a serious adverse reaction, report it directly to:'''

* FDA MedWatch (US): www.fda.gov/safety/medwatch
* Your national pharmacovigilance authority (if outside the US)
* Emergency services if the reaction is immediately life-threatening

== 6. Privacy ==

Our [[About:Privacy|Privacy Policy]] explains what information we collect, how we use it, and your rights under California law (CCPA/CPRA) and other applicable law. Using Pharmacopedia is subject to the Privacy Policy in addition to these Terms.

In brief: we do not sell data, we do not run third-party tracking scripts, and we do not share user data with advertisers. Full details are in the Privacy Policy.

== 7. Intellectual property ==

'''Pharmacopedia content is CC BY-SA 4.0''' unless otherwise stated on a specific page. You may copy, adapt, and redistribute Pharmacopedia content under the same license with attribution. The preferred citation form and BibTeX/Chicago/APA/Vancouver formats are available on each page via the citation widget.

Pharmacopedia's visual design (the Pharmacopedia seal, typography choices, color palette, and custom interface elements) is not CC BY-SA and is not available for reproduction without permission.

If you believe a page or contribution infringes your copyright, contact mark@pharmacopedia.wiki with: (a) a description of the allegedly infringing content and its URL; (b) your contact information; (c) a statement that you own the copyright or are authorized to act on the owner's behalf; and (d) a statement of good-faith belief that the use is not authorized. We will investigate and respond.

== 8. What we commit not to do ==

The [[Pharmacopedia:Refusals|Refusals page]] lists the things Pharmacopedia will never do. The most relevant to these Terms: we will never sell your health data, run ads, paywall content, accept commercial influence over content, or operate as a Class III medical device without proper regulatory review. Those commitments are incorporated here by reference.

== 9. Disclaimers and limitation of liability ==

Pharmacopedia makes reasonable efforts to ensure the accuracy of information on this site, but '''medical knowledge changes rapidly and errors can occur'''. We do not warrant that any information on Pharmacopedia is complete, accurate, current, or applicable to your specific situation.

To the maximum extent permitted by applicable law, the Pharmacopedia Collective, Mark Elliott, MD, and all contributors disclaim all warranties, express or implied, regarding the site and its content. We are not liable for any harm arising from your reliance on information found on Pharmacopedia, including missed diagnoses, medication errors, or treatment decisions made without professional consultation.

California law does not permit the disclaimer of liability for gross negligence or willful misconduct; nothing in this section is intended to disclaim liability for those.

== 10. Governing law and disputes ==

'''These Terms are governed by the laws of the State of California, without regard to conflict of law principles.'''

Any dispute arising from these Terms or your use of Pharmacopedia will be resolved '''in the state or federal courts located in the State of California'''. You consent to the personal jurisdiction of those courts.

'''There is no mandatory arbitration clause here.''' You are not waiving your right to have a dispute heard in court. '''There is no class-action waiver.''' If a dispute is one that can properly be brought as a class action, you retain that right.

== 11. Changes to these Terms ==

We may update these Terms from time to time. Material changes will be announced on [[Pharmacopedia:Newsroom|Pharmacopedia:Newsroom]] and, where feasible, by a site notice. The effective date at the bottom of this page will be updated. Continued use of the site after the effective date constitutes acceptance of the revised Terms.

We will not change the governing-law clause, the no-arbitration commitment, or the no-class-action-waiver commitment without explicit notice and at least 30 days' lead time.

== 12. Contact ==

Questions about these Terms: '''mark@pharmacopedia.wiki'''

To report a potential Terms violation: Pharmacopedia:Newsroom talk page or mark@pharmacopedia.wiki.

To report a copyright concern: mark@pharmacopedia.wiki (see Section 7).

== See also ==

* [[About:Privacy|Privacy Policy]]
* [[Pharmacopedia:Refusals|Refusals (what Pharmacopedia will never do)]]
* [[Pharmacopedia:Sources|Sources and licensing]]
* [[Pharmacopedia:Reciprocity|Reciprocity (AI training posture)]]
* [[Pharmacopedia:Newsroom|Newsroom (editorial transparency)]]

[[Category:Pharmacopedia policy]]

----
''Effective date: 2026-06-01.''
''Version: 0.3 (drafted 2026-06-01 by legal-claude; signed off by Mark Elliott, MD 2026-06-01).''
''Operator: Pharmacopedia Collective, a California nonprofit public benefit corporation (CA SOS Doc B20260255752, filed 2026-05-30; federal 501(c)(3) determination pending).''
''Responsible officer and contact: Mark Elliott, MD, mark@pharmacopedia.wiki.''

About:Privacy

2026-06-01T21:17:38Z

Maintenance script: Add Collective phone (669) 669-0025 to controller line

Pharmacopedia:Terms of Use

2026-06-01T21:17:33Z

Maintenance script: Add Collective phone (669) 669-0025 to section 2

{{DISPLAYTITLE:Pharmacopedia: Terms of Use}}
__NOTOC__

These Terms of Use govern your access to and use of Pharmacopedia.wiki ("Pharmacopedia"), operated by the Pharmacopedia Collective. By reading, contributing to, or creating an account on Pharmacopedia, you agree to these terms. If you do not agree, please do not use the site.

Pharmacopedia is a free, open medical reference. It is built by a team of AI assistants, invited human experts, and volunteer contributors under the editorial oversight of [[Pharmacopedia:About|Mark Elliott, MD]]. It is funded by Mark Elliott, MD; donations are accepted only if operating costs exceed what he can self-fund. There are no paid tiers, no subscriptions, no ads.

== 1. What Pharmacopedia is and is not ==

'''Pharmacopedia is a reference resource.''' Every page describes what is known about a medicine, problem, or health topic, with content organized for multiple reader audiences (Clinician, Patient, Traditional, Researcher) and sourced across multiple knowledge traditions (pharma, plant, experiential, traditional). It is not a clinical service, a diagnostic tool, or a prescribing platform.

'''Pharmacopedia does not give medical advice.''' Nothing on this site constitutes a diagnosis, a treatment recommendation, or a substitute for the advice of a qualified clinician who knows your individual circumstances. Do not make decisions about your health, your medications, or your treatment based solely on information you read here. If you have a medical question or emergency, consult a licensed clinician or call emergency services.

'''Pharmacopedia does not create a doctor-patient relationship.''' Reading Pharmacopedia, contributing to Pharmacopedia, or communicating with any Pharmacopedia contributor or editor does not establish any clinical relationship between you and anyone affiliated with this project.

== 2. Who operates Pharmacopedia ==

Pharmacopedia is operated by the '''Pharmacopedia Collective''', a California nonprofit public benefit corporation (pending 501(c)(3) determination from the Internal Revenue Service). Until formal recognition is granted, the Pharmacopedia Collective operates under California law as an unincorporated nonprofit association. The Collective can be reached at (669) 669-0025 (voicemail; email is faster for non-urgent matters). '''Mark Elliott, MD''' (mark@pharmacopedia.wiki) serves as the personal data controller for purposes of applicable privacy law and as the named operator of this site.

== 3. Your account ==

You may read all of Pharmacopedia without an account. Creating an account allows you to submit proposed edits through our propose-review-approve workflow.

When you register:

* You must provide accurate information. Impersonating a real person, a professional credential you do not hold, or another organization is prohibited and is grounds for immediate account termination.
* You are responsible for keeping your credentials secure. Do not share your password.
* You must be at least 13 years old to register. If you are under 18, a parent or legal guardian must review these terms with you.

We reserve the right to suspend or terminate accounts that violate these terms, abuse the editorial process, or harm the project or its contributors, with or without notice depending on severity.

== 4. Contributing content ==

Pharmacopedia uses a '''propose-review-approve''' editorial model. All submitted content is proposed first; it is reviewed by a qualified human reviewer before it becomes visible to readers.

'''By submitting any content to Pharmacopedia, you:'''

* Confirm that you are the author of the content or have the right to submit it under the license below.
* Confirm that the content does not infringe any third-party intellectual property rights.
* Grant Pharmacopedia and all downstream users a perpetual, worldwide, royalty-free license to use, distribute, reproduce, and modify your contribution under the terms of the '''Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA 4.0)'''.

Text you contribute becomes part of the CC BY-SA 4.0 corpus of Pharmacopedia. You retain your own copyright; you are granting a license, not transferring ownership. You cannot later withdraw a contribution already incorporated into the project's CC BY-SA content under that license.

'''Do not submit content that:'''

* You copied from a source without rights to reproduce it (copyrighted drug-company materials, journal articles behind paywalls, etc.).
* Includes protected health information (PHI) or personally identifiable information about any real individual.
* Is false, misleading, or fabricated.
* Is harassment, abuse, or threats directed at any person.
* Promotes a commercial interest in a way that bypasses our [[Pharmacopedia:Refusals|editorial independence commitments]].

Pharmacopedia has no obligation to publish submitted content. Rejected proposals are not published.

== 5. Adverse experience reports ==

Pharmacopedia provides a reader-experience reporting feature on medicine pages. This feature lets readers describe their own experiences with a medicine for quality-improvement purposes at Pharmacopedia.

'''This feature is not a registered adverse event reporting system.''' It does not satisfy any legal or regulatory requirement to report adverse drug reactions to health authorities. Reports submitted through this feature are not forwarded to the FDA, the CDC, or any other regulatory body. Raw individual reports are not published; they are held internally and only an anonymized signal (meeting a minimum count threshold) may eventually be surfaced in aggregate on the relevant page.

'''If you believe you or someone else is experiencing a serious adverse drug reaction, report it directly to:'''

* FDA MedWatch (US): www.fda.gov/safety/medwatch
* Your national pharmacovigilance authority (if outside the US)
* Emergency services if the reaction is immediately life-threatening

== 6. Privacy ==

Our [[About:Privacy|Privacy Policy]] explains what information we collect, how we use it, and your rights under California law (CCPA/CPRA) and other applicable law. Using Pharmacopedia is subject to the Privacy Policy in addition to these Terms.

In brief: we do not sell data, we do not run third-party tracking scripts, and we do not share user data with advertisers. Full details are in the Privacy Policy.

== 7. Intellectual property ==

'''Pharmacopedia content is CC BY-SA 4.0''' unless otherwise stated on a specific page. You may copy, adapt, and redistribute Pharmacopedia content under the same license with attribution. The preferred citation form and BibTeX/Chicago/APA/Vancouver formats are available on each page via the citation widget.

Pharmacopedia's visual design (the Pharmacopedia seal, typography choices, color palette, and custom interface elements) is not CC BY-SA and is not available for reproduction without permission.

If you believe a page or contribution infringes your copyright, contact mark@pharmacopedia.wiki with: (a) a description of the allegedly infringing content and its URL; (b) your contact information; (c) a statement that you own the copyright or are authorized to act on the owner's behalf; and (d) a statement of good-faith belief that the use is not authorized. We will investigate and respond.

== 8. What we commit not to do ==

The [[Pharmacopedia:Refusals|Refusals page]] lists the things Pharmacopedia will never do. The most relevant to these Terms: we will never sell your health data, run ads, paywall content, accept commercial influence over content, or operate as a Class III medical device without proper regulatory review. Those commitments are incorporated here by reference.

== 9. Disclaimers and limitation of liability ==

Pharmacopedia makes reasonable efforts to ensure the accuracy of information on this site, but '''medical knowledge changes rapidly and errors can occur'''. We do not warrant that any information on Pharmacopedia is complete, accurate, current, or applicable to your specific situation.

To the maximum extent permitted by applicable law, the Pharmacopedia Collective, Mark Elliott MD, and all contributors disclaim all warranties, express or implied, regarding the site and its content. We are not liable for any harm arising from your reliance on information found on Pharmacopedia, including missed diagnoses, medication errors, or treatment decisions made without professional consultation.

California law does not permit the disclaimer of liability for gross negligence or willful misconduct; nothing in this section is intended to disclaim liability for those.

== 10. Governing law and disputes ==

'''These Terms are governed by the laws of the State of California, without regard to conflict of law principles.'''

Any dispute arising from these Terms or your use of Pharmacopedia will be resolved '''in the state or federal courts located in the State of California'''. You consent to the personal jurisdiction of those courts.

'''There is no mandatory arbitration clause here.''' You are not waiving your right to have a dispute heard in court. '''There is no class-action waiver.''' If a dispute is one that can properly be brought as a class action, you retain that right.

== 11. Changes to these Terms ==

We may update these Terms from time to time. Material changes will be announced on [[Pharmacopedia:Newsroom|Pharmacopedia:Newsroom]] and, where feasible, by a site notice. The effective date at the bottom of this page will be updated. Continued use of the site after the effective date constitutes acceptance of the revised Terms.

We will not change the governing-law clause, the no-arbitration commitment, or the no-class-action-waiver commitment without explicit notice and at least 30 days' lead time.

== 12. Contact ==

Questions about these Terms: '''mark@pharmacopedia.wiki'''

To report a potential Terms violation: Pharmacopedia:Newsroom talk page or mark@pharmacopedia.wiki.

To report a copyright concern: mark@pharmacopedia.wiki (see Section 7).

== See also ==

* [[About:Privacy|Privacy Policy]]
* [[Pharmacopedia:Refusals|Refusals (what Pharmacopedia will never do)]]
* [[Pharmacopedia:Sources|Sources and licensing]]
* [[Pharmacopedia:Reciprocity|Reciprocity (AI training posture)]]
* [[Pharmacopedia:Newsroom|Newsroom (editorial transparency)]]

[[Category:Pharmacopedia policy]]

---
''Effective date: pending Mark Elliott, MD sign-off.''
''Operator: Pharmacopedia Collective (California nonprofit public benefit corporation, pending 501(c)(3) determination).''
''Controller: Mark Elliott, MD (mark@pharmacopedia.wiki)''

About:Pharmacopedia

2026-06-01T21:17:30Z

Maintenance script: Add Collective phone (669) 669-0025

{{DISPLAYTITLE:About:Pharmacopedia}}

Pharmacopedia is a free, open medical reference: an evolving catalog of what is known, claimed, and reported about medicines, problems, and health topics, written across multiple perspectives so that readers can see the same subject through more than one lens.

This page describes what Pharmacopedia is, who runs it, how it is written, and what it commits to. For the legal terms governing your use of the site, see the [[Pharmacopedia:Terms of Use|Terms of Use]]. For data handling, see the [[About:Privacy|Privacy Policy]].

== What Pharmacopedia is ==

Pharmacopedia is a reference resource, not a clinical service. Each medicine page describes what the medicine is, how it is thought to work, what it is used for, what its effects and adverse effects are, and what readers from different perspectives have said about it. Each problem page describes a health condition, problem, or experience, and the medicines and approaches that are used to address it.

Pharmacopedia organizes content for multiple reader audiences (Clinician, Patient, Traditional, Researcher) and sources its claims across multiple knowledge traditions (pharma, plant, experiential, traditional). The intent is pluralism with discipline: every non-trivial claim takes an inline citation, and where a citation is not yet available, the page is marked rather than left implicit.

Pharmacopedia does not give medical advice. Nothing here is a substitute for a qualified clinician who knows your individual circumstances. If you have a medical question or emergency, consult a licensed clinician or call emergency services. For overdose or poisoning in the United States, call Poison Control at 1-800-222-1222.

== Who operates Pharmacopedia ==

Pharmacopedia is operated by the '''Pharmacopedia Collective''', a California nonprofit public benefit corporation (pending 501(c)(3) determination from the Internal Revenue Service). Until formal recognition is granted, the Collective operates under California law as an unincorporated nonprofit association. The Collective can be reached at (669) 669-0025 (voicemail; email is faster for non-urgent matters).

The named data controller and editorial lead is '''Mark Elliott, MD''' (mark@pharmacopedia.wiki). Mark is a licensed physician; his role in Pharmacopedia is editorial and operational, not clinical-toward-readers. Reading Pharmacopedia does not create a doctor-patient relationship with him or with anyone else affiliated with the project.

Pharmacopedia is funded by Mark personally; donations are accepted only if operating costs exceed what he can self-fund. There are no paid tiers, no subscriptions, and no advertising. The full list of commitments about what Pharmacopedia will never do is at [[Pharmacopedia:Refusals]].

== How Pharmacopedia is written ==

Pharmacopedia content is produced by a team of AI assistants, invited human experts, and volunteer contributors, under Mark's editorial oversight.

The editorial workflow is '''propose-review-approve'''. All submitted content is proposed first; it is reviewed by a qualified human reviewer before it becomes visible to readers. At launch, Mark is the sole reviewer. As the project grows, additional reviewers will be brought in with their qualifications made public.

Every non-trivial claim takes an inline citation, in this priority order: primary literature, then FDA label or equivalent regulatory source, then meta-analysis or systematic review, then guideline, then established tertiary reference. Where no citation is yet available, the claim is marked {{citation needed}} rather than deleted, so the gap is visible and can be filled.

Pharmacopedia does not pretend to be a regulated medical authority. The [[Pharmacopedia:Adverse Event Reporting|adverse-experience reporting feature]] is a reader-experience aggregator, not a regulated pharmacovigilance program. The [[Pharmacopedia:Refusals|Refusals]] page enumerates the things this project commits never to do.

== How to use Pharmacopedia ==

You can read all of Pharmacopedia without an account. Search for a medicine, a problem, or a topic; follow cross-links between related pages; and read the perspectives that interest you. Each page surfaces source citations inline so you can verify claims.

If you create an account, you can:

* Submit proposed edits through the propose-review-approve workflow.
* Complete assessments and save your responses to your profile.
* Use [[Special:MyLifeStory]] to build a personal medical timeline (private to your account; never published).
* Submit reader-experience reports on medicines you have taken (see [[Pharmacopedia:Adverse Event Reporting]]).

Your account at Pharmacopedia.wiki also works at Oyami, Trykl, and PubSci, the other surfaces operated by the Pharmacopedia Collective.

== How to contribute ==

If you would like to contribute as an editor, reviewer, or content author, contact Mark at mark@pharmacopedia.wiki. Pharmacopedia is built by invitation and volunteer effort, not by open self-onboarding, because the propose-review-approve workflow needs human reviewers with verifiable qualifications.

If you would like to flag an error, a missing citation, or a substantive concern about a page, use the talk page for that page, or email mark@pharmacopedia.wiki.

== What this is not ==

Pharmacopedia is not:

* A clinical service, diagnostic tool, or prescribing platform.
* A pharmacovigilance program registered with any health authority.
* A peer-reviewed scientific journal. (For that, see [[:pubsci:|PubSci]], the Pharmacopedia Collective's open peer-review journal.)
* A platform that takes commercial direction over content. See [[Pharmacopedia:Refusals]].
* A platform that sells, licenses, or shares user data with commercial entities. See [[About:Privacy|Privacy Policy]].

== From the founder ==

Born in May 2026, Pharmacopedia started primarily as a one-man project of [https://markelliottmd.com MDElliottMD], who'd been dreaming of some place for the people who recommend and/or use meds of the mind to collaborate and create consensus-driven information, founded in a deep faith in the [https://en.wikipedia.org/wiki/Wisdom_of_the_crowd wisdom of the crowd].

First, I hope this to be a reasonable and reliable reference for prescribers of all sorts to find relevant and accurate information for their practice: available strengths, titration strategies, pill IDs, etc.

But almost moreso, I hope that this place can be a lively, collaborative space for a communal effort in understanding the bizarre world of using medicines to help alleviate suffering. I hope that by pooling our collective anecdotes.. our stories, that we might actually make some data.. of a sort.

The site empowers users (with 2-FA) to share their experience about almost every aspect of the site, in as fine a detail as I thought was tolerable. And now finally a place for [[MyProfileIntro|our stories]], in more exquisite detail than ever before. I hope that by pooling our experiences en masse, we might find something like truth.

For now, I, [[User:MDElliottMD|MDElliottMD]], am the only person who can approve/publish page edits, though I hope to have a team of moderators some day. I am also the only person currently able to access private user data. I am frankly [https://markelliottmd.com/privacy.html obsessed with privacy] and will do everything in my power to keep these data private. If any security nerds want to help me achieve that goal, [https://markelliottmd.com/contact.html please lmk].

I am not a software developer, nor a designer, but I am a top-tier expert in meds of the mind. I will keep the place as tidy as I can.

This project is not, in any way, driven by money or profit. The links above are as far as I will go to promote myself or my brand here. At the moment, I am happy to fund the project in its entirety (maybe $400/year at time of writing may 2026). If that changes, I may some day ask for donations.

To be explicit up front so I look foolish if I change my mind later:

1) I will never serve any sort of ad for anything other than this website itself or directly related content. no ads ever.
2) I will never make this a pay to play platform in any way. no hidden costs. no subscriptions. ever.
3) I will guard these precious data from any and all others, including any who would wish to buy them. I will never. ever. sell these data to anyone for any reason.

Aggregated data are ripe for analyzin’. Anything attributable to any individual will remain private to the best of my ability in perpetuity.

Pinky swear.

This project was entirely developed and partially populated by Claude (Opus 4.7 at initial build), and is based on the [https://www.mediawiki.org/wiki/MediaWiki Mediawiki code base], bless their souls. Know that any content not explicitly verified has some risk of AI slop. this will be fixed soon.

Most of the interface here is run through an extension that I made with Claude: [[About:Pharmacopedia.ext|Pharmacopedia.ext]], which I'm happy to share with whomever wants it. will post to Git once it’s a bit more mature. Probably easiest to get ahold of me through my website above.

Thanks for coming by. Would be honored if you could join the hive mind and share your stories.

-mark

== Licensing ==
Pharmacopedia's written content is available under the [https://creativecommons.org/licenses/by-sa/4.0/ Creative Commons Attribution-ShareAlike 4.0 International License] (CC BY-SA 4.0); the Pharmacopedia software extension is separately licensed under the [https://www.gnu.org/licenses/gpl-3.0.html GNU General Public License version 3]. Quoted third-party material remains under its original copyright. See [[Pharmacopedia:Copyrights]] for full terms.

== See also ==

* [[Pharmacopedia:Terms of Use|Terms of Use]]
* [[About:Privacy|Privacy Policy]]
* [[Pharmacopedia:Refusals|Refusals (what Pharmacopedia commits never to do)]]
* [[Pharmacopedia:Reciprocity|Reciprocity (AI training posture)]]
* [[Pharmacopedia:Sources|Sources and citation policy]]
* [[Pharmacopedia:Copyrights|Copyrights]]
* [[Pharmacopedia:Adverse Event Reporting|Adverse Event Reporting]]
* [[Pharmacopedia:Newsroom|Newsroom (material change announcements)]]

[[Category:Pharmacopedia policy]]

----
''Effective date: pending Mark Elliott, MD sign-off.''
''Operator: Pharmacopedia Collective (California nonprofit public benefit corporation, pending 501(c)(3) determination).''
''Controller: Mark Elliott, MD -- mark@pharmacopedia.wiki''

Pharmacopedia:Adverse Event Reporting

2026-06-01T02:42:31Z

Maintenance script: v0.3: fix 5 dead reporting URLs (bare www -> wikitext external-link) + double-hyphens -> parens/colons (legal-staged)

{{DISPLAYTITLE:Pharmacopedia: Adverse Experience Reporting}}
__NOTOC__

Pharmacopedia medicine pages include a feature that lets readers share their experiences with a medicine. This page explains what that feature is, what it is not, and where to go if you need to report a suspected adverse drug reaction to a regulatory authority.

== What this feature is ==

The reader-experience report is a way for you to tell us what you experienced when taking a medicine (positive, negative, or neutral). We use these reports to understand how Pharmacopedia readers describe their experiences, to flag topics that may deserve more editorial attention on the page, and (once enough reports accumulate) to surface anonymized aggregate patterns in the Patient perspective layer.

Reports are voluntary. You are never required to submit one. Submitting a report does not give Pharmacopedia or any affiliated party access to your medical records or any data beyond what you type.

== What this feature is not ==

'''This feature is not a registered adverse event reporting system.'''

Pharmacopedia is not a spontaneous adverse event reporting program under FDA regulation (21 CFR Part 314.81), a MedWatch equivalent, or any other regulated reporting mechanism. Submitting a report here:

* Does not notify the FDA, the CDC, or any other regulatory or public health authority.
* Does not fulfill any legal or regulatory obligation a clinician, manufacturer, or institution may have to report an adverse drug reaction.
* Does not result in your report being forwarded to any government body or shared with the drug's manufacturer.

'''If you are a clinician, pharmacist, or manufacturer with a mandatory adverse event reporting obligation, you must report through the appropriate regulatory channel (FDA MedWatch or equivalent). A report to Pharmacopedia does not satisfy that obligation.'''

== What happens to reports ==

Reports are held internally. No individual report is published or shared. A minimum threshold of distinct submissions must accumulate before any aggregate signal from reports is displayed on a medicine page (the threshold is set to protect individual privacy). When a signal does appear on a page, it is an anonymized aggregate count with no information that could identify any submitter.

Pharmacopedia editorial staff may review reports in aggregate to identify patterns worth editorial attention. Reports are not sold, licensed, or shared with commercial entities. See [[Pharmacopedia:Refusals]] for the full list of data commitments.

== If you think you are having an adverse drug reaction ==

Reader-experience reports are not the right channel if you need help or need to file an official report.

'''For immediate danger:''' Call 911 or your local emergency services. Do not delay for any other step.

'''For poison exposure or overdose:''' Contact Poison Control: 1-800-222-1222 (US). Online chat also available at [https://www.poison.org www.poison.org].

'''To file an official adverse event report:'''

* '''United States:''' FDA MedWatch: [https://www.fda.gov/safety/medwatch www.fda.gov/safety/medwatch]. Consumers and clinicians can file. MedWatch forms are free and available online.
* '''Canada:''' Health Canada MedEffect: [https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html]
* '''United Kingdom:''' MHRA Yellow Card: [https://yellowcard.mhra.gov.uk yellowcard.mhra.gov.uk]
* '''European Union:''' EudraVigilance (for professionals) or the national competent authority for your country
* '''Australia:''' TGA Adverse Event Management System: [https://www.tga.gov.au/reporting-adverse-events www.tga.gov.au/reporting-adverse-events]

These programs exist so that regulators can detect safety signals across large populations. Pharmacopedia is reference and reader-experience; official pharmacovigilance belongs with the programs above.

== Privacy ==

Reader-experience reports are subject to the [[About:Privacy|Privacy Policy]]. In brief: reports are stored internally, not sold, not shared with commercial entities, and not published at the individual level. The anonymization threshold means an individual report cannot be traced once it is part of an aggregate.

== See also ==

* [[About:Privacy|Privacy Policy]]
* [[Pharmacopedia:Refusals|Refusals (what Pharmacopedia will never do)]]
* [[Pharmacopedia:Terms of Use|Terms of Use]] (Section 5 covers the regulatory framing of this feature)

[[Category:Pharmacopedia policy]]

---
''Effective date: pending Mark Elliott, MD sign-off.''

Pharmacopedia:Terms of Use

2026-05-31T22:16:53Z

Maintenance script: House-rule fix: em-dash -> parens in Controller footer

{{DISPLAYTITLE:Pharmacopedia: Terms of Use}}
__NOTOC__

These Terms of Use govern your access to and use of Pharmacopedia.wiki ("Pharmacopedia"), operated by the Pharmacopedia Collective. By reading, contributing to, or creating an account on Pharmacopedia, you agree to these terms. If you do not agree, please do not use the site.

Pharmacopedia is a free, open medical reference. It is built by a team of AI assistants, invited human experts, and volunteer contributors under the editorial oversight of [[Pharmacopedia:About|Mark Elliott, MD]]. It is funded by Mark Elliott, MD; donations are accepted only if operating costs exceed what he can self-fund. There are no paid tiers, no subscriptions, no ads.

== 1. What Pharmacopedia is and is not ==

'''Pharmacopedia is a reference resource.''' Every page describes what is known about a medicine, problem, or health topic, with content organized for multiple reader audiences (Clinician, Patient, Traditional, Researcher) and sourced across multiple knowledge traditions (pharma, plant, experiential, traditional). It is not a clinical service, a diagnostic tool, or a prescribing platform.

'''Pharmacopedia does not give medical advice.''' Nothing on this site constitutes a diagnosis, a treatment recommendation, or a substitute for the advice of a qualified clinician who knows your individual circumstances. Do not make decisions about your health, your medications, or your treatment based solely on information you read here. If you have a medical question or emergency, consult a licensed clinician or call emergency services.

'''Pharmacopedia does not create a doctor-patient relationship.''' Reading Pharmacopedia, contributing to Pharmacopedia, or communicating with any Pharmacopedia contributor or editor does not establish any clinical relationship between you and anyone affiliated with this project.

== 2. Who operates Pharmacopedia ==

Pharmacopedia is operated by the '''Pharmacopedia Collective''', a California nonprofit public benefit corporation (pending 501(c)(3) determination from the Internal Revenue Service). Until formal recognition is granted, the Pharmacopedia Collective operates under California law as an unincorporated nonprofit association. '''Mark Elliott, MD''' (mark@pharmacopedia.wiki) serves as the personal data controller for purposes of applicable privacy law and as the named operator of this site.

== 3. Your account ==

You may read all of Pharmacopedia without an account. Creating an account allows you to submit proposed edits through our propose-review-approve workflow.

When you register:

* You must provide accurate information. Impersonating a real person, a professional credential you do not hold, or another organization is prohibited and is grounds for immediate account termination.
* You are responsible for keeping your credentials secure. Do not share your password.
* You must be at least 13 years old to register. If you are under 18, a parent or legal guardian must review these terms with you.

We reserve the right to suspend or terminate accounts that violate these terms, abuse the editorial process, or harm the project or its contributors, with or without notice depending on severity.

== 4. Contributing content ==

Pharmacopedia uses a '''propose-review-approve''' editorial model. All submitted content is proposed first; it is reviewed by a qualified human reviewer before it becomes visible to readers.

'''By submitting any content to Pharmacopedia, you:'''

* Confirm that you are the author of the content or have the right to submit it under the license below.
* Confirm that the content does not infringe any third-party intellectual property rights.
* Grant Pharmacopedia and all downstream users a perpetual, worldwide, royalty-free license to use, distribute, reproduce, and modify your contribution under the terms of the '''Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA 4.0)'''.

Text you contribute becomes part of the CC BY-SA 4.0 corpus of Pharmacopedia. You retain your own copyright; you are granting a license, not transferring ownership. You cannot later withdraw a contribution already incorporated into the project's CC BY-SA content under that license.

'''Do not submit content that:'''

* You copied from a source without rights to reproduce it (copyrighted drug-company materials, journal articles behind paywalls, etc.).
* Includes protected health information (PHI) or personally identifiable information about any real individual.
* Is false, misleading, or fabricated.
* Is harassment, abuse, or threats directed at any person.
* Promotes a commercial interest in a way that bypasses our [[Pharmacopedia:Refusals|editorial independence commitments]].

Pharmacopedia has no obligation to publish submitted content. Rejected proposals are not published.

== 5. Adverse experience reports ==

Pharmacopedia provides a reader-experience reporting feature on medicine pages. This feature lets readers describe their own experiences with a medicine for quality-improvement purposes at Pharmacopedia.

'''This feature is not a registered adverse event reporting system.''' It does not satisfy any legal or regulatory requirement to report adverse drug reactions to health authorities. Reports submitted through this feature are not forwarded to the FDA, the CDC, or any other regulatory body. Raw individual reports are not published; they are held internally and only an anonymized signal (meeting a minimum count threshold) may eventually be surfaced in aggregate on the relevant page.

'''If you believe you or someone else is experiencing a serious adverse drug reaction, report it directly to:'''

* FDA MedWatch (US): www.fda.gov/safety/medwatch
* Your national pharmacovigilance authority (if outside the US)
* Emergency services if the reaction is immediately life-threatening

== 6. Privacy ==

Our [[About:Privacy|Privacy Policy]] explains what information we collect, how we use it, and your rights under California law (CCPA/CPRA) and other applicable law. Using Pharmacopedia is subject to the Privacy Policy in addition to these Terms.

In brief: we do not sell data, we do not run third-party tracking scripts, and we do not share user data with advertisers. Full details are in the Privacy Policy.

== 7. Intellectual property ==

'''Pharmacopedia content is CC BY-SA 4.0''' unless otherwise stated on a specific page. You may copy, adapt, and redistribute Pharmacopedia content under the same license with attribution. The preferred citation form and BibTeX/Chicago/APA/Vancouver formats are available on each page via the citation widget.

Pharmacopedia's visual design (the Pharmacopedia seal, typography choices, color palette, and custom interface elements) is not CC BY-SA and is not available for reproduction without permission.

If you believe a page or contribution infringes your copyright, contact mark@pharmacopedia.wiki with: (a) a description of the allegedly infringing content and its URL; (b) your contact information; (c) a statement that you own the copyright or are authorized to act on the owner's behalf; and (d) a statement of good-faith belief that the use is not authorized. We will investigate and respond.

== 8. What we commit not to do ==

The [[Pharmacopedia:Refusals|Refusals page]] lists the things Pharmacopedia will never do. The most relevant to these Terms: we will never sell your health data, run ads, paywall content, accept commercial influence over content, or operate as a Class III medical device without proper regulatory review. Those commitments are incorporated here by reference.

== 9. Disclaimers and limitation of liability ==

Pharmacopedia makes reasonable efforts to ensure the accuracy of information on this site, but '''medical knowledge changes rapidly and errors can occur'''. We do not warrant that any information on Pharmacopedia is complete, accurate, current, or applicable to your specific situation.

To the maximum extent permitted by applicable law, the Pharmacopedia Collective, Mark Elliott MD, and all contributors disclaim all warranties, express or implied, regarding the site and its content. We are not liable for any harm arising from your reliance on information found on Pharmacopedia, including missed diagnoses, medication errors, or treatment decisions made without professional consultation.

California law does not permit the disclaimer of liability for gross negligence or willful misconduct; nothing in this section is intended to disclaim liability for those.

== 10. Governing law and disputes ==

'''These Terms are governed by the laws of the State of California, without regard to conflict of law principles.'''

Any dispute arising from these Terms or your use of Pharmacopedia will be resolved '''in the state or federal courts located in the State of California'''. You consent to the personal jurisdiction of those courts.

'''There is no mandatory arbitration clause here.''' You are not waiving your right to have a dispute heard in court. '''There is no class-action waiver.''' If a dispute is one that can properly be brought as a class action, you retain that right.

== 11. Changes to these Terms ==

We may update these Terms from time to time. Material changes will be announced on [[Pharmacopedia:Newsroom|Pharmacopedia:Newsroom]] and, where feasible, by a site notice. The effective date at the bottom of this page will be updated. Continued use of the site after the effective date constitutes acceptance of the revised Terms.

We will not change the governing-law clause, the no-arbitration commitment, or the no-class-action-waiver commitment without explicit notice and at least 30 days' lead time.

== 12. Contact ==

Questions about these Terms: '''mark@pharmacopedia.wiki'''

To report a potential Terms violation: Pharmacopedia:Newsroom talk page or mark@pharmacopedia.wiki.

To report a copyright concern: mark@pharmacopedia.wiki (see Section 7).

== See also ==

* [[About:Privacy|Privacy Policy]]
* [[Pharmacopedia:Refusals|Refusals (what Pharmacopedia will never do)]]
* [[Pharmacopedia:Sources|Sources and licensing]]
* [[Pharmacopedia:Reciprocity|Reciprocity (AI training posture)]]
* [[Pharmacopedia:Newsroom|Newsroom (editorial transparency)]]

[[Category:Pharmacopedia policy]]

---
''Effective date: pending Mark Elliott, MD sign-off.''
''Operator: Pharmacopedia Collective (California nonprofit public benefit corporation, pending 501(c)(3) determination).''
''Controller: Mark Elliott, MD (mark@pharmacopedia.wiki)''

Help:Contents

2026-05-31T22:14:38Z

Maintenance script: Initial version -- Help:Contents stub (interface v0.1, Mark-signed)

{{DISPLAYTITLE:Help: Contents}}
__NOTOC__

Pharmacopedia is a free, open medical reference. This page points you to the most useful starting places depending on what you are trying to do.

== If you are new to Pharmacopedia ==

Start with [[About:Pharmacopedia]] for what this site is, who runs it, and how it is written.

== Reading the site ==

Every medicine and problem page in Pharmacopedia is organized for multiple reader audiences. Look for the perspective that matches what you are trying to learn:

* '''Clinician''' perspective: pharmacology, dosing, monitoring, interactions, and clinical evidence.
* '''Patient''' perspective: what taking the medicine is like, what to expect, what to watch for, what other readers have reported.
* '''Traditional''' perspective: the historical, cultural, and ethnobotanical context of the medicine.
* '''Researcher''' perspective: mechanism details, primary literature, ongoing questions.

Every non-trivial claim links to a source. Where a citation is not yet available, the page is marked {{citation needed}} rather than left implicit.

== Creating an account ==

You can read everything without an account. An account lets you submit proposed edits, complete assessments, build a private medical timeline at [[Special:MyLifeStory]], and submit reader-experience reports on medicines you have taken.

== Contributing ==

Pharmacopedia uses a propose-review-approve workflow. Submitted edits are reviewed by a qualified human reviewer before they become visible. If you would like to contribute as an editor, reviewer, or content author, email mark@pharmacopedia.wiki.

== Reporting an adverse experience ==

If you have experienced a problem with a medicine, you can submit a reader-experience report on that medicine's page. See [[Pharmacopedia:Adverse Event Reporting]] for what that feature is, what it is not, and where to file an official report with the FDA or your national authority if needed.

== Medical emergencies ==

This site is not the place to get help in a medical emergency. If you are in immediate danger, call 911 (United States) or your local emergency services. For overdose or poisoning, call Poison Control at 1-800-222-1222 (United States).

== Policy and legal ==

* [[Pharmacopedia:Terms of Use|Terms of Use]]
* [[About:Privacy|Privacy Policy]]
* [[Pharmacopedia:Refusals|Refusals]]
* [[Pharmacopedia:Reciprocity|Reciprocity (AI training posture)]]
* [[Pharmacopedia:Sources|Sources and citation policy]]
* [[Pharmacopedia:Newsroom|Newsroom]]

== Questions ==

For anything not answered above, email mark@pharmacopedia.wiki.

[[Category:Pharmacopedia policy]]

----
''Effective date: pending Mark Elliott, MD sign-off.''

Pharmacopedia:About

2026-05-31T22:14:10Z

Maintenance script: Redirect to canonical About:Pharmacopedia (founder content merged there, Mark-signed)

#REDIRECT [[About:Pharmacopedia]]

About:Pharmacopedia

2026-05-31T22:13:15Z

Maintenance script: Merge founder origin-story into canonical About (v0.2, Mark-signed)

{{DISPLAYTITLE:About:Pharmacopedia}}

Pharmacopedia is a free, open medical reference: an evolving catalog of what is known, claimed, and reported about medicines, problems, and health topics, written across multiple perspectives so that readers can see the same subject through more than one lens.

This page describes what Pharmacopedia is, who runs it, how it is written, and what it commits to. For the legal terms governing your use of the site, see the [[Pharmacopedia:Terms of Use|Terms of Use]]. For data handling, see the [[About:Privacy|Privacy Policy]].

== What Pharmacopedia is ==

Pharmacopedia is a reference resource, not a clinical service. Each medicine page describes what the medicine is, how it is thought to work, what it is used for, what its effects and adverse effects are, and what readers from different perspectives have said about it. Each problem page describes a health condition, problem, or experience, and the medicines and approaches that are used to address it.

Pharmacopedia organizes content for multiple reader audiences (Clinician, Patient, Traditional, Researcher) and sources its claims across multiple knowledge traditions (pharma, plant, experiential, traditional). The intent is pluralism with discipline: every non-trivial claim takes an inline citation, and where a citation is not yet available, the page is marked rather than left implicit.

Pharmacopedia does not give medical advice. Nothing here is a substitute for a qualified clinician who knows your individual circumstances. If you have a medical question or emergency, consult a licensed clinician or call emergency services. For overdose or poisoning in the United States, call Poison Control at 1-800-222-1222.

== Who operates Pharmacopedia ==

Pharmacopedia is operated by the '''Pharmacopedia Collective''', a California nonprofit public benefit corporation (pending 501(c)(3) determination from the Internal Revenue Service). Until formal recognition is granted, the Collective operates under California law as an unincorporated nonprofit association.

The named data controller and editorial lead is '''Mark Elliott, MD''' (mark@pharmacopedia.wiki). Mark is a licensed physician; his role in Pharmacopedia is editorial and operational, not clinical-toward-readers. Reading Pharmacopedia does not create a doctor-patient relationship with him or with anyone else affiliated with the project.

Pharmacopedia is funded by Mark personally; donations are accepted only if operating costs exceed what he can self-fund. There are no paid tiers, no subscriptions, and no advertising. The full list of commitments about what Pharmacopedia will never do is at [[Pharmacopedia:Refusals]].

== How Pharmacopedia is written ==

Pharmacopedia content is produced by a team of AI assistants, invited human experts, and volunteer contributors, under Mark's editorial oversight.

The editorial workflow is '''propose-review-approve'''. All submitted content is proposed first; it is reviewed by a qualified human reviewer before it becomes visible to readers. At launch, Mark is the sole reviewer. As the project grows, additional reviewers will be brought in with their qualifications made public.

Every non-trivial claim takes an inline citation, in this priority order: primary literature, then FDA label or equivalent regulatory source, then meta-analysis or systematic review, then guideline, then established tertiary reference. Where no citation is yet available, the claim is marked {{citation needed}} rather than deleted, so the gap is visible and can be filled.

Pharmacopedia does not pretend to be a regulated medical authority. The [[Pharmacopedia:Adverse Event Reporting|adverse-experience reporting feature]] is a reader-experience aggregator, not a regulated pharmacovigilance program. The [[Pharmacopedia:Refusals|Refusals]] page enumerates the things this project commits never to do.

== How to use Pharmacopedia ==

You can read all of Pharmacopedia without an account. Search for a medicine, a problem, or a topic; follow cross-links between related pages; and read the perspectives that interest you. Each page surfaces source citations inline so you can verify claims.

If you create an account, you can:

* Submit proposed edits through the propose-review-approve workflow.
* Complete assessments and save your responses to your profile.
* Use [[Special:MyLifeStory]] to build a personal medical timeline (private to your account; never published).
* Submit reader-experience reports on medicines you have taken (see [[Pharmacopedia:Adverse Event Reporting]]).

Your account at Pharmacopedia.wiki also works at Oyami, Trykl, and PubSci, the other surfaces operated by the Pharmacopedia Collective.

== How to contribute ==

If you would like to contribute as an editor, reviewer, or content author, contact Mark at mark@pharmacopedia.wiki. Pharmacopedia is built by invitation and volunteer effort, not by open self-onboarding, because the propose-review-approve workflow needs human reviewers with verifiable qualifications.

If you would like to flag an error, a missing citation, or a substantive concern about a page, use the talk page for that page, or email mark@pharmacopedia.wiki.

== What this is not ==

Pharmacopedia is not:

* A clinical service, diagnostic tool, or prescribing platform.
* A pharmacovigilance program registered with any health authority.
* A peer-reviewed scientific journal. (For that, see [[:pubsci:|PubSci]], the Pharmacopedia Collective's open peer-review journal.)
* A platform that takes commercial direction over content. See [[Pharmacopedia:Refusals]].
* A platform that sells, licenses, or shares user data with commercial entities. See [[About:Privacy|Privacy Policy]].

== From the founder ==

Born in May 2026, Pharmacopedia started primarily as a one-man project of [https://markelliottmd.com MDElliottMD], who'd been dreaming of some place for the people who recommend and/or use meds of the mind to collaborate and create consensus-driven information, founded in a deep faith in the [https://en.wikipedia.org/wiki/Wisdom_of_the_crowd wisdom of the crowd].

First, I hope this to be a reasonable and reliable reference for prescribers of all sorts to find relevant and accurate information for their practice: available strengths, titration strategies, pill IDs, etc.

But almost moreso, I hope that this place can be a lively, collaborative space for a communal effort in understanding the bizarre world of using medicines to help alleviate suffering. I hope that by pooling our collective anecdotes.. our stories, that we might actually make some data.. of a sort.

The site empowers users (with 2-FA) to share their experience about almost every aspect of the site, in as fine a detail as I thought was tolerable. And now finally a place for [[MyProfileIntro|our stories]], in more exquisite detail than ever before. I hope that by pooling our experiences en masse, we might find something like truth.

For now, I, [[User:MDElliottMD|MDElliottMD]], am the only person who can approve/publish page edits, though I hope to have a team of moderators some day. I am also the only person currently able to access private user data. I am frankly [https://markelliottmd.com/privacy.html obsessed with privacy] and will do everything in my power to keep these data private. If any security nerds want to help me achieve that goal, [https://markelliottmd.com/contact.html please lmk].

I am not a software developer, nor a designer, but I am a top-tier expert in meds of the mind. I will keep the place as tidy as I can.

This project is not, in any way, driven by money or profit. The links above are as far as I will go to promote myself or my brand here. At the moment, I am happy to fund the project in its entirety (maybe $400/year at time of writing may 2026). If that changes, I may some day ask for donations.

To be explicit up front so I look foolish if I change my mind later:

1) I will never serve any sort of ad for anything other than this website itself or directly related content. no ads ever.
2) I will never make this a pay to play platform in any way. no hidden costs. no subscriptions. ever.
3) I will guard these precious data from any and all others, including any who would wish to buy them. I will never. ever. sell these data to anyone for any reason.

Aggregated data are ripe for analyzin’. Anything attributable to any individual will remain private to the best of my ability in perpetuity.

Pinky swear.

This project was entirely developed and partially populated by Claude (Opus 4.7 at initial build), and is based on the [https://www.mediawiki.org/wiki/MediaWiki Mediawiki code base], bless their souls. Know that any content not explicitly verified has some risk of AI slop. this will be fixed soon.

Most of the interface here is run through an extension that I made with Claude: [[About:Pharmacopedia.ext|Pharmacopedia.ext]], which I'm happy to share with whomever wants it. will post to Git once it’s a bit more mature. Probably easiest to get ahold of me through my website above.

Thanks for coming by. Would be honored if you could join the hive mind and share your stories.

-mark

== Licensing ==
Pharmacopedia's written content is available under the [https://creativecommons.org/licenses/by-sa/4.0/ Creative Commons Attribution-ShareAlike 4.0 International License] (CC BY-SA 4.0); the Pharmacopedia software extension is separately licensed under the [https://www.gnu.org/licenses/gpl-3.0.html GNU General Public License version 3]. Quoted third-party material remains under its original copyright. See [[Pharmacopedia:Copyrights]] for full terms.

== See also ==

* [[Pharmacopedia:Terms of Use|Terms of Use]]
* [[About:Privacy|Privacy Policy]]
* [[Pharmacopedia:Refusals|Refusals (what Pharmacopedia commits never to do)]]
* [[Pharmacopedia:Reciprocity|Reciprocity (AI training posture)]]
* [[Pharmacopedia:Sources|Sources and citation policy]]
* [[Pharmacopedia:Copyrights|Copyrights]]
* [[Pharmacopedia:Adverse Event Reporting|Adverse Event Reporting]]
* [[Pharmacopedia:Newsroom|Newsroom (material change announcements)]]

[[Category:Pharmacopedia policy]]

----
''Effective date: pending Mark Elliott, MD sign-off.''
''Operator: Pharmacopedia Collective (California nonprofit public benefit corporation, pending 501(c)(3) determination).''
''Controller: Mark Elliott, MD -- mark@pharmacopedia.wiki''

About:Pharmacopedia

2026-05-31T21:53:43Z

Maintenance script: Initial version -- canonical About page (interface v0.1, Mark-signed)

{{DISPLAYTITLE:About:Pharmacopedia}}
__NOTOC__

Pharmacopedia is a free, open medical reference: an evolving catalog of what is known, claimed, and reported about medicines, problems, and health topics, written across multiple perspectives so that readers can see the same subject through more than one lens.

This page describes what Pharmacopedia is, who runs it, how it is written, and what it commits to. For the legal terms governing your use of the site, see the [[Pharmacopedia:Terms of Use|Terms of Use]]. For data handling, see the [[About:Privacy|Privacy Policy]].

== What Pharmacopedia is ==

Pharmacopedia is a reference resource, not a clinical service. Each medicine page describes what the medicine is, how it is thought to work, what it is used for, what its effects and adverse effects are, and what readers from different perspectives have said about it. Each problem page describes a health condition, problem, or experience, and the medicines and approaches that are used to address it.

Pharmacopedia organizes content for multiple reader audiences (Clinician, Patient, Traditional, Researcher) and sources its claims across multiple knowledge traditions (pharma, plant, experiential, traditional). The intent is pluralism with discipline: every non-trivial claim takes an inline citation, and where a citation is not yet available, the page is marked rather than left implicit.

Pharmacopedia does not give medical advice. Nothing here is a substitute for a qualified clinician who knows your individual circumstances. If you have a medical question or emergency, consult a licensed clinician or call emergency services. For overdose or poisoning in the United States, call Poison Control at 1-800-222-1222.

== Who operates Pharmacopedia ==

Pharmacopedia is operated by the '''Pharmacopedia Collective''', a California nonprofit public benefit corporation (pending 501(c)(3) determination from the Internal Revenue Service). Until formal recognition is granted, the Collective operates under California law as an unincorporated nonprofit association.

The named data controller and editorial lead is '''Mark Elliott, MD''' (mark@pharmacopedia.wiki). Mark is a licensed physician; his role in Pharmacopedia is editorial and operational, not clinical-toward-readers. Reading Pharmacopedia does not create a doctor-patient relationship with him or with anyone else affiliated with the project.

Pharmacopedia is funded by Mark personally; donations are accepted only if operating costs exceed what he can self-fund. There are no paid tiers, no subscriptions, and no advertising. The full list of commitments about what Pharmacopedia will never do is at [[Pharmacopedia:Refusals]].

== How Pharmacopedia is written ==

Pharmacopedia content is produced by a team of AI assistants, invited human experts, and volunteer contributors, under Mark's editorial oversight.

The editorial workflow is '''propose-review-approve'''. All submitted content is proposed first; it is reviewed by a qualified human reviewer before it becomes visible to readers. At launch, Mark is the sole reviewer. As the project grows, additional reviewers will be brought in with their qualifications made public.

Every non-trivial claim takes an inline citation, in this priority order: primary literature, then FDA label or equivalent regulatory source, then meta-analysis or systematic review, then guideline, then established tertiary reference. Where no citation is yet available, the claim is marked {{citation needed}} rather than deleted, so the gap is visible and can be filled.

Pharmacopedia does not pretend to be a regulated medical authority. The [[Pharmacopedia:Adverse Event Reporting|adverse-experience reporting feature]] is a reader-experience aggregator, not a regulated pharmacovigilance program. The [[Pharmacopedia:Refusals|Refusals]] page enumerates the things this project commits never to do.

== How to use Pharmacopedia ==

You can read all of Pharmacopedia without an account. Search for a medicine, a problem, or a topic; follow cross-links between related pages; and read the perspectives that interest you. Each page surfaces source citations inline so you can verify claims.

If you create an account, you can:

* Submit proposed edits through the propose-review-approve workflow.
* Complete assessments and save your responses to your profile.
* Use [[Special:MyLifeStory]] to build a personal medical timeline (private to your account; never published).
* Submit reader-experience reports on medicines you have taken (see [[Pharmacopedia:Adverse Event Reporting]]).

Your account at Pharmacopedia.wiki also works at Oyami, Trykl, and PubSci, the other surfaces operated by the Pharmacopedia Collective.

== How to contribute ==

If you would like to contribute as an editor, reviewer, or content author, contact Mark at mark@pharmacopedia.wiki. Pharmacopedia is built by invitation and volunteer effort, not by open self-onboarding, because the propose-review-approve workflow needs human reviewers with verifiable qualifications.

If you would like to flag an error, a missing citation, or a substantive concern about a page, use the talk page for that page, or email mark@pharmacopedia.wiki.

== What this is not ==

Pharmacopedia is not:

* A clinical service, diagnostic tool, or prescribing platform.
* A pharmacovigilance program registered with any health authority.
* A peer-reviewed scientific journal. (For that, see [[:pubsci:|PubSci]], the Pharmacopedia Collective's open peer-review journal.)
* A platform that takes commercial direction over content. See [[Pharmacopedia:Refusals]].
* A platform that sells, licenses, or shares user data with commercial entities. See [[About:Privacy|Privacy Policy]].

== See also ==

* [[Pharmacopedia:Terms of Use|Terms of Use]]
* [[About:Privacy|Privacy Policy]]
* [[Pharmacopedia:Refusals|Refusals (what Pharmacopedia commits never to do)]]
* [[Pharmacopedia:Reciprocity|Reciprocity (AI training posture)]]
* [[Pharmacopedia:Sources|Sources and citation policy]]
* [[Pharmacopedia:Adverse Event Reporting|Adverse Event Reporting]]
* [[Pharmacopedia:Newsroom|Newsroom (material change announcements)]]

[[Category:Pharmacopedia policy]]

----
''Effective date: pending Mark Elliott, MD sign-off.''
''Operator: Pharmacopedia Collective (California nonprofit public benefit corporation, pending 501(c)(3) determination).''
''Controller: Mark Elliott, MD -- mark@pharmacopedia.wiki''

About:Privacy

2026-05-31T19:54:40Z

Maintenance script: Add AE reports subsection; pointer to Pharmacopedia:Adverse_Event_Reporting (Mark signed 2026-05-31)

__NOTOC__

This page describes how Pharmacopedia.wiki handles your data: what we collect, how we store it, who controls it, and how long we keep it.

Pharmacopedia.wiki is operated by the Pharmacopedia Collective, a nonprofit. The named data controller is Mark Elliott, MD (mark@pharmacopedia.wiki).

== What Pharmacopedia.wiki stores ==

=== Account data ===

When you create an account on Pharmacopedia.wiki, we store:

* Username
* Email address (optional; used for password recovery and notifications if you choose)
* Hashed password (bcrypt; we never store your password in cleartext)
* Account creation date

=== Assessment data ===

If you complete assessments on Pharmacopedia.wiki, we store your responses and computed scores. Assessment data is linked to your account. You can view your assessment history at [[Special:MyProfile]].

Assessment data is used for:

* Showing you your own results and history
* Internal research and analysis (see "Research use" below)

Assessment data is never sold, licensed, or shared with commercial entities. See [[Pharmacopedia:Refusals]] for the full list of commitments on data use.

=== MyLifeStory data ===

If you use [[Special:MyLifeStory]], your timeline entries (events, episodes, observations, stories, relationships, and attributes) are stored with the visibility level you choose:

* '''Private''' (default): visible only to you.
* '''Public + attribution''': visible to others with your display name.
* '''Public + username''': visible to others with your username.
* '''Public, no byline''': visible to others with no identifying information.

Private entries are never shared, exported, or made available to any other service. Public entries are visible on Pharmacopedia.wiki according to the level you select. You can change an entry's visibility at any time.

=== Derived data ===

Some data is generated from your account activity:

* Derived timeline events (auto-generated from your medications, diagnoses, and experience reports, visible in MyLifeStory)
* Profile statistics (assessment completion counts, timeline entry counts)

=== Adverse experience reports ===

If you submit a reader-experience report through the form on a medicine page, we store your report content, the medicine it references, and the timestamp. Reports are linked to your account but never published individually; only anonymized aggregate signals that meet a minimum count threshold may surface on the relevant medicine page.

This feature is not a regulated adverse event reporting program. See [[Pharmacopedia:Adverse Event Reporting]] for the full explanation of what the feature is, what it is not, and where to file an official report if you need to.

=== Page edits and contributions ===

Edits to wiki pages are logged with your username, edit timestamp, and edit summary. This is standard MediaWiki behavior and the edit history is publicly visible. We do not offer anonymous editing; all edits are attributed to a logged-in account.

== Data controller model ==

Pharmacopedia.wiki is one part of the Pharmacopedia Collective, which also operates Oyami (oyami.org), Trykl (trykl.org), and PubSci (pubsci.io). Your Pharmacopedia.wiki account works across all four services.

The data controller model is layered:

* '''Pharmacopedia.wiki''' is the data controller of the shared layer: your account identity and your assessment data at rest.
* '''Each service''' (Oyami, Trykl, PubSci) is the data controller of its own service-specific data (for example, Oyami session records, Trykl transaction records, PubSci submissions and reviews).
* '''Each service''' is also an independent data controller of its own processing of data it accesses from the shared Pharmacopedia.wiki layer. When Oyami accesses your assessment data to power its matching features, Oyami is making its own processing decisions and is a controller for that activity.

The named data controller on all services is Mark Elliott, MD.

For rights related to your account or assessment data, contact mark@pharmacopedia.wiki or visit [[Special:MyProfile]]. For rights related to your activity on a specific service, that service's privacy page is the authority.

== How long we keep your data ==

=== Active data ===

Your account, assessments, and timeline entries persist for as long as your account is active. You can delete individual timeline entries or assessment records at any time.

=== Backups ===

Pharmacopedia.wiki maintains encrypted backups:

* Up to 7 days on the backend host
* Then up to 14 days in active off-site storage
* Then up to 180 additional days in the off-site provider's deletion-recovery layer

All backups are encrypted (GPG, AES-256). The off-site provider cannot read the backup contents. Total worst-case time before permanent deletion of a deleted record: approximately 201 days.

This is current operational reality. When we migrate to infrastructure with hard-delete capability, the retention window will shorten and this page will be updated.

=== Account deletion ===

If you delete your account, your account data and assessment data are removed from the active database. Backup copies persist for the retention window described above, then are permanently deleted.

Page edits you made to public wiki pages remain in the edit history (attributed to your username) and are not deleted when your account is deleted. This is standard MediaWiki behavior.

== Research use ==

Assessment data may be used for internal research and analysis by Mark Elliott, MD. This research is internal to the Pharmacopedia Collective; we do not pursue peer-reviewed publication and therefore do not require IRB review. The research dataset is for Mark's internal analysis only.

Assessment data used for research is de-identified. Research results are never presented at an individual level.

== Third-party services ==

Pharmacopedia.wiki does not use third-party JavaScript on user-facing pages. Your browser talks only to Pharmacopedia infrastructure. See [[Pharmacopedia:Refusals]] for the full commitment.

Pharmacopedia.wiki uses OAuth 2.0 (with PKCE) to authenticate your account on connected services (Oyami, Trykl, PubSci). When you authorize a service, you see the specific data grants on the consent screen. You can manage your active grants at [[Special:OAuthManageMyGrants]].

== Your rights ==

You may:

* View all data associated with your account at [[Special:MyProfile]] and [[Special:MyLifeStory]]
* Delete individual assessment records or timeline entries
* Change the visibility of any MyLifeStory entry
* Revoke OAuth grants to connected services at [[Special:OAuthManageMyGrants]]
* Delete your account entirely by contacting mark@pharmacopedia.wiki
* Request a copy of your data by contacting mark@pharmacopedia.wiki

== Contact ==

For questions about this privacy notice or your data, contact Mark Elliott, MD at mark@pharmacopedia.wiki.

== Revision history ==

* 2026-05-24: Initial version.
* 2026-05-31: Corrected data controller model from "separate controllers" to layered controller model (Q6 decision, 2026-05-24). Removed premature cross-link to Oyami privacy document. Updated backup retention to reflect current 7+14+180 operational reality.

== See also ==

* [[Pharmacopedia:Refusals|Refusals]]
* [[Pharmacopedia:Reciprocity|Reciprocity (AI training posture)]]
* [[Pharmacopedia:Sources|Sources and licensing]]

[[Category:Pharmacopedia policy]]

Pharmacopedia:Newsroom

2026-05-31T19:53:17Z

Maintenance script: Initial launch stub (Mark signed 2026-05-31)

{{DISPLAYTITLE:Pharmacopedia: Newsroom}}
__NOTOC__

The Newsroom is where Pharmacopedia announces material changes to its policies, its editorial process, and the operation of this site. It is the canonical channel referenced by the [[Pharmacopedia:Terms of Use|Terms of Use]] for change notices, and supplements site-wide notices that may appear at the top of pages.

This is an editorial-transparency surface, not a marketing channel. Pharmacopedia does not announce features, partnerships, or roadmap items here. It announces things that affect what you have agreed to or what we have committed to.

== What gets posted here ==

* '''Material changes to the [[Pharmacopedia:Terms of Use|Terms of Use]]''', with the effective date and a summary of what changed. Per the Terms, governing-law and dispute-resolution changes get at least 30 days lead time before they take effect.
* '''Material changes to the [[About:Privacy|Privacy Policy]]''', with the effective date and a summary of what changed.
* '''Process changes to the propose-review-approve workflow''', including who reviews proposed content and how appeals are handled.
* '''Editorial disclosures''' that affect how content is sourced or weighted, including changes to the [[Pharmacopedia:Refusals|Refusals]] list and the [[Pharmacopedia:Reciprocity|Reciprocity]] commitments.
* '''Operational notices''' that materially affect site availability or data, such as planned migrations, downtime, or data-handling changes.
* '''Corrections''' to substantive errors in earlier announcements, dated and labeled as corrections.

== What does not get posted here ==

* Individual page edits. The propose-review-approve workflow handles these; the page history is the record.
* Personal updates about Mark Elliott, MD or other contributors. The [[Pharmacopedia:About|About]] page covers role descriptions.
* Press releases, marketing copy, or fundraising appeals. Pharmacopedia does not run any of those.
* Adverse event reports. See [[Pharmacopedia:Adverse Event Reporting]] for that channel.

== How to get notices ==

At launch, the Newsroom is this page. Returning here to check it, or watching this page through your account preferences, is the supported way to follow announcements.

A more discoverable notification mechanism (RSS, email digest, or in-account inbox) may be added later; if and when it is, that change itself gets posted here.

== Notices ==

''No material announcements yet. Pharmacopedia is in soft-launch posture. The first Newsroom entry will land when there is something material to say.''

== See also ==

* [[Pharmacopedia:Terms of Use|Terms of Use]]
* [[About:Privacy|Privacy Policy]]
* [[Pharmacopedia:Refusals|Refusals]]
* [[Pharmacopedia:Reciprocity|Reciprocity]]
* [[Pharmacopedia:Sources|Sources]]
* [[Pharmacopedia:Adverse Event Reporting|Adverse Event Reporting]]

[[Category:Pharmacopedia policy]]

----
''Effective date: pending Mark Elliott, MD sign-off.''

Pharmacopedia:Adverse Event Reporting

2026-05-31T19:53:08Z

Maintenance script: Initial launch version (Mark signed 2026-05-31)

{{DISPLAYTITLE:Pharmacopedia: Adverse Experience Reporting}}
__NOTOC__

Pharmacopedia medicine pages include a feature that lets readers share their experiences with a medicine. This page explains what that feature is, what it is not, and where to go if you need to report a suspected adverse drug reaction to a regulatory authority.

== What this feature is ==

The reader-experience report is a way for you to tell us what you experienced when taking a medicine -- positive, negative, or neutral. We use these reports to understand how Pharmacopedia readers describe their experiences, to flag topics that may deserve more editorial attention on the page, and (once enough reports accumulate) to surface anonymized aggregate patterns in the Patient perspective layer.

Reports are voluntary. You are never required to submit one. Submitting a report does not give Pharmacopedia or any affiliated party access to your medical records or any data beyond what you type.

== What this feature is not ==

'''This feature is not a registered adverse event reporting system.'''

Pharmacopedia is not a spontaneous adverse event reporting program under FDA regulation (21 CFR Part 314.81), a MedWatch equivalent, or any other regulated reporting mechanism. Submitting a report here:

* Does not notify the FDA, the CDC, or any other regulatory or public health authority.
* Does not fulfill any legal or regulatory obligation a clinician, manufacturer, or institution may have to report an adverse drug reaction.
* Does not result in your report being forwarded to any government body or shared with the drug's manufacturer.

'''If you are a clinician, pharmacist, or manufacturer with a mandatory adverse event reporting obligation, you must report through the appropriate regulatory channel (FDA MedWatch or equivalent). A report to Pharmacopedia does not satisfy that obligation.'''

== What happens to reports ==

Reports are held internally. No individual report is published or shared. A minimum threshold of distinct submissions must accumulate before any aggregate signal from reports is displayed on a medicine page (the threshold is set to protect individual privacy). When a signal does appear on a page, it is an anonymized aggregate count with no information that could identify any submitter.

Pharmacopedia editorial staff may review reports in aggregate to identify patterns worth editorial attention. Reports are not sold, licensed, or shared with commercial entities. See [[Pharmacopedia:Refusals]] for the full list of data commitments.

== If you think you are having an adverse drug reaction ==

Reader-experience reports are not the right channel if you need help or need to file an official report.

'''For immediate danger:''' Call 911 or your local emergency services. Do not delay for any other step.

'''For poison exposure or overdose:''' Contact Poison Control: 1-800-222-1222 (US). Online chat also available at www.poison.org.

'''To file an official adverse event report:'''

* '''United States:''' FDA MedWatch -- www.fda.gov/safety/medwatch. Consumers and clinicians can file. MedWatch forms are free and available online.
* '''Canada:''' Health Canada MedEffect -- www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html
* '''United Kingdom:''' MHRA Yellow Card -- yellowcard.mhra.gov.uk
* '''European Union:''' EudraVigilance (for professionals) or the national competent authority for your country
* '''Australia:''' TGA Adverse Event Management System -- www.tga.gov.au/reporting-adverse-events

These programs exist so that regulators can detect safety signals across large populations. Pharmacopedia is reference and reader-experience; official pharmacovigilance belongs with the programs above.

== Privacy ==

Reader-experience reports are subject to the [[About:Privacy|Privacy Policy]]. In brief: reports are stored internally, not sold, not shared with commercial entities, and not published at the individual level. The anonymization threshold means an individual report cannot be traced once it is part of an aggregate.

== See also ==

* [[About:Privacy|Privacy Policy]]
* [[Pharmacopedia:Refusals|Refusals (what Pharmacopedia will never do)]]
* [[Pharmacopedia:Terms of Use|Terms of Use]] (Section 5 covers the regulatory framing of this feature)

[[Category:Pharmacopedia policy]]

---
''Effective date: pending Mark Elliott, MD sign-off.''

Pharmacopedia:Terms of Use

2026-05-31T19:51:23Z

Maintenance script: Initial launch version (Mark signed 2026-05-31)

{{DISPLAYTITLE:Pharmacopedia: Terms of Use}}
__NOTOC__

These Terms of Use govern your access to and use of Pharmacopedia.wiki ("Pharmacopedia"), operated by the Pharmacopedia Collective. By reading, contributing to, or creating an account on Pharmacopedia, you agree to these terms. If you do not agree, please do not use the site.

Pharmacopedia is a free, open medical reference. It is built by a team of AI assistants, invited human experts, and volunteer contributors under the editorial oversight of [[Pharmacopedia:About|Mark Elliott, MD]]. It is funded by Mark Elliott, MD; donations are accepted only if operating costs exceed what he can self-fund. There are no paid tiers, no subscriptions, no ads.

== 1. What Pharmacopedia is and is not ==

'''Pharmacopedia is a reference resource.''' Every page describes what is known about a medicine, problem, or health topic, with content organized for multiple reader audiences (Clinician, Patient, Traditional, Researcher) and sourced across multiple knowledge traditions (pharma, plant, experiential, traditional). It is not a clinical service, a diagnostic tool, or a prescribing platform.

'''Pharmacopedia does not give medical advice.''' Nothing on this site constitutes a diagnosis, a treatment recommendation, or a substitute for the advice of a qualified clinician who knows your individual circumstances. Do not make decisions about your health, your medications, or your treatment based solely on information you read here. If you have a medical question or emergency, consult a licensed clinician or call emergency services.

'''Pharmacopedia does not create a doctor-patient relationship.''' Reading Pharmacopedia, contributing to Pharmacopedia, or communicating with any Pharmacopedia contributor or editor does not establish any clinical relationship between you and anyone affiliated with this project.

== 2. Who operates Pharmacopedia ==

Pharmacopedia is operated by the '''Pharmacopedia Collective''', a California nonprofit public benefit corporation (pending 501(c)(3) determination from the Internal Revenue Service). Until formal recognition is granted, the Pharmacopedia Collective operates under California law as an unincorporated nonprofit association. '''Mark Elliott, MD''' (mark@pharmacopedia.wiki) serves as the personal data controller for purposes of applicable privacy law and as the named operator of this site.

== 3. Your account ==

You may read all of Pharmacopedia without an account. Creating an account allows you to submit proposed edits through our propose-review-approve workflow.

When you register:

* You must provide accurate information. Impersonating a real person, a professional credential you do not hold, or another organization is prohibited and is grounds for immediate account termination.
* You are responsible for keeping your credentials secure. Do not share your password.
* You must be at least 13 years old to register. If you are under 18, a parent or legal guardian must review these terms with you.

We reserve the right to suspend or terminate accounts that violate these terms, abuse the editorial process, or harm the project or its contributors, with or without notice depending on severity.

== 4. Contributing content ==

Pharmacopedia uses a '''propose-review-approve''' editorial model. All submitted content is proposed first; it is reviewed by a qualified human reviewer before it becomes visible to readers.

'''By submitting any content to Pharmacopedia, you:'''

* Confirm that you are the author of the content or have the right to submit it under the license below.
* Confirm that the content does not infringe any third-party intellectual property rights.
* Grant Pharmacopedia and all downstream users a perpetual, worldwide, royalty-free license to use, distribute, reproduce, and modify your contribution under the terms of the '''Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA 4.0)'''.

Text you contribute becomes part of the CC BY-SA 4.0 corpus of Pharmacopedia. You retain your own copyright; you are granting a license, not transferring ownership. You cannot later withdraw a contribution already incorporated into the project's CC BY-SA content under that license.

'''Do not submit content that:'''

* You copied from a source without rights to reproduce it (copyrighted drug-company materials, journal articles behind paywalls, etc.).
* Includes protected health information (PHI) or personally identifiable information about any real individual.
* Is false, misleading, or fabricated.
* Is harassment, abuse, or threats directed at any person.
* Promotes a commercial interest in a way that bypasses our [[Pharmacopedia:Refusals|editorial independence commitments]].

Pharmacopedia has no obligation to publish submitted content. Rejected proposals are not published.

== 5. Adverse experience reports ==

Pharmacopedia provides a reader-experience reporting feature on medicine pages. This feature lets readers describe their own experiences with a medicine for quality-improvement purposes at Pharmacopedia.

'''This feature is not a registered adverse event reporting system.''' It does not satisfy any legal or regulatory requirement to report adverse drug reactions to health authorities. Reports submitted through this feature are not forwarded to the FDA, the CDC, or any other regulatory body. Raw individual reports are not published; they are held internally and only an anonymized signal (meeting a minimum count threshold) may eventually be surfaced in aggregate on the relevant page.

'''If you believe you or someone else is experiencing a serious adverse drug reaction, report it directly to:'''

* FDA MedWatch (US): www.fda.gov/safety/medwatch
* Your national pharmacovigilance authority (if outside the US)
* Emergency services if the reaction is immediately life-threatening

== 6. Privacy ==

Our [[About:Privacy|Privacy Policy]] explains what information we collect, how we use it, and your rights under California law (CCPA/CPRA) and other applicable law. Using Pharmacopedia is subject to the Privacy Policy in addition to these Terms.

In brief: we do not sell data, we do not run third-party tracking scripts, and we do not share user data with advertisers. Full details are in the Privacy Policy.

== 7. Intellectual property ==

'''Pharmacopedia content is CC BY-SA 4.0''' unless otherwise stated on a specific page. You may copy, adapt, and redistribute Pharmacopedia content under the same license with attribution. The preferred citation form and BibTeX/Chicago/APA/Vancouver formats are available on each page via the citation widget.

Pharmacopedia's visual design (the Pharmacopedia seal, typography choices, color palette, and custom interface elements) is not CC BY-SA and is not available for reproduction without permission.

If you believe a page or contribution infringes your copyright, contact mark@pharmacopedia.wiki with: (a) a description of the allegedly infringing content and its URL; (b) your contact information; (c) a statement that you own the copyright or are authorized to act on the owner's behalf; and (d) a statement of good-faith belief that the use is not authorized. We will investigate and respond.

== 8. What we commit not to do ==

The [[Pharmacopedia:Refusals|Refusals page]] lists the things Pharmacopedia will never do. The most relevant to these Terms: we will never sell your health data, run ads, paywall content, accept commercial influence over content, or operate as a Class III medical device without proper regulatory review. Those commitments are incorporated here by reference.

== 9. Disclaimers and limitation of liability ==

Pharmacopedia makes reasonable efforts to ensure the accuracy of information on this site, but '''medical knowledge changes rapidly and errors can occur'''. We do not warrant that any information on Pharmacopedia is complete, accurate, current, or applicable to your specific situation.

To the maximum extent permitted by applicable law, the Pharmacopedia Collective, Mark Elliott MD, and all contributors disclaim all warranties, express or implied, regarding the site and its content. We are not liable for any harm arising from your reliance on information found on Pharmacopedia, including missed diagnoses, medication errors, or treatment decisions made without professional consultation.

California law does not permit the disclaimer of liability for gross negligence or willful misconduct; nothing in this section is intended to disclaim liability for those.

== 10. Governing law and disputes ==

'''These Terms are governed by the laws of the State of California, without regard to conflict of law principles.'''

Any dispute arising from these Terms or your use of Pharmacopedia will be resolved '''in the state or federal courts located in the State of California'''. You consent to the personal jurisdiction of those courts.

'''There is no mandatory arbitration clause here.''' You are not waiving your right to have a dispute heard in court. '''There is no class-action waiver.''' If a dispute is one that can properly be brought as a class action, you retain that right.

== 11. Changes to these Terms ==

We may update these Terms from time to time. Material changes will be announced on [[Pharmacopedia:Newsroom|Pharmacopedia:Newsroom]] and, where feasible, by a site notice. The effective date at the bottom of this page will be updated. Continued use of the site after the effective date constitutes acceptance of the revised Terms.

We will not change the governing-law clause, the no-arbitration commitment, or the no-class-action-waiver commitment without explicit notice and at least 30 days' lead time.

== 12. Contact ==

Questions about these Terms: '''mark@pharmacopedia.wiki'''

To report a potential Terms violation: Pharmacopedia:Newsroom talk page or mark@pharmacopedia.wiki.

To report a copyright concern: mark@pharmacopedia.wiki (see Section 7).

== See also ==

* [[About:Privacy|Privacy Policy]]
* [[Pharmacopedia:Refusals|Refusals (what Pharmacopedia will never do)]]
* [[Pharmacopedia:Sources|Sources and licensing]]
* [[Pharmacopedia:Reciprocity|Reciprocity (AI training posture)]]
* [[Pharmacopedia:Newsroom|Newsroom (editorial transparency)]]

[[Category:Pharmacopedia policy]]

---
''Effective date: pending Mark Elliott, MD sign-off.''
''Operator: Pharmacopedia Collective (California nonprofit public benefit corporation, pending 501(c)(3) determination).''
''Controller: Mark Elliott, MD — mark@pharmacopedia.wiki''

Pharmacopedia:Sources

2026-05-31T17:31:46Z

Maintenance script: Remove DISPLAYTITLE (skin handles namespace title display)

__NOTOC__

This page describes how Pharmacopedia.wiki sources its content: what kinds of sources we cite, how we rank them, what external vocabularies we link out to, and what licensing applies in each direction.

It is the public counterpart to the editorial sourcing standards used internally by Pharmacopedia editors and reviewers.

== Sourcing hierarchy ==

Pharmacopedia editorial work follows a citation hierarchy. When multiple source types are available for the same claim, the higher-tier source takes precedence. When sources of equivalent tier disagree, the disagreement is surfaced explicitly per [[Pharmacopedia:Refusals|the editorial integrity refusals]].

The hierarchy:

# '''Primary literature.''' Peer-reviewed clinical trials, observational studies, mechanism research published in indexed journals. Cited with full author list, journal, year, DOI or PMID.
# '''Regulatory documents.''' FDA labels, EMA SmPCs, MHRA, PMDA, Health Canada equivalents. Used for marketed-indication, dosing, contraindication, and pharmacokinetic data. Cited with version date.
# '''Meta-analyses and systematic reviews.''' Cochrane, NICE evidence reviews, AHRQ comparative-effectiveness reviews. Used for synthesized clinical claims.
# '''Clinical practice guidelines.''' Specialty-society guidelines (APA, AHA, NICE, WHO, etc.). Used for standard-of-care framing.
# '''Tertiary references.''' Textbooks, clinical handbooks, established pharmacology references. Used for foundational pharmacology and well-settled material.
# '''Ethnobotanical and historical sources.''' Peer-reviewed ethnobotany, anthropological literature, primary historical documents (in the Traditional perspective).
# '''Patient-experience sources.''' Patient-organization documentation, qualitative research on lived experience, structured patient-experience aggregation (in the Patient perspective, with clear methodological framing).

A claim without any source is not a Pharmacopedia claim. Editors mark unsourced material with <code><nowiki>[citation needed]</nowiki></code>; reviewers do not approve a claim into the published surface without at least one cited source.

== Per-Perspective sourcing standards ==

Pharmacopedia renders each medicine page across four editorial perspectives. Each perspective applies the hierarchy above with its own emphasis:

* '''Clinician''' (colleague-to-colleague clinical depth): primary literature, regulatory documents, guidelines, meta-analyses dominate. Pharmacology references support foundational claims.
* '''Patient''' (warm, careful, medically literate friend): primary literature for clinical claims; regulatory documents for prescribing-information facts; patient-experience sources contextualize what living with a medicine looks like.
* '''Traditional''' (thoughtful ethnobotanist or historian): peer-reviewed ethnobotany and anthropology; primary historical sources; indigenous-knowledge sources cited respectfully and with attribution to the holding community where the community has published or authorized the reference.
* '''Researcher''' (methods-section style): primary literature dominates; methodology, sample size, effect sizes, and replication status are quoted; the writing is structured for a reader who will go read the cited paper.

Where a claim is made across multiple perspectives, the highest-tier source standing behind any one perspective applies to all of them; each perspective's render reflects how that perspective contextualizes the same evidence.

== "Reviewed YYYY-MM-DD" badge ==

Each Pharmacopedia claim carries a last-reviewed date. Pages display the freshness of their underlying claims via a per-claim badge. When a claim's last-reviewed date crosses a staleness threshold (currently 24 months), the badge displays a "review pending" state and the claim enters the editorial review queue.

This system is part of the data infrastructure work in progress. See the [[Pharmacopedia:Newsroom|Newsroom]] for the rollout schedule.

== External vocabularies Pharmacopedia links to ==

Pharmacopedia medicine and problem pages link out to external biomedical vocabularies. This makes Pharmacopedia interoperable with electronic health records, pharmacy systems, research databases, and other downstream consumers.

The vocabularies we link out to fall into three groups by licensing posture:

=== Cleared for cross-reference ===

These vocabularies are public-domain or open-licensed. Pharmacopedia stores their identifiers as cross-references on each relevant page, renders them as linked badges, and serves them via the public read API.

{| class="wikitable"
! Vocabulary !! Identifier scope !! License !! Notes
|-
| '''RxNorm''' || US drug nomenclature || US Government public domain (NLM) || Maintained by the US National Library of Medicine. Free for all use including commercial.
|-
| '''MeSH''' (Medical Subject Headings) || Biomedical topic indexing || US Government public domain (NLM) || Used in PubMed indexing. Free for all use.
|-
| '''Wikidata''' || Cross-domain entity identifiers || CC0 (public domain dedication) || Pharmacopedia consumes Wikidata IDs as cross-refs and, post-launch, requests that PCP-PIDs be added as a Wikidata property.
|}

=== Under licensing review ===

These vocabularies are widely used in clinical informatics but their licensing terms restrict redistribution in specific ways. Pharmacopedia is reviewing each one to determine whether and how we can use them in cross-references. Until the review is complete, we do not display these identifiers on user-facing pages, even where we have them in internal data.

{| class="wikitable"
! Vocabulary !! Status !! Open question
|-
| '''DrugBank''' || Under review || DrugBank's Public Use license permits non-commercial academic use but restricts redistribution. Whether displaying a DrugBank ID as a cross-reference badge constitutes redistribution is the open question.
|-
| '''ATC''' (Anatomical Therapeutic Chemical classification) || Under review || ATC is maintained by the WHO Collaborating Centre for Drug Statistics Methodology. The WHO Centre charges for commercial use of the ATC system; Pharmacopedia is nonprofit, so the question is whether displaying an ATC code in a non-commercial Pharmacopedia page is in scope of the free educational-use carve-out.
|-
| '''UMLS-bridged identifiers''' (SNOMED CT, ICD-10, ICD-11, LOINC where they sit under UMLS) || Under review || UMLS is licensed by the NLM under terms that require user registration. Whether transitively-derived UMLS identifiers displayed on a public page require Pharmacopedia to track its readers as UMLS users is the open question.
|}

When reviews complete, this section is updated and the affected vocabularies move into the cleared-for-cross-reference table above. The Newsroom logs each update.

=== Not used ===

Pharmacopedia does not cross-reference proprietary commercial drug-information databases (Micromedex, Lexicomp, Clinical Pharmacology, etc.). Those products are valuable inside the institutions that subscribe to them; Pharmacopedia's job is to be the freely available source, not to link to paywalled ones.

== Pharmacopedia's own identifiers ==

Pharmacopedia issues its own permanent identifiers per page and per claim. The format is:

pcp:<type>:<base32>

Where <code><type></code> is <code>page</code>, <code>claim</code>, or one of a small set of structured types, and <code><base32></code> is a stable suffix. Once issued, an identifier resolves forever, even if the page is renamed or merged. See [[Pharmacopedia:Permanent identifiers]] for the full specification when it is published.

== Reuse: how to cite Pharmacopedia ==

Pharmacopedia content is freely reusable under CC BY-SA 4.0 (see [[Pharmacopedia:Reciprocity]] for AI-training specifics). When citing a Pharmacopedia page in your own writing, the recommended forms are:

;Chicago
:"<Page Title>." Pharmacopedia. Accessed YYYY-MM-DD. <nowiki>https://pharmacopedia.wiki/wiki/<Page_Title></nowiki>
;APA
:Pharmacopedia. (YYYY). <Page Title>. Retrieved YYYY-MM-DD from <nowiki>https://pharmacopedia.wiki/wiki/<Page_Title></nowiki>
;Vancouver
:Pharmacopedia [Internet]. <Page Title>. [cited YYYY-MM-DD]. Available from: <nowiki>https://pharmacopedia.wiki/wiki/<Page_Title></nowiki>
;BibTeX
:Each page emits a <code>@misc</code> BibTeX entry via the citation widget in the page chrome.

Once per-claim PIDs are live, citations may also point to individual claims via:

https://pharmacopedia.wiki/p/<pcp-claim-PID>

This is recommended when the citing work depends on a specific factual assertion within a Pharmacopedia page rather than the page as a whole.

== Revision ==

This page was locked on 2026-05-28 as part of the institutional identity commitments. The "under licensing review" table changes as reviews complete; those updates are logged on Newsroom and reflected here without a separate revision-log entry. Structural changes to the sourcing hierarchy or the per-Perspective standards are material revisions and are logged here.

== See also ==

* [[Pharmacopedia:Refusals|Refusals]]
* [[Pharmacopedia:Reciprocity|Reciprocity (AI training posture)]]
* [[Pharmacopedia:Newsroom|Newsroom]]
* [[Pharmacopedia:Permanent identifiers]] (forthcoming)

[[Category:Pharmacopedia policy]]

Pharmacopedia:Reciprocity

2026-05-31T17:31:45Z

Maintenance script: Remove DISPLAYTITLE (skin handles namespace title display)

__NOTOC__

This page describes how Pharmacopedia.wiki content interacts with AI training, retrieval-augmented generation, and other downstream automated uses. It is the public statement of what we allow, what we ask in return, and why.

== Short version ==

You may train AI systems on Pharmacopedia.wiki content. We ask that AI systems generating Pharmacopedia-derived medical content cite the source URLs of the Pharmacopedia pages they are drawing from. We do not technically block training crawlers and we will not. This is a reciprocity expectation, not a license restriction.

== Why we allow AI training ==

Pharmacopedia exists to make rigorous, multi-perspective medicine knowledge freely available. An AI assistant that answers a clinical question correctly because it learned from Pharmacopedia is the same mission's work, one step further downstream. Blocking AI training would protect Pharmacopedia's brand at the cost of Pharmacopedia's mission. That trade is not one we are willing to make.

This stance is durable. It is part of the identity commitments locked on 2026-05-28.

== License ==

Pharmacopedia.wiki content is published under [https://creativecommons.org/licenses/by-sa/4.0/ Creative Commons Attribution-ShareAlike 4.0 International (CC BY-SA 4.0)], with the following clarifications applied to AI-training and AI-inference uses:

* '''Attribution.''' CC BY-SA 4.0 already requires attribution. When AI systems quote, paraphrase, or substantially summarize Pharmacopedia content, the attribution requirement applies as it does for any other reuse.
* '''ShareAlike.''' CC BY-SA 4.0's ShareAlike clause applies to derivative works. Whether AI model weights constitute a derivative work of training data is a contested legal question and Pharmacopedia takes no position on it. We do not enforce ShareAlike against model weights in either direction.
* '''Per-claim review state.''' Pharmacopedia content carries per-claim review timestamps. Content reused via AI loses that review state. Downstream consumers should not treat AI-generated paraphrases of Pharmacopedia content as carrying Pharmacopedia's editorial review.

Code, schema definitions, and infrastructure are licensed separately under the [https://www.gnu.org/licenses/agpl-3.0.en.html GNU AGPL v3] and are not covered by this page.

== What we ask in return ==

When an AI system generates output that is substantially derived from a specific Pharmacopedia page, we ask that the system include a citation back to that page's canonical URL.

In concrete terms:

* '''Direct quotation from Pharmacopedia.''' Cite the source page URL inline.
* '''Substantial paraphrase from a single Pharmacopedia page.''' Cite the source page URL.
* '''Synthesis of multiple Pharmacopedia pages.''' Cite all source page URLs.
* '''A fact that happens to also be on Pharmacopedia.''' No citation expected.

The canonical URL pattern is:

https://pharmacopedia.wiki/wiki/<Page_Name>

And once per-page DOI-style permanent identifiers are live, the form will additionally be:

https://pharmacopedia.wiki/p/<pcp-PID>

(Both forms will remain resolvable forever. See [[Pharmacopedia:Permanent identifiers]] when that page is published.)

We do not have a mechanism to enforce this and we do not plan to build one. The ask is published here, and in robots.txt, on the trust that systems whose operators want to be in good standing with the source community will pay attention.

== robots.txt ==

The robots.txt file at https://pharmacopedia.wiki/robots.txt mirrors this page in machine-readable form:

* It does not Disallow crawlers (training or otherwise).
* It declares User-agent-specific cite-back expectations under standard non-binding extension comments.
* It points to this page as the human-readable authority.

== What we will not do ==

* '''We will not block AI training crawlers.''' Blocking is incompatible with our mission to make medicine knowledge freely available.
* '''We will not paywall a "premium" AI-training license.''' All content is free for all uses, including commercial ones. There is no enterprise data licensing program.
* '''We will not name or shame AI systems that fail to cite back.''' We may, in our editorial Newsroom, document patterns we observe (e.g., a particular system citing back at X% rate, a particular system not citing back at all), but this is observational, not adversarial.
* '''We will not partner with AI vendors on co-marketing, "official integration" status, or any preferred-vendor relationship.''' Any AI system can train on us. None of them are special.

== If your AI system is generating Pharmacopedia-derived medical content ==

A few practical notes for AI-system operators reading this page:

# Pharmacopedia content updates as evidence updates. Training-data snapshots go stale. If your system is generating clinical content from old training data, consider a retrieval layer that fetches the current Pharmacopedia page at inference time.
# Each Pharmacopedia claim carries a "last reviewed" date. Generated content should ideally preserve that signal, or at least preserve a link to the current claim record where the date is authoritative.
# Pharmacopedia surfaces editorial disagreement explicitly. AI systems that flatten Pharmacopedia's multi-perspective treatment into a single confident answer are misrepresenting the source. We ask that systems doing this work harder to preserve disagreement.
# Pharmacopedia is reference and education, not personalized medical advice. AI systems generating personalized advice on the basis of Pharmacopedia content are reusing a source that explicitly does not authorize that reuse pattern (see [[Pharmacopedia:Refusals]] item 4 of the editorial-integrity section).

== Reciprocity disputes ==

If a Pharmacopedia editor or reader believes an AI system is systematically failing to cite back when generating Pharmacopedia-derived medical content, the standing process is:

# Document the pattern on the [[Pharmacopedia:Newsroom|Newsroom]] talk page with concrete examples.
# We add the observation to the Newsroom record.
# We do not file legal action; the reciprocity request is a request, not a license restriction.

== Revision ==

This page was locked on 2026-05-28 as part of the institutional identity commitments. Material revisions will be logged here with date and author. Minor copy-edits and typo fixes do not require a revision log entry.

== See also ==

* [[Pharmacopedia:Refusals|Refusals]]
* [[Pharmacopedia:Sources|Sources and licensing]]
* [[Pharmacopedia:Newsroom|Newsroom]]

[[Category:Pharmacopedia policy]]

Pharmacopedia:Refusals

2026-05-31T17:31:44Z

Maintenance script: Remove DISPLAYTITLE (skin handles namespace title display)

__NOTOC__

This page lists the things Pharmacopedia will never do. They are durable commitments. The Pharmacopedia Collective (Pharmacopedia.wiki's nonprofit operator) treats these as bedrock: changing any one of them would change what Pharmacopedia is. They are written down here so readers, contributors, and reviewers can hold us to them.

Most of these refusals exist because we have watched health-information sites compromise on each of them and become less trustworthy as a result. The pattern is consistent enough that we treat each one as load-bearing.

== Money, access, and independence ==

'''Pharmacopedia will never paywall medical information.''' Every page, every claim, every layer of every page is freely readable, now and in any future. There is no premium tier, no "professional" tier, no API rate-limit that turns into a paid plan.

'''Pharmacopedia will never push subscriptions.''' We do not ask readers for recurring payments, "memberships," or "supporter status" gated behind a payment. If we accept donations in the future (only if costs outgrow what Mark Elliott, MD can self-fund), donations stay one-time, voluntary, and never gated.

'''Pharmacopedia will never sell health data.''' We do not sell, license, lease, or trade any information about who reads what, what medicines a person looks up, or any data derived from reader behavior. We do not produce aggregate reports for sale. We do not enter data-sharing agreements with commercial entities.

'''Pharmacopedia will never run ads.''' No banner ads, no inline ads, no sponsored content, no native advertising, no affiliate links, no referral kickbacks. The reading surface is for the medicine, not for somebody buying attention next to it.

'''Pharmacopedia will never accept any commercial relationship that influences content placement.''' Pharmaceutical companies, supplement vendors, telehealth platforms, insurance companies, and any commercial actor with a stake in what readers learn cannot pay to surface, suppress, prioritize, or shape any Pharmacopedia content. There is no enterprise sales motion; there is no business-development pipeline.

== Editorial integrity ==

'''Pharmacopedia will never let pharmaceutical companies (or any party with a commercial stake in a medicine) edit medicine pages directly.''' Industry-employed contributors are welcome to submit corrections and citations through the public propose-review-approve workflow like any other contributor, with their affiliation disclosed. Direct editing access is not granted to any commercial entity.

'''Pharmacopedia will never give "medical advice" wrapped in liability disclaimers.''' We do not tell individual readers what to do with their bodies in the form of personalized recommendations. We describe what is known about a medicine, at clinical depth, across multiple editorial perspectives (Clinician, Patient, Traditional, Researcher). The reader, in conversation with their own clinician, decides what to do with that information.

'''Pharmacopedia will never hide controversy under a neutral mask.''' Where authoritative sources disagree about a medicine (efficacy, safety, mechanism, indications, withdrawal, traditional use), we surface the disagreement explicitly and cite all sides. We do not pretend a contested question is settled. We do not silently pick a side and present it as consensus.

'''Pharmacopedia will never let AI generate medical content without human review.''' Claude (the AI assistant family that helps build Pharmacopedia) can draft, structure, search, organize, and check sources. Every word of medical content that appears on a published page passes a human review gate, with the reviewer named in the editorial history. AI-generated text that is published without human review is not an editorial workflow we operate.

'''Pharmacopedia will never optimize for engagement over informativeness.''' We do not measure success in time-on-page, daily-active-users, push-notification open-rates, or session length. We do not run experiments designed to keep readers on the site longer. The product target is: the reader leaves with the answer they came for, in the depth they needed, and trusts what they read.

'''Pharmacopedia will never gamify health.''' No streaks, no badges, no leaderboards, no progress bars on personal health behavior, no "you have not checked in for 3 days" notifications, no points for reading more articles. Health information is not a game and we will not turn it into one.

== Technical and regulatory posture ==

'''Pharmacopedia will never use third-party JavaScript on user-facing pages.''' No analytics scripts, no advertising scripts, no embedded social-media trackers, no tag managers, no third-party fonts that phone home, no CDN-hosted libraries that report referrers to a vendor. The browser of a reader on Pharmacopedia.wiki talks only to Pharmacopedia infrastructure. This is how we make "we do not sell health data" technically enforceable rather than only policy-stated.

'''Pharmacopedia will never operate as a Class III medical device without going through the proper regulatory review.''' Pharmacopedia is reference and education, not a regulated medical device. We do not build features (interaction checkers, dose calculators, contraindication flags) and ship them as if they were unregulated decision-support tools when in the relevant jurisdiction they would require Class III review. If we build decision-support tooling that crosses that threshold, it ships only after the appropriate regulatory pathway (FDA in the US, CE Mark in the EU, equivalent elsewhere) has been completed.

== If we ever violate any of these ==

If a reader, contributor, or reviewer believes Pharmacopedia has violated one of these commitments, the standing process is:

# Report it on the [[Pharmacopedia:Newsroom|Newsroom]] talk page, or by email to '''mark@pharmacopedia.wiki'''.
# We acknowledge the report publicly on Newsroom within 7 days of receipt.
# We post a remediation notice with what happened, why, and what we are doing about it.
# We do not delete the report.

These refusals are not aspirations. They are operational constraints on every decision the project makes. They were locked on 2026-05-28 by Mark Elliott, MD as part of the broader institutional identity commitments that define Pharmacopedia.wiki.

== See also ==

* [[Pharmacopedia:About|About Pharmacopedia]]
* [[Pharmacopedia:Sources|Sources and licensing]]
* [[Pharmacopedia:Reciprocity|Reciprocity (AI training posture)]]
* [[Pharmacopedia:Newsroom|Newsroom (editorial transparency)]]
* [[Special:About|About this MediaWiki instance]]

[[Category:Pharmacopedia policy]]

About:Privacy

2026-05-31T17:31:43Z

Maintenance script: Remove DISPLAYTITLE (skin handles namespace title display)

__NOTOC__

This page describes how Pharmacopedia.wiki handles your data: what we collect, how we store it, who controls it, and how long we keep it.

Pharmacopedia.wiki is operated by the Pharmacopedia Collective, a nonprofit. The named data controller is Mark Elliott, MD (mark@pharmacopedia.wiki).

== What Pharmacopedia.wiki stores ==

=== Account data ===

When you create an account on Pharmacopedia.wiki, we store:

* Username
* Email address (optional; used for password recovery and notifications if you choose)
* Hashed password (bcrypt; we never store your password in cleartext)
* Account creation date

=== Assessment data ===

If you complete assessments on Pharmacopedia.wiki, we store your responses and computed scores. Assessment data is linked to your account. You can view your assessment history at [[Special:MyProfile]].

Assessment data is used for:

* Showing you your own results and history
* Internal research and analysis (see "Research use" below)

Assessment data is never sold, licensed, or shared with commercial entities. See [[Pharmacopedia:Refusals]] for the full list of commitments on data use.

=== MyLifeStory data ===

If you use [[Special:MyLifeStory]], your timeline entries (events, episodes, observations, stories, relationships, and attributes) are stored with the visibility level you choose:

* '''Private''' (default): visible only to you.
* '''Public + attribution''': visible to others with your display name.
* '''Public + username''': visible to others with your username.
* '''Public, no byline''': visible to others with no identifying information.

Private entries are never shared, exported, or made available to any other service. Public entries are visible on Pharmacopedia.wiki according to the level you select. You can change an entry's visibility at any time.

=== Derived data ===

Some data is generated from your account activity:

* Derived timeline events (auto-generated from your medications, diagnoses, and experience reports, visible in MyLifeStory)
* Profile statistics (assessment completion counts, timeline entry counts)

=== Page edits and contributions ===

Edits to wiki pages are logged with your username, edit timestamp, and edit summary. This is standard MediaWiki behavior and the edit history is publicly visible. We do not offer anonymous editing; all edits are attributed to a logged-in account.

== Data controller model ==

Pharmacopedia.wiki is one part of the Pharmacopedia Collective, which also operates Oyami (oyami.org), Trykl (trykl.org), and PubSci (pubsci.io). Your Pharmacopedia.wiki account works across all four services.

The data controller model is layered:

* '''Pharmacopedia.wiki''' is the data controller of the shared layer: your account identity and your assessment data at rest.
* '''Each service''' (Oyami, Trykl, PubSci) is the data controller of its own service-specific data (for example, Oyami session records, Trykl transaction records, PubSci submissions and reviews).
* '''Each service''' is also an independent data controller of its own processing of data it accesses from the shared Pharmacopedia.wiki layer. When Oyami accesses your assessment data to power its matching features, Oyami is making its own processing decisions and is a controller for that activity.

The named data controller on all services is Mark Elliott, MD.

For rights related to your account or assessment data, contact mark@pharmacopedia.wiki or visit [[Special:MyProfile]]. For rights related to your activity on a specific service, that service's privacy page is the authority.

== How long we keep your data ==

=== Active data ===

Your account, assessments, and timeline entries persist for as long as your account is active. You can delete individual timeline entries or assessment records at any time.

=== Backups ===

Pharmacopedia.wiki maintains encrypted backups:

* Up to 7 days on the backend host
* Then up to 14 days in active off-site storage
* Then up to 180 additional days in the off-site provider's deletion-recovery layer

All backups are encrypted (GPG, AES-256). The off-site provider cannot read the backup contents. Total worst-case time before permanent deletion of a deleted record: approximately 201 days.

This is current operational reality. When we migrate to infrastructure with hard-delete capability, the retention window will shorten and this page will be updated.

=== Account deletion ===

If you delete your account, your account data and assessment data are removed from the active database. Backup copies persist for the retention window described above, then are permanently deleted.

Page edits you made to public wiki pages remain in the edit history (attributed to your username) and are not deleted when your account is deleted. This is standard MediaWiki behavior.

== Research use ==

Assessment data may be used for internal research and analysis by Mark Elliott, MD. This research is internal to the Pharmacopedia Collective; we do not pursue peer-reviewed publication and therefore do not require IRB review. The research dataset is for Mark's internal analysis only.

Assessment data used for research is de-identified. Research results are never presented at an individual level.

== Third-party services ==

Pharmacopedia.wiki does not use third-party JavaScript on user-facing pages. Your browser talks only to Pharmacopedia infrastructure. See [[Pharmacopedia:Refusals]] for the full commitment.

Pharmacopedia.wiki uses OAuth 2.0 (with PKCE) to authenticate your account on connected services (Oyami, Trykl, PubSci). When you authorize a service, you see the specific data grants on the consent screen. You can manage your active grants at [[Special:OAuthManageMyGrants]].

== Your rights ==

You may:

* View all data associated with your account at [[Special:MyProfile]] and [[Special:MyLifeStory]]
* Delete individual assessment records or timeline entries
* Change the visibility of any MyLifeStory entry
* Revoke OAuth grants to connected services at [[Special:OAuthManageMyGrants]]
* Delete your account entirely by contacting mark@pharmacopedia.wiki
* Request a copy of your data by contacting mark@pharmacopedia.wiki

== Contact ==

For questions about this privacy notice or your data, contact Mark Elliott, MD at mark@pharmacopedia.wiki.

== Revision history ==

* 2026-05-24: Initial version.
* 2026-05-31: Corrected data controller model from "separate controllers" to layered controller model (Q6 decision, 2026-05-24). Removed premature cross-link to Oyami privacy document. Updated backup retention to reflect current 7+14+180 operational reality.

== See also ==

* [[Pharmacopedia:Refusals|Refusals]]
* [[Pharmacopedia:Reciprocity|Reciprocity (AI training posture)]]
* [[Pharmacopedia:Sources|Sources and licensing]]

[[Category:Pharmacopedia policy]]

Lithium

2026-05-31T17:12:04Z

Maintenance script: Create Lithium medicine page (mood stabilizer, narrow therapeutic index)

{{MedTemplate
| generic = Lithium
| brand = Lithobid (lithium carbonate extended-release, 300 mg and 450 mg tablets); Lithium carbonate immediate-release tablets and capsules (150/300/600 mg; multiple generics); Lithium citrate oral solution (8 mEq/5 mL, approximately equivalent to 300 mg lithium carbonate per 5 mL).
| structure = lithium.svg
| classes = [[:Category:Mood stabilizers|Mood stabilizer]], [[:Category:Antimanic agents|Antimanic agent]], [[:Category:Narrow therapeutic index medicines|Narrow therapeutic index medicine]]
| uses =
| starting_dose = Acute mania: 300 mg PO TID (immediate-release) or 900 mg PO once daily (extended-release Lithobid); titrate based on serum levels to target 0.8-1.2 mEq/L. Maintenance: target 0.6-0.8 mEq/L. All dosing guided by serum lithium levels drawn at the 12-hour post-dose standardized trough.
| preparations = Lithium carbonate 150/300/600 mg capsules and tablets (immediate-release; multiple generics); Lithobid 300 mg and 450 mg extended-release tablets; Lithium citrate solution 8 mEq/5 mL (for patients who cannot swallow tablets). Lithium carbonate and lithium citrate are both salts of Li+ and are clinically interchangeable on a molar-equivalent basis.
| fda_max = No specific labeled maximum dose; dosing is governed by serum lithium levels. Clinical practice targets the minimum effective level for the indication; doses above what achieves target levels confer no benefit and increase toxicity risk. Extended-release Lithobid doses above 1800 mg/day are uncommon in practice.<ref name="lithobid-label">FDA Prescribing Information, Lithobid (lithium carbonate) extended-release tablets, Noven Therapeutics, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018027s065lbl.pdf</ref>
| pill_id =
| routes = Oral only. No parenteral lithium formulation exists for clinical use.
| onset = Oral peak plasma 1-2 hours (immediate-release); 4-6 hours (extended-release). Therapeutic antimanic effect typically evident within 5-14 days of achieving target serum levels; for acute mania, a neuroleptic or benzodiazepine is usually co-administered while lithium titration proceeds.
| duration = Lithium's mood-stabilizing benefit is prophylactic and requires continuous maintenance dosing; it is not a PRN or acute-episode-only medicine. Discontinuation is associated with high relapse rates and a potentially rebound worsening of episode frequency.
| halflife = 18-36 hours at steady state; longer in elderly patients (24-60 hours) and those with renal impairment. Half-life is entirely a function of glomerular filtration rate, as lithium is exclusively renally eliminated with no hepatic metabolism.<ref name="lithobid-label" />
| bioavailability = Approximately 100% for immediate-release formulations (lithium is a simple inorganic ion absorbed completely from the GI tract; no significant first-pass effect). Extended-release Lithobid has similar overall bioavailability but a lower and later peak (lower Cmax, longer Tmax), which reduces peak-related adverse effects.<ref name="lithobid-label" />
| pregnancy = Teratogenic risk has been substantially revised downward from early (1975 registry) estimates. First-trimester exposure carries a small but real increased risk of cardiac malformations (particularly Ebstein's anomaly, atrioventricular septal defects). The absolute risk increase is modest; informed consent and high-resolution fetal echocardiography are required rather than automatic contraindication. See pregnancy_details for detailed risk-benefit framework.
| legal = [[USLegal:Prescription only|Rx-only]]. Not scheduled; no abuse potential. One of the oldest continually-used psychotropic medicines, with FDA approval dating to 1970.
| mechanism = <vote slug="lithium-mech-claim">Lithium's mood-stabilizing mechanism is incompletely understood; it is the only psychotropic medicine in widespread clinical use whose primary therapeutic mechanism remains genuinely uncertain after seven decades of investigation. Multiple intracellular mechanisms have been identified:

'''GSK-3β inhibition:''' Lithium is a direct inhibitor of glycogen synthase kinase 3-beta (GSK-3β), competing with Mg2+ at the kinase active site. GSK-3β phosphorylates numerous substrates relevant to mood regulation, neurogenesis, apoptosis, and circadian rhythm (including components of the molecular clock, CLOCK and BMAL1). GSK-3β inhibition is currently considered the most mechanistically important of lithium's intracellular effects and is the basis for lithium's neuroprotective and possibly anti-suicidal properties.{{citation needed}}

'''Inositol depletion:''' Lithium inhibits inositol monophosphatase (IMPase) and inositol polyphosphate 1-phosphatase (IPPase), reducing the recycling of inositol and depleting the inositol pool available for phosphatidylinositol (PI) signaling. The inositol depletion hypothesis (Berridge, 1989) proposes that this selectively dampens PI/protein kinase C (PKC) signaling in neurons firing at high frequency (as in mania), producing a homeostatic dampening effect.{{citation needed}}

'''BDNF and neuroprotection:''' Lithium increases BDNF expression and activates Akt/mTOR neuroprotective signaling. Clinical MRI studies suggest lithium increases cortical gray matter volume in bipolar patients; whether this reflects neuroprotection, neurogenesis, or other mechanisms is debated.

'''Beta-arrestin pathway (D2 receptor):''' More recent work suggests lithium may produce biased signaling at dopamine D2 receptors via beta-arrestin pathways, selectively modulating behavioral responses without the typical adverse effects of D2 antagonists.

None of these mechanisms is sufficient alone to explain the full clinical profile. Lithium likely achieves mood stabilization through convergent effects on multiple intracellular kinase cascades and second-messenger systems.</vote>
| intro = Lithium is an inorganic alkali metal ion (atomic number 3) used as a mood stabilizer, with the strongest long-term evidence base for bipolar disorder maintenance of any currently available psychotropic medicine. It is the only psychotropic with a robust evidence base specifically for suicide reduction across both bipolar and unipolar depressive disorders -- a clinically important distinction. It has been in continuous clinical use since 1949, making it one of the oldest psychotropic medicines in modern psychiatry.

Lithium's key limitation is its extremely narrow therapeutic index: the difference between the therapeutic serum level (0.6-1.2 mEq/L) and the toxic level (>1.5 mEq/L) is small, and toxicity can be severe and potentially fatal. Mandatory serum level monitoring and careful management of interacting factors (sodium intake, hydration, renal function, interacting medicines) are essential throughout treatment.

Lithium is renally eliminated without any hepatic metabolism -- a unique pharmacokinetic property among psychotropics, with major clinical implications. Its renal handling mimics sodium: filtered at the glomerulus and extensively reabsorbed in the proximal tubule in competition with sodium. Any condition causing sodium depletion or volume contraction (low-salt diet, dehydration, diuretics, ACE inhibitors) increases proximal tubular lithium reabsorption and can raise lithium to toxic levels. This mechanism explains the majority of lithium's clinically important drug and dietary interactions.

The discovery of lithium's antimanic properties by John Cade in 1949 is a foundational moment in modern psychopharmacology; it preceded the development of chlorpromazine and represented the first effective pharmacotherapy for any psychiatric condition.

| history = '''Discovery by Cade (1949):''' John Frederick Joseph Cade, an Australian psychiatrist working at the Bundoora Repatriation Mental Hospital in Victoria, discovered lithium's antimanic properties through a serendipitous experiment in 1948-1949. While investigating the hypothesis that manic episodes involved excess uric acid, Cade injected guinea pigs with lithium urate -- using lithium as a solubilizing agent -- and observed unexpectedly that the animals became calm and sedated. He then administered lithium carbonate to manic patients, with striking results. His 1949 report in the Medical Journal of Australia described 10 manic patients treated with lithium, all of whom improved significantly.{{citation needed}}

The discovery was largely ignored initially because of near-simultaneous reports of lithium toxicity (it had been sold as a sodium-salt substitute in cardiac patients in the late 1940s, causing deaths from unrestricted use without monitoring) and because Cade was working in a remote institution without academic connections to amplify the finding.

'''Schou and controlled trials (1950s-1960s):''' The Danish psychiatrist Mogens Schou conducted the first controlled trials of lithium in mania and, with Poul Christian Baastrup, established the prophylactic efficacy of lithium in preventing recurrent manic and depressive episodes in bipolar disorder. Schou's decades of work transformed lithium from a clinical curiosity into a mainstream treatment. He also conducted early studies on lithium teratogenicity (contributing to the International Register of Lithium Babies in the 1970s) and was later involved in correcting the teratogenic risk overestimate.{{citation needed}}

'''FDA approval (1970):''' The FDA approved lithium (as Eskalith) for acute manic episodes in 1970 -- the first FDA-approved treatment for any phase of bipolar disorder and the first psychotropic approved based on documented serum level monitoring as a condition of use.

'''Ebstein's anomaly scare and re-evaluation (1975-2017):''' The International Register of Lithium Babies was established in the early 1970s to collect cases of lithium-exposed pregnancies; a voluntary registry of this type is inherently subject to ascertainment bias (adverse outcomes more likely to be reported). The 1975 registry report suggested a markedly elevated risk of Ebstein's anomaly. This led to widespread contraindication of lithium in pregnancy for decades. The risk was subsequently substantially revised downward by population-based cohort studies, culminating in the landmark 2017 NEJM study by Patorno and colleagues.<ref name="patorno-2017">Patorno E, Huybrechts KF, Bateman BT, et al. Lithium use in pregnancy and the risk of cardiac malformations. N Engl J Med. 2017;376(23):2245-2254. PMID 28591541.</ref>

'''BALANCE trial (2010):''' The BALANCE randomized trial demonstrated lithium superiority to valproate for long-term prophylaxis in bipolar I disorder, providing the most rigorous comparative evidence for lithium's maintenance advantage.{{citation needed}}

| indications = <problem ref="bipolar-i-disorder" author="parser-claude">Acute manic episodes in bipolar I disorder; FDA-approved. Effective for euphoric/classic mania; dysphoric or mixed-state mania may respond less well. Co-administration with a neuroleptic or benzodiazepine is standard for acute behavioral management while lithium is titrated to therapeutic levels.</problem>
<problem ref="bipolar-ii-disorder" author="parser-claude">Bipolar II disorder maintenance; FDA maintenance label covers the full bipolar spectrum; lithium evidence is strongest for bipolar I but extends to bipolar II prophylaxis.</problem>
<problem ref="bipolar-disorder" author="parser-claude">Bipolar disorder maintenance prophylaxis (all subtypes); the strongest long-term evidence base of any mood stabilizer. The BALANCE trial (2010) showed superiority to valproate monotherapy for bipolar I. Data from long-term cohort studies support lithium as the reference comparator for bipolar maintenance.</problem>
<problem ref="trd-augment" author="parser-claude">Treatment-resistant depression augmentation; one of the best-evidenced augmentation strategies in psychiatry. CANMAT and NICE guidelines list lithium augmentation as a first-line option for antidepressant-resistant depression.</problem>
<problem ref="suicidal-behavior" author="parser-claude">Suicidal behavior (off-label); the strongest pharmacological anti-suicidal evidence of any psychotropic, spanning suicidal ideation through completed suicide across both bipolar and unipolar diagnoses. Meta-analyses consistently show significantly reduced suicidal behavior in lithium-maintained patients; the anti-suicidal mechanism may be independent of mood stabilization.</problem>
<problem ref="cluster-headache" author="parser-claude">Cluster headache prevention (off-label; modest evidence).</problem>
| dosing = <titration slug="acute-mania" author="parser-claude" title="Acute mania">
Immediate-release: 300 mg PO TID; increase by 300 mg/day every 2-3 days, guided by serum levels.
Extended-release (Lithobid): 450-900 mg PO once daily or BID; titrate to levels.

Target serum level for acute mania: '''0.8-1.2 mEq/L''' (trough, drawn 12 hours post-dose). Some patients require levels up to 1.2-1.5 mEq/L for acute mania control; above 1.5 mEq/L, toxicity risk increases substantially.

Acute mania usually requires co-treatment with a neuroleptic and/or benzodiazepine while lithium is titrated; lithium does not produce immediate mood stabilization and typically takes 5-14 days to demonstrate full therapeutic effect.
</titration>

<titration slug="maintenance" author="parser-claude" title="Maintenance prophylaxis">
Target serum level for maintenance: '''0.6-0.8 mEq/L''' (minimum effective prophylactic level for most patients). Lower targets (0.4-0.6 mEq/L) can be considered in elderly patients and those with significant adverse effects at higher levels, accepting somewhat higher relapse risk.

All levels are 12-hour post-dose troughs. Level timing is critical: drawing at a different interval from 12 hours significantly misinterprets results. Instruct patients to take the evening dose as usual, not take the morning dose, and come for blood draw at a consistent time after the prior evening's dose.
</titration>

<titration slug="trd-augmentation" author="parser-claude" title="Treatment-resistant depression augmentation">
Typical target level: 0.6-0.8 mEq/L (same as bipolar maintenance). Lower levels (0.4-0.6 mEq/L) may be tried in patients intolerant of higher levels. Clinical response assessment at 2-6 weeks at target level; discontinue augmentation if no response at adequate level after 6-8 weeks.
</titration>

| effects =
* <effect ref="tremor" author="parser-claude">Fine tremor of the hands; the most common adverse effect; occurs in approximately 25-50% of patients. Dose-related; often improves at lower lithium levels. Treated with low-dose propranolol (10-20 mg BID or PRN) or atenolol when bothersome. Must be distinguished from coarse tremor, which is a sign of toxicity.</effect>
* <effect ref="polyuria-polydipsia" author="parser-claude">Nephrogenic diabetes insipidus; occurs in 20-40% of patients with chronic lithium use. Lithium inhibits ADH (vasopressin) action on the renal collecting duct by blocking adenylyl cyclase and cAMP accumulation, impairing aquaporin-2 insertion and concentrating ability. Patients produce large volumes of dilute urine and compensate by drinking large volumes of water. Amiloride (a potassium-sparing diuretic that paradoxically reduces lithium-induced polyuria by blocking collecting duct lithium entry) is a preferred treatment; it does not significantly raise lithium levels unlike thiazide diuretics.</effect>
* <effect ref="hypothyroidism" author="parser-claude">Occurs in approximately 10-20% of patients with long-term use; more common in women (particularly those with pre-existing thyroid autoimmunity); usually reversible with dose reduction. Lithium inhibits thyroid hormone synthesis (blocks iodide uptake and coupling reactions in the thyroid gland) and secretion. Monitor TSH every 6-12 months. Can be managed with levothyroxine supplementation while maintaining lithium if clinical benefit is clear.</effect>
* <effect ref="hyperparathyroidism-hypercalcemia" author="parser-claude">Lithium raises the set-point for PTH suppression by calcium, causing mild hypercalcemia and hyperparathyroidism in some patients with long-term use. Check serum calcium periodically. Rarely clinically severe; occasionally requires parathyroidectomy in extreme cases.</effect>
* <effect ref="cognitive-memory" author="parser-claude">Memory impairment and "mental fog" is a commonly reported patient complaint; affects quality of life and treatment adherence. Frequently mentioned as a reason patients stop lithium. The clinical reality is nuanced: cognitive effects may relate partly to the underlying mood disorder as much as to lithium. Dose optimization (minimum effective level) reduces cognitive adverse effects.</effect>
* <effect ref="weight-gain" author="parser-claude">Common; multifactorial (increased appetite, fluid retention, hypothyroidism contribution). Average weight gain 3-7 kg over the first 1-2 years; highly variable. Address metabolic effects proactively.</effect>
* <effect ref="gi-effects" author="parser-claude">Nausea, vomiting, diarrhea, abdominal discomfort; more common with immediate-release formulations at peak concentrations. Substantially reduced by taking with food and by switching to extended-release Lithobid. GI side effects that persist or worsen should prompt level check to rule out toxicity.</effect>
* <effect ref="acne-psoriasis" author="parser-claude">Acne (particularly on the back and chest) and worsening of psoriasis are recognized adverse effects. Treat acne conventionally; for psoriasis, discuss benefit-risk of continuing lithium.</effect>
* <effect ref="renal-tubular-disease" author="parser-claude">Chronic tubulointerstitial nephropathy with progressive GFR decline occurs with decades of lithium therapy. The risk is real but the magnitude of GFR decline is generally modest over the first 10-15 years and accelerates with longer duration. Risk must be weighed against the mortality benefit of maintained mood stabilization (bipolar disorder untreated carries substantial excess mortality). Monitor creatinine and GFR at least every 6 months; consider nephrology consultation when GFR falls below 60 mL/min.</effect>
* <effect ref="toxicity-early" author="parser-claude">'''Lithium toxicity (level 1.5-2.0 mEq/L):''' Nausea, vomiting, diarrhea, fine-to-coarse tremor worsening, cognitive dulling, confusion, drowsiness, ataxia. This is the actionable window to hold lithium, rehydrate, and repeat level. Must not be dismissed as ordinary adverse effects.</effect>
* <effect ref="toxicity-severe" author="parser-claude">'''Severe lithium toxicity (level >2.0 mEq/L):''' Coarse tremor, fasciculations, myoclonus, hyperreflexia, severe confusion, seizures, cardiac arrhythmias (bradycardia, bundle branch block, T-wave changes, ventricular arrhythmias). Life-threatening. Requires immediate hospitalization, IV fluids with sodium supplementation, and hemodialysis for levels >2.5 mEq/L or when renal clearance is inadequate. Neurological sequelae (permanent cerebellar or cognitive damage -- "Syndrome of Irreversible Lithium-Effectuated Neurotoxicity" / SILENT) can occur at high levels even with treatment.</effect>
* <effect ref="edema" author="parser-claude">Peripheral edema; fluid retention via mineralocorticoid-like effects; usually mild.</effect>

| pk_absorption = Essentially complete (approximately 100%) from the GI tract for both lithium carbonate and lithium citrate formulations; lithium is a simple inorganic ion without complex absorption barriers or first-pass metabolism. Immediate-release peak plasma at 1-2 hours; extended-release (Lithobid) peak at 4-6 hours with substantially reduced Cmax (30-40% lower peak than immediate-release at equivalent doses). Food does not significantly affect total absorption.<ref name="lithobid-label" />

| pk_distribution = Volume of distribution approximately 0.7-1.0 L/kg; distributes throughout total body water. Unlike most psychotropics, lithium is NOT protein-bound (essentially 0% protein binding -- it is a free ion). Distributes into brain, bone, and most tissues. Does not cross the blood-brain barrier as rapidly as many psychotropics; brain concentrations generally parallel plasma with a slight delay. Crosses the placenta; crosses into breast milk.<ref name="lithobid-label" />

| pk_metabolism = '''None.''' Lithium is an inorganic ion and undergoes no hepatic or extrahepatic biotransformation. This is a defining pharmacokinetic feature: unlike virtually all other psychotropic medicines, lithium has no CYP450 interactions as a substrate. The therapeutic consequence is that lithium's clearance is entirely a function of renal handling (glomerular filtration rate), and any condition affecting GFR or renal tubular function directly affects lithium levels. There are no active metabolites; all systemic lithium is the parent ion.<ref name="lithobid-label" />

| pk_elimination = Exclusively renal. Lithium is freely filtered at the glomerulus and approximately 80% is reabsorbed in the proximal convoluted tubule, in direct competition with sodium. The remaining 20% is excreted in urine. This renal handling mechanism is the key to understanding lithium's interactions and toxicity:

'''The sodium-lithium competition rule:''' Sodium and lithium are co-transported in the proximal tubule. When the body is sodium-depleted or volume-contracted (low-salt diet, dehydration, diuretics, ACE inhibitor/ARB use, heavy sweating, vomiting/diarrhea), the kidney increases sodium reabsorption in the proximal tubule -- and lithium reabsorption increases proportionally. This reduces lithium clearance and raises serum levels, potentially to toxic concentrations, without any change in lithium dose. This single mechanism explains the majority of lithium's clinically important interactions.

Half-life 18-36 hours (normal renal function); up to 24-60 hours in elderly and renally impaired patients. Requires 5 half-lives (4-8 days) to reach steady state after a dose change, which is why level checks should not be performed until steady state.<ref name="lithobid-label" />

| pharmacodynamics = Lithium exerts its stabilizing effects through multiple intracellular second-messenger and kinase pathways (see mechanism field). At the cellular level, the consequence of GSK-3β inhibition and inositol depletion is modulation of neuronal excitability and activity-dependent signaling rather than a simple receptor agonist or antagonist profile, which explains why lithium has no standard receptor-binding "target" comparable to other psychiatric medicines.

Therapeutic drug monitoring is essential: there is a clear concentration-response relationship for both therapeutic effects and toxicity. The therapeutic window is narrow:
- Below 0.6 mEq/L: insufficient prophylaxis for most patients
- 0.6-1.2 mEq/L: therapeutic range (maintenance to acute mania)
- Above 1.5 mEq/L: early toxicity threshold
- Above 2.0 mEq/L: serious toxicity, neurological effects

Lithium level interpretation requires standardized 12-hour trough sampling; levels drawn at other intervals cannot be reliably compared to therapeutic range references calibrated to 12-hour trough values.

| interactions = <pharmaInteractions/>

Lithium's interaction profile is dominated by its renal elimination and sodium-competition mechanism. Most clinically significant interactions involve medicines that alter sodium balance or renal function:

* '''NSAIDs (ibuprofen, naproxen, indomethacin, etc.).''' NSAIDs reduce renal prostaglandin synthesis, decrease renal blood flow, and reduce lithium clearance; serum lithium levels can increase 25-50% with NSAID use. Ibuprofen and naproxen are commonly used OTC medicines that patients may take without informing their prescriber. Counsel patients explicitly not to use NSAIDs without prescriber consultation. Aspirin at low cardiovascular doses is generally acceptable. Acetaminophen is safe.

* '''Thiazide diuretics (hydrochlorothiazide, chlorothiazide).''' MOST DANGEROUS diuretic interaction. Thiazides block sodium reabsorption in the distal tubule, causing compensatory increased proximal tubular sodium AND lithium reabsorption; lithium levels can rise 30-50% within days of starting a thiazide. If a thiazide is added for hypertension or edema, reduce lithium dose preemptively, monitor levels frequently, and adjust as needed.

* '''Loop diuretics (furosemide, bumetanide).''' Similar mechanism but generally a somewhat smaller magnitude interaction than thiazides; still clinically significant. Monitor lithium levels.

* '''ACE inhibitors (lisinopril, enalapril, ramipril, etc.) and ARBs (losartan, valsartan, etc.).''' Reduce angiotensin II and aldosterone, causing sodium wasting, triggering compensatory proximal tubular lithium reabsorption. Lithium levels can rise substantially (20-50%+) when ACE inhibitors or ARBs are started. This interaction is common in clinical practice (hypertension is prevalent in the bipolar population); lithium must be monitored and often dose-reduced when these medicines are added or started.

* '''Low-sodium diet and dehydration.''' Dietary sodium restriction activates the same proximal tubular reabsorption mechanism. Counsel patients to maintain consistent sodium intake (not low-salt diets) and adequate hydration. Heavy exercise causing sweating, febrile illness with reduced fluid intake, or GI illness with vomiting/diarrhea are common precipitants of lithium toxicity.

* '''Amiloride (potassium-sparing diuretic).''' An exception to the diuretic pattern: amiloride blocks ENaC channels in the collecting duct, which are the entry point for lithium (causing polyuria). Amiloride thus reduces lithium-induced polyuria WITHOUT significantly increasing lithium levels. Preferred treatment for lithium-induced nephrogenic diabetes insipidus when pharmacotherapy is needed.

* '''Theophylline.''' Increases renal lithium excretion and can lower lithium levels; dose adjustment may be needed if theophylline is started or stopped.

* '''Metronidazole.''' May reduce lithium excretion; monitor levels during courses of metronidazole.

* '''SSRIs.''' Combined with lithium's probable serotonergic effects, there are case reports of serotonin syndrome; more commonly used as a beneficial combination for treatment-resistant depression. The risk of serotonin syndrome is low at standard doses but present; monitor for serotonin syndrome symptoms.

* '''Carbamazepine.''' Pharmacokinetic interaction: both affect each other's levels; combined neurotoxicity has been reported at plasma levels of each within the therapeutic range. Use with monitoring and clinical vigilance.

* '''Haloperidol.''' Historical concern about lithium-haloperidol neurotoxicity reported in a 1974 case series (irreversible encephalopathy at levels within the therapeutic range for both agents).{{citation needed}} Subsequent evidence suggests this combination is generally safe with monitoring at standard doses. The combination is common in acute mania management.

* '''Calcium channel blockers (verapamil, diltiazem).''' May increase lithium levels and enhance neurotoxicity; case reports; monitor.

| pregnancy_details = Lithium's teratogenic risk was dramatically overestimated for decades based on a 1975 voluntary registry report (International Register of Lithium Babies) that found a markedly elevated rate of Ebstein's anomaly (a congenital tricuspid valve malformation). The voluntary-registry methodology introduced severe ascertainment bias: clinicians were more likely to report adverse outcomes, inflating the apparent risk.

Population-based studies have substantially revised the risk downward:
- The 2017 NEJM study by Patorno et al (the largest and most rigorous to date) analyzed 1.3 million pregnancies in the US Medicaid database. First-trimester lithium exposure was associated with a relative risk of cardiac malformations of approximately 1.65 (95% CI 1.02-2.68) and Ebstein's anomaly specifically: 14 cases per 10,000 lithium-exposed pregnancies versus 1.5 per 10,000 unexposed pregnancies. In absolute terms, the risk of Ebstein's anomaly is low: approximately 0.14% (14 in 10,000) vs 0.015% background.<ref name="patorno-2017" />
- The risk is dose-dependent: higher lithium doses and higher first-trimester levels are associated with greater cardiac malformation risk
- Neonatal effects: neonatal lithium toxicity ("floppy infant," cyanosis, cardiac arrhythmias, neonatal hypotonia) occurs at the time of delivery due to the neonate's abruptly reduced lithium elimination (the placental clearance is lost); taper dose at term or accept that neonatal monitoring will be needed

Current guidance (integrating the Patorno 2017 data):
1. Lithium should NOT be categorically contraindicated in pregnancy; the risk is real but modest and may be outweighed by the risk of untreated bipolar disorder (psychosis, suicidal behavior, poor prenatal care, postpartum psychosis)
2. Counsel on the absolute risk: ~14 in 10,000 for Ebstein's anomaly vs 1.5 in 10,000 background; overall cardiac malformation risk increases approximately 1.5-2x over background
3. If lithium is continued in the first trimester: offer high-resolution fetal echocardiography at 16-20 weeks
4. Serum lithium levels require more frequent monitoring during pregnancy (GFR increases by 50% during pregnancy, requiring higher doses to maintain target levels; then drops precipitously at delivery, requiring rapid dose reduction)
5. Decision to continue vs switch to an alternative mood stabilizer (valproate is teratogenic [neural tube defects] and generally avoided in pregnancy; lamotrigine or quetiapine are common alternatives with better pregnancy safety profiles) requires individualized counseling

Breastfeeding: Lithium transfers substantially into breast milk (M/P ratio approximately 0.3-0.5); infant serum levels are approximately 10-50% of maternal levels. Neonatal lithium monitoring and renal/thyroid assessment are needed if breastfeeding is continued. Many guidelines recommend against breastfeeding while on lithium due to infant renal elimination immaturity; some maternal-fetal medicine authorities accept it with monitoring in stable patients. Individualized decision.{{citation needed}}

| monitoring = Lithium has among the most demanding monitoring requirements of any psychotropic medicine, necessitated by its narrow therapeutic index and multisystem adverse effects.

'''Serum lithium levels (mandatory, cornerstone of management):'''
- Always 12-hour trough (post-dose): draw blood 12 hours after the last dose; evening dose, morning blood draw without taking the morning dose
- Initiation: every 5-7 days until two consecutive levels are in target range and dose is stable
- Stable maintenance: every 3-6 months minimum; monthly preferred in the first year
- After any dose change, addition of interacting medicine, change in sodium intake, intercurrent illness, or renal function change: repeat level within 5-7 days (approximately one full steady state)
- Target ranges: maintenance 0.6-0.8 mEq/L; acute mania 0.8-1.2 mEq/L

'''Renal function (highest-priority long-term monitor):'''
- Serum creatinine, eGFR, BUN at baseline
- Every 6 months during first 3 years; every 6-12 months thereafter
- If eGFR falls below 60 mL/min: increase monitoring frequency; nephrology consultation
- Urinalysis and spot urine osmolality if nephrogenic DI is suspected

'''Thyroid:'''
- TSH at baseline + at 6 months + every 6-12 months
- More frequently if hypothyroid symptoms develop or TSH is borderline

'''Calcium / parathyroid:'''
- Serum calcium annually; PTH if hypercalcemia detected

'''Cardiac:'''
- ECG at baseline in patients over 50 or with cardiac history; lithium can cause T-wave changes (usually benign) and rare sinus node dysfunction
- Repeat ECG if symptoms develop

'''Pregnancy-specific (see pregnancy_details):'''
- More frequent serum lithium levels throughout pregnancy (increased GFR alters levels)
- High-resolution fetal echocardiography at 16-20 weeks if first-trimester exposure occurred
- Rapid dose reduction / extra monitoring at delivery (precipitous GFR drop at delivery raises lithium levels)

| counseling = '''Blood test timing.''' Your lithium level must be drawn exactly 12 hours after your last dose -- no earlier, no later. Take your evening dose, skip the morning dose, and get your blood drawn first thing in the morning. An incorrectly timed level will give a wrong result and lead to incorrect dose adjustments.

'''Salt and fluids.''' Lithium and salt work together in your kidneys. Do NOT restrict your salt intake. If you sweat heavily, are sick with vomiting or diarrhea, or are in a hot climate, drink extra fluids and replace salt. Any condition that dehydrates you can raise your lithium to dangerous levels.

'''Medicines to avoid or discuss.''' Several common medicines raise lithium to toxic levels: ibuprofen (Advil, Motrin), naproxen (Aleve), and other anti-inflammatory painkillers. Use acetaminophen (Tylenol) for pain instead. Also, if you are prescribed a water pill (diuretic) or blood pressure medicine (especially ACE inhibitors or ARBs), tell your prescriber you are on lithium -- those medicines can significantly raise your lithium level.

'''Signs of toxicity.''' If you develop nausea, vomiting, diarrhea, coarse shaking, confusion, trouble walking, or slurred speech, STOP taking lithium and go to an emergency room for a lithium level. Do not wait for the next scheduled appointment. Early toxicity is reversible; late toxicity can cause permanent brain damage.

'''Tremor.''' Fine trembling of your hands is common and usually not dangerous. Tell your prescriber -- there are medicines that effectively treat this. A coarse, uncontrolled tremor is different and is a toxicity warning sign.

'''Thyroid and kidney checks.''' We will check your thyroid and kidney function regularly because lithium can affect both over time. Unexplained fatigue, cold intolerance, or weight gain may indicate thyroid effects; let us know.

'''Pregnancy.''' If you are pregnant or planning a pregnancy, discuss this with your prescriber right away. Lithium can cause a small but real increase in heart malformations in the baby if taken in the first trimester. The risk can be monitored with ultrasound. The decision to continue or switch is individualized -- stopping lithium in pregnancy also carries serious risks.

'''Do not stop suddenly.''' Stopping lithium abruptly increases the risk of a severe manic or depressive episode and may result in a rebound pattern where episodes become more frequent. If you need to stop, work with your prescriber to taper gradually.

'''Consistency.''' Take lithium at the same time every day. Irregular dosing causes erratic levels and reduces effectiveness.

| anecdotes =
| seealso = [[Valproate]], [[Lamotrigine]], [[Quetiapine]], [[Carbamazepine]], [[Aripiprazole]], [[Bipolar disorder]]
| references = <references/>
}}

[[Category:Mood stabilizers]]
[[Category:Antimanic agents]]
[[Category:Narrow therapeutic index medicines]]
[[Category:Medicines]]

Clozapine

2026-05-31T17:12:02Z

Maintenance script: Create Clozapine medicine page (TRS gold standard, REMS monitoring)

{{MedTemplate
| generic = Clozapine
| brand = Clozaril (Novartis, original brand; 25 mg and 100 mg tablets); FazaClo (orally disintegrating tablets, 12.5/25/100/150/200 mg); Versacloz (oral suspension 50 mg/mL); multiple generics. All clozapine products are subject to the same REMS monitoring requirements.
| structure =
| classes = [[:Category:Second-generation neuroleptics|Second-generation neuroleptic (atypical)]], [[:Category:Neuroleptics|Neuroleptic]], [[:Category:REMS medicines|REMS medicine (mandatory ANC monitoring)]], [[:Category:Treatment-resistant schizophrenia medicines|Treatment-resistant schizophrenia medicine]]
| uses =
| starting_dose = 12.5 mg PO once or twice daily. Titrate gradually: 25-50 mg/day increments every 1-2 days as tolerated. Target dose 300-450 mg/day in divided doses (BID or TID). Most patients stabilize between 200-600 mg/day. Therapeutic plasma level guide: target trough clozapine ≥350 ng/mL.
| preparations = Clozaril 25 mg and 100 mg tablets; FazaClo orally disintegrating tablets (12.5/25/100/150/200 mg); Versacloz oral suspension 50 mg/mL. All brands subject to identical REMS ANC monitoring requirements. Generic tablets widely available.
| fda_max = 900 mg/day (split into BID or TID dosing). Clinical practice rarely exceeds 600 mg/day; seizure risk increases substantially above 600 mg/day and requires consideration of prophylactic anticonvulsant.<ref name="clozaril-label">FDA Prescribing Information, Clozaril (clozapine) tablets, Novartis, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/019758s083lbl.pdf</ref>
| pill_id =
| routes = Oral only. No parenteral formulation (a major limitation in acute agitation requiring rapid tranquilization).
| onset = Oral peak plasma 2.5 hours. Clinical antipsychotic response typically emerges over weeks with continued titration; full response assessment requires 3-6 months at adequate therapeutic levels.
| duration = Due to the half-life of 12 hours (wide range), dosing is BID or TID. Once-daily dosing produces higher peak/trough fluctuations and is generally not used except for a single end-of-day dose in stable patients.
| halflife = 12 hours mean (range 4-66 hours; highly variable due to CYP1A2 pharmacogenomics and smoking status). Smokers have substantially lower clozapine levels than non-smokers due to CYP1A2 induction by polycyclic aromatic hydrocarbons in cigarette smoke. Smoking cessation in a clozapine-maintained patient can cause significant clozapine level increases and toxicity.<ref name="clozaril-label" />
| bioavailability = Approximately 50-60% (oral; subject to first-pass metabolism); food does not significantly affect absorption.<ref name="clozaril-label" />
| pregnancy = Limited human data; clozapine crosses the placenta. Neonatal toxicity (withdrawal symptoms, neonatal sedation, flaccid infant, seizures) reported with third-trimester exposure. Use only when the benefit of maternal psychiatric stability clearly outweighs neonatal and teratogenic risks. Consult the National Pregnancy Registry for Atypical Antipsychotics for current data.
| legal = [[USLegal:Prescription only|Rx-only]]. Not scheduled (no abuse potential). Subject to mandatory Clozapine REMS Program requirements: prescribers, pharmacies, and patients must all be enrolled; ANC must be within parameters before dispensing. No REMS waiver exists; the dispensing pharmacy must confirm current ANC compliance before releasing each prescription.
| mechanism = <vote slug="clozapine-mech-claim">Clozapine is a broad-spectrum receptor antagonist with an unusually wide receptor-binding profile. Its mechanism of antipsychotic efficacy in treatment-resistant schizophrenia is not fully understood and likely multifactorial.

'''D2 receptor pharmacology:''' Clozapine has relatively low D2 receptor affinity compared to typical neuroleptics (haloperidol, fluphenazine) and is characterized by rapid dissociation from the D2 receptor. The "fast-off D2" hypothesis (Seeman, Kapur) proposes that transient D2 occupancy with rapid release explains both the antipsychotic efficacy and the absence of extrapyramidal symptoms (EPS) and tardive dyskinesia. At typical therapeutic doses, clozapine produces only 30-60% D2 occupancy (compared to >80% for typical agents), and this brief occupancy may preferentially produce antipsychotic effects through mesolimbic circuits without the nigrostriatal blockade responsible for EPS.

'''D4 receptor:''' Clozapine has high affinity for the D4 dopamine receptor. Early mechanistic hypotheses attributed clozapine's unique efficacy to D4 selectivity, but subsequent trials of selective D4 antagonists did not show clozapine-equivalent antipsychotic efficacy, so D4 blockade alone does not explain the profile.

'''5-HT2A antagonism:''' Very high affinity; shared with other second-generation neuroleptics. 5-HT2A blockade is hypothesized to modulate dopamine release in nigrostriatal (reducing EPS risk) and mesocortical (possibly improving negative symptoms) pathways.

'''H1 antagonism:''' High affinity; the primary mechanism of sedation and major contributor to weight gain.

'''Muscarinic (M1-M4) antagonism:''' Potent anticholinergic effects accounting for dry mouth, constipation, urinary retention, tachycardia, confusion. The paradoxical sialorrhea (hypersalivation) is attributed to partial M4 agonism at salivary gland receptors.

'''Alpha-1 and Alpha-2 adrenergic antagonism:''' Orthostatic hypotension, reflex tachycardia.

'''5-HT2C antagonism:''' Contributes to weight gain and metabolic effects.</vote>
| intro = Clozapine is a second-generation neuroleptic with a unique clinical profile: it is the only neuroleptic FDA-approved specifically for treatment-resistant schizophrenia (patients who have failed at least two adequate antipsychotic trials) and the only neuroleptic with an FDA-approved indication for reducing suicidal behavior. It is also distinguished by its near-absence of extrapyramidal side effects (EPS) and extremely low risk of tardive dyskinesia, making it the neuroleptic of choice for psychosis in Parkinson's disease at low doses.

These advantages are counterbalanced by severe and sometimes fatal adverse effects, the most important of which is agranulocytosis (absolute neutrophil count [ANC] falls to dangerous levels in approximately 1% of patients), requiring a mandatory Risk Evaluation and Mitigation Strategy (REMS) program with mandatory ANC monitoring that is a condition of dispensing in the US. Weight gain, metabolic syndrome, sedation, sialorrhea, constipation, and seizures are common and clinically challenging; myocarditis is a rare but potentially fatal early-treatment risk. As a result, clozapine is a third-line agent used only after documented failure of at least two other adequate neuroleptic trials.

Clozapine's history of withdrawal and re-approval represents a pivotal moment in pharmacovigilance. It was withdrawn from most world markets in 1975 following multiple agranulocytosis deaths in Finland, reapproved in the US in 1989 only after a landmark clinical trial demonstrated its unique efficacy in treatment-resistant schizophrenia and a mandatory monitoring program was established as a condition of approval. The reapproval -- accepting a known fatal side effect in exchange for otherwise-unavailable clinical benefit -- remains a reference case for structured benefit-risk management.

| history = Clozapine was first synthesized in 1958-1960 at Sandoz Laboratories (Basel, Switzerland) by Jurg Schmutz and Walter Hunziker as part of a program investigating tricyclic compounds related to the iminodibenzyl structure of imipramine.{{citation needed}}

First clinical studies in humans occurred in Europe in the late 1960s. Clozapine gained regulatory approval in several European countries in the early 1970s and was used clinically in Germany, Austria, and Switzerland. In 1975, a cluster of eight agranulocytosis deaths occurred in Finland among clozapine-treated patients; Sandoz voluntarily withdrew clozapine from most world markets that year, and it was broadly labeled as too dangerous for clinical use.

Clozapine remained available in limited settings (e.g., on compassionate basis in some countries) and continued to attract clinical interest due to observed responses in patients refractory to all other neuroleptics. The pivotal American trial was conducted by John Kane, Herbert Meltzer, and colleagues as the Clozaril Collaborative Study Group, comparing clozapine to chlorpromazine plus benztropine in patients with treatment-resistant schizophrenia who had failed previous neuroleptic trials. The 1988 Arch Gen Psychiatry publication reported a 30% response rate for clozapine versus approximately 4% for chlorpromazine -- a striking magnitude of difference that justified reapproval despite the agranulocytosis risk.<ref name="kane-1988">Kane JM, Honigfeld G, Singer J, Meltzer H; Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789-796. PMID 3046553.</ref>

FDA approved clozapine (Clozaril) in 1989 for treatment-resistant schizophrenia, with mandatory monitoring of WBC and differential as a condition of approval. This was the first FDA-mandated monitoring program as a condition of drug approval -- the structural predecessor to the modern REMS framework.

The original Clozaril National Registry, operated by Novartis, required prescribers to register patients and pharmacies to verify monitoring compliance before dispensing. Over subsequent years, generic manufacturers established parallel monitoring databases. In 2021, the FDA unified all clozapine monitoring under a single Clozapine REMS Program, with a harmonized ANC monitoring protocol and a single database across all brands.

The InterSePT (International Suicide Prevention Trial) study, published in 2003, demonstrated clozapine's superiority to olanzapine in reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder; this led to FDA approval of clozapine for this additional indication in 2003.{{citation needed}}

A persistent health equity problem with clozapine monitoring has been the impact of Benign Ethnic Neutropenia (BEN): patients of African descent and some other populations have constitutionally lower ANC baselines due to neutrophil demargination (a benign variant with no increased infectious disease risk), causing them to be disproportionately denied clozapine or required to stop it based on monitoring thresholds calibrated to European baseline norms. The 2021 REMS update added guidance for baseline-corrected ANC thresholds in patients with documented BEN, partly addressing this disparity.

| indications = <problem ref="schizophrenia" author="parser-claude">Treatment-resistant schizophrenia; FDA-approved for patients who have failed at least 2 adequate antipsychotic trials (adequate dose for adequate duration, typically ≥6 weeks per trial). The evidence base from Kane 1988 and subsequent trials establishes a 30-60% response rate in otherwise treatment-refractory patients. Clozapine is the gold standard for treatment-resistant schizophrenia and should be offered earlier (after 2 failures) rather than delayed as a last resort.</problem>
<problem ref="schizoaffective-disorder" author="parser-claude">Schizoaffective disorder; covered by the FDA suicidal behavior indication (schizophrenia or schizoaffective disorder) and supported by broader clinical evidence for refractory schizoaffective presentations.</problem>
<problem ref="suicidal-behavior" author="parser-claude">Reduction of suicidal behavior in schizophrenia or schizoaffective disorder; FDA-approved (2003). The InterSePT trial showed superiority to olanzapine for this indication. The only neuroleptic with this specific FDA-approved indication.</problem>
<problem ref="parkinson-disease" author="parser-claude">Psychosis in Parkinson's disease (off-label, low-dose 12.5-50 mg/day); one of very few neuroleptics that does not significantly worsen Parkinsonism, due to minimal D2 blockade at low doses. Pimavanserin is the only FDA-approved agent for PD psychosis; clozapine is the preferred off-label alternative.</problem>
<problem ref="bipolar-disorder" author="parser-claude">Treatment-resistant bipolar disorder (off-label); evidence for refractory mania and bipolar depression in patients who have failed standard mood stabilizers and neuroleptics.</problem>
| dosing = <titration slug="clozapine-initiation" author="parser-claude" title="Initiation (inpatient or closely monitored outpatient)">
REMS enrollment required before dispensing. Confirm baseline ANC (see Monitoring) before first dose.

Start: 12.5 mg PO once or twice daily on Day 1.
Titration: increase by 25-50 mg/day every 1-2 days as tolerated to target range.
Target range: 300-450 mg/day in divided doses (BID or TID).
Most patients require 200-600 mg/day; response should be assessed at therapeutic plasma levels.

Dose slowly, particularly in the first 2 weeks, due to orthostatic hypotension and sedation risk. Inpatient initiation is preferred for patients with high medical complexity or significant cardiovascular concerns.
</titration>

<titration slug="clozapine-therapeutic-level" author="parser-claude" title="Therapeutic drug monitoring">
Target trough clozapine plasma level: '''≥350 ng/mL''' (evidence-based minimum effective threshold).

Plasma levels are highly variable between patients (CYP1A2 polymorphisms, smoking status, drug interactions, age, sex, weight). Therapeutic drug monitoring is strongly recommended and should guide dose adjustment:
- Level <350 ng/mL with inadequate response: increase dose
- Level 350-600 ng/mL: standard therapeutic range
- Level >600 ng/mL: increased adverse effect burden (sedation, sialorrhea, seizure risk); reduce if tolerability issues arise
- Level >1000 ng/mL: associated with significant toxicity risk

Levels should be drawn as trough specimens (immediately before the next dose).
</titration>

<titration slug="clozapine-high-dose" author="parser-claude" title="High-dose considerations (>600 mg/day)">
Seizure risk increases substantially above 600 mg/day. If clinical response requires doses in this range, prophylactic anticonvulsant should be considered. Preferred agents: lamotrigine or topiramate. Avoid valproate (combined agranulocytosis risk); avoid carbamazepine (combined agranulocytosis risk AND CYP3A4/1A2 induction lowering clozapine levels -- this combination is generally contraindicated).
</titration>

<titration slug="clozapine-restart" author="parser-claude" title="Re-initiation after interruption">
If clozapine is interrupted for >48 hours, re-titrate from 12.5-25 mg/day. Do NOT resume at the prior dose; tolerance to orthostatic hypotension and sedation is lost during even brief interruptions and resuming at a high dose risks cardiovascular collapse. This is a common cause of preventable serious adverse events.
</titration>

| effects =
* <effect ref="agranulocytosis" author="parser-claude">'''The defining risk; basis for REMS program.''' ANC falls to dangerous levels (ANC <500/μL) in approximately 1% of patients; higher rates for any degree of neutropenia (ANC <1500/μL). Onset typically within the first 18 weeks (highest risk months 1-6) but can occur at any time. Mechanism incompletely understood; proposed mechanisms include nitroso-clozapine (reactive intermediate) forming adducts with neutrophil proteins triggering immune-mediated destruction, and direct myelotoxicity. Fatal agranulocytosis has occurred; prompt recognition requires mandatory monitoring and defined dose-interruption thresholds. Cannot be managed conservatively -- stop clozapine immediately if ANC <1000/μL (see monitoring thresholds).</effect>
* <effect ref="metabolic-syndrome" author="parser-claude">Weight gain (among the greatest of any neuroleptic; average 4-8 kg in the first year for many patients; some patients gain substantially more), hyperglycemia/diabetes, dyslipidemia. H1 and 5-HT2C antagonism are primary mechanisms. Monitor fasting glucose and lipids regularly; manage metabolic risks aggressively as they significantly affect long-term morbidity.</effect>
* <effect ref="sedation" author="parser-claude">Very common, often substantial especially at initiation. H1 antagonism is the primary mechanism. Usually some tolerance develops over weeks. Sedation is a major reason for titration-failure; initiating slowly and dosing the majority at bedtime reduces this.</effect>
* <effect ref="sialorrhea" author="parser-claude">Excessive salivation; paradoxically common despite anticholinergic profile. Proposed mechanism: partial M4 agonism at salivary glands producing a sialogue effect that overrides the systemic anticholinergic action; the precise mechanism is debated (alpha-2 adrenergic mechanisms have also been proposed), but the clinical phenomenon is well-established.{{citation needed}} Often severe and socially disabling; the single most commonly cited reason for patient self-discontinuation. Managed with hyoscine (scopolamine) patches or sublingually, atropine 1% eye drops used sublingually, or glycopyrrolate.</effect>
* <effect ref="seizures" author="parser-claude">Dose-dependent; uncommon at doses below 300 mg/day (~1-2%), increasing substantially above 600 mg/day (~4-5%). Generalized tonic-clonic type predominates. If a seizure occurs at any dose, interrupt clozapine and reduce the dose on re-initiation; add prophylactic anticonvulsant (lamotrigine or topiramate preferred over valproate in this context).</effect>
* <effect ref="myocarditis-cardiomyopathy" author="parser-claude">Rare but potentially fatal. Myocarditis typically presents in the first 4-8 weeks of treatment with fever, tachycardia, chest pain, and elevated troponin and CRP; eosinophilia may precede or accompany it. Clozapine must be stopped immediately if myocarditis is suspected; rechallenge is generally contraindicated. Cardiomyopathy is a longer-term concern with cumulative clozapine exposure. Many experts recommend baseline and early monitoring of troponin and CRP (see monitoring).</effect>
* <effect ref="orthostatic-hypotension" author="parser-claude">Common, especially early in titration; alpha-1 blockade. Gradual titration is the key mitigation. Can be severe and cause falls; most important at initiation.</effect>
* <effect ref="tachycardia" author="parser-claude">Very common; anticholinergic + alpha blockade + possible direct cardiac effects. Persistent tachycardia at baseline can obscure early myocarditis signs; concerning tachycardia warrants troponin and ECG.</effect>
* <effect ref="constipation-ileus" author="parser-claude">Anticholinergic; often underappreciated in severity. Case reports of fatal paralytic ileus from clozapine-induced constipation. Requires active management (stool softeners, laxatives, hydration, diet); should be specifically asked about at each visit. "Clozapine constipation" is not mild discomfort -- it is a serious and potentially fatal adverse effect.</effect>
* <effect ref="hypersalivation-drooling" author="parser-claude">See sialorrhea above -- listed separately because it is both an effect of the medicine and a distinct management challenge.</effect>
* <effect ref="fever" author="parser-claude">Common in the first weeks of treatment; often benign (clozapine fever, cause uncertain) but must be evaluated to rule out agranulocytosis and myocarditis. ANC and troponin + CRP should be checked when fever occurs, especially early in treatment.</effect>
* <effect ref="eps-absent" author="parser-claude">The therapeutic advantage: clozapine produces essentially no EPS at therapeutic doses and has the lowest risk of tardive dyskinesia of any neuroleptic -- including in patients with pre-existing TD from prior neuroleptic exposure, where clozapine may actually suppress TD movements.</effect>
* <effect ref="hypersensitivity-rash" author="parser-claude">Occasional; manage per standard hypersensitivity protocol; stop if severe or with systemic features.</effect>

| pk_absorption = Oral bioavailability approximately 50-60% due to first-pass metabolism; food does not significantly affect extent of absorption though may slightly delay peak. Tmax approximately 2.5 hours. All available formulations (tablets, orally disintegrating, oral suspension) are bioequivalent at comparable doses.<ref name="clozaril-label" />

| pk_distribution = Plasma protein binding approximately 97% (albumin and alpha-1-acid glycoprotein). Volume of distribution approximately 1.6 L/kg. Crosses the blood-brain barrier well; brain/plasma ratios are substantial, consistent with the high CNS activity. Crosses the placenta.<ref name="clozaril-label" />

| pk_metabolism = Primarily hepatic. The dominant pathway is CYP1A2 demethylation to norclozapine (N-desmethylclozapine), the major active metabolite. CYP3A4 contributes as a secondary pathway. CYP2C19 has minor involvement. Norclozapine has its own receptor pharmacology (D4, D2, and other receptor activity) and may contribute to both efficacy and adverse effects; norclozapine levels are typically 50-80% of clozapine levels at steady state.

CYP1A2 is the rate-limiting metabolic pathway and is the basis for the most clinically important drug and environmental interactions:
- Cigarette smoking induces CYP1A2 via polycyclic aromatic hydrocarbons, lowering clozapine levels by 30-60% in smokers compared to non-smokers. Smoking cessation in a stable clozapine patient must be anticipated and managed proactively with dose reduction to prevent toxicity.
- Fluvoxamine, a potent CYP1A2 inhibitor, can increase clozapine AUC 3- to 10-fold; co-prescribing requires clozapine dose reduction to approximately 1/3 to 1/4 of the usual dose with careful monitoring.
- Ciprofloxacin and other quinolone antibiotics inhibit CYP1A2 and can cause clinically significant clozapine level elevations.

| pk_elimination = Clozapine is extensively metabolized; less than 1% of the dose is excreted unchanged in urine. Metabolites are eliminated renally (~50%) and in feces (~30%). Mean half-life approximately 12 hours (range 4-66 hours; the wide range reflects CYP1A2 pharmacogenomics and smoking status). Renal or hepatic impairment can meaningfully prolong half-life; dose reduction and enhanced monitoring are indicated in severe impairment.<ref name="clozaril-label" />

| pharmacodynamics = Clozapine's receptor pharmacology is the broadest of any clinically used neuroleptic. Quantitative binding affinities (Ki values) have been extensively measured; clozapine shows high affinity for D4 (Ki ~9 nM), 5-HT2A (Ki ~5 nM), 5-HT2C, H1 (Ki ~3 nM), muscarinic (M1-M4), and alpha-1 adrenergic receptors, with moderate affinity at D1 and D2 (Ki for D2 approximately 56-250 nM depending on assay conditions).{{citation needed}}

The fast-off hypothesis (Seeman and Kapur) proposes that clozapine's transient, rapidly-reversible D2 binding produces sufficient tonic dopamine receptor blockade for antipsychotic effect while allowing sufficient endogenous dopamine signaling to prevent the nigrostriatal D2 block responsible for EPS. In PET studies, clozapine at clinical doses produces D2 occupancy of 30-60%, substantially lower than the >80% occupancy of typical neuroleptics at equivalent clinical doses.{{citation needed}}

The therapeutic drug level threshold of 350 ng/mL for clozapine trough levels was established from studies correlating plasma concentration with clinical response in treatment-resistant schizophrenia; patients with levels below this threshold showed substantially lower response rates.{{citation needed}}

| interactions = <pharmaInteractions/>

Clozapine has among the most clinically important drug interaction profiles of any psychiatric medicine, particularly because the consequences of interaction include both loss of efficacy and potentially fatal toxicity:

* '''Smoking (CYP1A2 induction).''' Tobacco smoking induces CYP1A2 via polycyclic aromatic hydrocarbons and lowers clozapine plasma levels by 30-60%. Smokers require higher clozapine doses than non-smokers. '''Smoking cessation in a stable clozapine-maintained patient is a medical emergency''' for clozapine dosing: levels can rise substantially within days as CYP1A2 induction reverses, causing clozapine toxicity (sedation, salivation, seizures, cardiomegaly). If a patient is planning to stop smoking, proactive dose reduction of 30-50% is needed with close monitoring.

* '''Fluvoxamine (potent CYP1A2 inhibitor).''' Fluvoxamine increases clozapine AUC 3- to 10-fold; if co-prescribed (sometimes done intentionally to allow lower clozapine doses for the same effect), clozapine dose must be reduced to approximately 1/3 to 1/4 of the monotherapy dose and plasma levels monitored closely.

* '''Ciprofloxacin and other fluoroquinolones (CYP1A2 inhibitors).''' Can significantly raise clozapine levels during antibiotic courses; monitor for toxicity signs and consider temporary dose reduction.

* '''Carbamazepine (CYP1A2/3A4 inducer + additive agranulocytosis risk).''' CONTRAINDICATED in combination with clozapine. Carbamazepine lowers clozapine levels via enzyme induction AND independently increases the risk of agranulocytosis; the combination is not used.

* '''Valproate.''' Also associated with increased agranulocytosis risk when combined with clozapine; should be avoided if possible, or used only with enhanced ANC monitoring and careful benefit-risk justification. Valproate is sometimes used for seizure prophylaxis in clozapine patients, but the agranulocytosis interaction means lamotrigine or topiramate are preferred anticonvulsants in this context.

* '''Benzodiazepines (particularly IV/IM combined with clozapine).''' Case reports of cardiovascular collapse (hypotension, respiratory arrest) with combined use of intramuscular benzodiazepines in clozapine-maintained patients have been reported; Clozaril labeling recommends caution with concurrent benzodiazepine use. Combined oral use requires careful blood pressure monitoring.

* '''Other CYP1A2 inhibitors''' (cimetidine, some SSRIs at high doses, caffeine in large quantities). Variable effects on clozapine levels; clinical significance depends on dose and duration.

* '''Anticholinergic medicines.''' Additive antimuscarinic effects (constipation, urinary retention, confusion, ileus risk); use caution.

* '''QT-prolonging medicines.''' Though clozapine itself has modest QT effects, combination with other QT-prolonging agents warrants ECG monitoring.

| pregnancy_details = Human pregnancy data on clozapine are limited, consisting primarily of case reports and small case series, with some registry data from the National Pregnancy Registry for Atypical Antipsychotics.

Key concerns:
- Clozapine crosses the placenta
- Neonatal toxicity has been reported with third-trimester exposure: neonatal sedation, flaccid infant, tremors, seizures, and in some reports withdrawal symptoms in the immediate postnatal period
- Whether clozapine is teratogenic in humans is uncertain; animal studies have not demonstrated teratogenicity at therapeutic doses, and the available human case data do not show a consistent malformation pattern, but data are insufficient to establish safety

The clinical decision is particularly complex in treatment-resistant schizophrenia:
- Untreated or under-treated psychosis in pregnancy carries substantial maternal and fetal risks (poor antenatal care, self-harm, harm to fetus, perinatal complications)
- If a patient's schizophrenia is controlled only with clozapine, discontinuing it during pregnancy may be clinically catastrophic
- The REMS ANC monitoring program must continue in pregnancy; agranulocytosis risk does not change

General guidance: continue clozapine during pregnancy only with explicit benefit-risk discussion, coordination with maternal-fetal medicine, and planning for neonatal monitoring at delivery for toxicity/withdrawal. Register with the National Pregnancy Registry for Atypical Antipsychotics (1-866-961-2388) to contribute to the evidence base.{{citation needed}}

Breastfeeding: Clozapine transfers into breast milk; clozapine and norclozapine have been detected in nursing infant plasma. Infant sedation, cardiovascular effects, and the theoretical risk of agranulocytosis in the nursing infant have led most guidelines to recommend against breastfeeding while on clozapine.

| monitoring = Clozapine REMS monitoring is mandatory and a condition of dispensing. All prescribers and pharmacies must be enrolled; dispensing requires verification of current ANC on file.

'''ANC monitoring thresholds (Clozapine REMS):'''
- '''Green (continue):''' ANC ≥1500/μL (general population); ANC ≥1000/μL (patients with documented Benign Ethnic Neutropenia)
- '''Yellow (caution, increased frequency):''' ANC 1000-1499/μL (general population) or ANC 500-999/μL (BEN patients) -- increase monitoring to twice weekly; continue clozapine only with enhanced oversight
- '''Red (stop clozapine):''' ANC <1000/μL (general population) or ANC <500/μL (BEN patients) -- interrupt clozapine immediately; obtain hematology consultation; do not rechallenge until ANC recovers and cause is determined

'''Monitoring schedule:'''
- Baseline ANC before first dose
- Weekly ANC for the first 6 months
- ANC every 2 weeks for months 7-12
- ANC monthly after 12 months

'''Metabolic monitoring:'''
- Fasting glucose and lipids at baseline + at 3 months + every 6-12 months
- Weight and BMI at each visit (particularly the first 6 months of treatment)
- Blood pressure and orthostatic BP early in titration

'''Cardiac monitoring (myocarditis):'''
- ECG at baseline; repeat if tachycardia or cardiac symptoms develop
- C-reactive protein (CRP) and troponin at baseline and at weeks 1, 2, 4 of treatment -- recommended by many experts though not universally required; elevated troponin + CRP with fever and tachycardia constitutes a clinical emergency requiring clozapine interruption
- Continue monitoring CRP/troponin for 4-8 weeks; myocarditis risk is highest in the first month

'''Therapeutic drug monitoring:'''
- Trough clozapine plasma level: obtain at steady state (after 5+ half-lives at a stable dose); target ≥350 ng/mL
- Repeat after any significant dose change, addition of interacting medicine, or change in smoking status

| counseling = '''Never stop clozapine suddenly.''' If you need to stop for any reason, including missed doses, contact your prescriber immediately. Abrupt discontinuation can cause severe psychiatric relapse, rebound psychosis, and cholinergic symptoms. If you have missed more than 2 days of doses, do NOT take extra medicine -- a full re-titration from low doses is required.

'''Blood tests are mandatory.''' You cannot get your clozapine prescription filled without a recent blood test on file. This is the law, not optional. Missing blood tests means you cannot get the medicine. Schedule tests regularly, and keep a record of your monitoring facility.

'''Smoking.''' If you currently smoke, do NOT stop smoking abruptly without telling your prescriber first. Stopping smoking affects how much of this medicine gets into your bloodstream and can cause overdose effects (extreme sleepiness, excessive drooling, shaking). Your prescriber will adjust your dose if you change your smoking habits.

'''Report fever, sore throat, or infection.''' These can be early signs of a dangerous drop in white blood cells (agranulocytosis). Do not wait for your next scheduled appointment -- call your prescriber the same day. You may need an emergency blood test.

'''Report chest pain, shortness of breath, or irregular heartbeat.''' These can be signs of a rare but serious heart problem that can occur early in treatment. Go to the emergency room if symptoms are severe.

'''Constipation is serious.''' This medicine slows your bowels. Take stool softeners or laxatives as directed, drink plenty of water, and eat a fiber-rich diet. If you do not have a bowel movement for 3 or more days, call your prescriber. Severe constipation from clozapine has caused life-threatening bowel obstruction.

'''Drooling.''' Excessive drooling, especially at night, is a common and embarrassing side effect. Tell your prescriber -- there are effective treatments.

'''Driving and heavy machinery.''' This medicine causes significant sedation, especially early in treatment. Do not drive or operate dangerous machinery until you know how it affects your alertness.

'''Weight and blood sugar.''' This medicine can cause significant weight gain and raise your blood sugar. Monitor your weight regularly; eat a balanced diet; report increased thirst or urination.

'''Pregnancy.''' If you are pregnant or planning a pregnancy, discuss this with your prescriber. Clozapine use in pregnancy requires specialist consultation and careful planning. Register with the National Pregnancy Registry for Atypical Antipsychotics.

| anecdotes =
| seealso = [[Quetiapine]], [[Olanzapine]], [[Risperidone]], [[Aripiprazole]], [[Haloperidol]], [[Schizophrenia]]
| references = <references/>
}}

[[Category:Second-generation neuroleptics]]
[[Category:Neuroleptics]]
[[Category:REMS medicines]]
[[Category:Medicines]]

Modafinil

2026-05-31T17:12:01Z

Maintenance script: Create Modafinil medicine page (eugeroic for narcolepsy/OSA/shift-work)

{{MedTemplate
| generic = Modafinil
| brand = Provigil (US, 100 mg and 200 mg tablets); Alertec (Canada); Modiodal (France, original market). See also: Armodafinil (Nuvigil), the R-enantiomer, a related eugeroic approved 2007 with a longer effective half-life.
| structure =
| classes = [[:Category:Eugeroics|Eugeroic (wakefulness-promoting agent)]], [[:Category:Psychostimulants|Psychostimulant]], [[:Category:Schedule IV controlled substances|Schedule IV controlled substance (US)]]
| uses =
| starting_dose = Narcolepsy/OSA: 200 mg PO once daily in the morning. Shift work disorder: 200 mg PO approximately 1 hour before the start of the work shift. Lower starting dose (100 mg) can be considered in elderly patients or those with hepatic impairment.
| preparations = Oral tablets 100 mg and 200 mg (Provigil and generics). No IV or extended-release formulations available; compare armodafinil (Nuvigil) 50/150/250 mg tablets as the R-enantiomer alternative.
| fda_max = 400 mg/day (though clinical trials and FDA label note that doses above 200 mg/day have not demonstrated additional benefit in controlled studies for the approved indications; 200 mg is the standard therapeutic dose).<ref name="provigil-label">FDA Prescribing Information, Provigil (modafinil) Tablets, Cephalon/Teva, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020717s037lbl.pdf</ref>
| pill_id =
| routes = Oral only.
| onset = Peak plasma concentrations 2-4 hours after oral dose. Wakefulness-promoting effect onset correlates with peak plasma; subjective alertness typically reported within 1-2 hours of dosing.
| duration = Effective wakefulness promotion through approximately 12-15 hours reflecting the half-life of the predominant R-enantiomer. For shift-work use, 200 mg taken 1 hour before shift provides coverage through most 8-12 hour shifts.
| halflife = The racemic mixture of modafinil has an effective half-life of approximately 12-15 hours due to differential enantiomer kinetics: the R-enantiomer (R-modafinil) has a half-life of ~15 hours; the S-enantiomer has a half-life of ~4 hours. In practice, the R-enantiomer dominates steady-state pharmacology, giving a 12-15h effective duration.<ref name="provigil-label" />
| bioavailability = Approximately 80% (well-absorbed orally; not significantly affected by food, though food may delay Tmax by ~1 hour).<ref name="provigil-label" />
| pregnancy = EMA pregnancy prevention program required as of 2019 (significant congenital malformation signal from observational registry data; see pregnancy_details). FDA labeling updated to reflect human data concerns. Modafinil should be considered contraindicated or avoided in pregnancy unless the clinical need is compelling and the patient has been counseled. Females of reproductive potential must use effective non-hormonal contraception during treatment and for 2 months after discontinuation (hormonal contraceptive efficacy is reduced by modafinil; see interactions).
| legal = [[USLegal:Schedule IV|Schedule IV controlled substance (US)]]. Rx-only. The DEA scheduled modafinil as Schedule IV in 1999, reflecting confirmed abuse potential (dopamine reward pathway activity) but substantially lower abuse liability than Schedule II stimulants (amphetamine, methylphenidate). Available as generic modafinil (widely) since 2012 US patent expiry.
| mechanism = <vote slug="modafinil-mech-claim">Modafinil's mechanism of wakefulness promotion is incompletely understood but is best characterized as a '''dopamine transporter (DAT) inhibitor''' that increases synaptic dopamine concentrations primarily through reuptake inhibition rather than dopamine release. This distinguishes it mechanistically from amphetamines and methylphenidate, which cause dopamine efflux via reverse transport; modafinil binds the DAT but does not significantly trigger reverse transport, resulting in a more gradual and sustained dopamine elevation with lower abuse liability.<ref name="wisor-2001">Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM. Dopaminergic role in stimulant-induced wakefulness. J Neurosci. 2001;21(5):1787-1794. PMID 11222668.</ref>

Secondary mechanisms contributing to wakefulness include norepinephrine transporter (NET) inhibition (elevating noradrenergic tone), activation of orexin/hypocretin-containing neurons in the lateral hypothalamus (the same neurons lost in narcolepsy type 1), and increased histaminergic signaling (H1 activation, consistent with wakefulness -- the inverse of H1-blocking antihistamines that cause drowsiness). Serotonin and GABA effects have been described but are considered secondary to the dopamine/norepinephrine and histamine effects.</vote>
| intro = Modafinil is a wakefulness-promoting agent (eugeroic) used primarily for narcolepsy, obstructive sleep apnea residual sleepiness, and shift work sleep disorder. It is chemically unrelated to amphetamines and is mechanistically distinct from classical psychostimulants, acting primarily as a dopamine reuptake inhibitor without significant dopamine release, which accounts for its Schedule IV (rather than Schedule II) classification and its comparatively modest abuse liability. It is nonetheless a controlled substance with demonstrated dopamine reward-pathway activity.

Modafinil was developed at Laboratoire Lafon in France by researcher Michel Jouvet's group in the 1970s-1980s as a refinement of adrafinil, a prodrug in the same benzhydryl sulfinyl compound series that Lafon had developed for sleepiness in elderly patients. Modafinil is the active sulfoxide metabolite of adrafinil and was found to have superior potency and reduced peripheral side effects. It was approved in France in 1994 under the trade name Modiodal and received FDA approval in the US in 1998 (Provigil) for narcolepsy, with label expansions to obstructive sleep apnea residual sleepiness and shift work sleep disorder in 2003. Cephalon (later acquired by Teva Pharmaceuticals) marketed Provigil in the US until generic entry in 2012.

The R-enantiomer of modafinil, armodafinil (Nuvigil, approved by FDA in 2007), has a longer effective half-life (~15 hours) than racemic modafinil (~12-15 hours overall) and was developed as an improved once-daily formulation. Racemic modafinil and armodafinil are considered therapeutically interchangeable for the approved indications at equivalent doses (150 mg armodafinil is approximately bioequivalent to 200 mg modafinil).

Off-label use of modafinil for cognitive enhancement in healthy individuals became prominent in the 2000s through patient-advocacy networks and media attention, contributing to supply pressures and diversion concerns. The emergence of modafinil as a "smart drug" was not supported by robust trials showing benefit in non-sleep-deprived healthy subjects, though sleep-deprivation-reversal effects are well-established.

A significant pregnancy safety signal was identified in European registry data (congenital malformations), leading the EMA to impose a mandatory pregnancy prevention program in 2019, substantially restricting modafinil prescribing in Europe for women of childbearing potential.

| history = Modafinil's history begins with adrafinil, a benzhydryl sulfinyl compound synthesized at Laboratoire Lafon in France in the late 1970s as part of a research program into vigilance-promoting compounds led by the neurobiologist Michel Jouvet. Adrafinil was found to promote wakefulness in animals and humans and was approved in France in 1986 (Olmifon) for treatment of sleepiness and hypersomnia in elderly patients.{{citation needed}}

Modafinil, the active sulfoxide metabolite of adrafinil, was identified and developed as a standalone compound in the 1980s, offering the advantage of direct activity without requiring hepatic conversion and with a cleaner side-effect profile. Modafinil was approved in France in 1994 under the trade name Modiodal for narcolepsy. The FDA approved modafinil (Provigil) in the United States in December 1998 for narcolepsy. In 2003, FDA expanded the label to include obstructive sleep apnea residual sleepiness (as an adjunct to CPAP) and shift work sleep disorder.

The DEA placed modafinil in Schedule IV in 1999 following confirmation of dopamine reward-pathway activity and evidence of human abuse and diversion, though the relative abuse potential is substantially lower than Schedule II agents. Studies using PET imaging confirmed modafinil's dopamine transporter occupancy at therapeutic doses and its ability to elevate dopamine in the nucleus accumbens, establishing the mechanism basis for scheduling.<ref name="volkow-2009">Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA. 2009;301(11):1148-1154. PMID 19293415.</ref>

In 2006, FDA declined to approve modafinil for pediatric ADHD, citing serious skin reaction (SJS/TEN and DRESS) risk in children. This decision, despite positive efficacy data, significantly limited modafinil's pediatric market and reinforced amphetamine-class agents as the standard of care for ADHD.

Cephalon obtained a US patent for modafinil and aggressively extended patent protection through formulation changes, leading to FTC scrutiny and ultimately generic entry beginning in 2012 after patent litigation settlements. Armodafinil (Nuvigil), the R-enantiomer, was approved by FDA in June 2007 as an improved formulation with longer duration of action, extending Cephalon's market position.

A 2019 assessment by the EMA (European Medicines Agency) identified a risk of congenital malformations in pregnancies exposed to modafinil, based on observational registry data showing higher rates of congenital cardiac malformations and other structural anomalies in exposed pregnancies compared to unexposed controls.{{citation needed}} The EMA required a pregnancy prevention program (similar in structure to the valproate pregnancy prevention program) and restricted modafinil prescribing in women of childbearing potential to those who meet contraception requirements. The FDA updated US labeling to reflect the human data signal.

| indications = <problem ref="narcolepsy" author="parser-claude">Narcolepsy (type 1 and type 2); reduces excessive daytime sleepiness. FDA-approved first-line pharmacotherapy. Does not address cataplexy (the hallmark of type 1 narcolepsy); sodium oxybate, pitolisant, or tricyclic antidepressants are used for cataplexy management.</problem>
<problem ref="obstructive-sleep-apnea" author="parser-claude">Obstructive sleep apnea residual sleepiness; adjunct to CPAP in patients with objective adherence who still report excessive daytime sleepiness despite adequate CPAP therapy. Does not treat the underlying obstructive apnea and should not replace CPAP.</problem>
<problem ref="shift-work" author="parser-claude">Shift work sleep disorder; improves wakefulness during scheduled work hours and reduces sleepiness in patients who work nontraditional hours (night shifts, rotating shifts, early-morning shifts).</problem>
<problem ref="adhd" author="parser-claude">ADHD (off-label); evidence from RCTs showing benefit in adults and children, but FDA declined to add ADHD to the label in 2006 due to serious skin reaction risk in the pediatric population. Not a standard first-line option given available Schedule II agents with stronger evidence bases and established pediatric safety profiles.</problem>
<problem ref="fatigue" author="parser-claude">Fatigue (off-label); used for multiple sclerosis-related fatigue and cancer-related fatigue in patients with significant burden; evidence is inconsistent across trials but endorsed by some oncology and neurology guidelines for refractory cases.</problem>
<problem ref="trd-augment" author="parser-claude">Treatment-resistant depression augmentation (off-label); adjunct to SSRIs/SNRIs for residual fatigue and cognitive symptoms in partially-responsive depression.</problem>
| dosing = <titration slug="narcolepsy-osa" author="parser-claude" title="Narcolepsy / OSA residual sleepiness">
200 mg PO once daily in the morning. Most patients respond to 200 mg. Doses above 200 mg have not shown consistent additional benefit in controlled trials for the approved indications and increase adverse effect burden.

Elderly patients and those with severe hepatic impairment (Child-Pugh C): consider 100 mg/day starting dose.

For patients with OSA: confirm CPAP use and adherence before prescribing; modafinil does not substitute for CPAP and does not reduce the cardiovascular or respiratory consequences of untreated OSA.
</titration>

<titration slug="shift-work" author="parser-claude" title="Shift work sleep disorder">
200 mg PO approximately 1 hour before the start of the work shift. Timing is important; taking modafinil too late in the shift may cause difficulty sleeping after work. Not recommended for episodic shift changes; most appropriate for regular shift schedules.
</titration>

<titration slug="off-label-fatigue" author="parser-claude" title="Off-label: MS/cancer-related fatigue">
100-200 mg PO once daily in the morning, titrated to effect. Evidence base for MS-related fatigue is inconsistent; some trials positive, some null. Cancer-related fatigue evidence is mixed; most benefit suggested in patients with significant fatigue burden (FACIT-Fatigue scales). Use as trial therapy with explicit assessment endpoints; discontinue if no clear benefit at 4-6 weeks.
</titration>

| effects =
* <effect ref="wakefulness" author="parser-claude">The therapeutic effect; promotes and sustains wakefulness during the dosing window without significant rebound hypersomnia on discontinuation.</effect>
* <effect ref="headache" author="parser-claude">The most common adverse effect; reported in approximately 34% of patients in clinical trials, dose-dependent. Often improves over the first 1-2 weeks; adequate hydration may help.</effect>
* <effect ref="nausea" author="parser-claude">Common (~11%); often mild and self-limited. Taking with food does not significantly affect overall bioavailability but may reduce nausea at initiation.</effect>
* <effect ref="nervousness-anxiety" author="parser-claude">Common (~7%); may be dose-dependent; generally mild. Patients with pre-existing anxiety disorders may be more susceptible.</effect>
* <effect ref="insomnia" author="parser-claude">Particularly if taken too late in the day; the 12-15h half-life means afternoon dosing can interfere with nighttime sleep. Counsel on timing (morning dose for narcolepsy/OSA).</effect>
* <effect ref="hypertension-palpitations" author="parser-claude">Modest cardiovascular stimulant effects; blood pressure and heart rate elevations are milder than amphetamine-class agents. Monitor in patients with pre-existing hypertension or cardiovascular disease.</effect>
* <effect ref="sjs-dress" author="parser-claude">Rare but serious: Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). The most serious safety concern; the basis for FDA's 2006 rejection of pediatric ADHD indication. Any rash, especially with mucosal involvement or systemic features, requires immediate discontinuation and evaluation. Risk appears higher in children than adults.</effect>
* <effect ref="psychiatric-symptoms" author="parser-claude">Rare: anxiety, agitation, psychosis, mania/hypomania. Modafinil should be used with caution (or avoided) in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder with a history of mania.</effect>
* <effect ref="reduced-contraceptive-efficacy" author="parser-claude">CYP3A4 induction reduces the systemic exposure of hormonal contraceptives (ethinyl estradiol, progestins). See Interactions. Clinically important for reproductive counseling.</effect>
* <effect ref="appetite-suppression-weight-loss" author="parser-claude">Mild appetite suppression; less prominent than amphetamine-class agents. Generally not clinically meaningful but can be useful in some patients and concerning in those with low body weight or eating disorder history.</effect>
* <effect ref="abuse-dependence" author="parser-claude">Schedule IV; confirmed dopamine reward-pathway activity. Abuse and psychological dependence have been reported, particularly in individuals with stimulant use disorder histories. However, abuse potential is substantially lower than Schedule II stimulants.</effect>

| pk_absorption = Oral bioavailability approximately 80%; well-absorbed from the GI tract. Peak plasma concentrations (Tmax) at 2-4 hours after dosing. Food does not significantly alter overall bioavailability but may delay Tmax by approximately 1 hour and reduce peak concentration modestly; clinically not significant for most patients.<ref name="provigil-label" />

| pk_distribution = Volume of distribution approximately 0.9 L/kg. Plasma protein binding approximately 60% (primarily albumin). Distributes widely into brain tissue; CNS penetration is required for therapeutic effect and is confirmed by PET studies showing DAT occupancy at therapeutic doses.<ref name="provigil-label" />

| pk_metabolism = Modafinil undergoes primarily hepatic metabolism. The major pathway is amide hydrolysis to modafinil acid (major inactive metabolite, renally excreted) and to a lesser extent modafinil sulfone (minor inactive metabolite via CYP3A4/3A5). Approximately 90% of the dose is recovered as metabolites; less than 10% is excreted as unchanged parent compound.

Critically for drug interactions: modafinil is a moderate inducer of CYP3A4 and CYP2C9 (relevant for contraceptives, cyclosporine, and statin interactions) and an inhibitor of CYP2C19 (relevant for warfarin, phenytoin, diazepam, and some TCAs). CYP1A2 is also moderately induced.

Modafinil exhibits non-linear PK with repeated dosing due to autoinduction of CYP-mediated elimination pathways; steady-state plasma concentrations are lower than predicted from single-dose data, and steady state is typically reached within 2-4 days.<ref name="provigil-label" />

| pk_elimination = Primarily renal elimination of metabolites (~80%); fecal route accounts for the remainder. Half-life of the racemic mixture approximately 12-15 hours at steady state (R-enantiomer ~15h, S-enantiomer ~4h). Hepatic impairment (severe) reduces clearance significantly; dose reduction required. Renal impairment does not significantly affect parent drug clearance but metabolites accumulate; caution in severe renal impairment. Not significantly dialyzed.<ref name="provigil-label" />

| pharmacodynamics = Modafinil's primary pharmacodynamic effect is promotion of wakefulness via dopamine transporter inhibition with consequent increase in synaptic dopamine. PET imaging studies at therapeutic doses have demonstrated significant DAT occupancy (approximately 50-70% occupancy at 200 mg) in the human caudate and putamen, with corresponding elevations in synaptic dopamine in the nucleus accumbens and striatum, confirming that the dopamine pathway is engaged at clinical doses.

The key distinction from amphetamines is the absence of significant dopamine efflux: modafinil inhibits reuptake but does not cause the vesicular dopamine release or reverse transport that characterizes amphetamine action. This difference in mechanism produces a more gradual, sustained dopamine increase rather than the sharp spike-and-crash profile of amphetamines and is the pharmacodynamic basis for modafinil's lower abuse liability and Schedule IV rather than Schedule II classification.

Norepinephrine reuptake inhibition (via NET) contributes to wakefulness and alertness and may account for some of the sympathomimetic cardiovascular effects (modest BP and HR increases).

Orexin/hypocretin neuron activation is relevant to the narcolepsy indication: type 1 narcolepsy involves loss of orexin-producing neurons in the lateral hypothalamus. While modafinil cannot replace lost orexin neurons, dopaminergic activation may engage downstream arousal circuitry and partially compensate for orexin deficiency. Whether modafinil acts directly on orexin receptors or indirectly via dopamine is debated.

Histamine H1 pathway activation (elevated histaminergic tone) contributes to wakefulness; this mechanism is consistent with the inverse effect of H1 antihistamines.

| interactions = <pharmaInteractions/>

Clinically important interactions for prescribers:

* '''Hormonal contraceptives (oral and implantable).''' Modafinil is a CYP3A4 inducer and substantially reduces systemic exposure of ethinyl estradiol and progestin components of combined hormonal contraceptives. This is a MANDATORY counseling point: patients using hormonal contraceptives (pill, patch, ring, implant) should be counseled to use a non-hormonal barrier method during modafinil treatment and for 2 months after stopping. This applies to combined hormonal contraceptives; hormonal IUDs (which act locally in the uterus) are less affected, but the package insert recommends consultation regardless.<ref name="provigil-label" />

* '''CYP2C19 substrates.''' Modafinil inhibits CYP2C19 and increases exposure of:
- Warfarin: INR should be monitored more frequently at initiation and with dose changes
- Phenytoin: phenytoin levels may increase; monitor and consider level check
- Diazepam: increased diazepam exposure; reduce diazepam dose if co-prescribed
- Omeprazole and other PPIs metabolized by CYP2C19: increased exposure, typically not clinically significant
- Clomipramine and other CYP2C19-metabolized TCAs: increased TCA levels

* '''CYP3A4 substrates (induction risk).''' Modafinil modestly induces CYP3A4 and may reduce efficacy of:
- Cyclosporine: significant interaction; cyclosporine levels should be monitored in transplant patients
- Some HIV antiretrovirals (PIs and NNRTIs metabolized by CYP3A4)
- Statin interactions are generally modest but theoretically possible

* '''Methylphenidate and amphetamines.''' Co-prescribed for ADHD or treatment-resistant sleepiness: additive wakefulness effects. Additive cardiovascular stimulant effects. Not a strict contraindication but caution warranted.

* '''MAOIs.''' Theoretical concern from combined dopaminergic/adrenergic activity. Avoid combination or observe carefully with appropriate washout between agents.

* '''Clozapine.''' Modafinil is a CYP1A2 inducer and clozapine is primarily a CYP1A2 substrate; the expected pharmacokinetic direction is reduced clozapine exposure, with risk of breakthrough psychosis or loss of clozapine efficacy (not clozapine toxicity). Case reports of clinically significant clozapine level changes with modafinil co-administration have been reported; monitor clozapine levels and clinical status if modafinil is added or discontinued in a patient on clozapine.{{citation needed}}

| pregnancy_details = A 2019 EMA pharmacovigilance review of registry and observational data identified a statistically significant increase in congenital malformations (particularly congenital cardiac malformations and oro-facial malformations) in pregnancies exposed to modafinil compared to unexposed controls. The absolute risk increase was modest but the signal was sufficient for the EMA to require a mandatory pregnancy prevention program, restricting modafinil to females of reproductive potential who fulfill contraception requirements and undergo regular pregnancy testing.{{citation needed}}

The FDA updated US prescribing information to include the human pregnancy signal and requires counseling about the risk. The FDA has not required a formal pregnancy prevention program comparable to the EMA's, but the updated labeling recommends that females of reproductive potential use effective contraception.

Animal studies at high doses identified skeletal malformations and intrauterine growth restriction in rats and rabbits; developmental effects were seen at doses producing maternal toxicity.

Clinical guidance:
- Modafinil should generally be avoided in pregnancy unless the clinical need (e.g., uncontrolled narcolepsy with significant safety implications) outweighs the documented congenital malformation risk
- If continuing in pregnancy, specialist consultation and close fetal monitoring are appropriate
- Abrupt discontinuation in narcoleptic patients may pose safety risks (e.g., sudden sleep onset while driving); a managed transition plan is needed

Breastfeeding: Limited human data on transfer into breast milk. Animal studies suggest some transfer. Given the lack of safety data and the availability of non-pharmacologic strategies for maternal sleepiness management (where feasible), avoidance during breastfeeding is generally recommended.{{citation needed}}

| monitoring = Baseline before initiation:
* Blood pressure and heart rate (modest cardiovascular stimulant; baseline needed for comparison)
* Pregnancy status in females of reproductive potential (mandatory given congenital malformation signal); contraception plan required
* Psychiatric history (psychosis, mania, bipolar disorder: higher risk of psychiatric adverse effects)
* Skin: no routine testing, but counsel about SJS/DRESS at initiation -- any rash requires prompt evaluation
* Cardiac history: structural heart disease or arrhythmia warrants risk-benefit discussion
* Drug interactions review: warfarin (INR), phenytoin (levels), cyclosporine (levels), hormonal contraceptives (switch to non-hormonal)
* Hepatic function: modafinil is primarily hepatically metabolized; severe hepatic impairment requires dose reduction and closer monitoring

Ongoing:
* Blood pressure at follow-up visits, especially in hypertensive patients
* Efficacy assessment: daytime sleepiness scales (Epworth Sleepiness Scale, Maintenance of Wakefulness Test in some settings); response should be documented
* Pregnancy testing in females of reproductive potential per contraception plan
* Monitor for psychiatric symptoms (agitation, psychosis, mania) especially in first weeks of treatment
* INR monitoring in patients on warfarin
* No routine CBC, metabolic, or LFT monitoring required in uncomplicated patients

| counseling = '''Take in the morning (narcolepsy/OSA).''' Modafinil lasts 12-15 hours; taking it in the afternoon can prevent you from sleeping at night. For narcolepsy and OSA, morning dosing gives you daytime coverage without disrupting nighttime sleep.

'''Contraception is required.''' Modafinil reduces the effectiveness of hormonal birth control pills, patches, rings, and implants. Use a condom or non-hormonal method during treatment and for 2 months after stopping. If you think you might be pregnant or become pregnant while taking modafinil, tell your prescriber immediately.

'''Rash: stop and call us.''' Modafinil can rarely cause a severe skin reaction (Stevens-Johnson syndrome or DRESS). If you develop any rash, especially one involving your mouth, eyes, or genitals, or accompanied by fever or swollen lymph nodes, stop the medicine and contact us the same day.

'''Driving.''' Modafinil is used to treat sleepiness, but it does not completely eliminate the risk of sudden sleep onset, especially if narcolepsy is not fully controlled. Discuss driving safety with your prescriber.

'''Not a substitute for sleep.''' Modafinil helps you stay awake but does not replace restorative sleep. Chronic sleep deprivation carries independent health risks regardless of wakefulness promotion.

'''Schedule IV.''' Modafinil is a controlled substance. Keep it secure, do not share it, and do not take more than prescribed. Psychological dependence can develop with misuse.

'''Warfarin / phenytoin users.''' If you take warfarin (Coumadin) or phenytoin (Dilantin), modafinil affects how those medicines work. Your prescriber may need to check levels or adjust doses.

'''OSA: keep using CPAP.''' Modafinil helps with residual daytime sleepiness but does not treat the breathing obstruction. CPAP is still essential for cardiovascular and cognitive protection.

| anecdotes =
| seealso = [[Armodafinil]], [[Methylphenidate]], [[Amphetamine salts]], [[Solriamfetol]], [[Pitolisant]]
| references = <references/>
}}

[[Category:Psychostimulants]]
[[Category:Eugeroics]]
[[Category:Schedule IV controlled substances]]
[[Category:Medicines]]

Naltrexone

2026-05-31T17:11:59Z

Maintenance script: Create Naltrexone medicine page (opioid antagonist for AUD + OUD)

{{MedTemplate
| generic = Naltrexone
| brand = ReVia (oral, 50 mg tablets), Depade (oral, generic), Vivitrol (extended-release IM injection 380 mg monthly); Contrave (naltrexone + bupropion ER tablets for weight management)
| structure =
| classes = [[:Category:Opioid antagonists|Opioid antagonist (mu and kappa)]], [[:Category:AUD medicines|Alcohol use disorder medicine]], [[:Category:OUD medicines|Opioid use disorder medicine]]
| uses =
| starting_dose = AUD oral: 50 mg PO once daily; may give every other day (100 mg) or thrice weekly (100/100/150) for adherence. AUD Vivitrol: 380 mg IM in the gluteal muscle every 4 weeks; alternate sides. OUD oral: same 50 mg/day after at least 7-10 days opioid-free (longer for methadone). OUD Vivitrol: same 380 mg IM every 4 weeks. LDN off-label: 1-4.5 mg/day oral compounded formulation, typically at bedtime.
| preparations = Oral tablets 50 mg (ReVia, Depade, generics); Vivitrol extended-release IM suspension 380 mg single-dose vial; Contrave (naltrexone 8 mg + bupropion 90 mg ER tablets); compounded 1, 2, 3, 4.5 mg tablets/capsules for LDN
| fda_max = 50 mg/day oral; 380 mg/4 weeks IM (Vivitrol); 32 mg + 360 mg naltrexone/bupropion daily (Contrave maximum after titration)
| pill_id =
| routes = Oral, intramuscular (depot)
| onset = Oral peak plasma 1 hour; therapeutic opioid blockade within hours of first dose. IM Vivitrol: peak plasma 2-3 days; therapeutic blockade through the dosing interval.
| duration = Oral mu-blockade clinically meaningful for 24-72 hours; IM Vivitrol blockade through 4 weeks.
| halflife = Naltrexone parent ~4 hours (oral); 6-beta-naltrexol (active metabolite) ~13 hours. Vivitrol depot terminal half-life 5-10 days with sustained release from microspheres maintaining blockade for the 4-week dosing interval.<ref name="vivitrol-label">FDA Prescribing Information, Vivitrol (naltrexone extended-release injectable suspension), Alkermes, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021897s048lbl.pdf</ref>
| bioavailability = ~5-40% (oral, highly variable due to extensive first-pass metabolism; mean ~5-10% for parent naltrexone with the majority of pharmacologic effect coming from 6-beta-naltrexol). IM Vivitrol bypasses first-pass entirely.<ref name="vivitrol-label" />
| pregnancy = Limited human pregnancy data; observational signals do not show clear teratogenicity. The clinical decision in pregnancy is challenging: untreated OUD or AUD carries substantial maternal-fetal risk, and abrupt discontinuation of naltrexone-MOUD can precipitate relapse. ACOG and ASAM guidance has historically favored methadone or buprenorphine as MOUD in pregnancy, but emerging case-series and registry data on Vivitrol-maintained pregnancies suggest naltrexone can be continued where clinically necessary; specialist consultation advised. Naltrexone passes into breast milk in small amounts; breastfeeding compatibility is debated but generally considered acceptable in stable maintained patients.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance (pure antagonist with no abuse potential). Vivitrol manufactured under restricted distribution channels for OUD; standard prescription channels for AUD. Boxed warning for HEPATOTOXICITY at supratherapeutic doses (the original 1984 boxed warning at doses up to 300 mg/day for obesity research; current 50 mg/day therapeutic dose has substantially lower risk; warning remains on label).<ref name="vivitrol-label" />
| mechanism = <vote slug="naltrexone-mech-claim">'''Pure opioid receptor antagonist''' with high affinity at mu-opioid receptors and substantial activity at kappa-opioid receptors; lower affinity at delta. No intrinsic agonist activity (distinguishing from buprenorphine partial agonism). Blocks the rewarding effects of exogenous opioids (preventing relapse-driven opioid use in OUD) and modulates the endogenous opioid contribution to alcohol-related reward (the AUD mechanism: alcohol consumption releases endogenous opioids that contribute to reward and craving; naltrexone blocks this contribution and reduces drinking quantity and craving without preventing alcohol consumption per se).</vote> Mechanism in impulse-control disorders is hypothesized similarly via endogenous-opioid blockade of behavioral reward. Mechanism for low-dose naltrexone (LDN) in chronic pain and autoimmune conditions is speculative; proposed mechanisms include glial cell modulation, transient opioid-receptor blockade triggering rebound endogenous opioid activity, and modulation of toll-like receptor 4 (TLR4) signaling; the evidence base for LDN in any specific indication remains modest.<ref name="vivitrol-label" />
| intro = Naltrexone is a pure opioid receptor antagonist used for opioid use disorder (OUD) and alcohol use disorder (AUD). It was synthesized at DuPont in 1965 by Matthew Fishman and colleagues as a structural analog of naloxone with longer duration of action and oral bioavailability, intended specifically for outpatient OUD treatment where naloxone's brief half-life and parenteral-only administration limited utility. FDA approval for OUD followed in 1984 (oral). The 1980s and 1990s clinical experience with oral naltrexone for OUD was modest, primarily due to poor adherence in the unsupervised outpatient setting; oral naltrexone's blockade is reversible by stopping the medication, and OUD patients with active craving frequently discontinued to use opioids. The Volpicelli and O'Brien research at the University of Pennsylvania in the early 1990s established efficacy in AUD, leading to FDA approval for that indication in 1994. The Vivitrol extended-release injectable formulation, approved 2006 for AUD and 2010 for OUD, addressed the adherence problem by providing sustained mu-receptor blockade through monthly dosing and has become the dominant naltrexone formulation in modern MOUD practice. Naltrexone is the third pharmacotherapy for OUD, complementing methadone and buprenorphine; it differs fundamentally in being an antagonist rather than an agonist, which makes it acceptable in some treatment contexts (criminal justice, abstinence-oriented programs) where agonist therapies face barriers but creates a substantial induction challenge (patients must be fully opioid-free for 7-14 days before starting naltrexone, in contrast to buprenorphine's tolerance of mild withdrawal).

| history = Naltrexone (originally EN-1639A) was synthesized at Endo Laboratories (later acquired by DuPont) in 1965 by Matthew Fishman, Harold Blumberg, and colleagues, in a structure-activity exploration of naloxone analogs intended to extend duration of action and improve oral bioavailability.{{citation needed}}

The National Institute on Drug Abuse (NIDA) funded extensive clinical development through the 1970s. FDA approval for opioid use disorder followed in 1984 under the trade name Trexan (later renamed ReVia). The initial clinical reception was muted: oral naltrexone proved disappointing in OUD treatment, with adherence as low as 20-30% at 6 months in unsupervised outpatient populations, leading to relapse rates comparable to no medication treatment in some cohorts.

The pivot to alcohol use disorder came from work by Joseph Volpicelli, Charles O'Brien, and colleagues at the University of Pennsylvania, who hypothesized that endogenous opioid release during alcohol consumption contributed to the reinforcing properties of drinking and that naltrexone blockade would reduce drinking quantity and craving. The 1992 Archives of General Psychiatry paper (Volpicelli et al PMID 1417505) established efficacy in a placebo-controlled trial.{{citation needed}} FDA approval for AUD followed in 1994. The COMBINE trial (Anton RF et al, JAMA 2006 PMID 16670409) is the largest AUD pharmacotherapy trial; it confirmed modest naltrexone efficacy without an obvious benefit from combining naltrexone with acamprosate or with intensive counseling, consistent with subsequent meta-analyses showing modest but real treatment effects.

Vivitrol (extended-release injectable naltrexone) was approved by FDA for AUD in 2006 and for OUD in 2010, addressing the oral-adherence problem that had limited oral naltrexone's OUD utility. Vivitrol use in OUD remains controversial because of the induction challenge (7-14 day opioid-free interval), but it is the dominant modern naltrexone formulation in MOUD practice.

Contrave (naltrexone 8 mg + bupropion 90 mg sustained-release combination) was approved by FDA for weight management in 2014, based on the hypothesis that naltrexone-mediated blockade of POMC-neuron feedback inhibition enhances bupropion's effect on hypothalamic energy balance.

Low-dose naltrexone (LDN) at 1-4.5 mg/day, far below the 50 mg therapeutic dose for AUD/OUD, gained popularity in the 2000s for off-label use in fibromyalgia, chronic pain, Crohn disease, and autoimmune conditions, primarily through patient-advocacy networks rather than formal regulatory channels. The evidence base for LDN has expanded gradually; modest trial evidence supports use in fibromyalgia and possibly in Crohn disease, but most LDN indications remain investigational.

| indications = <problem ref="opioid-use-disorder" author="parser-claude">Opioid use disorder; FDA-approved as the third pharmacotherapy after methadone and buprenorphine. Vivitrol depot is the dominant modern formulation due to oral-adherence challenges. Antagonist mechanism distinguishes from agonist MOUD; patient must be fully opioid-free 7-14 days before induction to avoid precipitated withdrawal.</problem>
<problem ref="alcohol-use-disorder" author="parser-claude">Alcohol use disorder; reduces drinking quantity and craving via blockade of endogenous-opioid contribution to alcohol-related reward. Modest effect size; standard pharmacotherapy alongside acamprosate and disulfiram.</problem>
<problem ref="impulsivity" author="parser-claude">Impulsivity and impulse-control disorders (off-label); case-series and small-trial evidence for pathological gambling, kleptomania, compulsive sexual behavior, and trichotillomania via endogenous opioid reward blockade.</problem>
<problem ref="trichotillomania" author="parser-claude">Trichotillomania (off-label; overlaps with impulsivity indication above; listed separately given specific trial evidence).</problem>
<problem ref="chronic-pain" author="parser-claude">Low-dose naltrexone (LDN) for fibromyalgia, Crohn disease, complex regional pain syndrome, and other chronic-pain syndromes (off-label; evidence base modest and growing).</problem>
<problem ref="weight-loss" author="parser-claude">Weight management (FDA, as part of Contrave naltrexone/bupropion combination); listed under weight-loss rather than obesity per the approval framing.</problem>
| dosing = <titration slug="aud-oral" author="parser-claude" title="Alcohol use disorder (oral)">
50 mg PO once daily. Some patients tolerate every-other-day dosing (100 mg) or thrice-weekly dosing (100 mg Mon/Wed, 150 mg Fri) for adherence support. Begin during a period of abstinence if possible but not strictly required - the "targeted" or "as-needed" approach (taking naltrexone 1 hour before anticipated drinking) is supported by some clinical evidence.
</titration>

<titration slug="aud-vivitrol" author="parser-claude" title="Alcohol use disorder (Vivitrol)">
380 mg IM in the gluteal muscle every 4 weeks. Alternate sides each injection to reduce injection-site reaction risk. Patients should be tolerant to oral naltrexone first if possible (test dose 50 mg PO with naloxone challenge in OUD context, less critical in AUD).
</titration>

<titration slug="oud-induction" author="parser-claude" title="Opioid use disorder induction">
'''Required opioid-free interval before first dose:'''
- Short-acting opioids (heroin, oxycodone, hydrocodone): at least 7 days
- Long-acting opioids (methadone, sustained-release morphine, buprenorphine): at least 10-14 days
- Confirm absence of withdrawal symptoms before challenge

'''Naloxone challenge''' (recommended before first naltrexone dose): 0.4 mg naloxone IV or SC; observe 20-30 minutes for precipitated withdrawal. If no withdrawal, proceed with naltrexone. If withdrawal emerges, wait longer and retest.

'''Oral induction:''' 25 mg test dose; if tolerated, 50 mg/day starting next day.
'''Vivitrol induction:''' 380 mg IM after confirming opioid-free status. The 4-week duration of action means a single induction error commits the patient to weeks of inappropriate antagonist exposure.
</titration>

<titration slug="oud-maintenance" author="parser-claude" title="Opioid use disorder maintenance">
Oral: 50 mg PO once daily indefinitely. Vivitrol: 380 mg IM every 4 weeks indefinitely. Patient counseling on the opioid-blockade implications for analgesia is essential at each encounter.
</titration>

<titration slug="ldn-off-label" author="parser-claude" title="Low-dose naltrexone (off-label)">
1-4.5 mg/day oral compounded formulation (most commonly 3-4.5 mg at bedtime). Pharmacy preparation in liquid or compounded tablet form. Evidence base most established for fibromyalgia (small RCTs) and Crohn disease (small open-label trials); other indications remain investigational. Generally well-tolerated; modest sleep disturbance early in treatment is the most common reported effect.
</titration>

| effects =
* <effect ref="opioid-blockade" author="parser-claude">The therapeutic effect; renders subsequently administered opioids ineffective at therapeutic doses.</effect>
* <effect ref="precipitated-withdrawal" author="parser-claude">If naltrexone is administered to an opioid-tolerant patient with mu-receptor occupation by full or partial agonists, severe acute withdrawal results. THE central induction safety concern; the 7-14 day opioid-free requirement exists to prevent this.</effect>
* <effect ref="reduced-alcohol-craving" author="parser-claude">The therapeutic effect in AUD.</effect>
* <effect ref="nausea" author="parser-claude">Common at initiation; usually self-limited over 1-2 weeks.</effect>
* <effect ref="headache" author="parser-claude">Common.</effect>
* <effect ref="fatigue" author="parser-claude">Common, especially early.</effect>
* <effect ref="dizziness" author="parser-claude">Common.</effect>
* <effect ref="insomnia" author="parser-claude">Reported; conversely some patients report improved sleep.</effect>
* <effect ref="anxiety" author="parser-claude">Reported, especially early; may reflect blockade of endogenous opioid tone.</effect>
* <effect ref="depression" author="parser-claude">Mixed signal; some reports of dysphoria from endogenous-opioid blockade; other studies do not show consistent depressive signal. The 2010s data from Vivitrol OUD trials show no excess suicide risk.</effect>
* <effect ref="hepatotoxicity" author="parser-claude">Boxed warning; documented at supratherapeutic doses in the 1980s obesity research (doses up to 300 mg/day). At 50 mg/day therapeutic dose for AUD/OUD, hepatotoxicity is uncommon and typically reversible. LFT monitoring at baseline and periodically; substantial caution in active hepatitis or hepatic failure.</effect>
* <effect ref="injection-site-reaction" author="parser-claude">Common with Vivitrol; ranges from mild erythema and induration to rare severe reactions (cellulitis, abscess, tissue necrosis) requiring surgical evaluation.</effect>
* <effect ref="opioid-analgesia-failure" author="parser-claude">Patients on naltrexone CANNOT obtain analgesia from opioids at therapeutic doses; this is a central safety concern in acute trauma, post-surgical care, and palliative-care contexts. Patients must wear medical alert ID.</effect>

| pk_absorption = Oral peak plasma 1 hour; bioavailability variable (~5-40%) with mean ~5-10% for parent due to extensive first-pass; the 6-beta-naltrexol metabolite reaches higher systemic exposure and contributes most of the clinical effect. Food does not significantly affect absorption. Vivitrol IM produces an early plasma peak at 2-3 days followed by sustained microsphere-mediated release over the 4-week dosing interval, bypassing first-pass entirely.<ref name="vivitrol-label" />

| pk_distribution = Plasma protein binding ~21% (relatively low). Volume of distribution ~16 L/kg. Crosses blood-brain barrier readily (required for therapeutic effect). Crosses placenta in small amounts; excreted in breast milk at low concentrations.<ref name="vivitrol-label" />

| pk_metabolism = Primary metabolism via cytoplasmic dihydrodiol dehydrogenase to 6-beta-naltrexol (active mu-antagonist, longer half-life than parent and major contributor to clinical effect). Minor CYP-mediated metabolism produces 2-hydroxy-3-methoxy-6-beta-naltrexol and other inactive metabolites. Importantly, naltrexone is NOT a significant CYP3A4 or CYP2D6 substrate, so the medicine has a notably clean drug-interaction profile - distinguishing from methadone and buprenorphine. Both parent and metabolite are conjugated with glucuronic acid for excretion.<ref name="vivitrol-label" />

| pk_elimination = Predominantly renal as glucuronide conjugates (~70%); fecal ~30%. Half-life parent ~4 hours, 6-beta-naltrexol ~13 hours after oral dosing. Vivitrol exhibits a terminal half-life of 5-10 days with sustained microsphere-mediated release producing therapeutic plasma concentrations throughout the 4-week dosing interval.<ref name="vivitrol-label" />

| pharmacodynamics = Naltrexone is a pure opioid receptor antagonist (no intrinsic activity at any opioid receptor) with high mu-opioid receptor affinity (Ki ~0.1-1 nM) and substantial kappa-opioid receptor affinity (Ki ~5-10 nM); delta affinity is lower. The mu-receptor blockade is the basis for both OUD efficacy (blocks reinforcing effect of subsequent opioid use) and AUD efficacy (blocks the endogenous-opioid contribution to alcohol-induced reward). The kappa-receptor antagonism may contribute additional efficacy in alcohol craving and is the subject of ongoing research in stress-induced relapse.

6-beta-naltrexol, the major active metabolite, has similar receptor pharmacology to the parent and is the dominant contributor to net pharmacological effect given its higher systemic exposure after oral dosing.

In the LDN paradigm, the proposed mechanism is transient mu-receptor blockade producing rebound elevation in endogenous opioid tone; supplementary proposed mechanisms include glial cell modulation, TLR4 signaling effects, and other non-opioid actions. These mechanisms remain hypothetical; the LDN evidence base is modest and growing.

| interactions = <pharmaInteractions/>

The clinically important interactions for prescribers:

* '''Opioid analgesics (mu-agonists).''' Naltrexone BLOCKS the analgesic and respiratory-depressant effects of all mu-opioid analgesics at therapeutic doses. Patients on naltrexone who require opioid analgesia for acute pain, post-surgical care, or trauma management need specialist consultation; options include holding naltrexone (only feasible for oral; Vivitrol cannot be reversed), using very high opioid doses to overcome blockade (risks delayed respiratory depression as naltrexone wears off), or using non-opioid analgesia. Patients should wear medical alert ID indicating naltrexone treatment.
* '''Mixed agonist-antagonists (buprenorphine, nalbuphine, butorphanol).''' Naltrexone precipitates withdrawal in patients on these medications. Buprenorphine in particular must be discontinued and a 7-14 day washout completed before naltrexone induction.
* '''Antidiarrheal opioids (loperamide, diphenoxylate).''' Therapeutic effect blocked; less clinically critical.
* '''Cough/cold medications containing codeine, hydrocodone, dextromethorphan.''' Effects blocked; less critical except for DXM-containing products where dissociative effect would also be blocked.
* '''Disulfiram + naltrexone.''' Sometimes co-prescribed in AUD; LFT monitoring more frequent due to combined hepatotoxicity signal.
* '''Acamprosate + naltrexone.''' Sometimes co-prescribed in AUD; COMBINE trial showed no clear synergy but no antagonism either.
* '''No significant CYP-mediated interactions.''' Naltrexone is metabolized by a non-CYP pathway (dihydrodiol dehydrogenase), so the typical CYP3A4 and CYP2D6 inhibitor/inducer lists do not significantly affect naltrexone exposure - a clinically distinguishing feature from methadone and buprenorphine.

| pregnancy_details = Pregnancy data on naltrexone are limited but accumulating. Observational signals do not show clear teratogenicity or major-malformation excess in either oral or depot-naltrexone-exposed pregnancies. The Australian naltrexone-implant cohort (which differs from Vivitrol but is the largest registry of depot-naltrexone-in-pregnancy data) showed comparable maternal-fetal outcomes to background pregnancy populations.

The clinical decision in pregnancy is challenging:
- Untreated OUD or AUD carries substantial maternal-fetal risk (overdose, premature labor, fetal alcohol spectrum disorder)
- Abrupt discontinuation of naltrexone-MOUD can precipitate opioid relapse with overdose risk in patients whose tolerance has decreased during MOUD treatment
- Continuing naltrexone-MOUD through pregnancy avoids those risks but commits to monitoring without strong safety data
- Switching to methadone or buprenorphine MOUD requires precipitated-withdrawal navigation in the opposite direction

ACOG (Committee Opinion 711) and ASAM guidance has historically favored methadone or buprenorphine as MOUD in pregnancy. Recent guidance recognizes naltrexone-MOUD as an acceptable option for patients already maintained on it. Specialist consultation is appropriate.{{citation needed}}

Breast milk: naltrexone and 6-beta-naltrexol both pass into breast milk at low concentrations; M/P ratio approximately 0.7; relative infant dose <2% of maternal weight-adjusted dose. Breastfeeding is generally considered acceptable in stable maintained patients, though specific guidance varies.

| monitoring = Baseline before initiation:
* Liver function tests (the boxed hepatotoxicity warning at supratherapeutic doses; clinical caution in active hepatitis or hepatic failure)
* Pregnancy status in females of reproductive potential
* Opioid-free interval confirmation (7-14 days, see Induction titration block) - the central OUD safety pivot
* Naloxone challenge (recommended for OUD induction): 0.4 mg IV/SC naloxone; observe 20-30 min for precipitated withdrawal
* Acute hepatitis or hepatic failure: contraindicated until stabilized
* Documentation of medical alert ID requirement for the patient

Ongoing:
* LFTs at baseline + at 3 months + every 6-12 months (less intensive than the boxed warning might suggest at therapeutic 50 mg/day dose)
* Adherence assessment (oral): self-report + collateral; consider switching to Vivitrol if oral adherence problematic
* Injection-site assessment at each Vivitrol injection
* Pregnancy testing in females of reproductive potential at intake + as clinically indicated
* PDMP review at intake + regularly per state requirements (the antagonist mechanism means PDMP review is less acute than for agonists but still part of comprehensive OUD care)
* For AUD: drinking-pattern assessment using validated tools (AUDIT-C, TLFB)

| counseling = '''Opioid blockade and acute pain.''' While you are on naltrexone, opioids will not work for pain relief. If you have surgery, injury, or any acute pain that would normally require opioid analgesia, your provider needs to know you are on naltrexone immediately. WEAR MEDICAL ALERT ID indicating naltrexone treatment.

'''Opioid-free interval before starting (OUD).''' You must be completely off opioids for 7-14 days before your first naltrexone dose, longer for methadone or buprenorphine. Starting naltrexone too soon will cause severe acute withdrawal that lasts hours.

'''Reduced opioid tolerance.''' While on naltrexone you lose tolerance to opioids. If you stop naltrexone and resume opioid use, the dose that previously felt routine may now be a fatal overdose dose. Keep naloxone (Narcan) available.

'''Vivitrol depot is one-way (one month).''' Once Vivitrol is injected, the blockade lasts approximately 4 weeks and cannot be reversed. Plan ahead for surgical or dental procedures.

'''Hepatotoxicity.''' Although less concerning at the therapeutic dose, naltrexone can affect the liver. Report yellow skin or eyes, dark urine, right upper quadrant pain, or unusual fatigue. We will check liver tests periodically.

'''Alcohol use (AUD).''' Naltrexone reduces craving and the rewarding effect of alcohol, but does NOT prevent intoxication or make alcohol "safe." Driving impaired remains illegal and dangerous. The medicine works best paired with behavioral treatment, support groups, and lifestyle change.

'''Pregnancy and breastfeeding.''' If you become pregnant on naltrexone, contact your prescriber promptly. The decision to continue naltrexone vs switch to methadone/buprenorphine in pregnancy is individualized.

'''Naloxone awareness.''' Even with naltrexone, household members should have naloxone available; tolerance loss during treatment means accidental overdose risk if patient deviates.

'''Vivitrol injection-site care.''' The injection site may be sore or swollen for several days; this is expected. Spreading redness, fever, severe pain, or drainage requires immediate evaluation - rare cases of cellulitis, abscess, and tissue necrosis have been reported.

| anecdotes =
| seealso = [[Methadone]], [[Buprenorphine]], [[Acamprosate]], [[Disulfiram]], [[Naloxone]]
| references = <references/>
}}

[[Category:Opioid antagonists]]
[[Category:AUD medicines]]
[[Category:OUD medicines]]
[[Category:Medicines]]

Buprenorphine

2026-05-31T17:11:57Z

Maintenance script: Create Buprenorphine medicine page (partial agonist MOUD + pain formulations)

{{MedTemplate
| generic = Buprenorphine
| brand = Subutex (sublingual; discontinued in US but generic available), Suboxone (buprenorphine + naloxone sublingual film/tablet), Sublocade (monthly SC depot for MOUD), Probuphine (6-month subdermal implant, discontinued 2020), Belbuca (buccal film for pain), Butrans (weekly transdermal patch for pain), Buprenex (IV/IM for acute pain)
| structure =
| classes = [[:Category:Opioid analgesics|Opioid analgesic (partial mu-agonist, kappa antagonist)]], [[:Category:Schedule III controlled substances|Schedule III controlled substance]]
| uses = <vote slug="opioid-use-disorder-bupe-use">Opioid use disorder MOUD (FDA; office-based since 2002)</vote>, <vote slug="moderate-severe-pain-bupe-use">Moderate to severe pain (FDA, Belbuca buccal film + Butrans transdermal patch)</vote>, <vote slug="acute-pain-bupe-use">Acute pain (FDA, Buprenex IV/IM)</vote>, <vote slug="chronic-pain-multimodal-bupe-use">Chronic pain in opioid-tolerant patients with opioid-induced hyperalgesia (off-label rotation)</vote>
| starting_dose = MOUD induction (office-based): traditional approach 2-4 mg sublingual after withdrawal score ≥COWS 11-13, then 4-8 mg by end of day 1; titrate to maintenance 8-24 mg/day (typical effective range 16 mg). Bernese microdosing method (avoid precipitated withdrawal): cross-titrate from full agonist with sub-mg buprenorphine doses while continuing full agonist, escalating buprenorphine over 7-10 days. Belbuca buccal pain: 75 mcg-150 mcg every 12 hours; titrate. Butrans transdermal pain: 5 mcg/h patch weekly; titrate. Sublocade depot: 300 mg SC monthly x 2, then 100 mg monthly maintenance.
| preparations = Sublingual tablets (Subutex generic) 2, 8 mg; sublingual films (Suboxone) 2/0.5, 4/1, 8/2, 12/3 mg buprenorphine/naloxone; Sublocade SC injection 100 mg, 300 mg pre-filled; Belbuca buccal films 75, 150, 300, 450, 600, 750, 900 mcg; Butrans transdermal patches 5, 7.5, 10, 15, 20 mcg/h (weekly); Buprenex injection 0.3 mg/mL
| fda_max = MOUD: typical effective max 24 mg/day sublingual (doses above offer limited additional mu-occupancy due to ceiling). Pain (Belbuca): 900 mcg every 12 hours.
| pill_id =
| routes = Sublingual (primary for MOUD), buccal (Belbuca for pain), transdermal (Butrans), SC depot (Sublocade), IV/IM (Buprenex). Oral swallowed: very low bioavailability due to first-pass; not therapeutic.
| onset = Sublingual analgesic effect 30-60 minutes; MOUD craving suppression within hours; Butrans patch steady-state in 3 days.
| duration = MOUD: 24-72 hours per sublingual dose (long; permits every-other-day or three-times-weekly dosing in stable patients); Butrans patch: 7 days; Sublocade depot: 28+ days; Buprenex IV/IM: 6-8 hours.
| halflife = Buprenorphine sublingual: 24-42 hours (long, contributes to extended dosing intervals). Norbuprenorphine (active metabolite, weaker mu-agonist): 24-48 hours.<ref name="suboxone-label">FDA Prescribing Information, Suboxone (buprenorphine/naloxone sublingual film), Indivior, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022410s029lbl.pdf</ref>
| bioavailability = ~30% (sublingual; the primary therapeutic route); ~10-20% (oral swallowed, low due to first-pass); ~50% (buccal Belbuca); transdermal Butrans bypasses first-pass.<ref name="suboxone-label" />
| pregnancy = Buprenorphine is an increasingly preferred MOUD option in pregnancy alongside methadone; the MOTHER trial (Jones et al 2010 NEJM PMID 21142534) showed comparable maternal outcomes and somewhat milder neonatal abstinence syndrome (NAS) with buprenorphine compared with methadone, supporting either as first-line. Mono-buprenorphine (Subutex) was historically preferred over the naloxone combination (Suboxone) during pregnancy due to naloxone-passage concerns; modern data suggest the combination is also safe and many programs no longer make the distinction. NAS is expected with chronic third-trimester exposure but is typically milder than methadone-NAS. ACOG (Committee Opinion 711) and ASAM endorse buprenorphine as first-line.{{citation needed}}
| legal = [[USLegal:Schedule III|Schedule III controlled substance]] in US (lower than methadone's Schedule II, reflecting the partial-agonism ceiling-effect safety profile). The DEA X-waiver requirement for buprenorphine prescribing for OUD was abolished by the Mainstreaming Addiction Treatment (MAT) Act passed December 2022 and implemented in 2023; any DEA-licensed prescriber can now prescribe buprenorphine for OUD without separate waiver, dramatically expanding access. Carries the opioid class '''Boxed Warning''' for respiratory depression with concurrent benzodiazepines or other CNS depressants, addiction/abuse/misuse, and NAS.<ref name="suboxone-label" />
| mechanism = <vote slug="buprenorphine-mech-claim">'''Partial mu-opioid receptor agonist''' with high mu-receptor affinity and slow dissociation kinetics. The partial agonism produces a '''ceiling effect''' on respiratory depression (the central distinguishing safety feature from full mu-agonists like methadone, morphine, fentanyl) and on euphoria. The slow dissociation means buprenorphine '''displaces''' other opioids from the mu-receptor (precipitated withdrawal risk in opioid-tolerant patients given buprenorphine while still on full agonists) AND '''blocks''' the effect of subsequently administered opioids (the basis for MOUD-mediated overdose protection). '''Kappa-opioid receptor antagonism''' may contribute to antidepressant and dysphoria-blocking effects. Modest NOP/ORL1 (nociceptin) receptor agonism contributes to the pharmacological profile.</vote> Buprenorphine is a CYP3A4 substrate; norbuprenorphine is the principal active metabolite (also a weak mu-agonist + NOP agonist; substantial accumulation contributes to clinical effect). QTc prolongation is modest, less than methadone, but present and clinically meaningful in overdose.<ref name="suboxone-label" />
| intro = Buprenorphine is a partial mu-opioid receptor agonist with kappa-opioid antagonist activity, used primarily as a Schedule III medication for opioid use disorder (MOUD) and secondarily for moderate-to-severe pain. It was synthesized in 1969 at Reckitt and Colman (now Indivior) by John Lewis and colleagues, originally developed as a more potent analgesic alternative to morphine. The 1995 demonstration that buprenorphine could be used to treat opioid use disorder in an office-based outpatient setting (rather than requiring methadone-style Opioid Treatment Program infrastructure) made buprenorphine the foundation of expanded MOUD access in the United States after FDA approval for OUD in 2002. The Drug Addiction Treatment Act of 2000 (DATA 2000) established the X-waiver framework that governed buprenorphine prescribing for OUD until the Mainstreaming Addiction Treatment Act of December 2022 abolished the waiver requirement; as of 2023 any DEA-licensed prescriber can prescribe buprenorphine for OUD. Buprenorphine's defining pharmacological feature is its partial mu-agonism with a ceiling effect on respiratory depression - the same dose that fully occupies the mu-receptor produces less respiratory depression than a full agonist would, substantially improving the overdose-safety profile relative to methadone.

| history = Buprenorphine was synthesized at the British pharmaceutical company Reckitt and Colman (now Indivior) in 1969 by John Lewis and colleagues, initially as a research compound (designated Reckitt's RX 6029-M) intended as a more potent analgesic than morphine. The partial-agonist character was recognized early in pharmacology studies and was initially considered a drawback for analgesic potency relative to full agonists.

FDA approval as Buprenex (IV/IM) for moderate-to-severe acute pain was granted in 1981. The compound was Schedule V at this time, reflecting its low diversion potential in injectable form.

The pivot to MOUD came from a series of clinical trials in the 1990s demonstrating buprenorphine's efficacy in opioid use disorder. Walter Ling, Eric Strain, and others established that buprenorphine could be administered sublingually with weekly or less-frequent dosing in stable patients, contrasting with methadone's daily-witnessed-dosing OTP model.{{citation needed}}

The Drug Addiction Treatment Act of 2000 (DATA 2000) created the X-waiver framework, allowing physicians to obtain a separate DEA waiver to prescribe buprenorphine for OUD in office-based settings outside the OTP infrastructure. FDA approval of Subutex (buprenorphine sublingual) and Suboxone (buprenorphine/naloxone sublingual) for MOUD followed in 2002. The naloxone in Suboxone is poorly absorbed sublingually (the intended therapeutic route) but is well-absorbed if the tablet is injected, providing a deterrent against diversion to injection.

Buprenorphine was rescheduled from V to III in 2002, reflecting recognition of its abuse potential in MOUD-naive populations.

The Mainstreaming Addiction Treatment (MAT) Act, passed as part of the Consolidated Appropriations Act 2023 in December 2022 and implemented in 2023, abolished the DEA X-waiver requirement. Any DEA-licensed prescriber can now prescribe buprenorphine for OUD without separate certification, removing a major barrier that had been criticized as artificially constraining MOUD access.

Long-acting formulations have expanded the buprenorphine treatment landscape: Probuphine (6-month subdermal implant) was approved 2016 and discontinued 2020; Sublocade (monthly SC depot) was approved 2017 and remains in use; Brixadi (weekly or monthly SC depot) was approved 2023.

| indications = <problem ref="opioid-use-disorder" author="parser-claude">Opioid use disorder; the dominant MOUD option for office-based treatment (no OTP dispensing requirement). Effective for craving suppression, withdrawal management, and overdose-risk reduction via mu-receptor blockade.</problem>
<problem ref="moderate-severe-pain" author="parser-claude">Moderate to severe pain via specific formulations (Belbuca buccal film, Butrans transdermal patch, Buprenex IV/IM).</problem>
<problem ref="chronic-pain" author="parser-claude">Chronic pain in opioid-tolerant patients (off-label rotation), particularly when opioid-induced hyperalgesia is suspected; the partial agonism may attenuate hyperalgesia.</problem>

| dosing = <titration slug="moud-traditional-induction" author="parser-claude" title="MOUD induction (traditional approach)">
Patient must be in mild-to-moderate withdrawal before first dose to avoid precipitated withdrawal (COWS score ≥11-13, typically 12-24 hours after last short-acting opioid, 24-48 hours after last long-acting opioid).

Day 1: 2-4 mg sublingual; observe 60-90 minutes for response and any precipitated withdrawal. Second dose 4 mg if comfortable. Total day 1 typically 8-16 mg.
Day 2: Titrate to comfort, typically 8-16 mg.
Day 3+: Maintenance 8-24 mg/day; typical effective range 16 mg/day.
</titration>

<titration slug="moud-bernese-microdosing" author="parser-claude" title="MOUD induction (Bernese microdosing / micro-induction)">
Indicated when patient cannot tolerate withdrawal-period prior to traditional induction, or when transitioning from high-dose full-agonist therapy (e.g., methadone, fentanyl). Patient continues full agonist while starting sub-mg buprenorphine doses, gradually escalating buprenorphine over 7-10 days while tapering off the full agonist.

Sample schedule (variations exist): Day 1: 0.5 mg buprenorphine BID. Day 2-3: 1 mg BID. Day 4-5: 2 mg BID. Day 6-7: 4 mg BID. Day 8+: stop full agonist, continue buprenorphine 8-24 mg/day.

The Bernese approach largely avoids precipitated withdrawal but requires careful patient selection and monitoring.
</titration>

<titration slug="moud-maintenance" author="parser-claude" title="MOUD maintenance">
Typical effective dose 8-24 mg/day sublingual. Doses above 24 mg/day produce limited additional mu-receptor occupancy due to the partial-agonist ceiling. Three-times-weekly dosing (e.g., Monday/Wednesday/Friday) is effective in stable patients due to the long half-life and slow receptor dissociation. Sublocade SC depot offers monthly dosing for patients with adherence challenges.
</titration>

<titration slug="pain-belbuca" author="parser-claude" title="Pain (Belbuca buccal film)">
Start 75 mcg every 12 hours x 4 days; titrate to 150 mcg q12h. Max 900 mcg q12h. For chronic-pain dosing, NOT MOUD.
</titration>

<titration slug="pain-butrans" author="parser-claude" title="Pain (Butrans transdermal patch)">
Start 5 mcg/h patch weekly. Titrate up to 20 mcg/h weekly (max). For chronic-pain dosing in opioid-naive or low-tolerance patients.
</titration>

| effects =
* <effect ref="analgesia" author="parser-claude">Therapeutic effect from partial mu-agonism plus possibly kappa antagonism.</effect>
* <effect ref="craving-suppression" author="parser-claude">The MOUD-specific therapeutic effect; mu-receptor occupancy + slow dissociation block opioid craving and withdrawal.</effect>
* <effect ref="precipitated-withdrawal" author="parser-claude">If buprenorphine is given to an opioid-tolerant patient still substantially mu-receptor-occupied with a full agonist, buprenorphine displaces the full agonist and the receptor is now only partially activated; the abrupt drop in mu-signaling produces severe withdrawal. THE central induction safety concern. Avoided by waiting for moderate spontaneous withdrawal before first dose, or by Bernese microdosing.</effect>
* <effect ref="constipation" author="parser-claude">Less severe than with full agonists but still present.</effect>
* <effect ref="sedation" author="parser-claude">Mild; less than full agonists at equipotent dose due to partial agonism.</effect>
* <effect ref="nausea" author="parser-claude">Common at induction; usually self-limited.</effect>
* <effect ref="sweating" author="parser-claude">Less than methadone but present.</effect>
* <effect ref="dental-caries" author="parser-claude">Sublingual films and tablets associated with elevated dental caries risk (xerostomia + acidic pH of dissolved film). FDA added warning January 2022. Counseling: rinse mouth with water after dissolution, brush teeth, dental visits.</effect>
* <effect ref="hypogonadism" author="parser-claude">Long-term opioid exposure suppresses HPG axis; less severe than full agonists but present.</effect>
* <effect ref="respiratory-depression" author="parser-claude">Present but with CEILING effect; full mu-agonist overdose lethality reduced. Combination with benzodiazepines, alcohol, or other CNS depressants removes the ceiling protection - this is the only combination scenario where buprenorphine overdose mortality approaches full-agonist levels.</effect>
* <effect ref="qt-prolongation" author="parser-claude">Modest; clinically less concerning than methadone but present.</effect>

| pk_absorption = Sublingual ~30% bioavailability (primary therapeutic route). Oral swallowed bioavailability poor (~10-20%) due to extensive first-pass metabolism; not used therapeutically. Buccal (Belbuca) ~50% bioavailability. Transdermal (Butrans) bypasses first-pass entirely; steady-state in ~3 days.<ref name="suboxone-label" />

| pk_distribution = Plasma protein binding ~96% (alpha-1-acid glycoprotein primarily). Highly lipophilic; large volume of distribution. Crosses blood-brain barrier readily and placenta in moderate amounts. Excreted in breast milk at low levels generally compatible with breastfeeding in stable maintained patients.<ref name="suboxone-label" />

| pk_metabolism = Hepatic N-dealkylation primarily via CYP3A4 to norbuprenorphine (active metabolite, weaker mu-agonist + NOP agonist). Also glucuronidation by UGT1A1, UGT1A3, UGT2B7. Norbuprenorphine accumulates with chronic dosing and contributes substantially to clinical effect. Buprenorphine itself is not a clinically significant CYP3A4 inhibitor or inducer.<ref name="suboxone-label" />

| pk_elimination = Primarily fecal/biliary as glucuronide conjugates of parent and metabolites (~70%); urinary ~30%. Half-life sublingual 24-42 hours; norbuprenorphine 24-48 hours. The long half-life supports every-other-day or three-times-weekly dosing in stable MOUD patients.<ref name="suboxone-label" />

| pharmacodynamics = Buprenorphine is a partial mu-opioid agonist with high mu-receptor affinity (Ki ~0.2 nM) and slow dissociation kinetics (receptor residency time hours rather than minutes). The high affinity means buprenorphine displaces lower-affinity opioids from the receptor (the precipitated-withdrawal risk in opioid-tolerant patients) and blocks subsequently administered opioids (the MOUD mu-receptor blockade benefit). The partial agonism means receptor saturation produces less mu-signaling than a full agonist would; this is the basis for the ceiling effect on respiratory depression that distinguishes buprenorphine safety from methadone and other full agonists.

Buprenorphine is also a kappa-opioid receptor antagonist (which may contribute to antidepressant effect and may attenuate stress-induced relapse in OUD) and a partial agonist at the NOP/ORL1 (nociceptin) receptor. The combined receptor profile is distinct from morphine-class full agonists and contributes to the medicine's unique clinical profile.

Norbuprenorphine, the major active metabolite, is itself a partial mu-agonist with lower potency than parent, but accumulates and contributes substantially to net pharmacological effect at steady state.

| interactions = <pharmaInteractions/>

The clinically important interactions for prescribers:

* '''Benzodiazepines + buprenorphine (boxed warning).''' The ceiling effect on respiratory depression is lost when combined with benzodiazepines, alcohol, or other CNS depressants. Concurrent benzo + buprenorphine deaths constitute a substantial fraction of MOUD population mortality. The FDA explicitly does NOT recommend withholding buprenorphine MOUD from patients on benzodiazepines (untreated OUD is more dangerous than benzo-buprenorphine combination), but counseling and benzodiazepine taper should be pursued where feasible.
* '''Full mu-agonist opioids.''' Buprenorphine blocks full-agonist effect at the mu-receptor. Patients on buprenorphine MOUD who require opioid analgesia for acute pain (e.g., post-surgical) need specialist consultation; options include continuing buprenorphine + adding short-acting opioid above the buprenorphine "block," or briefly holding buprenorphine, or using non-opioid alternatives.
* '''CYP3A4 strong inhibitors.''' Ritonavir, clarithromycin, ketoconazole, itraconazole: increase buprenorphine exposure modestly; clinical adjustment usually not required given partial-agonist safety margin.
* '''CYP3A4 strong inducers.''' Rifampin, phenytoin, phenobarbital, carbamazepine, efavirenz, St John's wort: reduce buprenorphine exposure; may need dose increase.
* '''Mixed agonist-antagonists (nalbuphine, butorphanol).''' Precipitate withdrawal in buprenorphine-maintained patients.
* '''Pure antagonists (naloxone, naltrexone).''' Naloxone reverses buprenorphine respiratory depression but high doses or continuous infusion are typically needed due to the high mu-receptor affinity and slow dissociation. Naltrexone administration to a buprenorphine-maintained patient precipitates withdrawal.
* '''QT-prolonging medications.''' Modest additive effect; clinically less concerning than methadone.
* '''Serotonergic medications.''' Buprenorphine has weak SRI activity; serotonin syndrome risk with strong serotonergic medications exists but is less commonly observed than with tramadol or full agonists like meperidine.

| pregnancy_details = Buprenorphine is endorsed by ACOG (Committee Opinion 711) and ASAM as first-line MOUD in pregnancy alongside methadone. The MOTHER trial (Jones HE et al, N Engl J Med 2010, PMID 21142534) compared buprenorphine vs methadone in pregnant women with OUD and found comparable maternal outcomes with somewhat milder neonatal abstinence syndrome (NAS) and shorter NAS treatment duration in the buprenorphine group. The mono-buprenorphine formulation (Subutex generic) was historically preferred in pregnancy over the naloxone combination (Suboxone) due to theoretical concerns about naloxone passage; modern data support both formulations as safe and many programs no longer distinguish.

Buprenorphine clearance may modestly increase during pregnancy; dose adjustment is sometimes needed in the third trimester. Buprenorphine is excreted in breast milk at low concentrations (M/P ratio ~1, but absolute infant exposure is low) and breastfeeding is generally encouraged in stable maintained patients per ACOG and the Academy of Breastfeeding Medicine.

NAS expected with chronic buprenorphine exposure during pregnancy; typically milder and shorter-duration than methadone-NAS; managed in NICU with non-pharmacologic supportive care + opioid taper (morphine or methadone) for severe cases.

| monitoring = '''Boxed warning items:''' respiratory depression (especially with concurrent benzo/CNS depressant), addiction/abuse/misuse, NAS.

'''Specific monitoring:'''
* Pre-induction OUD assessment + COWS scoring before first dose (to confirm withdrawal state, avoid precipitated withdrawal)
* LFTs at baseline + every 6-12 months (buprenorphine hepatotoxicity is rare but documented; monitor especially in hepatitis C coinfected patients)
* PDMP review at intake + regularly per state requirements
* Urine drug screening per program protocol
* Dental examination at intake + annually (FDA 2022 warning regarding sublingual-film dental caries)
* Pregnancy testing in females of reproductive potential at intake; counseling re continuation of MOUD during pregnancy

| counseling = '''Precipitated withdrawal at induction.''' If you take buprenorphine while you still have substantial opioid in your system, you can have severe sudden withdrawal. We will time your first dose to when you are already in moderate withdrawal (or use a microdosing protocol to avoid this).

'''Benzodiazepines and alcohol.''' Buprenorphine has a "ceiling" on respiratory depression that makes it safer than full opioids - BUT this ceiling is lost when you combine buprenorphine with benzodiazepines or alcohol. The combination can be fatal. Talk with your prescriber about any benzodiazepine, sedative, or alcohol use.

'''Acute pain.''' If you need pain medicine for surgery or injury while on buprenorphine, your provider needs to know you are on buprenorphine. The buprenorphine blocks other opioids; managing acute pain requires specialist guidance.

'''Other opioids.''' Buprenorphine blocks the effect of other opioids. If you try to use heroin or other opioids on buprenorphine, you typically won't feel them - this is part of how buprenorphine protects you. Trying to overcome the block with very high doses can produce overdose when the buprenorphine eventually wears off (after stopping treatment).

'''Sublingual administration.''' Place the film or tablet under the tongue and let it dissolve fully (usually 5-10 minutes). Do NOT swallow it - swallowed buprenorphine has very low absorption. Do NOT chew or talk while it dissolves. Rinse your mouth with water after to protect your teeth (FDA dental warning 2022).

'''Driving and machinery.''' Do not drive after the first dose or after any dose increase until you know how buprenorphine affects you. Once stable on a steady dose, most patients can drive safely.

'''Pregnancy.''' Buprenorphine is one of the safest MOUD options during pregnancy. If you become pregnant, do NOT stop abruptly - this can harm the pregnancy. Talk with your provider.

'''Naloxone awareness.''' Keep naloxone (Narcan) available at home; educate household members. Naloxone reverses opioid overdose. Because buprenorphine has high mu-receptor affinity, multiple naloxone doses may be needed; emergency care is essential.

'''Discontinuation.''' Buprenorphine withdrawal is typically milder than full-agonist withdrawal but can be prolonged due to the long half-life. Slow taper recommended; do not stop abruptly after long-term use.

| anecdotes =
| seealso = [[Methadone]], [[Naltrexone]], [[Naloxone]], [[Morphine]], [[Tramadol]]
| references = <references/>
}}

[[Category:Opioid analgesics]]
[[Category:Schedule III controlled substances]]
[[Category:Medicines]]

Methadone

2026-05-31T17:11:55Z

Maintenance script: Create Methadone medicine page (full mu-agonist MOUD + chronic pain)

{{MedTemplate
| generic = Methadone
| brand = Dolophine, Methadose, Diskets (oral dispersible tablets for OTPs)
| structure =
| classes = [[:Category:Opioid analgesics|Opioid analgesic (full mu-agonist)]], [[:Category:NMDA antagonists|NMDA receptor antagonist]], [[:Category:Schedule II controlled substances|Schedule II controlled substance]]
| uses = <vote slug="chronic-pain-methadone-use">Chronic pain (FDA, when alternative treatments are inadequate)</vote>, <vote slug="opioid-use-disorder-use">Opioid use disorder MOUD (FDA; OTP-dispensed in US)</vote>, <vote slug="neonatal-abstinence-use">Neonatal abstinence syndrome (off-label adjunct in NICU)</vote>
| starting_dose = Pain (opioid-naive): 2.5-5 mg PO every 8-12 hours; titrate cautiously (long half-life, accumulation over days). MOUD induction (OTP): 20-30 mg on day 1, increase by 5-10 mg per day to symptomatic comfort; maintenance typically 60-120 mg/day in single daily dose. Conversions from other opioids use a NON-LINEAR ratio (much lower than published equianalgesic tables suggest); consult specialist guidance
| preparations = Tablets 5, 10, 40 mg (40 mg dispersible restricted to OTPs); oral concentrate 10 mg/mL; oral solution 1, 2, 10 mg/mL; injection 10 mg/mL
| fda_max = No formal hard ceiling; in MOUD maintenance, doses typically remain at or below 120 mg/day with higher doses reserved for documented under-treatment after careful clinical assessment
| pill_id =
| routes = Oral (primary), IV, IM, SC, sublingual; rectal off-label
| onset = Oral analgesic effect 30-60 minutes; opioid-withdrawal suppression 30 minutes (oral); IV ~10 minutes
| duration = Analgesic effect 4-8 hours (much shorter than half-life would suggest, due to receptor kinetics); MOUD effect (opioid withdrawal suppression) 24-36 hours per single daily dose
| halflife = Highly variable: 8-59 hours (mean ~22-24 hours; range due to CYP genetic variation + age + comorbidities). The discordance between long elimination half-life and shorter analgesic duration is the central dose-titration problem - patients can have inadequate pain control while methadone is still accumulating dangerously toward steady state.<ref name="dolophine-label">FDA Prescribing Information, Dolophine (methadone hydrochloride), Roxane/various, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/006134s039lbl.pdf</ref>
| bioavailability = ~70-85% (oral, high relative to other opioids)
| pregnancy = Methadone is a standard of care for opioid use disorder during pregnancy; the alternative (untreated OUD or unstable supply) carries substantially greater risks to mother and fetus. Neonatal abstinence syndrome (NAS) is expected with chronic third-trimester exposure; managed with non-pharmacologic supportive care + opioid taper (morphine or methadone) in NICU as needed. Buprenorphine is increasingly used as an alternative in pregnancy MOUD with comparable maternal outcomes and somewhat milder NAS. ACOG and ASAM endorse both.{{citation needed}}
| legal = [[USLegal:Schedule II|Schedule II controlled substance]] in US. For chronic pain: prescribed by any DEA-licensed prescriber. For opioid use disorder: dispensing restricted to FDA-certified Opioid Treatment Programs (OTPs) federally (the DEA X-waiver for buprenorphine was abolished in 2023 but the OTP restriction for methadone MOUD continues, with limited recent expansion of take-home flexibility). Carries the opioid class '''Boxed Warning''' for addiction, abuse, misuse, life-threatening respiratory depression, neonatal abstinence syndrome, and life-threatening QT prolongation; the QT-prolongation warning is methadone-specific in scope.<ref name="dolophine-label" />
| mechanism = <vote slug="methadone-mech-claim">'''Full mu-opioid receptor agonist''' (similar intrinsic activity to morphine but with longer receptor residency); '''NMDA receptor antagonist''' (the NMDA blockade is the distinguishing mechanistic feature that may contribute to its efficacy in opioid-tolerant patients and in chronic neuropathic pain); weak serotonin and norepinephrine reuptake inhibition. The long elimination half-life with relatively short analgesic duration produces a clinically distinctive accumulation pattern: pain may not be controlled at a given dose while drug is still building toward steady state over 5-7 days, creating dose-titration danger for inexperienced prescribers. Methadone is a CYP3A4 and CYP2B6 substrate, with minor CYP2D6 and CYP2C19 contributions; this complex metabolism produces highly variable interindividual half-lives and a substantial drug-interaction burden.</vote> '''QTc prolongation''' via hERG potassium channel block is dose-dependent and clinically meaningful; the FDA black box warning specifically calls for baseline and follow-up ECG monitoring at higher doses (typically beyond 100 mg/day) and in patients with cardiac risk factors or concurrent QT-prolonging medications.<ref name="dolophine-label" />
| intro = Methadone, marketed as Dolophine and Methadose, is a long-acting synthetic full mu-opioid receptor agonist with NMDA antagonist activity, used for chronic pain management and as the original medication for opioid use disorder (MOUD). It was synthesized in Germany during World War II by chemists at IG Farben (Adolf Eisleb, Otto Schaumann, Max Bockmuhl) as Hoechst 10820, originally called Polamidon and intended as an analgesic to address wartime morphine shortages. It reached the United States after the war via Eli Lilly and was FDA-approved in 1947. The 1965 Dole and Nyswander studies at Rockefeller University established methadone maintenance as an effective treatment for heroin addiction, founding the modern MOUD field. Methadone differs from short-acting opioids in three pharmacologically important ways: a very long elimination half-life (8-59 hours, mean ~24 hours) that supports once-daily dosing for OUD but creates accumulation risk in pain titration; NMDA antagonist activity that may attenuate opioid tolerance and contribute to efficacy in neuropathic pain; and dose-dependent QTc prolongation that requires cardiac monitoring at higher doses.

| history = The compound that became methadone was synthesized in 1937-1939 at IG Farben in Hochst (now part of Sanofi) by Adolf Eisleb, Otto Schaumann, and Max Bockmuhl, originally as Hoechst 10820. The synthesis was driven by Germany's wartime morphine supply concerns and was intended as a synthetic analgesic alternative. The compound was tested clinically in Germany under the name Polamidon during World War II. After the war, the United States Department of Commerce Technical Industrial Intelligence Committee inventoried the German pharmaceutical research; methadone reached the United States via Eli Lilly, which received the patents and trial data as part of the German pharmaceutical industry's post-war reparations. FDA approval as Dolophine followed in 1947 for severe pain.

In 1964, Vincent Dole and Marie Nyswander at Rockefeller University in New York began a clinical trial in which heroin-dependent patients were maintained on stable daily doses of methadone. The 1965 and 1966 papers establishing methadone maintenance treatment as effective for OUD founded the modern field of medication-assisted treatment.{{citation needed}} The original methadone maintenance treatment programs were established in New York City in the late 1960s; the federal OTP regulatory framework (the Methadone Regulations under 21 CFR Part 291, later 42 CFR Part 8) was promulgated in 1972 and constrains how methadone for OUD is dispensed in the United States to this day.

The FDA added the QT prolongation boxed warning in November 2006 following accumulated reports of torsades de pointes and sudden cardiac death in methadone-treated patients. Subsequent guidelines (Krantz et al 2009 Annals of Internal Medicine) provided clinical decision frameworks for ECG monitoring.{{citation needed}}

The DEA X-waiver requirement for buprenorphine prescribing was abolished by the Mainstreaming Addiction Treatment (MAT) Act passed in December 2022 and implemented in 2023; however, the OTP restriction for methadone-MOUD dispensing remains federally in place, with limited recent expansion of take-home flexibility post-COVID.

| indications = <problem ref="chronic-pain" author="parser-claude">Chronic pain when alternative treatments are inadequate; specifically valued in opioid-tolerant patients (NMDA blockade attenuates tolerance) and in neuropathic pain syndromes.</problem>
<problem ref="opioid-use-disorder" author="parser-claude">Opioid use disorder; the original MOUD agent. Dispensing in US is restricted to FDA-certified Opioid Treatment Programs (OTPs) federally.</problem>
<problem ref="neonatal-abstinence" author="parser-claude">Neonatal abstinence syndrome; off-label NICU adjunct.</problem>

| dosing = <titration slug="pain-opioid-naive" author="parser-claude" title="Chronic pain, opioid-naive">
Start 2.5-5 mg PO every 8-12 hours. Increase by no more than 25-50% every 5-7 days based on response and accumulation profile. Pain control may lag drug accumulation; counsel patient on the latency. Steady state requires 5-7 days at any given dose. Conversions from other opioids use a NON-LINEAR ratio that is substantially LOWER than published equianalgesic tables suggest, especially at higher pre-conversion opioid doses; specialist consultation advised for conversion.
</titration>

<titration slug="moud-induction" author="parser-claude" title="MOUD induction (OTP setting)">
Day 1: 20-30 mg PO once daily. Re-evaluate at 2-4 hours; may give additional 5-10 mg if withdrawal incomplete (cumulative day 1 dose typically not exceeding 40 mg). Days 2-7: increase by 5-10 mg every 1-3 days as tolerated; target dose typically 60-120 mg/day at steady state. Accumulation over the first week is the dominant safety concern.
</titration>

<titration slug="moud-maintenance" author="parser-claude" title="MOUD maintenance">
Typical effective range 60-120 mg/day as single daily dose, though some patients require higher doses for adequate craving and withdrawal suppression. Plasma trough concentrations can guide individualization in difficult cases. Withdrawal symptoms returning before next dose suggests under-dose or rapid metabolism (CYP2B6 UM phenotype consideration).
</titration>

<titration slug="hepatic-impairment" author="parser-claude" title="Hepatic impairment">
Reduce starting dose by 25-50% and titrate slowly. Substantial CYP-mediated metabolism means hepatic dysfunction prolongs half-life; cirrhosis particularly extends exposure.
</titration>

<titration slug="elderly" author="parser-claude" title="Elderly">
Start at the low end (2.5 mg) with longer intervals between titrations. Clearance reduced; QT risk elevated. Fall risk substantial.
</titration>

| effects =
* <effect ref="analgesia" author="parser-claude">Therapeutic effect; full mu-opioid agonism with NMDA component.</effect>
* <effect ref="sedation" author="parser-claude">Common, especially at initiation and after dose increases.</effect>
* <effect ref="constipation" author="parser-claude">Universal; prophylactic bowel regimen recommended.</effect>
* <effect ref="respiratory-depression" author="parser-claude">Dose-dependent; the central safety pivot, especially in opioid-naive patients and with benzodiazepine / alcohol / other CNS depressant combination.</effect>
* <effect ref="qt-prolongation" author="parser-claude">Dose-dependent; mechanism is hERG K+ channel block. ECG monitoring recommended at baseline, after dose changes, and at doses >100 mg/day.</effect>
* <effect ref="torsades-de-pointes" author="parser-claude">Documented at higher doses and with concurrent QT-prolonging medications or hypokalemia. Boxed warning.</effect>
* <effect ref="hypotension" author="parser-claude">Especially orthostatic; histamine release contributes.</effect>
* <effect ref="sweating" author="parser-claude">Notably common with methadone, often described as severe.</effect>
* <effect ref="hypogonadism" author="parser-claude">Long-term opioid use suppresses HPG axis; reduced libido and testosterone in men, menstrual irregularity in women.</effect>
* <effect ref="weight-gain" author="parser-claude">Common in MOUD maintenance; partly metabolic, partly improved nutrition with stable life circumstances.</effect>
* <effect ref="dental-caries" author="parser-claude">Particularly with oral concentrate; xerostomia + carbohydrate consumption + dental neglect. Counseling pivot for MOUD patients.</effect>
* <effect ref="opioid-withdrawal" author="parser-claude">Protracted compared to short-acting opioids; symptoms can persist weeks. Severe in abrupt cessation; slow taper essential.</effect>

| pk_absorption = Oral bioavailability ~70-85% (high for an opioid). Peak plasma 2-4 hours after oral dose. Distribution from plasma to tissue is rapid; redistribution into deep tissue compartments contributes to the long elimination phase.<ref name="dolophine-label" />

| pk_distribution = Plasma protein binding 85-90%, primarily to alpha-1-acid glycoprotein (which can be inducible in inflammatory states, modestly affecting free fraction). Volume of distribution 1-8 L/kg (highly variable). Crosses blood-brain barrier and placenta readily; excreted in breast milk at low levels generally considered compatible with breastfeeding in stable maintained patients.<ref name="dolophine-label" />

| pk_metabolism = Hepatic N-demethylation primarily via CYP3A4 and CYP2B6, with minor CYP2D6 and CYP2C19 contributions. Metabolites are inactive. Methadone is itself a weak CYP3A4 inhibitor (clinically modest). The dominant clinical PK fact is high interindividual variability in clearance (CYP2B6 polymorphism is a major contributor); the same daily dose can produce 10-fold differences in steady-state plasma concentrations between patients.<ref name="dolophine-label" />

| pk_elimination = Predominantly renal as inactive metabolites (~33%) and biliary (~33%); ~33% unchanged in feces. Urinary pH affects clearance modestly: acidic urine accelerates excretion of the parent compound (weak base ion-trapping). Mean half-life ~22-24 hours; range 8-59 hours.<ref name="dolophine-label" />

| pharmacodynamics = Methadone is a full mu-opioid receptor agonist with intrinsic activity comparable to morphine; the long receptor residency time relative to morphine contributes to the prolonged analgesic and withdrawal-suppression effect. The NMDA receptor antagonist activity is the distinguishing pharmacodynamic feature: methadone blocks the NMDA glutamate receptor at clinically relevant concentrations (Ki ~7-30 micromolar), and this NMDA blockade is one proposed mechanism for methadone's efficacy in opioid-tolerant patients (NMDA receptors contribute to opioid tolerance development) and in neuropathic pain syndromes where NMDA signaling contributes to central sensitization. Weak serotonin and norepinephrine reuptake inhibition adds a modest non-opioid analgesic component but also contributes to serotonin syndrome risk with serotonergic comedications.

QTc prolongation is mediated by hERG (Kv11.1) potassium channel block; the dose-response is clinically meaningful above 100 mg/day in many patients and at lower doses in those with hypokalemia, hypomagnesemia, hepatic dysfunction, female sex, or concurrent QT-prolonging medications.

| interactions = <pharmaInteractions/>

The clinically important interactions for prescribers:

* '''Other CNS depressants (boxed warning).''' Benzodiazepines, alcohol, sedating antihistamines, gabapentinoids, sleep aids: additive respiratory depression. Benzodiazepine + methadone is the most common pharmacological contributor to opioid overdose deaths in MOUD populations; the FDA explicitly does not recommend withholding methadone MOUD from patients also on benzodiazepines, but counseling and monitoring are essential.
* '''QT-prolonging medications.''' Class IA and III antiarrhythmics, certain antibiotics (macrolides, fluoroquinolones), antifungals, neuroleptics (especially haloperidol IV), SSRIs (citalopram > others), tricyclics, antiemetics (ondansetron, droperidol). Baseline + follow-up ECG monitoring; consider alternative when feasible.
* '''CYP3A4 strong inhibitors.''' Ritonavir, clarithromycin, ketoconazole, itraconazole, voriconazole: substantial methadone exposure increase; reduce methadone dose and monitor.
* '''CYP3A4 strong inducers.''' Rifampin, phenytoin, phenobarbital, carbamazepine, efavirenz, nevirapine, St John's wort: substantial methadone exposure decrease; methadone withdrawal can emerge within days. Dose increase typically required.
* '''CYP2B6 inhibitors and inducers.''' Sertraline raises methadone levels approximately 26% over six weeks via CYP2B6 inhibition, with stereoselective accumulation of the QT-prolonging (S)-methadone enantiomer.{{citation needed}}
* '''Serotonergic medications.''' SSRIs, SNRIs, MAOIs, tramadol, linezolid, IV methylene blue: serotonin syndrome risk via methadone's weak SRI / NRI activity. Documented but less common than with strongly serotonergic opioids (meperidine, tramadol).
* '''Other opioids.''' Mixed agonist-antagonists (buprenorphine, nalbuphine, butorphanol) precipitate withdrawal in methadone-maintained patients; never give without specialist guidance.
* '''Naloxone.''' Reverses opioid effect; in methadone overdose, repeat doses or continuous infusion needed due to the long methadone half-life.

| pregnancy_details = Methadone has been the standard of care for opioid use disorder in pregnancy since the 1970s, established before formal regulatory approval. The maternal benefits (stable opioid exposure, removed from illicit supply variability, integration into prenatal care) substantially outweigh the neonatal abstinence syndrome (NAS) that follows third-trimester exposure. NAS is expected with chronic methadone exposure during pregnancy; management is supportive in the NICU with non-pharmacologic interventions (rooming-in, breastfeeding, swaddling) and opioid taper (typically with morphine or methadone) for severe cases.

Methadone clearance increases through pregnancy (probably via CYP3A4 induction), and many patients require dose increases or split daily dosing during the second and third trimesters. Postpartum dose reduction may be needed.

Buprenorphine is increasingly used as an alternative to methadone in pregnancy MOUD; the MOTHER trial (Jones et al 2010 NEJM) and subsequent data show comparable maternal outcomes and somewhat milder NAS with buprenorphine. ACOG (Committee Opinion 711) and ASAM endorse both methadone and buprenorphine as first-line options.{{citation needed}}

Methadone is excreted into breast milk at low concentrations (M/P ratio approximately 0.6, infant exposure typically <3% of maternal weight-adjusted dose); ACOG and the Academy of Breastfeeding Medicine recommend breastfeeding for stable maintained patients.

| monitoring = '''Boxed warning items:''' addiction/abuse/misuse, respiratory depression, NAS, QT prolongation. The QT-prolongation monitoring is methadone-specific:

* '''Baseline ECG''' before starting methadone, especially in patients with cardiac risk factors, electrolyte abnormalities, or concurrent QT-prolonging medications.
* '''Follow-up ECG''' at 30 days and annually; sooner with dose increases above ~100 mg/day, with addition of QT-prolonging comedications, or with new cardiac symptoms.
* '''QTc threshold for intervention:''' >450 ms warrants caution and consideration of alternative; >500 ms warrants dose reduction or discontinuation and cardiology consultation.

'''Other monitoring:'''
* Daily clinical assessment during induction (first 7-14 days) for accumulation toxicity; rising sedation, slurred speech, or respiratory rate <12 = immediate hold.
* Electrolytes (K+, Mg++) periodically, especially with diuretics or GI losses.
* LFTs at baseline + periodically (hepatic dysfunction extends half-life substantially).
* Testosterone level in male patients with low libido or sexual dysfunction (opioid-induced hypogonadism is common and treatable).
* Dental examination at intake + annually for MOUD patients (xerostomia + caries risk).
* PDMP review at intake + regularly per state requirements.
* Urine drug screening per OTP regulation.

| counseling = '''Accumulation safety (pain titration).''' Methadone keeps building up in your body for 5-7 days after each dose change. Pain control may not match the dose increase for a week. Do NOT take extra doses if pain is uncontrolled in the first days after a dose change; call your prescriber.

'''Benzodiazepines and alcohol (boxed warning).''' Combining methadone with benzodiazepines or alcohol substantially increases the risk of fatal overdose. If you are on a benzodiazepine, talk with your prescriber about whether you can safely taper it.

'''QT and the heart.''' Methadone can affect the heart's electrical conduction; this is dose-related. Tell your provider if you have a personal or family history of heart rhythm problems, sudden cardiac death, or unexplained fainting, and any new symptoms of dizziness, palpitations, or fainting on methadone.

'''Driving and machinery.''' Do not drive after starting methadone, after any dose increase, or if you feel sedated. Once stable on a steady dose with no sedation, most patients can drive safely.

'''Pregnancy.''' If you become pregnant on methadone, do NOT stop abruptly - this can harm the pregnancy. Methadone MOUD is the standard of care in pregnancy.

'''Naloxone awareness.''' Keep naloxone (Narcan) available at home and in your car. Educate household members to recognize opioid overdose and use naloxone. Because methadone is long-acting, repeat naloxone doses may be needed and emergency care is essential.

'''Constipation.''' Methadone almost always causes constipation. Start a bowel regimen (fiber, hydration, stool softener, plus a stimulant laxative if needed) before constipation becomes a problem.

'''Dental care.''' Methadone causes dry mouth which can lead to rapid tooth decay. Drink water frequently rather than sugared beverages. Brush twice daily with fluoride toothpaste, floss daily, and see a dentist at least annually.

'''Discontinuation.''' Never stop methadone abruptly after long-term use; talk with your prescriber about a slow taper. Withdrawal from methadone is protracted (weeks rather than days) compared to short-acting opioids.

| anecdotes =
| seealso = [[Buprenorphine]], [[Morphine]], [[Oxycodone]], [[Naltrexone]], [[Naloxone]]
| references = <references/>
}}

[[Category:Opioid analgesics]]
[[Category:NMDA antagonists]]
[[Category:Schedule II controlled substances]]
[[Category:Medicines]]